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1. OBESIDAD 
1.1. Definición y Epidemiología 
La obesidad es una enfermedad crónica de origen multifactorial 
que se caracteriza por un aumento del peso y grasa corporal. La obesidad 
se considera fruto de la interacción de factores ambientales con 
determinantes genéticos del individuo (Mathes et al., 2011).  
La fórmula que la Organización Mundial de la Salud (OMS) utiliza 
para definir sobrepeso y obesidad es el índice de masa corporal (IMC): 
peso/(estatura)
2
, con el peso expresado en kg y la estatura en metros. La 
OMS define como peso saludable el de aquellos sujetos con un IMC de 
20 a 25 kg/m², el sobrepeso cuando el IMC es igual o superior a 25 kg/m², 
y la obesidad cuando el IMC es igual o superior a 30 kg/m². También se 
considera signo de obesidad un perímetro abdominal en hombres mayor o 
igual a 102 cm y en mujeres mayor o igual a 88 cm. 
La grasa corporal y su distribución varían según el sexo, edad, 
grado de ejercicio físico e influencia de algunos fármacos. Tanto en el 
hombre como en la mujer, la grasa corporal aumenta con la edad. La capa 
de tejido adiposo que se localiza entre la dermis y la aponeurosis y fascia 
de los músculos y que incluye al tejido mamario, se define como tejido 
adiposo subcutáneo (TAS), mientras que el que se ubica en el interior del 
tórax, abdomen y pelvis se denomina tejido adiposo visceral (TAV) 
(Cinti, 2006).  
El TAV es  el principal depósito de grasa asociado al aumento en 
el riesgo de padecer enfermedades metabólicas; ya que se considera el 
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tejido que da inicio a la resistencia a la insulina asociada a  un incremento 
en el flujo de los ácidos grasos libres (AGL) desde éste al sistema portal y 
la circulación general, que tiene efectos sobre la captación de glucosa a 
nivel celular y el metabolismo glucídico intracelular (Doelle, 2004).  La 
acumulación de los AGL disminuye la utilización de glucosa por el 
músculo, es un potente estímulo de la producción hepática de glucosa, 
potencia la secreción de insulina estimulada por la glucosa y tiene un 
efecto lipotóxico a largo plazo sobre las células β-pancreáticas. 
Además, el síndrome metabólico se define como la conjunción de 
varios factores de riesgo o enfermedades entre los que se encuentran una 
circunferencia abdominal elevada (adiposidad central), concentraciones 
anormales de triglicéridos, colesterol HDL y glucosa e hipertensión 
(Scarpellini y Tack, 2012). Es una de las comorbilidades de la obesidad 
que, a su vez, incrementa el riesgo de desarrollar otras patologías (Alberti 
y Zimmet, 1998). 
La obesidad es una pandemia de extrema relevancia en nuestros 
días debido a que ocupa el sexto lugar entre las patologías que 
contribuyen al gasto global de enfermedades mundiales. Según la OMS, 
en 2013, más de 42 millones de niños menores de cinco años tenían 
sobrepeso. Antes, el sobrepeso y la obesidad se consideraban un problema 
inherente a los países desarrollados, actualmente ambos transtornos están 
aumentando en los países en vías de desarrollo. 
De acuerdo con el NHANES (National Health and Nutrition 
Examination Survey; un programa de estudios designado a evaluar la 
salud y el estado nutricional en adultos y en niños en EEUU) 2005-2006, 
en Estados Unidos 68.6% de los adultos de 60 años y más tienen 
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sobrepeso u obesidad (IMC ≥ 25) y 30.5% son obesos (IMC ≥ 30), 
comparado con 60.1 y 22.2%, respectivamente, del reportado por el 
NHANES 1988-1994. En España, según el Instituto Nacional de 
Estadística (INE), la prevalencia de obesidad en niños escolares entre 
1984 y 2000 ha aumentado del 5 al 15%; y la prevalencia de sobrepeso en 
niños de 2 a 17 años es del 24,7%. Además, según los últimos datos del 
INE, de cada 100 adultos de 18 y más años 17 padecen obesidad y 37 
presentan sobrepeso. Así, la obesidad ha aumentado del 7’4% al 17% en 
los últimos 25 años (Encuesta Nacional de Salud 2011-2012 del INE de 
marzo de 2013). 
1.2. Etiología y Clínica 
La etiología de la obesidad es múltiple, e incluye factores 
intrínsecos, como la herencia genética y el funcionamiento del sistema 
endocrino, nervioso y metabólico, y ambientales asociados al estilo de 
vida. Así, entre los factores que contribuyen a la obesidad en un 30% se 
atribuyen a los factores genéticos, y un 70% a los factores no 
heredables/sociales (dieta, actividad física, etc.) (Mazza, 2001).  
La mayoría de los investigadores han concluido que la 
combinación de un consumo excesivo de energía y el estilo de vida 
sedentaria son la principal causa del rápida incremento de la incidencia de 
la obesidad en la sociedad occidental en el último cuarto del siglo XX 
(Bleich et al., 2007). Sin embargo, también existe un consenso cada vez 
mayor sobre la influencia del componente genético que puede explicar el 
33% de los casos (Stunkard, 1996). 
I-Introducción general 
6 
 
          Investigaciones muestran que la descendencia de una pareja con 
peso adecuado tiene tan sólo entre 7 y 14% de probabilidades de padecer 
obesidad, la cifra aumenta a 40 y 80% respectivamente, cuando uno o 
ambos progenitores son obesos. No obstante, se ha observado la misma 
tendencia del peso corporal tanto en hijos biológicos como en hijos 
adoptivos de personas obesas. Esto indica claramente que los modelos de 
comportamiento de los padres o herencia social, también desempeñan un 
papel importante en la génesis de la obesidad. 
Actualmente, se sabe que existen varios genes capaces de causar 
obesidad o de aumentar la susceptibilidad a  desarrollarla; dos son los que 
han recibido mayor atención: el gen ob y el gen beta3-adrenorreceptor. 
El gen ob codifica la proteína leptina en las células adiposas. La leptina 
actúa a nivel del hipotálamo e influye en las señales de saciedad. El gen 
beta3-adrenorreceptor, localizado principalmente en el tejido adiposo, 
regula la tasa metabólica en reposo y la oxidación de grasa en el ser 
humano. Además destacar dos estudios recientes; por una parte, el gen 
KRS2 que ha sido identificado como implicado en la obesidad y en la tasa 
metabólica. La secuenciación del ADN en más de 2.000 personas obesas 
identificó múltiples mutaciones del gen KRS2, ligadas a resistencia a la 
insulina severa y una tasa metabólica reducida.  Por lo tanto, podría ser 
que la modulación de los efectos mediados-KSR2 pudiesen tener el 
potencial de derivar en dianas terapéuticas frente a la obesidad (Pearce et 
al., 2013). Por otra parte, otro estudio identificó numerosas mutaciones 
comunes en el gen fat mass and obesity-associated (FTO) expresado en el 
tejido adiposo, en cerebro y músculos, y cuyo producto proteico regula el 
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metabolismo energético. Los heterocigotos tuvieron un riesgo de obesidad 
30 % mayor, mientras que los homocigotos tuvieron un incremento en el 
riesgo de un 70 % (Frayling et al., 2007). Estos hallazgos  apuntaban, no 
obstante, a otro gen (iroquois 3 u IRX3) lejano que desempeña una acción 
crucial en el hipotálamo que es decisiva para la acumulación de la grasa 
corporal en cualquier órgano o víscera (Smemo  et al., 2014).  
 
Las enfermedades endocrinas hereditarias suponen el 3% de los 
casos de obesidad y, entre ellas, se encuentran patologías como el 
hipotiroidismo, el síndrome de Cushing, hipogonadismo, lesiones 
hipotalámicas o deficiencia de la hormona de crecimiento (Weaver, 
2008). 
Entre las enfermedades mentales que pueden incrementar el riesgo 
de desarrollar obesidad están los trastornos alimentarios tales como 
bulimia nerviosa y consumo compulsivo de comida o adicción a los 
alimentos, la depresión, etc. 
A parte del ya citado síndrome metabólico, existen otras 
comorbilidades asociadas a la obesidad como por ejemplo:  
hipertrigliceridemia y hipercolesterolemia (Toth, 2013), resistencia 
insulínica, diabetes mellitus tipo2 (Stevens et al., 2001), hipertensión 
arterial (Wolf et al., 1997), asma, problemas ortopédicos y músculo-
esqueléticos, apnea del sueño, síndrome del ovario poliquístico (Ambeba 
y Linkov, 2011), esteatosis hepática, cáncer (Bardou et al., 2013; Behrens 
y Leitzmann, 2013; Estores y Velanovich, 2013; Parsons et al., 2013), 
problemas de comportamiento y adaptación social (Zipper   et al., 2001). 
I-Introducción general 
8 
 
1.3. Obesidad e inflamación 
La obesidad es una patología asociada frecuentemente a una  
inflamación crónica de bajo grado (Medzhitov, 2008). Es común la 
presencia de macrófagos infiltrados en el tejido adiposo. La infiltración 
podría deberse al estrés oxidativo y la muerte de los adipocitos 
hipertrofiados y a la hipersecreción por parte del tejido adiposo de 
quimioquinas, como la proteína quimiotáctica de macrófagos (MCP-1). 
Los macrófagos representan cerca del 7% del total de las células presentes 
en el tejido adiposo en un sujeto con peso normal, pero el aumento de 
peso  conlleva un aumento en la infiltración de macrófagos, que pueden 
llegar a representar más del 60% de las células de ese tejido. Los 
macrófagos contribuyen de forma significativa al proceso inflamatorio 
que tiene lugar en el tejido adiposo y que constituye uno de los 
mecanismos fisiopatológicos que dan lugar al desarrollo de la resistencia 
a la insulina y la diabetes mellitus tipo 2 (Weisberg et al., 2003). Estudio 
recientes también indican  que los linfocitos CD8
+
 podrían ser unos de los 
primeros en infiltrarse en el tejido adiposo y ser responsables del 
reclutamiento de los  macrófagos (Nishimura  et al., 2009). Asimismo, 
otro estudio reciente sugiere que los linfocitos B CD19
+ 
 son reclutados 
aún más rápidamente  en el tejido adiposo y que contribuyen a activar a 
los linfocitos T y éstos a su vez a los macrófagos proinflamatorios, 
contribuyendo las alteraciones asociadas en el  metabolismo de la glucosa 
(Winer et al., 2011).  Por el contrario, linfocitos T reguladores (reducidos 
en el tejido adiposo obeso) contribuyen a reducir la inflamación e inhibir 
el reclutamiento de los macrófagos con fenotipo pro-inflamatorio 
(Cipolletta et al., 2012; Feuerer et al., 2009). 
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Adicionalmente, la muerte de los adipocitos, la cual está 
relacionada con la hipoxia que tiene lugar cuando el tejido adiposo se 
expande en breve tiempo, provoca el reclutamiento de los macrófagos 
para remodelar este tejido, eliminando las células muertas y retirando su 
contenido lipídico potencialmente citotóxico (Strissel et al., 2007). De 
hecho, se ha demostrado que la hipoxia es un factor que participa 
activamente en el desarrollo de inflamación asociada a la obesidad, con 
un importante papel en la alteración de la secreción de adipoquinas, en el 
aumento en la expresión de genes pro-inflamatorios y en la muerte de los 
adipocitos (Surmi y Hasty, 2008). 
Así, la obesidad debida al exceso de grasa y, especialmente, al 
acúmulo a nivel visceral, provoca el aumento de la secreción de 
cantidades más elevadas de adipoquinas en el tejido adiposo que 
contribuyen a la inflamación sistémica y alteraciones metabólicas; 
creando un "ambiente inflamatorio sistémico" caracterizado por aumento 
de las concentraciones de TNF-α, IL-6, resistina, inhibidor del activador 
del plasminógeno (PAI-1), leptina, fibrinógeno y componentes del 
sistema renina-angiotensina-aldosterona (SRAA) (Redinger, 2008). 
Algunas adipoquinas, sobre todo la leptina, activan a las células 
endoteliales y ayudan también a  la acumulación de macrófagos en el 
tejido adiposo, responsables de la liberación de moléculas pro-
inflamatorias, entre ellas el TNF-α, perpetuando el estado de inflamación 
descrito en la obesidad. De todo ello deriva que, no sólo el estado 
inflamatorio se centrará en el tejido adiposo, sino que a través del sistema 
portal tendrá repercusión en hígado; y claramente a nivel sistémico (Sanz 
y Moya-Pérez, 2014). 
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1.4. Diagnóstico y Tratamiento  
En adultos el diagnóstico se basa en el cálculo del IMC (Kg/m
2
) 
junto con una adecuada valoración clínica. Otros métodos diagnósticos 
resultan caros y costosos (TAC, ultrasonidos, etc.).  
En los niños, dado los cambios en la adiposidad y crecimiento, se 
debe usar una clasificación basada en los percentiles del IMC. La 
adiposidad infantil aumenta el primer año de vida, llegando a un nivel 
estable sobre los 5 o 6 años, para aumentar posteriormente a lo largo de la 
infancia. Las gráficas de IMC ayudan a identificar de manera temprana 
los niños con riesgo a desarrollar obesidad (OMS, Child growth 
standards). 
El tratamiento general de la obesidad y de sus complicaciones es 
multidisciplinar y combina dieta, ejercicio físico y modificaciones del 
comportamiento y del estilo de vida. En ciertas ocasiones, hay que 
recurrir a terapia farmacológica y/o a cirugía con todos los efectos 
secundarios que ello podría conllevar. Y es en este punto donde la 
microbiota intestinal, como se describirá posteriormente, podría constituir 
un objetivo nutricional y farmacológico para el tratamiento de la 
obesidad.  
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2. IMPLICACIONES DEL ESTRÉS 
2.1. Significado biológico del estrés e implicaciones 
neuroendocrinas 
Todos los seres vivos han de enfrentarse al medio ambiente para 
sobrevivir, y han de responder a diferentes estímulos, incluidos aquellos 
que ocasionan una  situación de estrés. 
Según el nivel de organización en la escala biológica y 
dependiendo del estímulo causante del estrés, existen  una serie de 
proteínas específicas, péptidos u hormonas con los que se pretende 
mantener la homeostasis de cada ser vivo. 
Resulta pues esencial desarrollar respuestas de adaptación al estrés 
adecuadas  no sólo en cuanto a la participación de las estructuras 
cerebrales afectadas por los mecanismos específicos de adaptación, sino 
también en cuanto a  la respuesta emocional y el comportamiento, que son 
fundamentales para conseguir el éxito de dicha adaptación a la nueva 
situación. Siendo el ajuste neuroendocrino el que permitirá completar 
dicha adaptación al estrés, iniciada mediante la plasticidad del sistema 
neural. Además, por su parte, el sistema endocrino está estrechamente 
regulado por el cerebro, mediante una comunicación bidireccional a 
través del eje Hipotalámico-Hipofisario-Adrenal. Concretamente, la 
función de las glándulas suprarrenales es la de regular las respuestas al 
estrés, a través de la síntesis de corticosteroides (principalmente cortisol) 
y catecolaminas (sobre todo adrenalina). De hecho, la secreción de la 
hormona liberadora de corticotropina (CRH) por parte del hipotálamo 
desencadena la secreción de la hormona corticotropina (ACTH) en la 
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hipófisis; y esta hormona es transportada por la sangre hasta la corteza 
suprarrenal, donde  desencadena la secreción del cortisol (u otros 
glucocorticoides como la corticosterona, según la especie animal). Estos 
son liberados en respuesta al estrés y actúan para restablecer la 
homeostasis. Sin embargo, la secreción prolongada de glucocorticoides, 
como consecuencia del estrés crónico (Gareau MG et al., 2007) o de una 
mala adaptación y respuesta al estrés (Allen AP et al., 2014), dan lugar a 
importantes cambios fisiológicos como por ejemplo alteraciones a nivel 
gastrointestinal (Kennedy PJ et al., 2014), afecciones cardiovasculares 
(Laukova M et al., 2014), etc.  
Esta relación entre los sistemas nervioso y endocrino,  influye 
tanto en la estructura y función del cerebro como en el comportamiento. 
  
 En este proceso de adaptación y respuesta al estrés, intervienen 
fundamentalmente los sistemas monoaminérgicos puesto que existen 
neuronas que transmiten su información a través de la liberación de 
diferentes catecolaminas: noradrenalina, serotonina y/o dopamina (Tabla 
1). 
 
Tabla1. Participación de los sistemas monoaminérgicos en las respuestas 
neuroendocrinas de adaptación al medio ambiente 
 Aminas biógenas          Sistema Activado           Sistema Inhibido 
 
 
Noradrenalina 
-Vigilancia 
general 
-Agresividad 
-Prontitud en 
acción  
-Anticipación en 
acción 
-Sedación 
-Apatía 
-Sumisión 
-Inhibición 
psicomotora 
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Serotonina 
-Satisfacción 
-Relajación 
-Ritmos diurnos 
normales 
-Insomnio 
-Desasosiego 
-Talante negativo 
 
 
Dopamina 
-Facilita el 
sistema 
gratificante 
-Atención 
selectiva 
-Comportamiento 
motor coactivo 
-Perturba la 
coordinación 
motora 
-Indiferencia 
emocional 
-Incapacidad de 
enfocar la atención 
Adaptado de Smelick; 1987. 
 
2.2. Efectos del estrés sobre la interacción neuroinmune 
Estudios neuroanatómicos, neuroquímicos y neuro-
endocrinológicos revelan la existencia de relaciones funcionales entre los 
sistemas nervioso central y autónomo y el sistema inmune. Desde el 
punto de vista anatómico hace tiempo que se descubrió la organización en 
la que permanecen asociados órganos nerviosos e inmunes que propician 
los fenómenos de inervación propia de la médula ósea (Kuntz y Richins, 
1945), timo (Hammar, 1935), bazo (Livett  et al., 1968) y nódulos 
linfáticos (Giron  et al., 1980). De tal modo es esto, que lesiones 
neurológicas en dichos órganos pueden facilitar el que a su vez se 
originen alteraciones inmunitarias a partir del hipotálamo u otras áreas 
cerebrales, ya sea en relación con el diencéfalo (Hall et al., 1978) o con el 
neocórtex (Renoux  et al., 1980; 1982). 
Desde el punto de vista neurobioquímico, también en las células 
responsables de la respuesta inmune -los linfocitos-, junto con otros 
receptores que influyen en la inmunomodulación  (Hadden, 1983), se han 
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encontrado receptores para agentes dopaminérgicos (Le Fur et al., 1980), 
para acetilcolina (Raimond et al., 1984) y para endorfinas, que son 
moduladoras de respuestas neuroinmunes (Besedovsky  et al., 1983). 
La integración a nivel endocrinológico de los sistemas nervioso e 
inmune empezó a sospecharse desde que las modificaciones en la 
actividad eléctrica de neuronas localizadas en la zona basal media del 
hipotálamo eran capaces de producir cambios a nivel de la 
neurotransmisión, y estos iban acompañados de variaciones en una 
respuesta inmunitaria (Besedovsky et al., 1977 a 1979). Otros indicios 
funcionales de las interrelaciones inmuno-neuroendocrinas pueden 
encontrarse en las distintas modificaciones de la actividad de hormonas 
peptídicas que pueden ser transferidas a células a través de un mensajero 
secundario (Lawrence et al., 1978;  Blalock, 1964). 
2.2.1. Modificación de la respuesta inmune en estados de 
ansiedad 
 Ante la autosuficiencia del sistema inmune para realizar su propio 
programa de reconocimiento de lo propio y de lo ajeno al huésped para 
articular las defensas de su organismo, está obligado a participar en las 
actividades de regulación de otros sistemas (nervioso y endocrino), con 
los que aparece integrado, manteniendo un perfecto equilibrio 
homeostático en su funcionamiento. De todas aquellas alteraciones de la 
homeostasis neuroinmune, las relacionadas con mecanismos de excitación 
emocional son las que han despertado mayor interés.  
Este efecto inmunomodulador de los estados depresivos a través de 
la función neuroendocrina fue estudiado por Stein et al., (1985). En estas 
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situaciones de estrés y enfermedad psiquiátrica, se observa que 
frecuentemente aparecen cuadros de inmunosupresión a un nivel más o 
menos específico y de una intensidad variable, que pueden conducir a 
patologías perfectamente definidas de hipersensibilización, 
inmunodeficiencia, autoinmunidad o carcinogénesis, entre otras. Pero 
también, dada la interacción bidireccional existente entre los sistemas 
nervioso e inmune, hay casos en que una situación de ansiedad va 
acompañada de una estimulación de la respuesta inmunitaria. 
 Por otra parte, numerosas investigaciones demuestran que otros 
sistemas neuroquímicos, no monoaminérgicos, probablemente juegan un 
papel importante en la etiología y tratamiento de las depresiones (Herbert, 
1997; Connor  y Leonard, 1998; Reid y Stewart, 2001). Entre los nuevos 
sistemas descritos se incluye el papel del sistema inmune, neuropéptidos 
transmisores, la hormona liberadora de corticotropina (CRH), hormona 
liberadora de tirotropina (TRH), etc. La CRH tiene acciones no sólo como 
factor liberador, sino también como neurotransmisor que cumple 
funciones como un mediador primario como se ha comentado en las 
respuestas endocrina, inmune y conductual de estrés (Herbert, 1997; Keck 
y Holsboer, 2001; Young  et al., 2000). 
Actualmente, se siguen estudiando las relaciones entre estrés, 
depresión y sistema inmunológico, comprobándose que este último tiene 
una relación recíproca con la enfermedad mental. Así pues, tanto el estrés 
como la depresión y la inflamación son capaces de activar el sistema de 
citoquinas. Éstas pueden tener un efecto depresivo, ya sea directamente, 
por medio de la activación del sistema CRH, o indirectamente, 
provocando resistencia de los receptores de glucorticoides, lo que causa 
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hiperactividad del eje Hipotalámico-Hipofisario-Adrenal, debido a 
inhibición del mecanismo de retroalimentación normal. Finalmente, 
existen receptores neuronales a citoquinas ampliamente distribuidos en el 
SNC, lo que sugiere que las citoquinas funcionan como 
neurotransmisores y ejercen una acción directa sobre el cerebro (Kronfol   
y Remick, 2000). 
 
2.3. SNC, Metabolismo y Sistema Inmune 
El control central del balance energético y el ajuste de la ingesta de 
alimentos, principalmente, ocurre a nivel del hipotálamo, donde se 
establece una compleja interacción entre insulina, leptina y otros neuro-
reguladores, como por ejemplo la serotonina, destacando la vía de 
señalización IRS/PI3K, que regula negativamente el balance energético, 
reduce la ingesta de alimentos y mejora la señalización de la insulina 
(Gerozissis et al., 2008).  
En este sentido, y atendiendo a la propia definición de la obesidad 
como un estado crónico de inflamación de bajo grado, la obesidad se 
asocia con la inflamación hipotalámica y la producción de citoquinas pro-
inflamatorias pueden causar resistencia a la leptina y permitir la reducción 
del control de la ingesta y de la disponibilidad de energía. La inflamación 
de SNC también contribuye a la resistencia a nivel sistémico de la 
insulina, particularmente en hígado, vía cerebro-hígado (Milanski et al., 
2012).  
En modelos animales, la inhibición de TLR4 o TNF-α reduce la 
inflamación hipotalámica, lo que se acompañará de una reducción de la 
resistencia a la leptina y una mejora de la transducción de la señal de la 
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insulina  y reducción de la esteatosis y  la gluconeogénesis. Todos estos 
efectos son mediados por señales parasimpáticas liberadas por el nervio 
vago. Los niveles de IL-6 circulantes también se sabe que estimulan el eje 
Hipotalámico-Hipofisario-Adrenal; la activación del cual se asocia con 
obesidad, hipertensión y resistencia insulínica (Berg y Scherer, 2005). 
 
 
3. MICROBIOTA INTESTINAL Y PROBIÓTICOS 
3.1. Composición y principales funciones  
El conjunto de microorganismos que colonizan la superficie de las 
mucosas del organismo se denomina microbiota.  En nuestro intestino 
habita una enorme población de bacterias, alrededor de 100 billones de 
microorganismos, un número 10 veces superior al de todas nuestras 
células somáticas y germinales juntas. Su peso también es  superior al de 
nuestro cerebro. 
 La microbiota que coloniza el tracto intestinal desempeña 
importantes funciones fisiológicas influyendo en el desarrollo y 
funcionamiento de los sistemas neuroendocrino e inmunológico. Las 
evidencias más claras sobre estas funciones se han obtenido a través de la 
comparación de animales libres de gérmenes y animales convencionales o 
intencionadamente colonizados. Los animales criados en condiciones de 
asepsia presentan ganglios linfáticos atróficos y niveles más bajos de 
inmunoglobulinas plasmáticas por lo que muestran mayor susceptibilidad 
a infecciones; y se considera que la colonización del intestino es necesaria 
I-Introducción general 
18 
 
para el adecuado desarrollo del sistema inmune y todas sus estructuras 
(Sartro, 2011).  
 
Otra de las funciones  que se le atribuyen a la microbiota intestinal 
es la metabólica, pues diversos estudios demuestran que la presencia de 
bacterias mejora la capacidad para digerir los nutrientes de la dieta (por 
ejemplo polisacáridos complejos) e interviene en la biosíntesis y aporte de 
micronutrientes (vitamina K, vitaminas del grupo B) (Jumpertz et al., 
2011; Guarner, 2011).  
 
Tabla2. Funciones de la microbiota intestinal 
  Funciones Metabólicas            Protección frente a infecciones/patógenos 
Producción de 
ácidos grasos de 
cadena corta 
Bloqueo de puntos de adhesión 
Metabolización 
parcial de grasas  
Producción de sustancias     
antimicrobianas 
Fermentación de 
carbohidratos no 
digeribles de la 
dieta 
Inmunomodulación 
Síntesis y 
degradación de  
aminoácidos y 
otros compuestos 
Inhibición competitiva por    
consumo de nutrientes 
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nitrogenados  
Síntesis de    
vitaminas 
 
Desconjugación 
de sales biliares 
 
 
La microbiota intestinal también se considera implicada en el 
desarrollo y función del sistema nervioso; pues en la actualidad sabemos 
que cepas específicas del género Bifidobacterium y Lactobacillus pueden 
regular la respuesta a estrés y modificar diversos aspectos del 
comportamiento como la ingesta de alimentos, la depresión y la ansiedad 
en modelos animales. Entre los posibles mecanismos de acción se 
incluyen, la habilidad de estas cepas para regular la producción de 
cortisol, neurotransmisores (catecolaminas) y citoquinas que influyen en 
la conexión entre el sistema inmune y nervioso (Dinan y Cryan, 2012; 
Cryan y Dinan, 2012). Además, los ratones libres de gérmenes tienen una 
conducta anormal (hiperactividad, respuesta exagerada al estrés), falta de 
regulación del eje Hipotalámico-Hipofisario-Adrenal (Neufeld et al., 
2011) e incluso afecciones a nivel cognitivo (Desbonnet  et al., 2013).   
 
Debido a todo esto, se considera actualmente apropiado entender al 
ser humano como un superorganismo en el que se integra la información 
del genoma humano con la del genoma microbiano (microbioma), lo que 
determina en conjunto nuestra diversidad fisiológica y nuestro mayor o 
menor riesgo de sufrir enfermedades (Li et al., 2014). Además, la 
microbiota interacciona y evoluciona en respuesta a factores ambientales, 
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fundamentalmente en respuesta a la dieta, lo que puede condicionar en 
gran parte sus funciones en el organismo. 
3.2. Microbiota y Obesidad 
Numerosos son los estudios que evidencian una relación entre la 
microbiota intestinal y la obesidad. De hecho, la colonización del 
intestino en animales libres de gérmenes provoca un aumento en la 
expresión en el hígado de dos enzimas claves implicadas en la ruta de 
biosíntesis “de novo” de ácidos grasos, la acetil-CoA carboxilasa y la 
sintasa de ácidos grasos, así como de los factores de transcripción 
ChREBP y SREBP-1, que están involucrados en la respuesta lipogénica 
de los hepatocitos a la insulina y glucosa (De Graaf y Venema,  2008). 
Por otra parte, Bäckhed y su equipo (2004) realizaron un estudio 
colonizando el tracto digestivo de ratones libres de gérmenes, con 
microbota de ratones alimentados con una dieta normal. Observando un 
incremento significativo en la grasa corporal sin haber aumentado la 
ingesta de alimento. Esto se atribuyó  a: 
 Fermentación microbiana de polisacáridos de la dieta que 
no pueden ser digeridos por las enzimas del hospedador 
 Incremento de la absorción intestinal, y en el íleon de 
monosacáridos y ácidos grasos de cadena corta 
 Conversión de los ácidos de cadena corta a lípidos más 
complejos en el hígado 
 Regulación microbiana de los genes del hospedador que 
promueven la deposición de los lípidos en adipocitos 
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Avanzando en el campo de la obesidad, recientemente, se ha 
demostrado en estudios llevados a cabo en ratones que la microbiota 
intestinal tiene un papel crucial en la homeostasis lipídica y de la glucosa 
y en diversas funciones metabólicas (Geurts  et al., 2011). La microbiota 
intestinal participa en el desarrollo de la masa adiposa y la inflamación de 
bajo grado sistémica que condiciona la aparición de resistencia insulínica, 
diabetes mellitus  tipo 2.  
De hecho, estudios posteriores en ratones también han revelado la 
función de la microbiota intestinal en el desarrollo del proceso 
inflamatorio asociado a la obesidad. Los lipopolisacáridos (LPS) de las 
bacterias Gram-negativas son las responsables del término endotoxemia. 
Caracterizándose ésta por un aumento a nivel sérico de LPS y se asocia a 
dietas ricas en grasa, la resistencia a la insulina y la diabetes. En modelos 
animales sometidos a una dieta rica en grasa, se considera que puede ser 
una factor inflamatorio crucial (Cani y Delzenne, 2007). En este contexto, 
los receptores receptores Toll Like (TLR) del sistema inmume innato 
responsables del reconocimiento de componentes bacterianos parecen 
desempeñar una función importante en el contexto de la obesidad (Sanz et 
al., 2008). Los TLR interactúan con diferentes proteínas adaptadoras que 
activan la transcripción de diferentes sistemas y la síntesis de diversas 
citoquinas. Los TLR2 y TLR4 están sobre-expresados en la obesidad y 
pueden ser activados tanto por  componentes bacterianos como el LPS de 
bacterias Gram-negativas como por los ácidos grasos saturados de la 
dieta, induciendo la  síntesis de TNFα, IL-6, IL-1β y quimioquinas 
proinflamatorias relacionadas por ejemplo con la resistencia a la insulina 
y el aumento de adiposidad  (Tsukmo, 2007) (Figura 1). 
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Figura1.  El LPS de las bacterias Gram-negativas activan vías de 
señalización TLR4 / MyD88 / NFkB y MAPKs (por ejemplo, JNK) en las 
células epiteliales que inducen la síntesis de mediadores de la inflamación y 
favorecen el reclutamiento y activación de células inmunocompetentes (por 
ejemplo el células dendríticas, macrófagos, etc.) en el tejido linfoide subyacente 
para contribuir a la inflamación. Lípidos de la dieta (ácidos grasos saturados) 
aumentan la expresión y la activación de los receptores de inmunidad innata 
(TLR4 y TLR2) y contribuyen a la translocación de productos bacterianos (LPS, 
PGN, etc.) por vías transcelulares y paracelulares que activan las células 
inmunocompetentes en el intestino y en los tejidos periféricos. La dieta rica en 
grasa induce también alteraciones en la microbiota que conducen a la producción 
de citoquinas inflamatorias y  también altera las uniones estrechas entre 
enterocitos aumentando así la permeabilidad paracelular de productos 
antigénicos bacterianos. Las bacterias y productos antigénicos bacterianos 
también pueden pasar a través de las células M y llegar a los tejidos. Los TLR2 
reconocen ácidos lipoteicoicos de las bacterias Gram-positivas y también LPS de 
bacterias Gram-negativas, que actúan sinérgicamente con TLR4 activación de la 
inflamación a través de NFkB y las vías de JNK (Adaptado de Sanz  y Moya-
Pérez; 2014). 
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Recientemente, se han realizado diversos estudios observacionales 
en humanos encaminados a poder establecer diferencias entre la 
composición microbiana de individuos normopeso e individuos obesos 
que puedan indicar que bacterias están implicadas. Numerosos resultados 
atribuyen estas diferencias principalmente a la relación entre dos filos: 
Firmicutes y Bacteroidetes Los resultados sugieren un descenso en la 
relación Bacteroidetes/Firmicutes o de grupos bacterianos incluidos en 
estos dos filos en los individuos obesos respecto a los normopeso (Sanz et 
al., 2013) y/o una disminución de la diversidad microbiana  y un 
incremento  del filo Actinobacteria en los obesos (Turnbaugh, 2009). No 
obstante, también hay resultados contradictorios que no confirman estas 
observaciones. También se ha establecido asociaciones con otros grupos 
bacterianos, aunque apoyadas por un número más reducido de estudios. 
Este tipo de evidencia está sirviendo de base para la evaluación de 
especies bacterianas concretas en modelos animales (Everard et al., 2013; 
Neef y Sanz, 2013), pero se carece de evidencias en humanos.  
 
Finalmente, citar que también existen estudios de especies 
microbianas concretas a las que se les atribuye un papel clave en este 
campo del metabolismo; como es el caso, por ejemplo, del trabajo de 
Basseri y colaboradores (2012), en el que se demostró que la principal 
bacteria responsable de metano es Methanobrevibacter smithii y que 
existe una estrecha relación entre la cantidad de metano en la cavidad oral 
y el aumento del IMC en animales.  Así, existe un interés creciente en 
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concretar exactamente la especificidad y funcionalidad a nivel de especie 
bacteriana e incluso de cepa (Eber  et al., 2014; Everard et al., 2013). 
3.3. Eje intestino-cerebro  
Actualmente, y como se ha citado previamente, es sabido  que el 
intestino mantiene un constante intercambio de información con el 
cerebro y con otros órganos a través de una compleja red de señales 
nerviosas, metabólicas y endocrinas. El sistema nervioso intestinal 
contiene  sustancias químicas (GABA, serotonina, acetilcolina, etc.) que 
se comportan como neurotransmisores capaces de operar en nuestro 
cerebro  como sustancias psicoactivas. De modo que, el sistema nervioso 
entérico se considera un segundo cerebro, en el que la microbiota 
intestinal estaría jugando un papel fundamental (Saulnier  et al., 2013; 
Mayer  et al., 2014). Destacando un período crítico y crucial en la 
reconstitución de dicha microbiota pues es en los primeros momentos de 
la vida cuando, atendiendo a resultados con modelos murinos, se pueden 
normalizar los patrones de comportamiento y neurorregulación; mientras 
que este efecto no se puede establecer claramente en la edad adulta (Díaz 
Heijtz R et al., 2011). Sin embargo, aún queda por profundizar a estos 
niveles de conocimiento y, principalmente, en estudios con humanos. 
3.4. Probióticos  
El término probiótico fue introducido por primera vez en 1965 por 
Lilly y Stillwell. No obstante, no fue hasta 1989 cuando Fuller redefinió 
los probióticos como aquellos suplementos alimenticios integrados por 
microorganismos vivos que afectan beneficiosamente al hospedador que 
los consume, mediante la mejora del equilibrio de su microbiota 
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intestinal. Posteriormente, en 2001 un comité de expertos los definió 
como organismos vivos que, en dosis definidas, ejercen efectos 
beneficiosos para la salud (FAO/OMS, 2001). Este concepto de 
probiótico implica dos requisitos fundamentales, el mantenimiento de la 
viabilidad en el producto hasta el final de su vida útil y la demostración de 
su efectividad a una determinada dosis. Los probióticos constituyen uno 
de los subgrupos más destacados dentro de los alimentos funcionales o 
con propiedades saludables. Los principales probióticos utilizados para 
consumo humano son cepas bacterianas de los géneros Lactobacillus y 
Bifidobacterium, que han sido tradicionalmente utilizadas en diversas 
fermentaciones alimentarias y, en menor número de casos, identificadas 
como comensales del tracto gastrointestinal. Los yogures y otras leches 
fermentadas constituyen los principales vehículos para el aporte de 
probióticos, ya que favorecen su viabilidad y, en Europa, tienen gran 
aceptación porque se consideran alimentos saludables. De hecho, el 
concepto de probiótico se considera derivado de los estudios del Elie 
Metchnikoff, premio Nobel de Medicina, que sugerían una asociación 
entre la alta ingesta de leches fermentadas y un mejor estado de salud y 
mayor esperanza de vida (Bibel, 1988); así como de los de Henry Tissier 
que aisló las primeras bifidobacterias de las heces de niños amamantados 
con leche materna asociada a una reducción de la tasa de infecciones 
(Tissier, 1990). Los probióticos se vehiculizan también en la actualidad en 
forma de leches infantiles y de una gran gama de alimentos diversos 
(zumos, chocolate, etc.) y suplementos alimentarios en forma liofilizada.  
En menor medida también se comercializan como probióticos cepas 
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comensales de Enterococcus, Bacillus, levaduras (Sacharomyces 
cerevisiae subtype boulardii) y una cepa de E. coli. 
Avances recientes en las investigaciones sobre la relación entre la 
composición de la microbiota intestinal y el estado de salud, gracias al 
uso de técnicas moleculares y especialmente de técnicas de secuenciación 
masiva de ácidos nucleicos, comparando la microbiota de personas sanas 
y sujetos con alguna patología o riesgo de padecerla, están permitiendo 
identificar nuevos micoorganismos comensales y simbiontes asociados a 
un fenotipo saludable que pueden constituir una nueva generación de 
probióticos más eficaces. El concepto de que la modulación de la 
microbiota o el reemplazamiento de ésta por una “saludable” puede 
constituir una estrategia terapéutica, se está demostrando con transplantes 
fecales de sanos a enfermos a nivel experimental. Estos han tenido 
resultados especialmente positivos en el caso del tratamiento de las 
infecciones recurrentes por Clostridium difficile y en un estudio en 
pacientes con síndrome metabólico (revisado por Neef y Sanz, 2013). Si 
bien esta estrategia no es la óptima debido a la falta de control total (por 
las posibilidades de “transplantar” también ciertos virus, resistencias a 
antibióticos, etc.) y la falta de reproducibilidad de la microbiota 
transplantada, constituye una prueba de concepto que hace prometedor el 
uso de nuevos consorcios de bacterias intestinales para mejorar la salud 
tal y como refleja la revisión del concepto de probiótico y otras 
publicaciones (Neef y Sanz, 2013; Hill et al., 2014). 
Las citadas asociaciones detectadas entre alteraciones en la 
composición de la microbiota intestinal y la obesidad y sus co-
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morbilidades en humanos, así como las evidencias de la función de la 
microbiota en el metabolismo y en el eje intestino-cerebro en modelos 
animales ha llevado a proponer el uso de probióticos convencionales y 
nuevos para su tratamiento y prevención.   
 
A día de hoy, entre  las principales aplicaciones de probióticos 
investigadas para su uso en población pediátrica se incluyen la prevención 
y tratamiento de infecciones/diarrea, alergias y cólicos, la mejora de la 
función intestinal (frecuencia de la defecación y consistencia de heces) y 
la ausencia de efectos adversos en el crecimiento. En adultos se ha 
investigado la efectividad  frente a infecciones y diarrea asociada a la 
ingesta de antibióticos, sobre la mejora del tránsito intestinal y sobre 
patologías inflamatorias crónicas (colitis ulcerosa y pouchitis). En la 
Tabla 3 se resumen ejemplos de aplicaciones para las que se dispone de 
cierta evidencia sobre la eficacia. 
 
 
Tabla 3. Evidencia de la eficacia de algunos probióticos en humanos 
Probiótico Efecto/Uso Referencia 
S. thermophilus y L. 
delbrueckii sbsp. 
bulgáricus 
Mejora la digestión de la 
lactosa  
EFSA 2010 
Bifidobacterium lactis 
Bb12 con Streptococcus 
thermophilus o con S. 
thermophilus y 
Lactobacillus helveticus 
Reduce el riesgo de 
infecciones no específicas, 
(diagnosticadas mediante la 
incidencia de diarrea) 
Braegger et al., 
2011 
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L. rhamnosus LGG or 
Saccharomyces boulardii 
Reducen el riesgo de 
diarrea asociada al uso de 
antibióticos 
Johnston et al., 
2011 
Lactobacillus GG solo o 
en combinación con  con  
Bifidobacterium spp. 
 
Reducción de riesgo de 
sensibilización atópica , IgE 
total, incidencia de 
dermatitis atópica y de IgE-
asociada, pero no reducen 
la incidencia de asma 
Elazab et al., 
2013 
B. lactis DN-173 010 
B. lactis HN019 
Reducción del tiempo de 
tránsito intestinal 
Miller y 
Ouwehand 2013 
VSL#3 (combinación de 
cepas de Lactobacillus 
casei, L. plantarum, L. 
acidophilus, L. 
delbrueckii subsp. 
bulgaricus, B. longum, B. 
breve, B. infantis and 
Streptococcus salivarius 
subsp. thermophilus) 
Favorece la remisión de la 
colitis ulcerosa y pouchitis 
Jonkers et al., 
2012 
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 El objetivo general de la presente Tesis ha sido  analizar la 
contribución de la microbiota intestinal a la función del  sistema inmune, 
metabolismo, Sistema Nervioso Central y evaluar el efecto de  potenciales  
probióticos en modelos animales de obesidad y ansiedad inducida por 
estrés. 
 
Los objetivos concretos han sido los siguientes: 
 
1. Evaluar la eficacia de  Bacteroides uniformis CECT 7771 en un 
modelo murino de  obesidad inducida por la dieta. 
2. Identificar el mecanismo de acción de la cepa Bifidobacterium 
pseudocatenulatum CECT 7765 sobre el metabolismo lipídico y 
el de la glucosa en hígado mediante el análisis de expresión 
génica global y proteínas en un modelo murino de  obesidad 
inducida por la dieta. 
3. Evaluar la eficacia de B. pseudocatenulatum CECT 7765  para 
reducir la inflamación intestinal y sistémica ocasionada por la 
obesidad en un modelo murino.  
4. Evaluar la eficacia de  B. pseudocatenulatum CECT 7765 frente  
al estrés crónico y las alteraciones del comportamiento asociadas 
en un modelo murino.  
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RESUMEN 
Antecedentes: Se han realizado asociaciones entre la obesidad y la reducción intestinal 
en el número de bacterias del filo Bacteroidetes, pero no existe una evidencia directa del 
papel de estas bacterias en la obesidad. Por ello, los efectos de Bacteroides uniformis 
CECT 7771 han sido evaluados a nivel de alteraciones metabólicas e inmunológicas 
relacionadas con la obesidad. 
Métodos y Resultados: Ratones machos adultos (6-8 semanas) de la cepa C57BL-6 
fueron alimentados con  una dieta estándar (SD) o una dieta  rica en grasa (HFD) para 
inducir la obesidad; suplementados o no con B.uniformis CECT 7771 durante 7 
semanas. Los animals fueron pesados semanalmente y, finalmente, evaluados a nivel 
histológico, bioquímico, a nivel de funciones celulares y a nivel de las características de 
la microbiota intestinal al final de la intervención. 
La administración oral de B.uniformis CECT 7771 redujo la ganancia de peso, la 
esteatosis hepática, las concentraciones de colesterol y triglicéridos en el hígado y 
provocó un aumento de los adipocitos de menor tamaño en el caso de los ratones 
alimentados con una dieta rica en grasa. Dicha cepa bacteriana también redujo los 
niveles de colesterol, triglicéridos, glucosa, insulina y leptina en suero; y mejoró la 
tolerancia oral a la glucosa en los ratones alimentados con la dieta rica en grasa. A 
demás, esta cepa redujo la absorción de lípidos de la dieta, como se reflejó en la 
reducción en el número de micelas lipídicas detectadas en los enterocitos. 
Por otra parte, B.uniformis CECT 7771 mejora los mecanismos de defensa que se ven 
afectados negativamente en la obesidad. La HFD provoca un descenso en la producción 
de TNF-α por macrófagos peritoniales estimulados con LPS; mientras que la 
administración de B.uniformis CECT 7771 aumenta la producción de TNF-α y de la 
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fagocitosis. Administrando tambien B.uniformis CECT 7771, se aumenta la producción 
de TNF-α por células dendríticas (DCs) en respuesta a la estimulación con LPS, lo que 
se había visto reducido significativamente por la HFD. 
Finalmente, la HFD inducía marcados cambios en la composición de la microbiota 
intestinal, que se vieron paracialmente restablecidos por la interveción. 
Conclusiones: Todos estos resultados indican que la administración de B.uniformis 
CECT 7771 mejora las disfunciones metabólicas e inmunológicas asociadas a una 
disbiosis en ratones con obesidad inducida por dieta. 
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ABSTRACT  
Background. Associations have been made between obesity and reduced intestinal 
numbers of members of the phylum Bacteroidetes, but there is no direct evidence of the 
role these bacteria play in obesity. Herein, the effects of Bacteroides uniformis CECT 
7771 on obesity-related metabolic and immune alterations have been evaluated. 
 Methods and Findings. Adult (6–8 week) male wild-type C57BL-6 mice were fed a 
standard diet or a high-fat-diet HFD to induce obesity, supplemented or not with B. 
uniformis CECT 7771 for seven weeks. Animal weight was monitored and histologic, 
biochemical, immunocompetent cell functions, and features of the faecal microbiota 
were analysed after intervention. The oral administration of B. uniformis CECT 7771 
reduced body weight gain, liver steatosis and liver cholesterol and triglyceride 
concentrations and increased small adipocyte numbers in HFD-fed mice. The strain also 
reduced serum cholesterol, triglyceride, glucose, insulin and leptin levels, and improved 
oral tolerance to glucose in HFD fed mice. The bacterial strain also reduced dietary fat 
absorption, as indicated by the reduced number of fat micelles detected in enterocytes. 
Moreover, B. uniformis CECT 7771 improved immune defence mechanisms, impaired 
in obesity. HFD-induced obesity led to a decrease in TNF-α production by peritoneal 
macrophages stimulated with LPS, conversely, the administration of B. uniformis CECT 
7771 increased TNF- production and phagocytosis. Administering this strain also 
increased TNF- production by dendritic cells (DCs) in response to LPS stimulation, 
which was significantly reduced by HFD. B. uniformis CECT 7771 also restored the 
capacity of DCs to induce a T-cell proliferation response, which was impaired in obese 
mice. HFD induced marked changes in gut microbiota composition, which were 
partially restored by the intervention.  
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Conclusions: Altogether, the findings indicate that administration of B. uniformis 
CECT 7771 ameliorates HFD-induced metabolic and immune dysfunction associated 
with intestinal dysbiosis in obese mice.  
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Introduction 
Obesity is considered a major health issue due to its increasing prevalence and 
associated co-morbidities (e.g. type 2 diabetes, fatty liver and cardiovascular disease) 
affecting both the developed and the developing world [1-2]. This disorder is the result 
of a long-term positive energy imbalance and is associated with a chronic state of low 
grade inflammation and immune dysfunction [3-5]. 
The microbiota of the human gastrointestinal tract has been considered as an organ 
that contributes to human physiological diversity by encoding additional metabolic 
capacities and regulating gene expression of pathways involved in host nutrient 
metabolism [6]. Animal studies indicate that colonisation of adult germ-free mice with a 
distal gut microbial community harvested from conventionally raised mice influences 
energy-balance by increasing both nutrient digestion and absorption, and adiposity [7]. 
This effect is mediated by different mechanisms, including microbial fermentation of 
dietary polysaccharides that are otherwise indigestible by the host, subsequent intestinal 
absorption of monosaccharides and short-chain fatty acids, conversion of these 
metabolites to more complex lipids in the liver; and microbial regulation of host genes 
that promote lipid accumulation in adipocytes [8].  
In humans, the gut microbiota composition is also thought to play a role in energy 
balance, as inferred from observational studies reporting associations between obesity 
or weight loss and shifts in gut microbiota composition.  It has been reported that 80–
90% of bacterial phylotypes are members of two phyla, namely Bacteroidetes (including 
the genera Bacteroides and Prevotella) and  Firmicutes (including the genera 
Clostridium, Enterococcus, Lactobacillus and Ruminococcus), followed by the phyla 
Actinobacteria (including the genus Bifidobacterium) and  Proteobacteria (including 
Helicobacter and Escherichia) [9-10]. Therefore, relative proportions of Firmicutes and 
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Bacteroides are considered good indicators of major changes in intestinal microbiota 
constitution. So far, most studies have reported associations between obesity and 
reduced proportions of the phylum Bacteroidetes [11] which, in some cases, were 
accompanied by increased proportions of Actinobacteria [6] or Firmicutes [12], as also 
observed in mice [9, 13]. In addition, weight loss in obese human subjects subjected to 
dietary or surgical interventions has been associated with increases in Bacteroidetes [12] 
or in Bacteroides spp., Bacteroides-Prevotella spp. or Bacteroides fragilis group [14-
17]. Nevertheless, few observational studies have found no associations between 
weight-loss or obesity and numbers of Bacteroides spp. or Bacteroides-Prevotella spp. 
[18-19], reported opposite associations between obesity, and the relative proportion of 
Bacteroidetes to Firmicutes [19] or the numbers of Prevotellaceae, a subgroup of 
Bacteroidetes [20]. These discrepancies could partly be explained by differences in the 
analytical techniques used since, for example, real-time PCR or FISH target only 
specific groups of Bacteroidetes and underestimate some members of this phylum 
present in faecal samples [21]. By contrast, DNA sequence analyses of the phylum 
Bacteroidetes can cover up to 46 species of bacteria belonging to seven different genera 
of the order Bacteroidales [6], encompassing a taxonomic unit that is too broad to 
assess its possible implication in obesity [21].  
In this study, we hypothesised that modification of the gut microbiota structure by 
increasing numbers of specific Bacteroides spp. could contribute to restoring obesity-
related metabolic and immune dysfunction. To obtain direct evidence of the role of 
Bacteroides spp. in obesity and thus confirm such a hypothesis, we have evaluated in 
vitro the immunologic properties of different intestinal Bacteroides spp. on 
macrophages. Furthermore, we have assessed the effect of the selected strain (B. 
                                                                                                                            Capítulo I 
42 
  
uniformis CECT 7771) on metabolic and immune parameters of mice with high-fat-diet 
induced obesity.  
 
Methods 
Bacterial strain and culture conditions 
The following Bacteroides spp. and strains from the IATA-CSIC and Spanish 
Culture Collection (CECT) were studied: Bacteroides dorei SS1, Bacteroides ovatus 
SU2, Bacteroides distasonis CAY3, Bacteroides uniformis CECT 7771 (or CY1), 
Bacteroides thetaiotaomicron SAC4, Bacteroides fragilis SX3, Bacteroides caccae SV3 
and Bacteroides finegoldii SX2. These strains were isolated from stools of healthy 
infants (mean age 5.7 years, range 1.0–10.8 years). Briefly, fresh stool samples were 
diluted (1:10 [w/v]) in phosphate-buffered saline (PBS) solution (130 mM sodium 
chloride, 10 mM sodium phosphate, pH 7.2) and homogenised. Then, aliquots of serial 
dilutions in PBS and aliquots were plated on Schaedler Agar (Scharlau, Barcelona, 
Spain) supplemented with kanamycin (100 mg/L), vancomycin (7.5 mg/L) and vitamin 
K (0.5 mg/L) and incubated under anaerobic conditions at 37 ºC for 48 hours. Individual 
colonies were isolated from the highest dilution plate from each subject and their 
cellular morphology and Gram-staining characteristics were examined. The isolated 
clones were identified at species level by sequencing of amplified 16S rDNA regions 
with the primers 27f and 1401r as previously described [22]. The PCR products 
obtained were purified using the GFXtm PCR DNA and Gel Band DNA Purification 
Kit (GE Healthcare, Buckinghamshire, UK) for DNA sequencing. DNA sequencing was 
carried out by an ABI PRISM-3130XL Genetic Analyser (Applied Biosystems, 
California, USA). The closest relatives of the partial 16S rRNA gene sequences were 
sought in GenBank using the Basic Local Alignment Search Tool (BLAST) algorithm, 
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and sequences with more than 97% similarity were considered as belonging to the same 
species. All new data has been deposited in GenBank (Accession numbers:  JX183979, 
JX262250, JX183978, JX183977, JX183984, JX183983, JX183981 and JX183982, 
respectively).  
For experimental purposes, the bacterial strains were grown in Brain Heart Infusion 
Broth (BH) (Scharlab, SL- Barcelona, Spain) at 37 ºC in microaerophilic conditions 
(AnaeroGen; Oxoid, Basingstoke, UK). Cells were harvested by centrifugation (6,000 g 
for 15 min), washed twice in phosphate buffered saline (PBS, 130 ± sodium chloride, 10 
mM sodium phosphate, pH 7.4), and re-suspended in PBS plus 15% glycerol for in vitro 
trials and in 10% skimmed milk for animal trials. Aliquots of these suspensions were 
frozen in liquid nitrogen and stored at -80°C until used. The number of live cells after 
freezing and thawing was determined by colony-forming unit (CFU) counting on BH 
agar after 48 h incubation. For the strain tested, more than 90% cells were alive upon 
thawing and no significant differences were found during storage time (2 months). One 
fresh aliquot was thawed for every new experiment to avoid variability in the viability 
of cultures.  
 
Effect of Bateroides strains on induction of cytokine production by macrophages 
To evaluate the immunological properties of different Bacteroides strains, the RAW 
264 macrophage cell line, obtained from the American Type Culture Collection 
(Rockville, MD, USA), was cultured overnight in 24-well flat-bottom polystyrene 
microtiter plates (Corning, Cultek, Madrid, Spain) at a concentration of 1x10
5
 cells per 
ml in Dulbeco’s Modified Eagles Medium (DMEM) (SigmaTM– St. Louis, MO/USA). 
Media were changed before stimulation and, then, cells were incubated in the presence 
of 100 µl of a cell suspension (1x10
7
 cfu/ml) of each Bacteroides strain for 24 h. 
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Purified LPS from Salmonella enterica serotype Typhimurium (Sigma Chemical Co, 
Madrid, Spain) was used at a concentration of 1 µg/ml as a positive control. Non-
stimulated Raw 264.7 cells were also evaluated as controls of basal cytokine 
production. The cell culture supernatants were collected and stored at −20 ◦C until used 
for cytokine determination. TNF-α and IL-10 were quantified by ELISA Ready SET 
Go! Kit (BD Bioscience, San Diego, CA, USA). Every parameter was assayed in 
triplicate in two independent experiments. 
 
Animals, diets and experimental design  
Animal experiments were carried out in strict accordance with the recommendations 
in the Guide for the Care and Use of Laboratory Animals of University of Valencia 
(Central Service of Support to Research [SCSIE], University of Valencia, Spain) and 
the protocol was approved by its Ethic Committee (approval ID A1245740259386). 
Adult (age 6–8 week) male wild-type C57BL-6 mice were purchased from Harlan 
Laboratories. During the adaptation period (7 days), six animals were housed in each 
stainless-steel cage in a temperature-controlled (23 ºC) room with a 12-h light/dark 
cycle and 40–50% relative humidity. Then, mice were randomly divided into four 
groups (n=6-8 mice per group) as follows: (1) a control group, receiving a standard diet 
(SD); (2) an obese group, receiving a high-fat diet (HFD); (3) a group receiving a SD 
and a daily dose of 5.0x10
8
 CFU B. uniformis CECT 7771 by gavage; and (4) an obese 
group receiving the HFD and a daily dose of 5.0x10
8
 CFU B. uniformis CECT 7771 by 
oral gavage. To induce obesity, mice were switched from the SD (CA.170481-AIN-76A 
Purified Diet-Rats/Mice, Harlan Laboratories, Madison, WI 53744-4220) administered 
during the adaptation period to all mice, to a HFD (TD.06414 - Adjusted Calories Diet - 
60/Fat, Harlan Laboratories, Madison, WI 53744-4220) for 7 weeks. The HFD provided 
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18.4 % kcal as protein, 21.3 % kcal as carbohydrate and 60.3 % kcal as fat (5.1 kcal/g), 
whereas the SD provided 18.8 % kcal as protein, 68.8 % kcal as carbohydrate and 12.4 
% kcal as fat (3.8 kcal/g). Therefore, there was an increase in fat at expenses of a 
reduction in carbohydrates in the HFD. Mice had free access to feed and sterile water.  
Body weight was measured once a week and, at the end of study, animals were fasted 
for 16 h, anaesthetised, bled by aortic puncture and sacrificed by cervical dislocation. 
To analyse the metabolic parameters, blood samples were collected in tubes containing 
EDTA and centrifuged to obtain plasma that was stored at -20 °C. Stools were collected 
at the end of the experimental period (7 weeks) for microbiological analyses. The liver, 
white adipose (perirenal and epididymal) and small intestinal tissues were excised and 
rinsed with saline solution, and sections were fixed in 10% neutral formalin buffered 
solution for histological analysis. The white adipose deposits (perirenal and epididymal) 
were previously weighed. Liver sections were also used for lipid extraction and 
quantification as described below.  
 
Histology of liver, white adipose tissues and small intestine  
 Paraffin-embedded tissues were sectioned to a thickness of 4-5 µm and fixed to 
glass slides. Slides were deparaffinised and stained with haematoxylin-eosin. The 
severity of steatosis was determined in 100 hepatocytes of two liver tissue sections per 
mouse and scored as follows: grade 0 when fat was not detected in hepatocytes; grade 1 
when fat occupied less than 30% of hepatocytes; grade 2 when fat occupied between 30 
and 60 % of hepatocytes; grade 3, when fat occupied more than 60 % of hepatocytes.  
Adipocyte cell sizes were measured in 100 cells of two sections of epididymal 
adipose tissue per mouse
 
[23]. Adipocyte cell sizes were expressed as area ranges using 
the following ranges:  2000, 2000-4000,4000-6000 and 6000- 7000 µm2.  
                                                                                                                            Capítulo I 
46 
  
The ratio of fat micelles to enterocyte was determined in 100 cells from two sections 
of small intestinal tissue of each mouse by counting ten 100X light microscope fields. 
All parameters were measured in a NIKON Eclipse 90i Microscopic, using the NIS 
Elements BR 2.3 basic research software (Kingston,  
Surrey, KT2 5PR,  England). All histological analyses were conducted by an 
experienced histologist in a blind fashion.  
 
Analysis of serum and liver biochemical parameters and glucose tolerance 
Biochemical parameters were quantified in plasma using enzymatic assay kits for 
glucose (Glucose Liquid Kit; Química Analítica Aplicada SA, Spain), cholesterol 
(Cholesterol Liquid kit, Química Analítica Aplicada SA, Spain) and triglycerides 
(Triglyceride Liquid kit, Química Analítica Aplicada SA, Spain). Serum leptin 
concentration was determined by enzyme-linked immunosorbent assay (ELISA) (BD 
Bioscience, San Diego, CA, USA). Serum insulin was determined by Ultrasensitive 
Mouse Insulin ELISA (Mercondia AB, Sweden, 2010). 
Triglycerides and cholesterol were also quantified in liver. Lipids were extracted by 
homogenising the tissue with 2: 1 chloroform-methanol (v/v) making a 20-fold dilution, 
and filtering the homogenate through a nylon filter (Cell Strainer 40 micrometros 
Nylon.BD Falcon; BD BIOSCIENCIES). Non-lipidic substances were eliminated by 
adding 5-volumes of CaCl2 solution (5 mg/L) in water to the filtrate fraction. After 
centrifugation (4,000 g, for 5 minutes, at room temperature) the upper phase, containing 
all of the non-lipidic substances, was discarded. This process was repeated three times. 
Extracted lipids were dried under vacuum (Concentrator Plus 5301, Eppendorf Inc., 
NY, USA) and then triglyceride and total cholesterol concentrations were determined as 
described above. 
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Oral glucose tolerance tests were performed in vivo after 6 weeks of treatment. Food 
was removed 2 h after the onset of the daylight cycle and, after a 4-h fasting period, 
glucose was administered orally at a dose of 2 g/kg and blood samples were taken with  
heparinised capillary tubes from the tail vein before and 15, 30, 60, 90 and 120 minutes 
after glucose administration. Plasma glucose levels were analysed with glucose test 
strips (Ascensia Esyfill, Bayer, Tarrytown, NY; USA) and a glucometer (Ascensia 
VIGOR, Bayer Tarrytown, NY; USA), with a detection level ranging from 30 to 550 
mg glucose/dl. 
 
Isolation and assessment of cytokine production by peritoneal macrophages  
   Peritoneal cells were collected by washing the peritoneal cavity of different groups of 
mice, with 5 ml of sterile cold DMEM (Sigma), containing 10% inactivated (56 °C for 
30 min) foetal bovine serum (FBS) (Gibco, Barcelona, Spain), 100 µg/ml streptomycin 
and 100 U/ml penicillin (SigmaTM– St. Louis, MO/USA). Isolated macrophages were 
plated in flasks (Corning, Cultek, Madrid, Spain) at a concentration of 1x10
6
 cells per 
ml in DMEM and incubated for 2 h at 37 °C in an atmosphere containing 5% CO2. Non-
adhered cells were washed out with warm PBS. To evaluate differences in the response 
to a common stimulus, macrophages from different mouse groups were incubated in the 
presence of purified LPS from Salmonella enterica serotype Typhimurium (Sigma 
Chemical Co, Madrid, Spain) at a concentration of 1 µg/ml. Non-stimulated peritoneal 
macrophages were also evaluated as controls of basal cytokine production. To evaluate 
microbiota-related immune properties of faecal samples, macrophages from control 
mice were incubated in the presence of faecal samples (30 μl of 10-fold dilution) from 
the different mouse groups for 24 h. Stool samples used as stimuli were collected from 
six mice of each experimental group at the end of the study, diluted 10-fold in PBS and 
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homogenised for 3 min. Macrophage culture supernatants were collected and stored at 
−20 ◦C until used for cytokine determination. TNF-α and IL-10 were quantified by 
ELISA Ready SET Go! Kit (BD Bioscience, San Diego, CA, USA). Each parameter 
was assayed in triplicate in two independent experiments.  
 
Bactericidal activity of peritoneal macrophages 
   The bactericidal activity of peritoneal macrophages was analysed according to Vieira 
et al.
 
[24] Cells were washed with serum-free DMEM and nitroblue tetrazolium (NBT – 
SigmaTM– St. Louis, MO/USA) at 0.5 mg/ml together with a bacterial extract 
(Stimulant, No. 840-15-SigmaTM– St. Louis, MO/USA) in an equivalent concentration 
of McFarland Scale 2 in Lab-tek chamber slide w/cover (Nalge Nunc International, 
USA). After 1 h of incubation at 37 ºC in 5% CO2 atmosphere, the cells were washed 
with PBS, then fixed with 4% paraformaldehyde and observed in a NIKON Eclipse 90i 
Microscope, using the NIS Elements BR 2.3 basic research software (Kingston,  
Surrey, KT2 5PR,  England). One hundred cells were counted per mouse and the 
percentage of NBT positive cells was determined. This measurement was taken in 
triplicate, in two independent experiments.  
 
Isolation and cytokine production by bone marrow-derived dendrite cells (DC)   
   DCs were generated from bone marrow as described previously
 
[25]. Cells were 
seeded at a concentration of 1×10
6 
(90–94% DCs) in 1 ml of culture medium without rm 
GM-CSF in 24-well plates (Corning, Cultek, Madrid, Spain) and incubated in the 
presence of faeces (30 μl) from the respective mouse group at 37 °C under 5% CO2 for 
24 h. Purified LPS from S. enterica serotype Typhimurium (Sigma Chemical Co, 
Madrid, Spain) was used at a concentration of 1 µg/ml as a positive control. Non-
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stimulated DCs were also evaluated as controls of basal cytokine production. Stool 
samples were obtained and prepared as described above. The cell culture supernatants 
were collected and stored at −20 ◦C until used for cytokine determination (TNF-α and 
IL-10) as described above. Every parameter was assayed in triplicate, in two 
independent experiments.  
 
Interactions between DCs and CD4+ T lymphocytes 
   CD4+ T lymphocytes were isolated from mouse spleens, which were excised, 
suspended in complete medium and passed through a stainless steel wire mesh. The 
obtained crude cell suspension was washed once. CD4+ T cells were immune-
magnetically isolated by positive selection with “CD4+ (L3T4) microbeads” (Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany), following the manufacturer’s 
instructions. CD4+ T cells (purity exceeded 95%) were used for mixed lymphocyte 
reaction. 
Isolated DCs were incubated for 24 h in the presence of 1 µg/ml LPS from S. 
Typhimurium (Sigma Chemical Co, Madrid, Spain). Aliquots of mature DCs from 
different mouse groups were plated in triplicate with allogeneic CD4+ T cells (TL) at 
1:1, 1:2, and 1:4 TL / DC cell ratios, in 0.2 ml culture medium in 96-well flat-bottomed 
plates (Corning, Cultek, Madrid, Spain) at 37 ºC for 72 h. Lymphocyte proliferation was 
measured with the cell proliferation ELISA BrdU-colorimetric assay (Roche, 
Diagnostic, Germany). Individual cultures of DCs and TL stimulated with or without 
ConA, used as mitogen, were used as controls. 
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Samples and microbial analysis by quantitative PCR (qPCR)  
   Stool samples were weighed, diluted 1:5 (w/v) in PBS (pH 7.2), homogenised by 
shaking in a vortex and stored at -20 ºC till analysed. One aliquot of this dilution was 
used for DNA extraction using the QIAamp DNA stool Mini kit (Qiagen, Hilden, 
Germany). Specific primers (Table 1) [26-30] targeting different bacterial genera and 
species were used to characterise the composition of the microbiota by qPCR using  
LightCycler® 480 SYBR Green I Master (Roche, USA) with a an ABI PRISM 7000-
PCR sequence detection system (Applied Biosystems, UK), as described previously 
[14].  
Table 1. Oligonucleotide primers used in this study.  
 
Target bacterial 
groups 
 
Primers  
(name) 
Sequence (5'–3') 
 
Size 
(pb) 
Annealing 
Tmp (ºC) 
References 
 
Total bacteria  
HDA 1, 
HDA 2 
TGGCTCAGGACGAACGCTGGCGGC 
CCTACTGCTGCCTCCCGTAGGAGT 
200 59 (26) 
Bifidobacterium 
spp. 
BiFid F, 
BiFid R 
CTCCTGGAAACGGGTGG 
GGTGTTCTTCCCGATATCTACA 
550 55 (26,27) 
Bacteroides spp. 
Bfra F, 
Bfra R 
ATA GCC TTT CGA AAG RAA GAT 
CCA GTA TCA ACT GCA ATT TTA 
287 55 (26,27) 
Clostridium 
coccoides group 
Ccoc F, 
Ccoc R 
AAA TGA CGG TAC CTG ACT AA 
CTT TGA GTT TCA TTC TTG CGA A 
440 50 (26,27) 
Clostridium leptum 
group 
ClepF, 
Clep R3 
GCA CAA GCA GTG GAG T 
CTT CCT CCG TTT TGT CAA 
239 50 (26,27) 
Enterobacteriaceae 
Entero 
1, 
Entero 2 
CATTGACGTTACCCGCAGAAGAAGC 
CTCTACGAGACTCAAGCTTGC 
195 63 (28) 
Lactobacillus 
group 
Lac 1, 
Lac 2 
AGCAGTAGGGAATCTTCCA 
ATTYCACCGCTACACATG 
340 61 (29, 30) 
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Statistical analyses 
    Statistical analyses were carried out using SPSS 11.0 software (SPSS Inc., Chicago, 
IL, USA). Data of biochemical parameters were normally distributed and significant 
differences were determined by applying One-Way Anova with pos hoc Tukey’s test. 
Remaining data were non-normally distributed and the differences were determined by 
applying the Mann-Whitney U tests. In every case, P-values <0.05 were considered 
statistically significant. 
 
Results 
Bacteroides strain selection based on in vitro ability to induce cytokine production 
   Results in Table 2 show the ability of different Bacteroides strains to induce cytokine 
production by Raw264.7 macrophages. All strains induced the production of 
significantly higher amounts of the pro-inflammatory cytokine TNF-α than the non-
stimulated cells and LPS-stimulated macrophages, although the magnitude of this effect 
was strain-dependent. The strains B. dorei SS1, B. uniformis CECT 7771 and B. 
thetaiotaomicron SAC4 induced the lowest TNF-α production. Different bacterial 
strains also induced anti-inflammatory cytokine IL-10 production above basal levels to 
different extents, except for B. thetaiotaomicron SAC4, B. fragilis SX3 and B. finegoldii 
SX2 whose effects were not significant. B. uniformis CECT 7771 induced the highest 
IL-10 levels compared to the other Bacteroides strains under study. Therefore, this 
strain was selected for its greater anti-inflammatory properties.  
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Table 2. Effect of different Bacteroides strains on cytokine production by RAW264.7 
macrophages.  
Bacteroides strains Cytokine production  
 TNF-α (pg/ml) IL-10 (pg/ml) 
DEMEN 491.2(112.1)a, b’ 97.2(10.8)a,a’ 
LPS 1425.4(77.6)b, a’ 162.3(37.6)a,a’ 
B. dorei  SS1 3765.5(150.0)b,b’,a’’ 215.8(12.5)b,a’,b’’ 
B. ovatus SU2 4515.7(211.3)b,b’,b’’ 271.5(8.1)b,b’,b’’ 
B. distasonis  CAY3 4462.4(173.9) b,b’,b’’ 215.8(9.7)b,a’,b’’ 
B. uniformis CECT 7771 2998.4(50.4) b,b’,a’’ 341.3(13.5)b,b’,a’’ 
B. thetaiotaomicron SAC4 2931.2(464.5) b,b’,a’’ 109.2(3.0)a,a’,b’’ 
B. fragilis  SX3 6657.3(278.3) b,b’,b’’ 81.2(14.6)a,a’,b’’ 
B. caccae SV3 11622.0(818.3) b,b’,b’’ 171.7(12.9)b,a’,b’’ 
B. finegoldii SX2 6535.8(62.2) b,b’,b’’ 83.5(17.4)a,a’,b’’ 
Purified lipopolysaccharide (1 mg/ml) (LPS) from S. enterica serotype Typhimurium was used as a 
positive control. Non-stimulated cells were also evaluated as controls of basal cytokine levels (DEMEN). 
Results are expressed as mean (SD) of duplicate measures determined in three independent experiments. 
Significant differences were established at P<0.05 by applying ANOVA and post hoc Tukey’ test. Means 
in the same columns with different letters were significantly different in relation to non-stimulated cells 
(a-b) or to LPS (a’-b’) or to B. uniformis CECT 7771 (a’’-b’’).  
 
Body weight gain, adipose tissue weight and biochemical parameters in obese mice  
   Body weight gain and total adipose tissue weight of mice after a 7-week intervention 
are shown in Table 3. The time course body weight gain over the intervention period is 
also shown in Figure 1. HFD-fed mice experienced significant greater weight gain 
compared to SD-fed mice from the first 4 weeks of treatment till the 7
th
 week. The 
weights of total adipose tissues were also statistically significantly greater in obese mice 
than in lean mice. The administration of B. uniformis CECT 7771 significantly reduced 
body weight gain in HFD-fed mice by the end of the intervention, but did not 
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significantly modify total adipose tissue weight (Table 3, Figure 1). No mice died and 
all of them remained healthy throughout the study. 
Serum concentrations of biochemical and hormonal parameters of metabolic 
relevance are shown in Table 3. The HFD induced a significant increase in all serum 
parameters analysed compared to SD-fed mice. The administration of B. uniformis 
CECT 7771 significantly reduced serum glucose, insulin, triglycerides and cholesterol 
concentrations in HFD-fed mice but not in SD-fed mice. In HFD-fed mice B. uniformis 
CECT 7771 reduced cholesterol levels by 18% and triglyceride levels by 25%.  B. 
uniformis CECT 7771 administration also significantly lowered fasting glucose levels 
(Table 3) and improved glucose tolerance, reducing the maximum peak and the area 
under the curve during the oral glucose tolerance test (Figure 2). The increased serum 
leptin concentrations induced by the HFD were significantly reduced by the 
administration of B. uniformis CECT 7771 (Table 3).  
The specific concentrations of cholesterol and triglycerides present in total lipids 
extracted from the liver were also analysed (Table 3). The HFD induced a significant 
increase in both parameters compared to levels in SD-fed mice, while the administration 
of B. uniformis CECT 7771 significantly reduced triglycerides and cholesterol 
concentrations in the liver of HFD-fed mice (Table 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Biometric parameters and serum and liver biochemistry in mice fed either a high-fat diet (HFD) or standard diet (SD), supplemented or not with B. 
uniformis CECT 7771. 
Outcome measure 
Experimental Groups 
SD HFD SD+B HFD+B 
P- value 
HFD vs 
SD 
P- value 
(SD+B vs 
SD) 
P- value 
(HFD+B 
vs HFD) 
                                                 Mean         sd             Mean         sd               Mean         sd              Mean         sd 
Biometric parameters         
Body weight gain (%) 24.21 3.34 36.19 1.55 23.61 3.17 30.33 0.92 0.007* 0.890 0.005* 
Adipose tissue (g)/100g 
body weight 
0.06 0.04 0.15 0.03 0.03 0.02 0.14 0.04 0.016* 0.150 0.423 
Serum parameters            
Cholesterol (mg/dl) 120.00 13.67 176.02 14.91 128.22 11.91 143.97 17.29 <0.001* 0.222 0.003* 
Triglyceride (mg/dl) 130.31 11.56 156.99 27.47 129.77 13.94 118.21 10.04 0.041* 0.937 0.004* 
Glucose (mg/dl) 219.81 26.41 485.92 140.63 372.41 13.50 233.52 30.62 0.001* 0.237 0.002* 
Insulin (µg/l) 0.57 0.47 1.59 0.09 0.69 0.05 0.92 0.14 0.018* 0.892 0.018* 
Leptin (ng/ml) 8.07 1.12 18.28 4.28 6.80 1.23 12.98 3.24 <0.001* 0.048* 0.014* 
Liver lipids            
Cholesterol (mg/g ) 29.94 4.08 35.51 4.35 29.22 6.32 27.48 6.39 0.029* 0.801 0.024* 
Triglyceride (mg/g ) 22.93 13.03 45.99 11.53 31.36 4.76 34.17 9.51 <0.001* 0.142 0.039* 
SD: standard diet group (control) (n=6); SD+B: standard diet group receiving a daily dose of 5.0 x108 CFU B uniformis CECT 7771 by gavage for 7 weeks (n=6); HFD: high 
fat diet group (n=6); HFD+B: high fat diet group receiving a daily dose of 5.0x108 CFU B. uniformis CECT 7771 by gavage during 7 weeks (n=6). Body composition and 
biochemical parameters were determined after 7 weeks of intervention. Adipose tissue included epididymal and perirenal white adipose tissues. Values are expressed as 
means and standard deviation (sd) *Significant differences were established at P<0.050. 
 
  
 
Figure 1. Time course of relative body weight gain in control mice and mice with high fat diet-induced obesity, 
administered or not B. uniformis CECT 7771. SD: standard diet group (control) (n=6); HFD: high fat diet group 
(n=6); HFD+B: high fat diet group receiving a daily dose of 5.0x108 CFU B. uniformis CECT 7771 by gavage 
for 7 weeks (n=6). 
 
 
 
 
 
 
 
 
 
 
 
Time (weeks)
0 1 2 3 4 5 6 7 8
B
o
d
y
 w
e
ig
h
t 
g
a
in
 (
%
)
-20
-10
0
10
20
30
40
50
60
HFD+B 
HFD 
*
Time (weeks)
0 1 2 3 4 5 6 7 8
B
o
d
y
 w
e
ig
h
t 
g
a
in
 (
%
)
-20
-10
0
10
20
30
40
50
60
SD 
HFD 
**
*
*
*
                                                                                                                            Capítulo I 
56 
  
Figure 2. Glucose tolerance in control mice and mice with high fat diet-induced obesity, administered or not B. 
uniformis CECT 7771. SD: standard diet group (control) (n=6);; HFD: high fat diet group (n=6); HFD+B: high 
fat diet group receiving a daily dose of 5.0x108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n=6). A: 
Plasma glucose profile following 2 g/kg glucose oral challenge after 4 h fasting; B: Mean area under the curve 
measured between 0 and 120 min after glucose administration. 
 
Hepatic steatosis, adipocyte size, and fat absorption by enterocytes in obese mice  
   Figure 3 shows the effects on hepatic steatosis of the administration of B. uniformis CECT 
7771 to SD- or HFD-fed mice. The bacterial strain significantly reduced steatosis in HFD-fed 
animals, and also reduced lipid accumulation in the liver of SD-fed mice. The administration 
of B. uniformis CECT 7771 to SD mice significantly increased the number of hepatocytes 
with no steatosis (0-grade) and reduced those with steatosis grades 1 and 2. In HFD-fed 
animals, B. uniformis CECT 7771 administration contributed to increasing the number of 
hepatocytes with 0- and 1-grade steatosis and to reducing those with 2-and 3-grade steatosis.  
The effects of the intervention on adipocyte size on epididimal adipose tissue are shown in 
Figure 4. HFD induced a significant increase in adipocyte size in the following ranges 2000-
4000, 4000-6000 and 6000-7000 μm2, and reduced those of size <2000 μm2. The 
administration of B. uniformis CECT 7771 in SD-fed mice did not induce significant changes 
in adipocyte size, while a significant increase in the number of small adipocytes (< 2000) was 
observed in HFD-fed mice.  
The effects of the HFD and the administration of the bacterial strain on the number of fat 
micelles per enterocyte, which indicate dietary fat absorption, are shown in Figure 5. The 
HFD induced a significant increase in fat micelles in enterocytes, whereas the administration 
of B. uniformis CECT 7771 reduced these numbers. In the SD group, no significant changes 
were observed due to intervention with the aforementioned bacterium.  
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Figure 3. Determination of hepatic steatosis (hepatic histology) in control mice and mice with high fat diet-
induced obesity, administered or not B. uniformis CECT 7771. SD: standard diet group (control) (n=6); SD+B: 
standard diet group receiving a daily dose of 5.0 x108 CFU B. uniformis CECT 7771 by gavage for 7 weeks 
(n=6); HFD: high fat diet group (n=6); HFD+B: high fat diet group receiving a daily dose of 5.0x108 CFU B. 
uniformis CECT 7771 by gavage for 7 weeks (n=6).The fat vacuoles were measured in 100 hepatocytes of two 
liver tissue sections per mouse and scored for the severity of steatosis according to the following criteria: For 
grade-0 steatosis, no fatty hepatocytes; grade-1 steatosis, fat occupying less than 30% of the hepatocyte; grade-2 
steatosis, fat occupying less than 30 to 60 % of the hepatocyte; grade-3 steatosis, fat occupying more than 60 % 
of the hepatocyte.  
 
Photomicrographs 20X of representative HE-stained slides are shown.  (B) SD group, (C) SD+P group, (D) HFD 
group and (F) HFD+P group. Data are expressed as means ± SD and statistically significant differences are 
established at P<0.05.  
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 Figure 4. Distribution of adipocyte size in epididymal adipose tissue in control mice and mice with high fat 
diet-induced obesity, administered or not  B. uniformis CECT 7771 SD: standard diet group (control) (n=6); 
SD+B: standard diet group receiving a daily dose of 5.0 x108 CFU B. uniformis CECT 7771 by gavage for 7 
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weeks (n=6); HFD: high fat diet group (n=6); HFD+B: high fat diet group receiving a daily dose of 5.0x108 CFU 
B. uniformis CECT 7771 by gavage for 7 weeks (n=6). Adipocyte cell sizes were expressed as area ranges and 
were the following: <2000, 2000-4000, 4000-6000 and 6000-7000 µm2. Data are expressed as means ± SD and 
statistically significant differences are established at P<0.05. 
Photomicrographs 20X of representative HE-stained slides are shown.  (B) SD group, (C) SD+B group, (D) 
HFD group and (E) HFD+B group. 
 
 
 
Figure 5.  Number of fat micelles per enterocyte in control mice and mice with high fat diet-induced obesity, 
administered or not  B. uniformis CECT 7771 SD: standard diet group (control) (n=6); SD+B: standard diet 
group receiving a daily dose of 5.0 x108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n=6); HFD: high 
fat diet group (n=6); HFD+B: high fat diet group receiving a daily dose of 5.0x108 CFU B. uniformis CECT 
7771 by gavage for 7 weeks (n=6). The relation fat micelles/enterocyte was determined in 100 cells from two 
sections of the small intestine of each mouse by counting ten 100X light microscope fields. Data are expressed as 
means ± SD and statistically significant differences are established at P<0.05. 
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Macrophage functionality 
   The results of cytokine production by LPS-stimulated peritoneal macrophages from SD- and 
HFD-fed mice with and without B. uniformis CECT 7771 supplementation are shown in 
Figure 6. Obesity induced by a HFD led to a decrease in cytokine TNF-α production by 
peritoneal macrophages stimulated with LPS compared to macrophages of SD-fed mice 
(Figure 6A). The administration of B. uniformis CECT 7771 significantly increased the ability 
of LPS-stimulated macrophages to produce TNF- in HFD-fed mice but not in SD-fed mice 
(Figure 6A). The HFD did not affect the ability of LPS-stimulated macrophages to produce 
the anti-inflammatory cytokine IL-10 and this feature was not modified by the administration 
of B. uniformis CECT 7771 (Figure 6A). The oxidative burst in peritoneal macrophage after 
uptake of a microbial extract was also studied to analyse effects on phagocytosis function 
(Figure 6B). The results indicated that the oral administration of B. uniformis CECT 7771 
stimulated this function in macrophages in both SD- and HFD-fed mice (Figure 6B). 
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Figure 6. Cytokine production in LPS-stimulated peritoneal macrophages and phagocytosis function of control 
mice and mice with high-fat diet induced obesity, administered or not B. uniformis CECT 7771. SD: standard 
diet group (control) (n=6); SD+B: standard diet group receiving a daily dose of 5.0 x108 CFU B. uniformis 
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CECT 7771 by gavage for 7 weeks (n=6); HFD: high fat diet group (n=6); HFD+B: high fat diet group receiving 
a daily dose of 5.0x108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n=6). In the cytokine production 
study, peritoneal macrophages were stimulated with purified lipopolysaccharide (LPS) from S. enterica serotype 
Typhimurium (Figure 6A). Non-stimulated peritoneal macrophages were evaluated as controls of basal cytokine 
levels. In the phagocytosis study (Figure 6B), evidence of oxygen-radical production by macrophages was 
determined by the NBT test after in vitro interaction with a bacterial extract. Figure 6A:  TNF- α and IL-10 
cytokines produced by LPS-stimulated macrophages; Figure 6B: % NBT (+) cells. Data are expressed as mean 
and standard deviation of duplicate measurements determined in two independent experiments. Statistically 
significant differences of data are established at P<0.05. 
± SD of duplicate measures determined in two independent experiments. Statistically significant differences of 
data are established at P<0.05. 
 
 
Dendritic cell (DC) functionality 
   The results of cytokine production by LPS-stimulated DC from SD- and HFD-fed mice, 
with and without B. uniformis CECT 7771 supplementation are shown in Figure 7A. The 
administration of B. uniformis CECT 7771 to obese and lean mice increased the ability of DC 
to produce TNF- in response to LPS stimulation, which was significantly reduced by the 
HFD (Figure 7A). In HFD-fed mice, IL-10 production by LPS-stimulated DCs was 
significantly increased. The administration of B. uniformis CECT 7771 increased IL-10 
values even more in HFD-fed mice and also stimulated this cytokine production in SD-fed 
mice (Figure 7A). 
The results of the influence of HFD-induced obesity and oral administration of B. 
uniformis CECT 7771 on the ability of matured DCs to priming a T cell proliferative response 
are shown in Figure 7B. DCs from SD-fed mice were able to induce a significant increase in 
T cell proliferation in comparison to T cells alone (data not shown) in all the examined DC:T 
cell ratios. The HFD impaired the capacity of DCs to induce a T cell proliferation response, 
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but this function was restored by B. uniformis CECT 7771 administration, and the strongest 
effects were obtained at 1:4 DC:T ratio. This effect was also significant for SD-fed mice.  
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 Figure 7. Influence of LPS stimuli on cytokine production and activation of T-lymphocyte proliferation by 
dendritic cells (DCs) generated from control mice and mice with high-fat diet induced obesity, administered or 
not B. uniformis CECT 777. SD: standard diet group (control) (n=6); SD+B: standard diet group receiving a 
daily dose of 5.0 x108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n=6); HFD: high fat diet group 
(n=6); HFD+B: high fat diet group receiving a daily dose of 5.0x108 CFU B. uniformis CECT 7771 by gavage 
for 7 weeks (n=6). In the cytokine production study, DCs were stimulated with purified lipopolysaccharide 
(LPS) from S. enterica serotype Typhimurium (Figure 7A). Non-stimulated DCs were evaluated as controls of 
basal cytokine levels. In the lymphocyte proliferation study (Figure 7B), matured DCs were used for priming a 
T-cell proliferative response at the following LT/CD ratios: 1:1, 1:2, 1:4. Lymphocyte proliferation was 
measured with the cell proliferation ELISA BrdU-colorimetric assay. Figure 7A: TNF- α and IL-10 cytokines 
produced by LPS-stimulated CDs; Figure 7B: Lymphocyte proliferation. Data are expressed as means. 
 
Microbiota composition and inflammatory properties 
   The composition of the faecal microbiota in SD- and HFD-fed mice is shown in Table 4. 
The HFD led to reductions in the gene copy numbers of most of the bacterial groups analysed, 
including Lactobacillus, C. coccoides and C. leptum groups and the genus Bifidobacterium. 
This diet also caused increases in gene copy numbers of members of the Enterobacteriaceae 
family. In HFD-fed mice, B. uniformis CECT 7771 administration increased the gene copy 
numbers of the genera Bacteroides and Bifidobacterium and the group C. coccoides and 
reduced those of members of the Enterobacteriaceae family, partially restoring the alteration 
of the microbiota associated with the HFD. In SD fed mice, the administration of the strain 
led to an increase in the gene copy numbers of total bacteria the genera Bacteroides and 
Bifidobacterium and the group C. leptum. The numbers of the C. coccoides group followed 
the same trend, but the differences were not significant.   
To evaluate whether these changes in the microbiota could modify the inflammatory 
signals coming from the gut in the different mouse groups, the ability of faecal samples to 
induce the production of cytokines by immunocompetent cells in vitro was evaluated (Figure 
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8A and 8B). Stool samples from HFD-fed mice induced a higher production of TNF-α than 
those from SD-fed mice by macrophages (Figure 8A) and DCs (Figure 8B), indicating that 
the HFD induced an increase in the pro-inflammatory signals coming from the gut. The 
administration of B. uniformis CECT 7771 significantly reduced the production of this pro-
inflammatory cytokine in macrophages stimulated with stools from both mouse groups 
(Figure 8A), and in DCs stimulated with stools from the HFD group. Therefore, this bacterial 
strain seems to have ability to reduce the inflammatory properties of the gut content, although 
confirmatory studies measuring additional inflammatory markers in the gut would be required 
to draw definitive conclusions. 
In macrophages (Figure 8A) and DCs (Figure 8B), stool samples of HFD-fed mice induced 
significantly higher production of the anti-inflammatory cytokine IL-10 than those from SD-
fed mice, which could be due to the activation of regulatory mechanisms to counteract other 
inflammatory signals inducing also TNF-α. Stool samples from both SD and HFD mouse 
groups administered B. uniformis CECT 7771 induced a significant increase in IL-10 
production by DCs, suggesting an increase in the anti-inflammatory signals emanating from 
the gut (Figure 8B). These B. uniformis CECT 7771-related effects were not detected in 
macrophages (Figure 8A).  
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 Figure 8. Influence of stool samples from mice fed standard diet or high-fat diet, supplemented or not with B. 
uniformis CECT 7771, on cytokine production by peritoneal macrophages and dendritic cells (DCs) from control 
mice. SD: standard diet group (control) (n=6); SD+B: standard diet group receiving a daily dose of 5.0 x108 CFU 
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B. uniformis CECT 7771 by gavage for 7 weeks (n=6); HFD: high fat diet group (n=6); HFD+B: high fat diet 
group receiving a daily dose of 5.0x108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n=6). In the 
cytokine production study, peritoneal macrophages (Figure 8A) and DCs (Figure 8B) were stimulated with stool 
stimuli. Non-stimulated peritoneal macrophages and DCs were evaluated as controls of basal cytokine levels. 
Figure 8A:  TNF- α and IL-10 cytokines produced by stool-stimulated peritoneal macrophages; Figure 8B: TNF- 
α and IL-10 cytokines produced by stool-stimulated CDs. Data are expressed as means ± SD of duplicate 
measures determined in two independent experiments. Statistically significant differences of data are established 
at P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Microbiota composition of stool samples from different mouse groups analysed by quantitative PCRa 
Bacterial group Experimental groups 
 SD            HFD            SD+B          HFD+B 
 
aMedian (IQR) aMedian (IQR) p- valueb aMedian (IQR) p- valuec aMedian (IQR) p- valued 
Total bacteria  10.8 (10.6 – 11.1)   10.5 (10.3– 10.8) 0.092 11.4 (11.3 – 11.6)  0.010*  11.0 (10.7 – 11.2)  0.629 
Lactobacillus group   9.9 (9.4 – 10.5)   9.4 (9.2 – 9.5) 0.040*   9.6 (9.3 –9.8)  0.470   9.7 (9.5 – 10.1)  0.936 
Bacteroides spp.   8.4 (8.3 – 8.6)   8.7 (8.3 – 9.0) 0.674   9.3 (9.1 – 9.5)  0.004*   9.0 (8.8 – 9.3)  0.016* 
Bifidobacterium spp.   7.1 (6.8 – 7.2)   6.0 (5.9 – 6.3) 0.004*   8.1  (7.9 - 8.3)  0.013*   7.5 (7.0 – 7.7)  0.004* 
C. leptum group   8.4 (8.3 – 8.6)   7.6 (7.5 – 7.7) 0.004*   9.6 (9.4 – 9.8)  0.004*   8.5 (8.1 – 8.7)  0.936 
C. coccoides group   9.1 (8.6 – 9.3)   8.4 (8.2 – 8.5) 0.016*   9.9  (9.4 – 10.0)  0.054   9.6 (9.4 – 9.7)  0.036* 
Enterobacteriaceae   7.3 (7.2 – 7.7)   8.1 (7.8 – 8.2) 0.019*   8.1 (7.6 – 8.2)  0.052   7.9 (7.5 – 8.0)  0.029* 
SD: standard diet group (control) (n=6); SD+B: standard diet group receiving a daily dose of 5.0 x108 CFU B.  uniformis CECT 7771  by gavage for 7 weeks (n=6); HFD: 
high fat diet group (n=6); HFD+B: high fat diet group receiving a daily dose of 5.0x108 CFU B. uniformis CECT 7771  by gavage during 7 weeks (n=6). aData are expressed 
as median of log gene copy numbers of each bacterial group per gram of stools  . bSignificant differences in log gene copy numbers of specific bacterial groups between SD 
and HFD mouse groups. c Significant differences in  log gene copy numbers of specific bacterial groups between SD and SD+B mouse groups. dSignificant differences in log 
gene copy numbers of specific bacterial groups between HFD and HFD+B groups.* Significant differences were established at P<0.05 by using Mann–Whitney U-test.
Discussion   
   This study has provided direct evidence of the metabolic and immune effects of B. 
uniformis CECT 7771 in a murine model of diet-induced obesity. Previous scientific research 
was controversial and had only established associations between either a lean phenotype or 
weight loss with increased intestinal numbers of the phylum Bacteroidetes phylum, or the 
groups Bacteroides-Prevotella  or Bacteroides fragilis [9, 11-20]. The selection of the specific 
strain tested was based on its lower inflammatory potential in vitro on macrophages compared 
to strains belonging to other intestinal Bacteroides spp. This trait could be relevant in the 
context of obesity since it is considered a chronic inflammatory disorder, largely mediated by 
macrophage infiltration in the adipose tissue [31-33]. Our study demonstrated that B. 
uniformis CECT 7771 induced low TNF-α production and the highest IL-10 production in 
comparison with other strains of Bacteroides spp. Our recent studies also demonstrated that 
the prevalence of B. uniformis CECT 7771 in the gut of infants is favoured by breast-feeding 
[22] and breast-feeding seems to protect against later development of obesity as compared to 
formula feeding [34-35]. Considering these data altogether led us to hypothesise that the oral 
administration of B. uniformis CECT 7771 could exert beneficial effects in an obesity model 
as reported in this study.  
In our mouse obesity model, B. uniformis CECT 7771 administration induced significant 
modifications in total body weight gain by the end of intervention, although differences in 
adipose tissue weight were not significant, probably due to the limited duration of the trial. 
However, B. uniformis CECT 7771 increased the number of small adipocytes in obese mice, 
which could precede fat weight reduction. In contrast, colonisation of germ-free mice by B. 
thetaiotaomicron and Methanobrevibacter smithii augmented de novo lipogenesis and 
adiposity [36]. In this context, it was proposed that gut colonisation by the conventional 
microbiota or by specific commensal bacteria (e.g. B. thetaiotaomicron) provides the 
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hydrolases necessary to utilise complex polysaccharides and the resulting products are 
absorbed or metabolised to short-chain fatty acids. Subsequently, the latter are delivered to 
the liver and converted to triacylglycerols and, then, part of these de novo synthesised lipids 
are deposited in adipocytes [37-38].  In addition, it was considered that the gut microbiota 
could reduce the fasting-induced adipose factor (Fiaf, also known as angiopoietin-like 
protein-4), a secreted lipoprotein lipase (LPL) inhibitor [8], promoting storage of fatty acids 
released by the LPL in the host adipose tissue, but this mechanism was not confirmed in a 
latter study [39]. Although the animal models used in our and previous studies are not 
comparable, the results suggest that different Bacteroides spp. might exert different effects on 
energy balance and lipid storage. 
In obese subjects there is also an increased flux of free fatty acids to the liver due to their 
excessive accumulation in the adipose tissue and to the inability of insulin to suppress 
lipolysis in adipocytes due to insulin resistance, which leads to steatosis or fatty liver disease 
[40-41]. In our study, the administration of B. uniformis CECT 7771 significantly reduced 
steatosis in obese animals and, interestingly, also reduced liver cholesterol and triglyceride 
accumulation. In obese mice, liver steatosis and adipocyte hypertrophy is reported to be 
related to an increased energy input via intestinal lipid absorption, which is transported in the 
form of chylomicrons to peripheral tissues [42]. Therefore, we also analysed the number of fat 
micelles per enterocyte, which partly represents fat absorbed from the diet. B. uniformis 
CECT 7771 administration significantly reduced the fat micelles in enterocytes, particularly 
in obese mice, indicating that this is a mechanism by which this bacterial strain exerts a 
positive effect on liver steatosis and serum lipids. Other studies also demonstrated that 
specific lactobacilli or bifidobacterial strains might reduce the absorption of dietary fat, but 
this is the first evidence that a Bacteroides strain exerts this effect depending on the diet [40, 
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42, 43]. However, the involvement of other mechanisms, such as reduction of endogenous 
biosynthesis or reduction of lipid uptake by hepatocytes, cannot be disregarded [44]. 
Dyslipidaemia is also a frequent feature of obese subjects, with the most common being 
hypertriclyceridaemias and hypercholesterolaemias [45,46], which are also induced by HFD 
in mice. In this study, HFD-fed mice showed higher values of serum cholesterol and 
triglyceride levels than SD-fed mice. B. uniformis CECT 7771 administration reduced serum 
cholesterol and triglyceride levels in HFD-fed mice. These effects could also be partially 
related to a reduction of dietary fat absorption and possibly to modulation of the expression of 
genes and proteins involved in lipid homeostasis in the gut and liver, as indicated previously.  
Hyperglycaemia and insulin resistance are also frequently associated with obesity in humans 
[1-2]. This feature was also reproduced in our mice obesity model, which showed increased 
fasting glucose levels and reduced glucose tolerance.  However, the administration of B. 
uniformis CECT 7771 significantly improved the response to an oral glucose challenge and 
reduced the fasting glycaemia in parallel to insulin, suggesting an improvement in glucose 
metabolism and insulin sensitivity.  Comparisons between germ-free and conventional mice 
indicated that the commensal microbiota, as a whole, induced hyperglycaemia and insulin 
resistance [44] while administration of antibiotics causing a reduction in the intestinal 
bacterial load improved oral glucose tolerance in ob/ob and HFD-fed mice [47,48]. The 
adverse effects attributed to the microbiota were related to a reduction of AMPK activity and, 
therefore, reduced insulin-stimulated glucose transport in muscles [38] and to a reduction of 
inflammatory signals coming from the gut, such as LPS from Gram-negative bacteria and its 
correlation with intestinal and plasma TNF-α levels [49]. Nevertheless, our present and 
previous studies indicated that intervention in the gut ecosystem with specific strains may 
improve diet-induced insulin sensitivity and glucose tolerance above the commensal 
microbiota effects [40].  
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Obesity often manifests with hyperleptinemia, associated with leptin resistance, leading to 
different central and peripheral adverse effects, including increased hunger and reduced 
energy expenditure as well as increased lipid accumulation [50]. B. uniformis CECT 7771 
administration also led to reduced leptin levels in obese mice, which could be indicative of an 
improvement in leptin function or sensitivity, leading to lower leptin production [51]. These 
improved leptin levels could be related to improvements in glucose tolerance and reduced 
serum concentration since leptin favours insulin function [52]. In addition, the reduction of 
serum leptin levels could also be related to increases in smaller adipocytes and reduced liver 
steatosis in HFD-fed mice supplemented with the bacterial strain due to the role of leptin in 
fat accumulation in peripheral tissues [53].  
Our study also showed that B. uniformis CECT 7771 administration improves immune 
function of macrophages and DCs, which is particularly important in obese mice. It is known 
that macrophage function is impaired in obesity, showing reduced phagocytic capacity and 
oxidative burst, which has been linked to increased susceptibility to infections of obese 
subjects [54,55]. In our study, phagocytic function of macrophages was slightly reduced by 
the HFD, in accordance with others authors [56]. However, B. uniformis CECT 7771 
administration stimulated the oxidative burst of macrophages in both HFD and SD-fed mice. 
Our study also demonstrates that B. uniformis CECT 7771 administration improved the ability 
of macrophages and DCs to produce cytokines in response to a pathogenic bacterial stimulus 
(LPS).  B. uniformis CECT 7771 also restored the capacity of DCs to present antigens and 
stimulate T lymphocyte proliferation. A functional deficiency of DCs in ob/ob mice has also 
been described previously, suggesting that this damage could be generalised to the more 
frequent forms of obesity [41]. Altogether, our data indicates that B. uniformis CECT 7771 
can improve innate and adaptive defence mechanisms against infections in diet-induced 
obesity.  
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This study also confirms that diet has a tremendous impact on the intestinal microbiota 
composition and supports the hypothesis that its modulation through the use of dietary 
strategies could ameliorate the metabolic and immune dysfunctions associated with 
imbalanced diets. The HFD reduced gene copy numbers of Gram-positive bacteria, including 
Bifidobacterium spp. and C. coccoides group, in accordance with previous studies [49]. Our 
study also demonstrates that the HFD increased the gene copy numbers of enterobacteria, 
while B. uniformis CECT 7771 slightly reduced these numbers and increased those of C. 
coccoides group, Bifidobacterium spp. and Bacteroides spp. Furthermore, the B. uniformis 
CECT 7771-related changes in microbiota contributed to reducing the gut inflammatory 
signals, which could affect other peripheral tissues involved in obesity. In this context, 
endotoxins (LPS) from enterobacteria, present in the gut, have been shown to play an 
important role in the development of insulin resistance and non-alcoholic fatty liver disease 
[57]. In ob/ob mice, reductions of intestinal E. coli numbers by antibiotic treatment were 
associated with the reduction of metabolic endotoxaemia and inflammatory status as well as 
with improvements in insulin resistance [58]. Another recent study also reported that positive 
effects of prebiotics (oligofructose and inulin mixture) on body weight and fat and related 
metabolic parameters could be due to their ability to increase numbers of both bacteroides and 
bifidobacteria in the gut microbiota of obese JCR:LA-cp rats [13].  These changes were 
related to modifying the expression of anorexigenic and orexigenic peptides, but the role of 
each bacterial group on such effects remains unclear.  
In conclusion, the results support the hypothesis that the B. uniformis CECT 7771 
modulates the metabolic and immune dysfunction induced by HFD at least in mice. The study 
provides direct evidence of the potential beneficial roles played by B. uniformis CECT 7771 
in obesity, bringing us one step ahead of the mere associations inferred from previous 
observational studies. Therefore, the use of dietary strategies targeting the gut ecosystem may 
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be an additional tool to control metabolic disorders. However, further studies are required to 
support this hypothesis and to reveal plausible mechanisms of action of the specific bacterial 
strain used in this preclinical study. Furthermore, safety issues should also be addressed 
before proposing the possible use of the strain tested in humans.  
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RESUMEN 
Antecedentes y Objetivos: Bifidobacterium pseudocatenulatum CECT 7765 modula la ganancia 
de peso corporal y parámetros metabólicos en ratones alimentados con una dieta rica en grasa 
(HFD), pero su mecanismo de acción aún no se conoce. Para poder profundizar en los efectos de 
esta cepa bacteriana, nosotros hemos investigado los cambios moleculares en el hígado del ratón 
alimentado con la HFD y suplementado con la bacteria. 
Métodos y Resultados: La expresión de genes y de niveles proteicos fueros analizados en 
hígados de ratones C57BL/6 machos a los que se les administró de modo subcrónico una dieta 
rica en grasa y B.pseudocatenulatum CECT 7765. Nuestros resultados muestran que el consumo 
de dicha cepa bacteriana modula la expresión de genes fundamentales que intervienen en la 
regulación del metabolismo energético y en el transporte de lípidos que se ven afectados por la 
HFD. Así B. pseudocatenulatum CECT 7765 contrarresta significativamente los efectos causados 
por la dieta rica en grasa en el transportador de ácidos grasos CD36, en la transcripción del 
regulador de la biosíntesis de lípidos EGR1 y en reguladores del metabolismo de la glucosa, 
IGFB2 y PPP1R3R, ambos tanto a nivel de mRNA como a nivel proteico. Dicha cepa bacteriana 
induce los niveles del transcrito de PNPLA2, una lipasa que hidroliza triglicéridos. En ratones 
alimentados con dieta estándar (SD), la administración de  B.pseudocatenulatum CECT 7765 
provoca una regulación hacia una disminución en la expresión de los genes INSIG1 y HMGCR; 
ambos críticamente implicados en la regulación de los niveles de colesterol. 
Conclusión: B.pseudocatenulatum CECT 7765 modifica la expresión de reguladores claves en el 
metabolismo y transporte de ácidos grasos y colesterol, niveles de lípidos y niveles de glucosa en 
el hígado; lo que corrobora unos efectos metabólicos positivos de esta cepa bacteriana. 
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ABSTRACT  
Background and Aims: Bifidobacterium pseudocatenulatum CECT 7765 moderates body 
weight gain and metabolic parameters in high-fat diet-(HFD)-fed mice but, the mechanisms of 
action are not yet understood. To further understand the effects of this bacterial strain, we have 
investigated the molecular changes in the liver of mice fed a HFD and supplemented with the 
bacteria.   
Methods and Results: Gene expression and protein levels were measured in the liver of 
C57BL/6 male mice following sub-chronic consumption of a HFD and B. pseudocatenulatum 
CECT 7765. Our results show that the consumption of this bacterial strain modulated the 
expression of key genes involved in the regulation of energy metabolism and transport of lipids 
that were affected by the HFD. B. pseudocatenulatum CECT 7765 significantly counteracted 
the effects caused by the HFD on the fatty acid transporter CD36, the transcription regulator of 
lipid biosynthesis EGR1 and the regulators of glucose metabolism, IGFBP2 and PPP1R3B, both 
at the mRNA and protein levels. The bacterial strain slightly induced the transcript levels of 
PNPLA2, a lipase that hydrolyzes triglycerides in lipid droplets. In the standard diet (SD)-fed 
mice, the administration of B. pseudocatenulatum CECT 7765 donwregulated the expression of 
INSIG1 and HMGCR critically involved in the regulation of cholesterol levels.  
 Conclusion: B. pseudocatenulatum CECT 7765 modified the expression of key regulators of 
fatty acid and cholesterol metabolism and transport, lipid levels and glucose levels in the liver 
which supports the beneficial metabolic effects of this bacterial strain.  
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Introduction 
High-energy diets and sedentary lifestyles have dramatically increased the incidence of obesity 
and associated disorders (dyslipidemia, insulin resistance, diabetes, and hepatic steatosis) 
stressing the need for therapeutic and preventive measures [1]. Emerging evidence indicates that 
the gut microbiota play a role in the development of obesity [2]. Changes of the relative 
abundance of bacterial phyla, gender or species have been positively or negatively associated 
with obesity and metabolic alterations [3, 4]. Animal studies have provided evidence for plausible 
mechanisms by which the microbiota could play a role in body weight regulation, including 
metabolic, immune and neuroendocrine effects [4]. Thus it has been suggested that intentional 
manipulation of the gut microbiota could be an additional strategy to reduce the incidence of 
obesity and associated disorders. 
Diet has an important effect on gut microbiota composition, which opens the possibility of 
using dietary intervention strategies to induced modifications that can have an impact on human 
physiology. In recent years, several bacterial strains (Lactobacillus spp. or Bifidobacterium spp.) 
have been evaluated in different animal models of obesity and metabolic alterations to understand 
their possible role but differing effects have been reported [3, 5]. For instance, Lactobacillus 
reuteri ATCC PTA 4659 reduced body-weight gain, adipose and liver weights and serum insulin 
levels in Apoe–/– mice [6] whereas Lactobacillus ingluviei increased body and liver weight and 
inflammation in BALB/c mice [7]. Strains of the genus Bifidobacterium have been generally 
shown to exert beneficial effects against obesity in animal models [8–10]. For example, a mixture 
of Bifidobacterium spp. (including Bifidobacterium pseudocatenulatum) exerted anti-obesity and 
lipid lowering effects in HF-fed rats [9] and very recently, B. pseudocatenulatum CECT 7765 
was reported to ameliorate metabolic and immunological alterations related to obesity in HFD-
fed mice [10]. 
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Knowledge of the molecular mechanisms underlying the effects of probiotics is very limited. 
The gut microbiota interacts and regulates complex and multiple host metabolic, signalling and 
inflammatory pathways connecting the gut with the liver, adipose tissue, pancreas, muscle and 
brain [11, 12]. Evidence is also accumulating that gut microbiota manipulation causes significant 
molecular changes in the liver related to its lipid and glucose metabolism regulatory roles [13].  
Herein, we have applied a transcriptomic approach using Affymetrix microarrays to identify key 
genes significantly altered in the liver by a HFD and by simultaneous administration of B. 
pseudocatenulatum CECT 7765 to progress in the understanding of the mechanisms of action of 
this strain in lipid and glucose metabolism.  
 
Methods  
Bacterial strain 
B. pseudocatenulatum CECT 7765 was grown in MRS broth (Scharlau, Barcelona, Spain) 
supplemented with 0.05% (w/v) cysteine (MRS-C Sigma, St. Louis, MO), and incubated at 37 ºC 
for 22 h under anaerobic conditions (AnaeroGen, Oxoid, Basingstoke, UK). Cells were harvested 
(6000×g for 15 min), washed twice in phosphate buffered saline (PBS, 130 mM sodium chloride, 
10 mM sodium phosphate, pH 7.4), and re-suspended in 10% skimmed milk for oral 
administration to mice. Aliquots of these suspensions were frozen in liquid nitrogen and stored at 
-80°C until used. The number of live cells after freezing and thawing was determined by colony-
forming unit (CFU) counting on MRS-C agar following 48 h incubation. More than 90% cells 
were alive upon thawing and no significant differences were found during storage (2 months). 
One fresh aliquot was thawed each new experiment to avoid variability in the viability of 
cultures.  
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Animals and diets  
Seven-week-old wild-type C57BL/6 male mice were purchased from Charles River 
Laboratories International (Barcelona, Spain). This study was conducted in strict accordance with 
the recommendations included in the Guide for the Care and Use of Laboratory Animals of 
University of Valencia (Central Service of Support to Research, University of Valencia, Spain) 
and the experimental protocol was approved by its Ethic Committee. Mice were housed in 
stainless-steel cages in a temperature-controlled (23 ºC) room with a 12 h light/dark cycle and 
40–50% relative humidity and fed a standard diet (SD) for 6 days before being assigned to the 
experimental groups (n= 5 animals per group) as follows: (a) a control group fed the SD; (b) an 
obese group fed a high-fat diet (HFD); (c) a group fed the SD plus a daily dose of B. 
pseudocatenulatum CECT 7765  (1×10
9
 CFU/day) by oral gavage (SD+P); and (d) an obese 
group fed the HFD and a daily dose of B. pseudocatenulatum CECT 7765 (1×10
9
 CFU/day) by 
oral gavage (HFD+P). This regime was maintained for 7 weeks. Mice had free access to sterile 
water. Diets characteristics are indicated in Supplemental Table 1. At the end of study, animals 
were anaesthetized with isoflurane (2%) by inhalation, bled by aortic puncture and sacrificed by 
cervical dislocation. All efforts were made to minimize suffering. The livers were rapidly 
removed, rinsed with cold PBS and one portion kept in RNA Later (Qiagen, Madrid, Spain) at –
80 °C for RNA isolation and another one directly frozen at –80 °C for protein determination. In 
order to minimize the variability of the liver samples we always removed the same fragment from 
the same lobule and processed it rapidly under the same conditions. 
 
RNA extraction  
Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen, Madrid, Spain), and 
quantified in a NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, 
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Wilmington, DE). Samples with a ratio Abs260/Abs280 between 1.8 and 2.1 and a concentration > 
100 ng/mL were used for microarrays. RNA was kept at –80 ºC until further analysis. 
 
Microarray Analysis 
RNA samples (n=5 per group) were hybridized on to the GeneChip® Mouse Gene 1.0 ST 
(Affymetrix, Santa Clara, CA, USA) following the manufacturer’s  protocol and using the 
GeneChip® Whole Transcript (WT) Sense Target Labelling protocol, the Ambion® WT 
Expression Kit (Life Technologies) and the WT terminal Labelling kit. Samples were hybridized 
for 16 h at 45 ºC, washed and stained in the Affymetrix Fluidics Station 450 and scanned using 
the GeneChip Scanner 3000. The CEL files were used to extract and normalize the data using 
Robust Multichip Average (RMA) implemented with RMA Sketch for 1.0 ST arrays in the 
GeneChip Expression Console software version 1.1.2 (Affymetrix). RMA-normalized data were 
tested for differential gene expression between groups using the Class Comparison tool and an 
empirical Bayes method (Limma) implemented with Babelomics 
(http://babelomics.bioinfo.cipf.es). Adjusted p-values were estimated by the false discovery rate 
(FDR, Benjamini & Hochberg). Probes differentially expressed between groups were defined as 
those with: 1) a p-value < 0.0030 (corresponding to an FDR adjusted p-value < 0.15) and 2) ratios 
≥ 1.2 (up-regulation) or ≤ 0.83 (down-regulation). Differentially expressed genes were uploaded 
into Ingenuity Pathway Analysis (IPA) software (Ingenuity
®
 Systems, Redwood City, CA) for 
functional analyses. Minimum information about a microarray experiment compliant data has 
been submitted to the Gene Expression Omnibus database: accession number GSE40638. 
 
RT- PCR analysis 
Primers and probes were selected from Assays-on-demand (Taqman system, Applied 
Biosystems, ABI, Madrid, Spain; Suplemental Table 2). One-step real-time RT-PCRs were run 
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on the ABI 7500 system following manufacturer’s conditions (reaction volume 25 µL, 
MicroAmp Optical 96-well plate, optical adhesive covers, and Taqman Universal Master Mix, 
ABI, Madrid, Spain). All assays for a particular gene were undertaken at the same time under 
identical conditions and in triplicate. The expression levels of target genes were normalized to 
ACTB (beta actin) using the standard curve method. 
 
Protein analysis 
Frozen liver samples ( 200 mg) were homogenized in ice-cold RIPA buffer (1× solution, 150 
mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, 
pH 8.0) (Sigma, Madrid, Spain) and centrifuged at 10000×g and 4 ºC for 10 min. Protein 
concentration was determined in the filtered supernatants by the Lowry´s method. The levels of 
IGFBP2, EGR1, and PPP1R3B were determined using the IGFBP2 Mouse ELISA Kit (Abcam, 
Cambridge, UK), EGR1 Mouse ELISA Kit (antibodies-online GMBH, Aachen, Germany) and 
PPP1R3B Mouse ELISA Kit (American Research Products, Inc. Waltham, MA, EEUU), 
respectively. For the extraction of CD36, the first supernatant was discarded and the pellet was 
incubated again with fresh RIPA buffer at 4 ºC for 1 min prior to a second centrifugation at 
10000×g and 4ºC for 10 min. The protein levels were determined using a CD36 Mouse ELISA 
Kit (Abcam, Cambridge, UK). Results are presented as pg/g or ng/g of tissue weight. 
 
Statistical analysis 
Results are expressed as the mean value ± SD. Differences between groups were established 
using an unpaired Student´s t-test. Results with a two-sided p-value <0.05 were considered 
statistically significant and p-values < 0.2 were considered indicative of a trend.  
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Results 
Effects of B. pseudocatenulatum CECT 7765 on liver gene expression  
Microarrays comparison between HFD-fed mice and SD-fed mice (effect of the HFD) and 
between HFD-fed mice supplemented with B. pseudocatenulatum CECT 7765 (HFD+P) and 
HFD-fed mice (effect of the bacterial strain on the HFD-fed mice) are shown in Supplemental 
Tables 3 and 4, respectively. Results revealed that only a small number of probes (< 2%) 
exhibited significant but moderate changes with ratios between 1.2 and 1.5 (upregulation) and 
between 0.5 and 0.8 (downregulation). Differential gene expression analysis between mice fed 
the SD+P and those fed the SD are also presented in Supplemental Table 5. Using the IPA 
software we identified several genes that were modulated by the HFD and (or) exposure to B. 
pseudocatenulatum CECT 7765 and that are critically involved in the regulation of lipid and 
carbohydrate metabolism in the liver in response to nutritional stimuli (Table 1): three key 
upstream transcription regulators PPARA, PPARGC1A, and EGR1 which interact with and (or) 
regulate other genes with crucial roles in lipid  transport (CD36, FABP5 and APOA4), synthesis 
and hydrolysis of lipids (HMGCR, INSIG1 and PNPLA2) and carbohydrate metabolism 
(PPP1R3B and IGFBP2). The HFD significantly increased the expression of CD36 and 
PPP1R3B which was downregulated by the bacterial strain. The HFD also markedly decreased 
the expression of EGR1 and IGFBP2 and the administration of B. pseudocatenulatum CECT 
7765 counteracted this effect. The intake of the bacterial strain with the SD did not alter 
significantly the expression of any of these four genes (Table 1; Supplemental Figure 1). The 
HFD downregulated the levels of HMGCR and INSIG1 and B. pseudocatenulatum CECT 7765 
did not appear to modulate these changes. However, the bacterial strain downregulated these two 
genes in mice fed the SD, more significantly for INSIG1. Also, PNPLA2 was not significantly 
modified by the HFD whereas the intake of B. pseudocatenulatum CECT 7765 both in HFD-fed 
mice and SD-fed mice slightly increased the expression of this gene (Table1; Supplemental 
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Figure 2). Our analysis also indicated that the HFD moderately induced the expression of PPARA 
and APOA4 and slightly downregulated PPARGC1A and FABP5 and that B. pseudocatenulatum 
CECT 7765 did not affect these genes (Table 1; Supplemental Figure 3). 
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Table 1 - Relative changes in the expression of selected target genes involved in metabolic 
regulation in the liver of male C57BL/6 mice fed a high-fat diet (HFD) or a standard diet (SD) 
alone or in the presence of B. pseudocatenulatum CECT 7765 (P) as determined by Affymetrix 
microarrays and quantitative real time RT-PCR. 
  Ratio HFD/SD Ratio HFD+P/HFD Ratio SD+P/SD 
Gene 
symbol 
IPA identified 
biological function(s) 
related to lipids and 
glucose metabolism 
Microarraysa RT-
PCRb 
Microarrays RT-
PCR 
Microarrays RT-PCR 
CD36 
 
Transmembrane 
protein involved in 
long chain fatty acid 
transport in 
hepatocytes. 
2.19 
(0.0002)c 
(0.062)d 
1.94 ± 
0.67 
(0.023)e 
0.73 
(0.009)  
(NS)  
0.59 ± 
0.37 
(0.095)  
1.08 
NC 
0.91 ± 
0.63 
NC 
PPP1R3B 
 
Regulation of glycogen 
metabolising enzymes 
in muscle and liver. 
Also associated with 
circulating LDL-
cholesterol. 
1.35 
(NS) 
(NS) 
2.42 ± 
0.52 
(0.003) 
0.76 
(0.002)  
(0.143)  
0.68 ± 
0.32 
(0.084)  
0.68 
(0.0001) 
(NS) 
1.06±0.72 
NC 
EGR1 
 
Transcription regulator 
implicated in the 
control of cholesterol 
biosynthetic genes in 
liver. 
0.33 
(NS) 
(NS) 
0.17 ± 
0.02 
(0.056)  
2.64 
(0.002)  
(0.139)  
7.68 ± 
0.17 
(0.001) 
0.69 
(0.079) 
(NS) 
0.46 ± 
0.12 
(NS) 
IGFBP2 
 
Regulation of glucose 
metabolism and 
diabetes. Reduced 
expression in obesity 
and Type 2 diabetes.  
0.48 
(0.008) 
(NS) 
0.40± 
0.11 
(0.006) 
1.50 
(0.0006) 
(0.094)  
1.64 ± 
0.13 
(0.089) 
0.97 
NC  
 
0.92 ± 
0.10 
NC 
HMGCR 
 
Catalyses a rate-
limiting step in 
cholesterol and sterols 
biosynthesis. 
0.59 
(0.012) 
(NS) 
0.23 ± 
0.10 
(0.002) 
1.33 
(0.003) 
(NS) 
0.78 ± 
0.18 
(NS) 
0.69 
(0.0005) 
(NS) 
0.78 ± 
0.23 
(0.167) 
INSIG-1 
 
Plays a critical role in 
regulating cholesterol 
concentrations in cells 
by preventing the 
activation of the genes 
for lipid biosynthesis. 
Binds to the HMG 
CoA reductase. 
0.73 
(NS) 
(NS) 
0.78 ± 
0.12 
(0.011) 
1.30 
(0.002) 
(0.143) 
0.91 ± 
0.10 
NC 
0.78 
(0.003) 
(NS) 
0.56 ± 
0.26 
(0.013) 
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a: Microarrays changes (n = 5 animals per group); b: RT-PCR values are shown as the mean ± SD (n = 5 animals per 
group); c: non adjusted p-value microarrays; d: FDR adjusted p-value microarrays (Benjamini-Hochberg); e: two-
sided p-value as determined by an unpaired Student´s t test; p-value <0.05 were considered statistically significant; 
p-values < 0.2 were considered indicative of a trend; (NS): Not significant; NC: No change: cut-off values  ≥ 1.2 (up-
regulation) or ≤ 0.83 (down-regulation).  
 
PNPLA2 Triacylglycerol lipase 
that catalyses the first 
step in the hydrolysis 
of triglycerides in 
lipids droplets.  
0.81 
(0.049)  
(NS) 
0.87 ± 
0.10 
NC 
1.06 
NC 
 
1.27 ± 
0.23 
(0.085) 
1.30 
(0.002) 
(NS) 
1.53 ± 
0.33 
(0.049) 
PPARA 
 
Nuclear receptor 
involved in lipid and 
glucose metabolism 
regulation: negative 
regulation of 
cholesterol storage, 
glycolysis and 
sequestering of 
triglyceride. 
1.20 
(0.004) 
(0.176) 
1.24 ± 
0.20 
(0.104) 
1.07 
(NS) 
(NS) 
0.87 ± 
0.45 
NC 
0.91 
NC 
NC 
0.89 ± 
0.43 
NC 
PPARGC1A 
 
Transcriptional 
coactivator that 
regulates genes 
involved in oxidative 
energy metabolism.  It 
provides a direct link 
between external 
physiological stimuli 
and the regulation of 
mitochondrial 
biogenesis.  
0.64 
(0.00001) 
(0.016) 
0.82 ± 
0.23 
(0.150) 
0.90 
NC 
 
0.61 ± 
0.47 
(NS) 
0.89 
NC 
 
1.05 ± 
0.31 
NC 
APOA4 Secreted to the 
extracellular space. 
Member of LDL and 
HDL particles. 
Regulates cholesterol, 
APOB, chylomicron, 
triacylglycerol, D-
glucose. Regulated by 
PPARA. 
1.64 
(0.00001) 
(0.016) 
1.51 ± 
0.48 
(0.171) 
1.10 
NC 
NC 
1.01 ± 
0.74 
NC 
1.05 
NC 
NC 
0.81 ± 
0.21 
(NS) 
FABP5 
 
Intracellular lipid 
carrier. High 
specificity for fatty 
acids. Regulates D-
glucose, 
triacylglycerol, 
cholesterol. 
0.20 
(0.0001) 
(0.031) 
0.43 ± 
0.35 
(NS) 
1.61 
(0.074) 
(NS) 
0.80  ± 
0.84 
(NS) 
1.20 
(NS) 
(NS) 
0.86 ± 
0.64 
NC 
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Effects of B. pseudocatenulatum CECT 7765 on protein levels 
CD36, EGR1, IGFBP2 and PPP1R3B proteins were expressed in the liver of control animals 
as follows: IGFBP2 (51.4 ± 17.3 g/g) >> CD36 (0.78 ± 0.04 g/g) >> PPP1R3B (4.2 ± 0.9 
ng/g) > EGR1 (1.7 ± 0.5 ng/g). In agreement with the mRNA changes, CD36 increased (Fig. 1a, 
fold-change: 1.2 ± 0.1, p = 0.015) whereas EGR1 and IGFBP2 decreased (Fig. 1b and 1c, -1.7 ± 
0.5, p = 0.027 and -1.7 ± 0.6, p = 0.037, respectively) in the HFD-fed mice compared to the SD-
fed mice. The administration of B. pseudocatenulatum CECT 7765 decreased the protein levels 
of CD36 (-1.2 ± 0.1, p = 0.019) and moderately upregulated the protein levels of EGR1 and 
IGFBP2 (1.5 ± 0.3, p = 0.192 and 1.5 ± 0.3, p = 0.141, respectively). In contrast to the observed 
gene expression induction of PPP1R3B, the levels of this protein were significantly reduced in 
the HFD-fed mice (-1.5 ± 1.1, p = 0.024) and this effect was also counteracted by the 
administration of B. pseudocatenulatum CECT 7765 (1.4 ± 0.3, p = 0.046) (Fig. 1d). 
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Figure 1. Whisker box plots of protein levels for CD36, PPP1R3B, EGR1 and IGFBP2 in the liver of C57BL/6 
male mice fed a standard diet (SD), a high-fat diet (HFD), a high-fat diet supplemented with the bacterial strain B. 
pseudocatenulatum CECT 7765 (1×109 CFU/day) (HFD+P) and a standard diet supplemented with the bacterial 
strain B. pseudocatenulatum CECT 7765 (1×109 CFU/day) (SD+P). Differences between groups were established 
using an unpaired Student´s t-test.  
 
Discussion 
In this study, sub-chronic supplementation with B. pseudocatenulatum CECT 7765 to HF-fed 
C57BL/6J mice was found to modulate the liver expression of key molecules involved in the 
regulation of energy metabolism and transport of lipids that were affected by the HF intake. 
Although the liver tissue contains different types of cells and this heterogeneity may contribute to 
the variance of the gene expression data, hepatocytes constitute 60 % of the tissue and perform 
the majority of metabolic liver functions [14] and thus, our results may be indicative of changes 
occurring mostly in hepatocytes.  
We herein report that the hepatic steatosis and serum hyperlipidemia induced in the C57BL/6J 
mice by the HFD [10] is accompanied by hepatic molecular changes that indicate an activation of 
lipid metabolism (Fig. 2a). The key metabolic sensors PPARA and PPARGC1A are known to 
interact and to regulate molecules such as acyl CoA oxidase, acyl CoA synthase, enoyl-CoA 
hydratase, malic enzyme, HMG-CoA synthase, carnitine palmitoyl trasnferase 1a (CPT1a), fatty 
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acid transporters and APO proteins, involved in the regulation of fatty acid β-oxidation and 
cholesterol synthesis and transport [15, 16]. In agreement with this, our microarray data show that 
the HFD alters the expression of many of these genes in the mice liver (Supplemental Table 3) 
and indicates a general effect in fatty acid and cholesterol metabolism. Particularly, the HFD 
upregulated the levels of CD36, involved in fatty acid uptake and reported to be induced in 
subjects with steatosis [17], which could partially explain the hepatic fat accumulation in the 
HFD-fed C57BL/6 mice [10]. The transcription factor EGR1 is predominantly expressed in the 
liver and binds to cholesterol biosynthetic promoters [18]. Its repression has been linked to 
reduced cholesterol levels in association with the downregulation of HMGCR, a rate-limiting 
enzyme in the synthesis of cholesterol [18, 19] also regulated by INSIG1 [19]. In accordance with 
a general decrease of cholesterol synthesis, our data confirmed the downregulation of EGR1, 
INSIG1 and HMGCR in the HFD-fed mice. Additionally, the HFD upregulated the mRNA levels 
of APOA4, a major component of lipoprotein particles and activator of lecithin-cholesterol acyl 
transferase [20], which suggests an activation of cholesterol reverse transport.  
Administration of B. pseudocatenulatum CECT 7765 to mice fed a HFD diminished the levels 
of serum cholesterol, triglycerides, glucose, insulin and leptin as well as liver steatosis [10] and 
some of the detected hepatic gene and protein changes associated to the intake of the bacteria 
support these effects (Fig. 2b). Notably, the bacteria counteracted the effects of the HFD on the 
expression of CD36, both at the transcript and protein levels. In agreement with these results, a 
strain of Pediococcus pentosaceus LP28 was also reported to reduce body weight and liver 
adiposity and to downregulate the transcript levels of CD36 in a high-fat mice model [21]. CD36 
repression has been related to the prevention of fatty liver [17] and, thus, reduction of the levels 
of this molecule and of fatty acid uptake may be an important contributor to the lipid lowering 
effects of potential probiotics. Also, PNPLA2 which encodes for adipose triacyl glycerol lipase 
(ATGL) and whose inactivation increases triglycerides accumulation in the liver [22] was slightly 
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upregulated by B. pseudocatenulatum CECT 7765 which may be indicative of an increase in the 
hydrolysis of triglycerides contributing to depletion of fat in the liver. The bacteria also 
upregulated the mRNA and protein levels of EGR1 in the HF-fed mice which suggest an 
activation of cholesterol metabolism. On the other hand, the transcript levels of HMGCR or 
INSIG1 were downregulated by B. pseudocatenulatum CECT 7765 only in the SD-mice. In a 
similar manner, L. plantarum KCTC3928 has been reported to lower plasma cholesterol and 
triglycerides in mice and to marginally downregulate the transcription of HMGCR [23]. 
Inhibition of HMGCR is a major pharmacologic strategy to lower plasma cholesterol levels [19] 
and probiotics may provide a dietary alternative with a similar mechanism of action.  
 
 
Figure 2. Ingenuity Pathways Analysis (IPA) software was used for the exploration of molecular interactions and to 
build a graphical representation of a liver cell displaying the specific selected target genes involved in lipid and 
glucose metabolism and that were: a) associated to the high-fat intake and b) to the administration of the bacterial 
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strain B. pseudocatenulatum CECT 7765 in high-fat fed C57BL/6 male mice. Up- or down-regulation is indicated by 
the thick arrows. Some of the reported interactions between these molecules are indicated by thin arrows. The 
expected biological outcome in diagram a) associated to the high-fat intake would be a general increase in fatty acid 
and cholesterol metabolism, transport and lipids storage. Molecules represented: CD36: CD36 molecule 
(thrombospondin receptor); EGR1, early growth response 1; IGFBP2 insulin-like growth factor binding protein 2; 
PPP1R3B: protein phosphatase 1, regulatory (inhibitor) subunit 3B; PNPLA2: patatin-like phospholipase domain 
containing 2; INSIG1: insulin induced gene 1; HMGCR: 3-hydroxy-3-methylglutaryl-Coenzyme A reductase; 
PPARA: peroxisome proliferator activated receptor alpha; PPARGC1A: peroxisome proliferative activated receptor, 
gamma, coactivator 1 alpha ; APOA4: apolipoprotein A-IV; FABP5: fatty acid binding protein 5; ER: endoplasmic 
reticulum. 
 
Two other important genes involved in hepatic energy metabolism are IGFBP2 and PPP1R3B. 
IGFBP2 is implicated in glucose regulation and insulin sensitivity. Its overexpression diminishes 
weight gain, fasting glucose, insulin and leptin levels [24] and may protect against the 
development of obesity by HFDs. In our study, the mRNA and protein levels of IGFBP2 were 
upregulated by the bacteria in the HF-fed mice in accordance with the reported reduction of 
weight, glucose, insulin and leptin levels [10]. PPP1R3B is also involved in the control of plasma 
glucose by regulating glycogen metabolism [25] and is associated with altered serum cholesterol 
and hepatic steatosis [26, 27]. The mRNA and protein levels of PPP1R3B were also found to be 
significatively modulated by the HF-intake and counteracted by the bacterial strain. At the time 
point of the analysis the regulation of this transcript was not correlated with the change in protein 
which may be due to differences in the rate of transcription and translation and (or) in the half-
life and stability of the mRNA and protein molecules [28].  
In relation to our work, the anti-obesity effects of prebiotics with an effect on the microbiota 
and the regulation of molecular markers in the liver of C57BL/6J mice have been investigated. In 
agreement with the metabolic benefits and hepatic response to B. pseudocatenulatum CECT 
7765, C57BL/6J mice treated with a mixture of fermentable dietary fructo-oligosaccharides 
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(FOS) exhibited higher caecal Bifidobacterium spp., reduced hepatic triglycerides mediated by 
PPARA stimulation of fatty acid oxidation and lessened cholesterol accumulation by inhibiting 
cholesterol synthesis [29]. Also recently, multiple-targeted analysis using microarrays has been 
implemented to investigate the molecular changes induced by L. ingluviei in liver. The authors 
reported a significant increase in body and liver weight concomitant with multiple changes in 
genes involved in metabolism and inflammation [7]. We have also applied microarrays to analyze 
the molecular changes associated with the intake of B. pseudocatenulatum CECT 7765 with a 
HFD and have shown a general modulation of the metabolism of lipids and carbohydrates in the 
liver, more specifically, in the regulation of fatty acid and cholesterol metabolism and transport, 
lipid levels and glucose levels through the regulation of key genes and proteins. These results 
corroborate some of the general adaptative responses promoted in the liver by the intake of 
probiotics. The precise mechanism(s) that links the oral intake of B. pseudocatenulatum  CECT 
7765 with the liver molecular response remains to be elucidated and it may involve altering lipid 
absorption as suggested previously [10] as well as the alteration of cell-signaling mechanisms via 
the gut-brain axis. A full understanding of these processes will require the combination of multi-
organ and multi-target analyses in an extended time scale. 
 
Supplementary data related to this article can be found online at 
http://dx.doi.org/10.1016/j.numecd.2013.04.011. 
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Supplemental Table 1: The Standard Diet (SD) and the High-Fat Diet (HFD) were provided by 
Harlan Laboratories (Madison, WI 53744-4220). Kcal provided by the diet main constituents 
(%). 
 SD HFD 
Reference CA.170481 - AIN-76A Purified Diet-
Rats/Mice 
TD.06414 - Adjusted Calories 
Diet - 60/Fat,  
Protein 18.8 % kcal 18.4 % kcal 
Carbohydrate 68.8 % kcal 21.3 % kcal 
Fat 12.4 % kcal (3.8 kcal/g) 60.3 % kcal (5.1 kcal/g) 
 
 
 
Supplemental Table 2: Primers and probes selected from Assays-on-demand (Taqman system, 
Applied Biosystems, ABI, Madrid, Spain) for RT-PCR analyses. 
Gene Symbol Gene name Assay 
APOA4 apolipoprotein A-IV Mm00431814_m1 
PPARGC1A peroxisome proliferative activated receptor, 
gamma, coactivator 1 alpha 
Mm01208835_m1 
PPARA peroxisome proliferator activated receptor alpha Mm00440939_m1 
CD36 CD36 antigen Mm01135198_m1 
IGFBP2 insulin-like growth factor binding protein 2 Mm00492632_m1 
EGR1 early growth response 1 Mm00656724_m1 
HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase 
Mm01282499_m1 
PNPLA2 patatin-like phospholipase domain containing 2 Mm00503040_m1 
INSIG1 insulin induced gene 1 Mm00463389_m1 
FABP5 fatty acid binding protein 5 Mm00783731_s1 
PPP1R3B protein phosphatase 1, regulatory inhibitor; 
subunit 3B 
Mm01202257_m1 
ACTB beta actin Mm00607939_s1 
 
 
 
 
 
 
 
      
 
 
 
Bifidobacterium pseudocatenulatum CECT 7765 reduces obesity-
associated inflammation by restoring the lymphocyte-macrophage 
balance and gut microbiota structure in high-fat-diet fed mice  
Moya-Pérez Angela, Neef Alexander, Sanz Yolanda* 
  
Microbial Ecology and Nutrition Research Group, Institute of Agrochemistry and Food 
Technology (IATA), National Research Council (CSIC), Valencia, Spain. 
 
PLoS ONE. Received September 2014; accepted April 2015 
Keywords: Obesity, inflammation, Bifidobacterium, gut microbiota, next generation sequencing 
 
 
 
 
 
 
 
 
 
 
 
Capítulo III                                                                                                                                                                                                                     
110 
 
RESUMEN 
Antecedentes y Objetivos: El papel de la disbiosis intestinal en la inflamación sistémica asociada 
a la obesidad a través de la diafonía con tejidos está aún bajo debate. Nuestro objetivo fue 
dilucidar los mecanismos por los que, al intervenir a nivel intestinal con una bifidobacteria, se 
podría reducir la inflamación sistémica y mejorar ciertas alteraciones metabólicas en ratones 
alimentados con una dieta rica en grasa (HFD). 
Métodos: Ratones machos adultos de la cepa C57BL-6 fueron alimentados con una dieta estándar 
(SD) o con una dieta rica en grasa (HFD), suplementados o no con Bifidobacterium 
pseudocatenulatum CECT 7765, durante 14 semanas. 
Linfocitos, macrófagos y las concentraciones de citoquinas/quimioquinas fueron cuantificadas/os 
en sangre, intestino, hígado y tejido adiposo usando un “Multiplex Assay”. Parámetros 
bioquímicos en suero fueron determinados por ELISA y ensayos enzimáticos. Las muestras de 
histología fueron evaluadas por tinción hematoxilina-eosina. Y la microbiota analizada por 
pirosecuenciación del 16S rRNA y por PCR cuantitativa. 
Resultados: B. pseudocatenulatum CECT 7765 reduce la  inflamación sistémica asociada a la 
obesidad restableciendo el balance entre células T reguladoras (Tregs) y linfocitos B y 
reduciendo citoquinas proinflamatorias de la inmunidad adaptativa (IL-17A) y la innata (TNF-α) 
así como la endotoxemia. 
A nivel intestinal, la administración de la bifidobacteria parcialmente restablece las alteraciones 
que la dieta rica en grasa había causado sobre la microbiota, reduciendo la abundancia de 
Firmicutes y el LPS de Proteobacterias; paralelamente junto con reducciones de células B, 
macrófagos y citoquinas (IL-6, MCP-1, TNF-α, IL-17A), que podrían contribuir a efectos 
sistémicos. 
En tejido adiposo, la administración de nuestra cepa bacteriana reduce los niveles de células B 
mientras que en el hígado el tratamiento conlleva un aumento de las Tregs; y se ven afectadas 
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también diferentes citoquinas (MCP-1 y IP-10 en tejido adiposo y INF-γ y IL-1β en hígado). Pero 
en ambos tejidos, la bifidobacteria reduce los macrófagos inflamatorios y las concentraciones de 
TNF-α e IL-17A. 
Todos estos efectos fueron acompañados de reducciones en la ganancia de peso corporal y de 
reducción en los niveles de colesterol, triglicéridos, glucosa e insulina en suero, así como se 
observa una mejora en la tolerancia oral a la glucosa y a la sensibilidad a la insulina en ratones 
obesos. 
Conclusiones: Mostramos evidencias de los mecanismos de inmunidad celular por los que la 
cascada inflamatoria asociada a la obesidad inducida por dieta es revertida como consecuencia de 
la administración de una bacteria intestinal concreta; y estos efectos son asociados con una 
modulación de la estructura de la microbiota intestinal. 
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ABSTRACT  
Background/Objectives: The role of intestinal dysbiosis in obesity-associated systemic 
inflammation via the cross-talk with peripheral tissues is under debate. Our objective was to 
deciphering the mechanisms by which intervention in the gut ecosystem with bifidobacteria could 
reduce systemic inflammation and improve metabolic derangements in obese high-fat diet 
(HFD)-fed mice.  
Methods: Adult male wild-type C57BL-6 mice were fed a standard diet or high-fat diet (HFD), 
supplemented with placebo or Bifidobacterium pseudocatenulatum CECT7765, for 14 weeks. 
Lymphocytes, macrophages and cytokine/chemokine concentrations were quantified in blood, 
gut, liver and adipose tissue using bead-based multiplex assays. Serum biochemical parameters 
were determined by ELISA and enzymatic assays. Histology was assessed by hematoxylin-eosins 
staining. Microbiota was analyzed by 16S rRNA gene pyrosequencing and quantitative PCR.   
Results: B. pseudocatenulatum CECT 7765 reduced obesity-associated systemic inflammation 
by restoring the balance between regulatory T cells (Tregs) and B lymphocytes and reducing pro-
inflammatory cytokines of adaptive (IL-17A) and innate (TNF-α) immunity and endotoxemia. In 
the gut, the bifidobacterial administration partially restored the HFD-induced alterations in 
microbiota, reducing abundances of Firmicutes and of LPS-producing Proteobacteria, paralleled 
to reductions in B cells, macrophages, and cytokines (IL-6, MCP-1, TNF-α, IL-17A), which 
could contribute to systemic effects. In adipose tissue, bifidobacterial administration reduced B 
cells whereas in liver the treatment increased Tregs and shifted different cytokines (MCP-1 plus 
IP-10 in adipose tissue and INF-γ plus IL-1β in liver). In both tissues, the bifidobacteria reduced 
pro-inflammatory macrophages and, TNF-α and IL-17A concentrations. These effects were 
accompanied by reductions in body weight gain and in serum cholesterol, triglyceride, glucose 
and insulin levels and improved oral glucose tolerance and insulin sensitivity in obese mice.  
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Conclusions: Here, we provide evidence of the immune cellular mechanisms by which the 
inflammatory cascade associated with diet-induced obesity is reversed by administration of a 
specific intestinal bacterium and that the effects were associated with modulation of gut 
microbiota structure.  
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Introduction 
   Obesity has become a major global health challenge due to its increasing prevalence and the 
associated health risks [1].Obesity results from a positive energy imbalance associated with 
alterations in the metabolic-immune axis, leading to chronic low-grade inflammation [2]. The 
inflammatory process is characterized by infiltration of macrophages and lymphocytes in the 
adipose tissue and other peripheral organs. This is accompanied by an imbalance in the cytokine 
network with increased production of pro-inflammatory cytokines and adipokines, which 
contribute to associated metabolic dysfunctions, such as insulin resistance [3]. White adipose 
tissue has been considered the main contributor to systemic inflammation in obesity. 
Inflammation of this tissue is mediated by increased infiltration of macrophages and the ratio of 
“classically activated macrophages” (M1) to “alternatively activated macrophages” (M2), which 
produced pro-inflammatory (e.g.  TNF-α, IL-1β and IL-6) and anti-inflammatory (IL-10 and IL-
4) cytokines, respectively [4]. Obese adipose tissue is also characterized by increased infiltration 
of B cells and shifts in CD8+/CD4+ T lymphocytes and reduced CD4+ regulatory T (Treg) cells 
[5-7].  The adipose tissue is also thought to provide an immediate source of free fatty acids and 
pro-inflammatory cytokines (e.g. TNF-α, IL-6, and IL-1β) to the liver, which may trigger hepatic 
inflammation [8,9]. A connection between visceral fat and intestinal inflammation has also been 
identified in Crohn disease [8,10]. However, whether adipose tissue or intestinal inflammation is 
the origin of systemic inflammation associated with diet-induced obesity is under debate [8,9,11]. 
   The gut microbiota interacts and regulates multiple host metabolic and immunologic pathways, 
some of which could mediate the communication between the gut and other distal organs, such as 
the liver [8,12,13] and the adipose tissue [8,14]. Studies in animal models have provided evidence 
for a role of the microbiota in bodyweight regulation by influencing energy extraction, 
inflammation and neuroendocrine secretions [15]. Thus intentional manipulation of the gut 
microbiota could be an additional strategy to reduce the incidence of obesity and its 
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comorbidities. In human observational studies, reduced numbers of Bifidobacterium spp. have 
been associated with the development of overweight [15]. Moreover, dietary interventions based 
on the use of potential probiotics or prebiotics, leading to increase the numbers of 
Bifidobacterium spp., in the gut have demonstrated pre-clinical efficacy, by ameliorating some of 
the obesity-associated metabolic alterations and immune dysfunction in animal models [16,17]. 
Nevertheless, the mechanisms by which specific intestinal bacteria may reduce systemic and 
peripheral tissue inflammation associated with diet-induced obesity are largely unknown, 
particularly regarding their potential ability to regulate components of adaptive immunity.  
   This study is based on the hypothesis that B. pseudocatenulatum CECT 7765 can reduce HFD-
induced intestinal inflammation, thereby helping to ameliorate systemic and peripheral tissue 
inflammation and to improve metabolic function. To this end, we orally administered B. 
pseudocatenulatum CECT 7765 to mice with HFD-induced obesity and monitored its effects on 
the intestinal ecosystem and on immune cell infiltration and inflammatory and metabolic markers 
in serum and different tissues (adipose tissue, gut, and liver).  
 
Methods and Materials 
Bacterial strain and culture conditions 
Bifidobacterium pseudocatenulatum CECT 7765 was originally isolated from stools of breast-
fed infants and identified by sequencing of amplified 16S rDNA regions as described previously 
[17]. This strain was initially selected among other isolates as potential probiotic for preventing 
obesity-associated inflammation on the basis of its anti-inflammatory properties in a macrophage 
cell line [17]. The bacterial strain was grown in MRS broth (Scharlau, Barcelona, Spain) 
supplemented with 0.05% (w/v) cysteine (MRS-C) (Sigma, St. Louis, MO), and incubated at 37 
◦C for 24 h under anaerobic conditions (AnaeroGen, Oxoid, Basingstoke, UK). Cells were 
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harvested by centrifugation (2,000 g for 15 min), washed twice in phosphate buffered saline 
(PBS, 130 mM sodium chloride, 10 mM sodium phosphate, pH 7.4), and re-suspended in 10% 
skimmed milk for oral administration to mice. Aliquots of these suspensions were frozen in liquid 
nitrogen and stored at -80°C until used. The number of live cells after freezing and thawing was 
determined by colony-forming unit (CFU) counting on MRS-C agar after 48 h incubation. For 
each strain tested, more than 90% cells were alive upon thawing and no significant differences 
were found during storage time (2 months). One fresh aliquot was thawed for every new 
experiment to avoid variability in the viability of cultures. 
 
Animals, diets and experimental design  
Adult (aged 6–8 week) male wild-type C57BL-6 mice were purchased from Charles River 
Laboratories (L'Arbresle Cedex, France). In the adaptation period (7 days), animals of each 
experimental group were housed together in a stainless-steel cage in a temperature-controlled (23 
ºC) room with a 12-h light/dark cycle and 40–50% relative humidity and were fed a standard diet 
(SD) ad libitum. Then, mice were randomly divided into four groups (n=10 mice per group) as 
follows: (1) control mice receiving a SD plus placebo (10% skimmed milk)  (SD group); (2) 
obese mice receiving a high-fat diet (HFD) plus placebo (HFD group); (3) control mice receiving 
SD and a daily dose of 1 x10
9 
CFU B. pseudocatenulatum CECT 7765 (SD+Bif group); (4) obese 
mice receiving HFD and a daily dose of 1 x10
9 
CFU B. pseudocatenulatum CECT 7765 
(HFD+Bif group) by oral gavage.  
This regime was maintained for fourteen weeks. To induce obesity, mouse groups 2 and 4 
were switched from the SD (CA.170481 - AIN-76A Purified Diet-Rats/Mice, Harlan 
Laboratories, Madison, WI 53744-4220) administered during the adaptation period to a HFD 
(TD.06414 - Adjusted Calories Diet - 60/Fat [lard 31% and soybean oil 3%] Harlan Laboratories, 
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Madison, WI 53744-4220) for 14 weeks. The HFD provided 18.4% kcal as protein, 21.3% kcal as 
carbohydrate and 60.3% kcal as fat (5.1 kcal/g), whereas the SD provided 18.8% kcal as protein, 
68.8% kcal as carbohydrate and 12.4% kcal as fat (3.8 kcal/g). Mice had free access to water and 
feed.  
   Experiments were carried out in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the University of Valencia (Central Service of 
Support to Research [SCSIE], University of Valencia, Spain) and the study protocol was 
approved by its Ethical Committee.  
   Body weight was measured once a week. Faecal samples were collected a few days before 
slaughter. After 14weeks of dietary intervention animals were fasted for 16 h, anaesthetized with 
isoflurane and sacrificed by cervical dislocation. For analysis of hormonal and metabolic 
parameters, blood samples were collected in tubes, two for each animal, containing EDTA, one of 
them was centrifuged (2,000 g for 10 min at 4 ºC) and the supernatant (serum) was kept at -20 
°C, the other one was used for blood cell flow cytometry analysis. The left parts of liver and 
white adipose tissue (epididymal) and small intestine (ileo) were suspended in phosphate buffered 
saline solution (PBS,130 mM sodium chloride and 10 mM sodium phosphate, pH 7.4) and kept at 
4ºC until processing for further flow cytometry analysis. Moreover, liver and white adipose tissue 
(epididymal) sections were fixed in 10% neutral formalin buffered solution for histological 
analysis. The right parts of liver, white adipose tissue (epididymal) and small intestine (ileo) were 
suspended in RNA Later (Qiagen, Madrid, Spain) and kept at -80ºC for cytokine quantification. 
 
Hormonal and metabolic parameter analyses 
Serum leptin concentration was determined by the Assay Max Mouse Leptin ELISA kit 
(Assay pro, LLC; Ireland) with a sensitivity threshold of 0.3 ng/mL. Biochemical parameters 
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were also quantified in serum using enzymatic kits for glucose (Glucose Liquid Kit), cholesterol 
(Cholesterol Liquid kit) and triglycerides (Triglyceride Liquid kit, all from Química Analítica 
Aplicada SA, Spain), according to the manufacturer’s instructions. Insulin was measured using a 
Rat/Mouse ELISA kit (Merck Millipore, Germany) with a sensitivity threshold of 0.2 ng/mL. The 
enzymes aspartate amino-transferase (AST) and alanine aminotransferase (ALT) were measured 
using two assay kits from BioVision (Milpitas, USA) both with a sensitivity threshold of 10mU.   
 
Oral glucose tolerance test (GTT) and intraperitoneal insulin sensitivity test (ITT) 
The GTT was performed in vivo after 13 weeks of dietary intervention. The GTT was 
performed after 6 h of food deprivation, after which 2.0 g/kg body weight glucose was 
administered orally to the mice. Blood samples were taken with heparinised capillary tubes from 
the saphenous vein at baseline and 15, 30, 45, 60 and 120 minutes after oral glucose 
administration. Plasma glucose levels were analysed with glucose test strips (AscensiaEsyfill, 
Bayer, Tarrytown, NY; USA) and a glucometer (Ascensia VIGOR, Bayer Tarrytown), with a 
detection level ranging from 30 to 550 mg glucose/dl. The area under the glucose curve (AUC) 
was estimated by plotting the glucose concentration (mg/dl) versus time (min). 
The IST was conducted after 6 h of food deprivation, followed by intraperitoneal injection of 
1.5 U/kg body weight insulin (Humulin®R, Eli Lilly,Egypt) and then glucose was administered 
orally as described above. Blood glucose was measured as described for the GTT.  
 
Histology of liver and white adipose tissues  
Paraffin-embedded tissues were sectioned to a thickness of 4–5 µm and fixed to glass slides. 
Slides were deparaffinised and stained with hematoxylin-eosin. The severity of steatosis was 
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determined in 100 hepatocytes of two liver tissue sections per mouse and scored as follows: grade 
0 when fat was not detected in hepatocytes; grade 1when fat occupied less than 30% of 
hepatocytes; grade 2 when fat occupied between 30 and 60% of hepatocytes; grade 3, when fat 
occupied more than 60% of hepatocytes as described previously [17]. 
Adipocyte cell sizes were measured in 100 cells of two sections of epididymal adipose tissue 
per mouse and adipocyte cell sizes were expressed as area ranges using the following ranges: 
<2000, 2000–4000, 4000–6000 and 6000–7000 µm2, as described previously [17].  All 
parameters were measured in a NIKON Eclipse 90i Microscopic, using the NIS Elements BR 2.3 
basic research software (Kingston, Surrey, KT2 5PR, England). All histological analyses were 
conducted by an experienced histologist in a blind fashion. 
 
Cytokine quantification in serum and different tissues  
   Frozen tissues (small intestine, liver and adipose tissue) were weighed and homogenized using 
a Tissue Ruptor (Qiagen, Madrid, Spain) in RIPA buffer (1× solution, 150 mM NaCl, 1.0% 
IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0) (Sigma, 
Madrid, Spain). This method enables efficient cell lysis and protein solubilisation while avoiding 
protein degradation and interference with the proteins immunoreactivity. These samples were 
incubated for 10 min, homogenised with Tissue Ruptor (Qiagen, Madrid, Spain) at 4ºC for 1 min 
and centrifuged at 10,000×g, at 4 ºC for 5 min. Supernatants were stored at -80ºC until analysed.  
For cytokine quantification, the Mouse/Rat Basic Kit Flow Cytomix BMS8440FF combined 
with a bead-based Analyte Detection Assay for each cytokine (FlowCytomix Simplex Kits; 
eBioscience, Affymetrix Company, Viena, Austria) were used.  Cytokines were quantified with a 
FACS Canto cytometer (Becton, Dickinson and Company, NJ, USA). The following cytokines 
and chemokines were analysed: IFN-γ, IL-6, TNF-α, IL-10, MCP-1, IL-18, IL-4, IL-1β and IP-10 
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(eBioscience, Affymetrix Company, Viena, Austria). Sensitivity thresholds for each cytokine 
were: 6.5 pg/ml for IFN-γ, 2.2 pg/ml for IL-6, 2.9 pg/ml for TNF-α, 13.3 pg/ml for IL-10, 42 
pg/ml for MCP-1, 116.9 pg/ml for IL-18, 0.7 pg/ml for IL-4,, 34.3 pg/ml for IL-1β and 9.8 pg/ml 
for IP-10. Also IL-17 was analysed using a Mouse IL-17A ELISA kit (eBioscience, Affymetrix 
Company, Viena, Austria) with a sensitivity threshold of 4 pg/mL. Data are presented as pg 
cytokine/g of tissue weight or ml for serum samples.  
 
Lymphocyte and macrophage populations and TLR4 and TLR2 expression  
Epididymal white adipose tissue, a well-accepted source of intra-abdominal fat, mesenteric 
lymph nodes (MLN) from small intestine (ileo) and liver were used for immune-cell analysis by 
flow cytometry. For adipose tissue visible vessels and connective tissue were carefully removed 
and the tissue was washed extensively with PBS, minced with fine scissors and digested with 
0.1% collagenase from Clostridium histolyticum C6885 (Sigma Aldrich) at 37 ºC for 30 minutes. 
Liver and MLN were also cut in small pieces. Afterwards, cut tissues were passed through 40 µm 
mesh filters and washed in FACS buffer (PBS with 0.5% BSA and 2 mM EDTA). The 
suspension in the FACS buffer was left to settle-down into a conical tube for 5-6 minutes and 
then centrifuged at 400 g for 5 min to the cells to be analysed in the pellet. To evaluated 
lymphocyte populations in peripheral blood, 100 µl blood were re-suspended in antibody solution 
and incubated for 30 min in darkness; then, 2 ml cell lysis buffer for red blood cells (160 mmol 
NH, 0.1 mmol EDTA, 12 mmol NaHCO) were added and the samples were centrifuged (300 g 
for 5 min). Thereafter, the cell pellet was washed twice with 2 ml FACS buffer (PBS, 0.03% 
sodium azide, 0.1% bovine serum albumin) and centrifuged again. Then, the cell pellet was re-
suspended in 300 µl FACS buffer and analysed by flow cytometry [18]. 
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Cells were stained with the following fluorescent-labeled mouse monoclonal antibodies:  
CD3-FITC, CD4-PE and CD8-APC for detection of total lymphocytes (CD3+) and the T helper 
(CD3+CD4+CD8-) and T cytotoxic (CD3+CD4-CD8+) subtypes; CD4-APC, CD25-PE and 
Foxp3-FITC for detection of regulatory T cells (CD4+CD25+CDFoxp3+); CD19-eFluor®450 for 
detection of B cells (CD19+); and F/480-PE, CD11c-FITC and CD206-APC for detection of total 
macrophages (F4/80+), M1 macrophages (F4/80+CD11c+CD206-) and M2 macrophages 
(F4/80+CD11c-CD206+). The expression of TLR4 and TLR2 in small intestine was determined 
using the antibodies CD282-FITC and CD284-PE, respectively. All conjugated antibodies were 
from BD Biosciences (San Jose, CA, USA) except for CD206 that was from BioLegend (San 
Diego, CA, USA) and they were used according to the manufacturer’s instructions. Flow 
cytometry analyses were performed on a BD LSRFortessa
TM
 cytometer (Becton, Dickinson and 
Company, NJ, USA). Data were analyzed using BD FACS DIVA Software v.7.0. For detection 
of B cells with CD19-eFluor®450 flow cytometry analysis was performed on a BD 
FACSVerse
TM
 cytometer (Becton, Dickinson and Company, NJ, USA). Data were analyzed using 
BD FACS Suite Software v.1.0.3.2942. 
 
Detection of Gram-negative bacterial endotoxin  
Serum samples were extracted and instantly frozen at -20 ºC in glass vials. Lipopolysaccharide 
(LPS) endotoxin was quantified using a commercially available Limulus Amebocyte Lysate 
(LAL) Chromogenic Endotoxin Quantitation Kit (Thermo Scientific, Rockford, USA), according 
to the supplier’s instructions and as described previously [19].  
 
Microbiota composition analyses by pyrosequencing of 16S rDNA amplicons and 
quantitative PCR (qPCR) 
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Stool samples were weighed, diluted 1:5 (w/v) in PBS (pH 7.2), homogenised by shaking in a 
vortex and stored at -80 ºC till analysed. Aliquots (200µl) of this dilution were used for DNA 
extraction using the QIAamp DNA stool Mini kit (Qiagen, Hilden, Germany) after an initial step 
to favour cell disruption mechanically by mixing (1:1) the cell suspension with sterile 
zirconia/silica beads (diameter, 0.1mm) in  a bead-beater during 2 minutes.   
Extracted DNA was used to amplify the V3 to V5 regions of the 16S rRNA using the primers 
340F 5´- CCTACGGGAGGCAGCAG -3´ and 926R 5´- CCGTCAATTYMTTTRAGT -3´, a 
primer optimized to detect also bifidobacteria [20]. Pyrosequencing was carried out at 
LifeSequencing (Paterna, Spain) using primer A on a 454 Life Sciences Genome Sequencer FLX 
instrument (Roche, Basel, Switzerland) yielding in total 411,536 reads for the 32 sequenced 
samples.  
For sequence and clustering analysis original reads were filtered by length (> 300 bp) and 
quality (average Phred value > 25, no ambiguities) and then for chimeras using the mothur 
package [21] resulting in 251,002 classifiable sequence reads with an average length of 513 bp. 
Reads were identified at phylum, family and genus level using the Ribosomal Database Project 
(RDP) multiclassifier tool at an 80% confidence level [22]. Sequences that had confidence values 
below 0.8 were assigned to a group of "unclassified" organisms on the respective next higher 
taxonomic level. BlastN comparisons were performed to identify sequences on the species and 
genus level using a database containing 9,701 16S rRNA gene reference sequences (SILVA 111 
Living Tree Project dataset, www.arb-silva.de). Rarefaction curves and alpha-diversity indices 
(Sobs, Shannon, Simpson) were calculated with the mothur package [21]. For rarefaction curves 
1000 randomizations were applied. 
   Similarity of microbiota among different samples was evaluated by cluster analysis on genus 
level using the following two type of analysis. Bray-Curtis distances between microbiota of 
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individual samples were computed on the basis of the relative abundances of different genera and 
a heatmap was generated for 52 genera with abundances > 0.1% in at least one sample using the 
algorithm implemented in the "vegan" package for R (http://vegan.r-forge.r-project.org). Also, 
weighted UniFrac analysis was performed using QIIME [23] and the FastUniFrac tool at the URL 
http://unifrac.colorado.edu with 1289 sequence types with abundances of at least 10 reads that 
represented in total 65,104 reads. Read data are deposited at ENA under accession numbers 
ERR692069-ERR692100. 
   Bifidobacteria were also quantified using 16S rRNA gene-specific primers for this genus 
[24,25] by qPCR using LightCyclerH 480 SYBR Green I Master (Roche, USA) with a an ABI 
PRISM 7000- PCR sequence detection system (Applied Biosystems, UK), as described 
previously [26]. 
 
Statistical analyses 
All data were analyzed using Graph Pad Prism software (LaJolla, Ca, USA). Data distribution 
was analyzed by the Kolmogorov-Smirnov normality test. For normally distributed data 
differences were determined applying one or two-way ANOVA (as appropriate) with post hoc 
Bonferroni’s test. Non-normally distributed data were analyzed by applying the non-parametric 
Mann-Whitney U test. Statistically significant differences in taxon abundances obtained by 
pyrosequencing were determined using a permutation test (DAAG package version 1.18 for R). 
Correlations between variables were established with the Spearman rank correlation coefficient. 
In every case, p-values < 0.05 were considered statistically significant. 
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Results 
B. pseudocatenulatum CECT 7765 reduced metabolic alterations in obese mice  
   The administration of B. pseudocatenulatum CECT 7765 significantly reduced relative body 
weight gain by approximately 30% (p=0.002) in HFD-fed mice at the end of the intervention, but 
did not modify body weight gain in SD-fed mice (Table 1). After the intervention, HFD-mice 
supplemented with B. pseudocatenulatum CECT 7765 exhibited a slight reduction in the weight 
of epididymal adipose tissue compared to mice fed the HFD and placebo (p=0.082) (Table 1). 
Hepatic steatosis and adipocyte hypertrophy was also reduced by B. pseudocatenulatum CECT 
7765 in obese mice. The administration of B. pseudocatenulatum CECT 7765 to HFD-fed mice 
increased the number of small adipocytes (<2000 and 2000-4000 µm
2
) and reduced the largest 
ones (>6000 µm
2
) (Supplementary Table 1).The bifidobacteria also reduced hepatic steatosis in 
HFD-fed mice by increasing the number of hepatocytes with 0 and 1-grade steatosis and reducing 
those with 2 and 3-grade steatosis (Supplementary Table 2). The administration of B. 
pseudocatenulatum CECT 7765 to HFD-fed mice also led to a significant reduction in serum 
cholesterol (p=0.039), triglyceride (p=0.003) and glucose (p<0.001) concentrations by 
approximately 7, 50 and 30%, respectively, as compared to the levels reached in the HFD-fed 
mouse group receiving placebo (Table 1). B. pseudocatenulatum CECT 7765 administration also 
reduced the HFD-increased leptin (p=0.034) and fasting insulin levels (p=0.038, (Table 1). 
Amylase activity and ALT were higher in the obese mice than in the lean ones (p<0.001 and 
0.064, respectively) and the bifidobacterial strain slightly reduced the serum levels (p=0.075 and 
0.082), but none of the changes was statistically significant (Table 1). 
   B. pseudocatenulatum CECT 7765 also improved oral glucose tolerance (Figure 1a) and insulin 
sensitivity in obese mice (Figure 1b). The bifidobacterial strain administration reduced the 
increase of area under the curve of the GTT test (p=0.015; Figure 1a) and the area under the 
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curve of the ITT test (p=0.007; Figure 1b). B. pseudocatenulatum CECT 7765 administration to 
SD-fed mice did not modify these parameters. 
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Figure 1. Oral glucose tolerance (A) and insulin sensitivity (B) in different mouse groups after 14 weeks of dietary 
intervention. SD: standard diet group receiving placebo (control) (n=10); HFD: high fat diet group receiving placebo 
(n=10); HFD+Bif: high fat diet group receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 7765 by 
gavage (n=10 per group). Data are expressed as means of area under curve (AUC) from the plots of glucose 
concentration (mmol/L) versus time (min) (standard errors in bars). Statistically significant differences were 
determined by ANOVA with Bonferroni’s post hoc test a p< 0.050.  
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Table 1. Weight gain and serum hormonal and biochemical parameters in different mouse groups after 14 weeks of dietary intervention 
 
Outcome measure 
Experimental Groups 
SD HFD SD+Bif HFD+Bif 
P- value 
(HFD vs. 
SD) 
P- value 
(SD+ Bif 
vs. SD) 
P- value 
(HFD+ Bif 
vs. HFD) 
                                         Mean          se           Mean          se           Mean          se             Mean              se 
Body weight gain (%) 35.03 4.02 62.30 4.39 32.83 1.29 44.00 2.66 <0.001* 0.625   0.002* 
Epididymal adipose 
tissue weight (%) 
1.09 0.04 5.88 0.42 1.11 0.04 4.52 0.38   0.001* 0.175     0.082 
Cholesterol (mg/dl) 93.15 4.78 171.20 6.09 97.96 4.14 159.32 3.75 <0.001* 0.474   0.039* 
Triglyceride (mg/dl) 102.21 8.28   151.91 13.84 98.39 8.31 70.83 5.04   0.022* 0.777   0.003* 
Glucose (mg/dl) 161.93
 
10.51
 
251.25 8.97 147.20 6.89 176.05 11.22 <0.001* 0.241 <0.001* 
Insulin (ng/ml) 0.47 0.04 2.09 0.29 0.43 0.09 1.05 0.21   0.004* 0.234  0.038* 
Leptin (ng/ml) 9.29 0.37 36.53 2.70 8.84 0.62 29.78 2.57 <0.001* 0.596  0.034* 
Amylase (Um/ml) 0.91 0.01 1.08 0.02 0.89 0.02 0.99 0.04 <0.001* 0.395 0.075 
ALT (nmol/µl) 0.06 0.01 0.09 0.01 0.07 0.00 0.07 0.01 0.064 0.290 0.082 
SD: standard diet group receiving placebo (control); SD+Bif: standard diet group receiving a daily dose of 1 x109 CFU B. pseudocatenulatum CECT 7765 by 
gavage; HFD: high fat diet group receiving placebo; HFD+Bif: high fat diet group receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 7765 by 
gavage. *Data are expressed as mean and standard error of the mean (se) of each mouse group (n=10 per group). Significant differences were established by 
ANOVA and post hoc Bonferroni’s test at p<0.050. 
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B. pseudocatenulatum CECT 7765 reduces B lymphocyte and macrophage infiltration in 
adipose tissue of obese mice.  
   Effects of B. pseudocatenulatum CECT 7765 administration on lymphocyte and macrophage 
infiltration in adipose tissue from SD-fed mice and HFD-fed mice are shown in Figure 2. Obesity 
induced by HFD increased the CD8+/CD4+ ratio (p=0.020), while reducing the population of 
CD4+ T cells (p=0.027) and of Foxp3+ Tregs (p=0.001) within the CD3+ CD4+ T cell 
population in adipose tissue compared to SD-fed mice (Figure 2a-c). B.pseudocatenulatum CECT 
7765 administration did not influence Foxp3+Tregs, but tended to reduce the CD8+/CD4+ ratio 
(p=0.131)in the obese mouse group. B cells were significantly increased in HFD-fed mice 
(p=0.001) compared to SD-fed mice and this alteration was ameliorated by the administration of 
B. pseudocatenulatum CECT 7765 (p=0.047) (Figure 2d). 
   Infiltration of F4/80+ macrophages into adipose tissue and specially the M1/M2 ratio were 
increased by the HFD compared to the SD-fed mice (p=0.105 and p=0.003, respectively, Figure 
2e-f), indicating an increase in the proportion of classical activated macrophages (M1) that 
produce inflammatory cytokines. B. pseudocatenulatum CECT 7765 administration tended to 
reduce total macrophages (p=0.078) (Figure 2e) and normalized the M1/M2 ratio in HFD-fed 
mice (p=0.029) (Figure 2f). 
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Figure 2. Lymphocyte and macrophage infiltration into epididymal adipose tissue of different mouse groups after 
14 weeks of dietary intervention. SD: standard diet group receiving placebo (control); SD+Bif: standard diet group 
receiving a daily dose of 1 x109 CFU B. pseudocatenulatum CECT 7765; HFD: high fat diet group receiving 
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placebo; HFD+Bif: high fat diet group receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 7765. The 
ratio of CD8+/CD4+ of total CD3+, T regulatory (CD4+CD25+Foxp3+), T helper (CD3+CD4+CD8-) and B 
lymphocytes (CD19+) as well as total of macrophages (F4/80+) and their subtypes M1 (F4/80+CD11c+CD206-) and 
M2 (F4/80+CD11c-CD206+) were analysed in each mouse group (n=10 per group) by flow cytometry. Data are 
expressed as means and standard error (error bars) and statistically significant differences were determined by 
ANOVA with Bonferroni’s post hoc test a p <0.050.  
 
B. pseudocatenulatum CECT 7765 reduced total macrophage infiltration and the M1 
polarization, and increased Tregs in liver of obese mice.   
Effects of B. pseudocatenulatum CECT 7765 administration on lymphocyte and macrophage 
infiltration in liver of SD-fed mice and HFD-fed mice are shown in Figure 3. The CD8+/CD4+ 
ratio (p=0.002; Figure 3a) as well as the CD8+ cell fraction (p=0.027; Figure 3c) were 
significantly larger in liver of HFD-fed mice than in SD-fed mice. B. pseudocatenulatum CECT 
7765 administration tended to reduce the  alterations in the cytotoxic T cell subpopulation 
(CD8+) but the effects were not statistically significant (p=0.277). In contrast, B. 
pseudocatenulatum CECT 7765 significantly increased the proportion of Tregs in HFD-fed mice 
(p=0.010), which was reduced by the HFD (p=0.066) and (Figure 3b). B cells were significantly 
higher in liver of HFD-fed mice than in SD-fed mice (p<0.001), but B. pseudocatenulatum CECT 
7765 did not restored their levels (p=0.160) (Figure 3d). 
In liver macrophage infiltration was significantly increased by the HFD (p<0.001) while 
reduced by the administration of B. pseudocatenulatum CECT 7765 relative to the obese mouse 
group (p=0.011) (Figure 3e). M1/M2 ratio was also increased in HFD-fed mice (p=0.067) but 
significantly reduced (p=0.002) by the administration of B. pseudocatenulatum CECT 7765 
(Figure 3f).        
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Figure 3. Lymphocyte and macrophage infiltration into the liver of different mouse groups after 14 weeks of dietary 
intervention. SD: standard diet group receiving placebo (control); SD+Bif: standard diet group receiving a daily dose 
of 1 x109 CFU B. pseudocatenulatum CECT 7765; HFD: high fat diet group receiving placebo; HFD+Bif: high fat 
diet group receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 7765. The ratio of CD8+/CD4+ of total 
CD3+, T regulatory (CD4+CD25+Foxp3+), T cytotoxic (CD3+CD4-CD8+) and B lymphocytes (CD19+) as well as 
total of macrophages (F4/80+) and their subtypes M1 (F4/80+CD11c+CD206-) and M2 (F4/80+CD11c-CD206+) 
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were analyzed in each mouse group (n=10 per group) by flow cytometry. Data are expressed as means and standard 
error (error bars) and statistically significant differences were determined by ANOVA with Bonferroni’s post hoc 
test a p <0.050. 
 
B. pseudocatenulatum CECT 7765 reduced B cells and increased Tregs in peripheral blood of 
obese mice  
Obesity induced by HFD increased the CD8+/CD4+ ratio (p<0.001) in blood compared to SD-
fed mice (Figure 4a), but this was only slightly reduced by B. pseudocatenulatum CECT 7765 
administration (p=0.172). However, B. pseudocatenulatum CECT 7765 administration 
significantly increased T reg cells in HFD-fed mice compared to HFD-fed mice receiving placebo 
(p=0.007; Figure 4b), which were significantly reduced by the HFD (p=0.012). B cells were also 
increased in peripheral blood of obese mice compared to lean mice (p=0.035, Figure 4c), but B. 
pseudocatenulatum CECT 7765 significantly their proportions in HFD-fed mice (p=0.034; Figure 
4c). Monocytes CD14+ were also increased by HFD compared to the SD (p=0.016) but the 
effects of B. pseudocatenulatum CECT 7765 were not statistically significant (Figure 4d). 
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Figure 4. Lymphocyte and monocyte proportions in peripheral blood of different mouse groups after 14 weeks of 
dietary intervention. SD: standard diet group receiving placebo (control); SD+Bif: standard diet group receiving a 
daily dose of 1 x109 CFU B. pseudocatenulatum CECT 7765; HFD: high fat diet group receiving placebo; HFD+Bif: 
high fat diet group receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 7765. The ratio of 
CD8+/CD4+ of total CD3+, T regulatory (CD4+CD25+Foxp3+) and B lymphocytes (CD19+) as well as of 
monocytes (CD14+) were analyzed in each mouse group (n=10 per group) by flow cytometry. Data are expressed as 
means and standard error (error bars) and statistically significant differences were determined by ANOVA with 
Bonferroni’s post hoc test a p <0.050. 
 
 
B. pseudocatenulatum CECT 7765 reduced B cells and macrophage infiltration and TLR4 
expression in small intestine of obese mice  
In the small intestine, obesity induced by the HFD slightly increased the CD8+/CD4+ ratio 
(p=0.069) while this trend was slightly changed by the bifidobacteria administration, but the 
differences were not statistically significant (Figure 5a). The proportion of B cells was 
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significantly increased by the HFD compared to the SD (p=0.009) and B. pseudocatenulatum 
CECT 7765 administration led to a significantly reduction in this lymphocyte population in obese 
mice (p=0.027; Figure 5c). Macrophage infiltration was also significantly increased in HFD-fed 
mice (p=0.019), while significantly reduced by B. pseudocatenulatum CECT 7765 in the obese 
mice (p=0.013) (Figure 5d), although differences were not significant in the M1/M2 ratio (data 
not shown). TLR4 and TLR2 expression were also increased significantly in HFD-fed mice 
(p=0.006 and p=0.009, respectively), while slightly reduced (p=0.044 and p=0.068, respectively) 
by the administration of B. pseudocatenulatum CECT 7765 in obese mice (Figure 5e and 5f).  
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Figure 5. Lymphocyte and macrophage infiltration and TLR4/2 expression in mesenteric lymph nodes (MLNs) 
from small intestine of different mouse groups after 14 weeks of dietary intervention. SD: standard diet group 
receiving placebo (control); SD+Bif: standard diet group receiving a daily dose of 1 x109 CFU B. pseudocatenulatum 
CECT 7765; HFD: high fat diet group receiving placebo; HFD+Bif: high fat diet group receiving a daily dose of 
1x109 CFU B. pseudocatenulatum CECT 7765. The ratio of CD8+/CD4+ of total CD3+, T regulatory 
(CD4+CD25+Foxp3+) and B lymphocytes (CD19+) as well as of total of macrophages (F4/80+) and cells expressing 
TLR4 (CD282+) and TLR2 (CD284) were determined in each mouse group (n=10 per group) by flow cytometry. 
Data are expressed as means and standard error (error bars) and statistically significant differences were determined 
by ANOVA with Bonferroni’s post hoc test a p <0.050. 
  
B. pseudocatenulatum CECT 7765 reduced cytokine and chemokine concentrations in 
different tissues and serum of obese mice  
Adipose tissue. The effects of B. pseudocatenulatum CECT 7765 administration to HFD and SD-
fed mice on immune related markers in adipose tissue are shown in Table 2. The HFD 
significantly induced the production of TNF-α, MCP-1, IP-10, IL-10 and IL-17A in comparison 
with SD. However, the administration of B. pseudocatenulatum CECT 7765 to HFD-fed mice 
significantly reduced production of four of these five cytokines (TNF-α, MCP-1, IP-10, IL-17A; 
p=0.001-0.016) and the trend was the same for IL-10 (p=0.054). IL-6 was also slightly increased 
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by the HFD (p=0.204), but significantly reduced (p=0.041) by B. pseudocatenulatum CECT 7765 
administration in obese mice.  
Liver. The HFD significantly induced (p<0.001-0.021) the production of TNF-α, IL-18, IFN-γ 
and IL-1β and also slightly increased IL-10 (p=0.064) and IL-17A (p=0.093) compared to the SD 
in liver (Table 2). Therefore, the only inflammatory cytokine commonly involved in both adipose 
tissue and liver inflammation that changed significantly was TNF-α, which increased by 313% 
and 178%, respectively. B. pseudocatenulatum CECT 7765 reduced the  concentrations of TNF-
α, IFN-γ, IL-1β and IL-17A compared to obese mice fed placebo (p=0.011-0.049). In liver, the 
administration of B. pseudocatenulatum CECT 7765 to SD-fed mice also significantly reduced 
MCP-1 (p=0.015) and the same trend was detected for IFN-γ (p=0.054), which seemed to be an 
effect of the bifidobacteria independent of diet (Table 2).  
Serum.  The most significant alterations of immune markers associated with HFD-induced 
obesity in serum were those of TNF-α, IL-18 and IL-17A, whose concentrations significantly 
increased (p<0.001-0.013; (Table 2). The same trend was detected for MCP-1 and IFN-γ, but the 
differences did not reach statistical significance (p=0.084 and p=0.058, respectively; Table 2). B. 
pseudocatenulatum CECT 7765 significantly reduced TNF-α, and IL-17A (p=0.009) and the 
same trend was detected for IL-18 (p=0.076) in obese mice.  
Small intestine. The HFD significantly induced the production of most of the cytokines analysed 
in the gut including TNF-α, MCP-1, IP-10, IL-18, IL-4, IL-6, IL-10 and IL-17A and the increases 
were also almost significant for IFN-γ (p=0.063; (Table 2). B. pseudocatenulatum CECT 7765 
administration significantly reduced all the immune markers induced by the HFD except for IL-
10. B. pseudocatenulatum CECT 7765 administration to SD-fed mice also tended to reduce IL-18 
production (p=0.065), which seemed to be an effect of the bifidobacteria independent of diet 
(Table 2).  
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Table 2. Cytokine and chemokine concentrations in tissues and serum from different mouse groups after 14 weeks dietary intervention 
 
 Cytokines 
(pg/g tissue 
 or ml) 
Experimental Groups 
     SD       HFD           SD+Bif        HFD+Bif 
P- value 
(HFD vs. 
SD) 
P- value 
(SD+Bif 
vs. SD) 
P- value 
(HFD+Bif 
vs. HFD) 
   Mean    se   Mean    se   Mean    se  Mean   se    
Adipose tissue            
TNF-α  135.60 19.76 560.50 200.70 143.90 14.95 123.60 3.99   0.014*  0.754  0.025* 
MCP-1  936.30 99.33 4177 732.26 915.80 128.30 1766 205.70   0.001*  0.899  0.005* 
IP-10  56.49 9.83 282.03 53.82 105.60 10.12 131.30 17.12   0.003*  0.006*  0.030* 
IL-18  512.20 53.37 710.60 80.53 561.5 54.13 563.50 80.68   0.074  0.533  0.221 
IFN-γ  141.30 23.03 263.20 78.78 155.00 17.61 138.51 10.05   0.157  0.635  0.161 
IL-4  75.53 4.91 143.90 32.22 86.48 10.08 79.26 7.70   0.063  0.299  0.081 
IL-6  139.40 10.03 195.50 21.04 157.40 16.37 137.70 14.63   0.204  0.341  0.041* 
IL-10 118.00 24.76 214.00 23.77 124.50 18.09 150.10 18.44   0.016*  0.865  0.054 
IL-1β  535.20 52.10 497.00 47.65 580.60 86.64 572.60 87.28   0.599  0.651  0.446 
IL-17A 222.20 36.14        621.00 33.92 345.90 60.58 352.90 25.14   0.002* 0.046*  0.005* 
Liver            
TNF-α  118.20 8.99 328.09 43.69 110.92 11.21 159.72 31.36 <0.001*  0.624  0.011* 
MCP-1  5551.19 331.39 5919.83 381.22 4447.38 218.28 5458.95 414.20   0.542  0.015*  0.476 
IP-10     n.d     n.d     n.d     n.d     
IL-18  4638.13 812.70 16051.94 1923 5173.91 1760 11032.21 2634 <0.001*  0.776  0.172 
IFN-γ  70.38 5.44 321.23 68.75 52.56 6.06 102.19 32.80   0.007*  0.054  0.049* 
IL-4    n.d     n.d     n.d     n.d     
IL-6  1974.81 223.50 1653.37 255.11 1184.95 238.84 1132.77 208.07  0.485  0.233  0.286 
IL-10 1360.00 25.70 3000.00 271.13 1369.00 94.49 1249.00 103.01  0.064  0.964  0.056 
IL-1β  130.11 16.08 498.23 108.30 85.34 24.08 74.89 3.03  0.021*  0.189  0.026* 
IL-17A 252.00 27.41 328.10 30.37 272.00 11.22 248.70 12.51  0.093  0.514  0.020* 
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Serum 
TNF-α  20.19 4.55 138.50 14.84 94.25 67.16 60.83 28.58 <0.001*   0.072   0.050* 
MCP-1  303.05 0.07 569.84 116.49 686.33 1.15 637.64 187.38   0.084 <0.001*   0.687 
IP-10     n.d     n.d     n.d     n.d     
IL-18  476.03 61.97 1057.66 294.11 736.57 196.40 678.70 173.01   0.013*   0.051   0.076 
IFN-γ  32.36 9.87 52.36 24.80 38.44 17.12 37.42 12.97   0.058   0.447   0.191 
IL-4     n.d     n.d     n.d     n.d     
IL-6  52.64 3.73 56.05 8.23 60.14 16.10 58.53 19.39   0.621   0.587   0.818 
IL-10    n.d     n.d     n.d     n.d     
IL-1β  1094 132.94 995.09 175.40 855.64 50.94 989.53 162.50   0.553   0.058   0.969 
IL-17A 18.71 1.86 26.41 1.94 22.70 3.54 18.04 1.99   0.011*   0.320   0.009* 
Small intestine            
TNF-α  80.16 4.03 135.00 20.30 85.44 7.36 87.16 10.63   0.012*    0.576   0.021* 
MCP-1  994.40 75.86 3349 281.00 1004 124.30 1708 185.80 <0.001*    0.946 <0.001* 
IP-10  125.90 28.80 328.60 59.63 121.60 17.76 171.60 35.13   0.017*    0.898   0.042* 
IL-18  462.10 76.25 1146 135.70 708.50 99.50 708.70 123.90 <0.001*    0.065   0.028* 
IFN-γ  124.60 11.96 159.50 12.62 129.50 11.30 131.50 12.63   0.063    0.770   0.139 
IL-4  66.81 4.96 110.10 16.10 72.14 9.86 69.95 6.94   0.025*    0.613   0.035* 
IL-6  127.11 11.32 170.60 15.01 132.10 11.44 130.50 8.86   0.032*    0.769   0.035* 
Il-10 133.10 21.79 209.30 18.66 163.90 24.71 162.50 16.57   0.016*    0.362   0.080 
IL-1β  231.90 27.89 252.41 32.29 224.50 48.49 237.70 55.85   0.634    0.889   0.835 
IL-17A 36.03 10.40 104.60 19.40 47.66 6.05 35.76 7.96   0.013*    0.501   0.012* 
SD: standard diet group receiving placebo (control); SD+Bif: standard diet group receiving a daily dose of 1 x109 CFU B. pseudocatenulatum CECT 7765 by 
gavage; HFD: high fat diet group receiving placebo; HFD+Bif: high fat diet group receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 7765 by 
gavage. *Data are expressed as mean and standard error of the mean (se) (n=10 per group). *Significant differences were established by ANOVA and post hoc 
Bonferroni’s test at p≤0.050. Symbol n.d. indicates non detectable values. 
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HFD-induced metabolic endotoxemia is reduced by B. pseudocatenulatum CECT 7765 
   Plasma endotoxin (LPS) concentrations were higher in HFD-fed mice than in SD-fed mice 
(Figure 6a); however, the administration of B. pseudocatenulatum CECT 7765 reduced metabolic 
endotoxemia in the HFD-fed mice (p=0.037). No effects on SD-fed mice were detected. 
Proteobacteria are among the best known sources for LPS and were almost absent in SD and 
SD+Bif-fed mice, while significantly increased in HFD-fed mice (Figure 6b). The administration 
of B. pseudocatenulatum CECT 7765 to HFD-fed mice tended to reduce Proteobacteria levels 
(p=0.117) parallel to LPS reduction in serum (Figure 6).  
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Figure 6. Lipopolysaccharide (LPS) concentration in serum of different mouse groups after 14 weeks of 
dietary intervention (a) and Proteobacteria abundance in faeces in obese mice (b). SD: standard diet group 
receiving placebo (control); SD+Bif: standard diet group receiving a daily dose of 1 x109 CFU B. pseudocatenulatum 
CECT 7765; HFD: high-fat diet group receiving placebo; HFD+Bif: high-fat diet group receiving a daily dose of 
1x109 CFU B. pseudocatenulatum CECT 7765. LPS concentrations are expressed as means and standard errors (error 
bars) of data from each mouse group (n=8 per group) and statistically significant differences were determined by 
ANOVA with Bonferroni’s post hoc test at p <0.050 (a). Proteobacteria abundances as relative fractions of all 454 
reads in each sample are represented as means and standard errors (error bars) of data from each mouse group (n=8) 
and statistically significant differences were determined using a permutation test at a p < 0.050 (b). 
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B. pseudocatenulatum CECT 7765 administration partially restores the HFD-induced 
alterations in gut microbiota structure  
   Compositional analysis of gut microbiota structure by pyrosequencing (7,844 [mean], 4,192 
[se] reads per sample on average) revealed that HFD is a major factor influencing gut microbiota 
structure. The weighted UniFrac clustering analysis principally separated SD and HFD mice 
microbiota (Figure 7B). All HFD+Bif samples except one clustered together whereas among the 
SD microbiota the ones with and without B. pseudocatenulatum administration were 
intermingled. Bray-Curtis clustering analysis also showed only a partial grouping of the samples 
according to the four experimental mouse groups (Figure 7A). Taxonomic assignment with the 
RDP multiclassifier showed specific profiles for each of the four mouse groups, but also revealed 
general similarities between the two groups fed a SD, supplemented (SD+Bif) or not with the 
bifidobacteria (SD), and between the two groups fed the HFD (HFD and HFD+Bif) (Figure 8, 
Supplementary Table 3).  
   On phylum level, Firmicutes dominated the microbiota of SD-fed mice and SD+Bif fed mice 
representing 65 and 66% of all reads, respectively, followed by Bacteroidetes, which represented 
31% (Supplementary Table 3). In the microbiota of both HFD-fed mouse groups, Firmicutes 
were significantly increased (p<0.001 for both comparisons, SD versus HFD group and SD+Bif 
versus HFD+Bif group), while Bacteroidetes were reduced (p<0.001 for both comparisons). 
Additionally, HFD feeding increased the proportion of Proteobacteria compared to SD feeding 
(p<0.001 for both comparisons). 
   On family level, Porphyromonadaceae showed significantly lower abundance in both HFD-fed 
mouse groups than in both SD-fed mouse groups (p<0.001 for all comparisons). In contrast, 
Ruminococcaceae were more abundant in both HFD-fed mouse groups than in both SD-fed 
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mouse groups (p<0.001-0.002). Desulfovibrionaceae, a major group of Proteobacteria, was also 
more abundant in HFD-fed mice than in SD-fed mice (p<0.001; Supplementary Table 3). 
   On genus level (Figure 7, Supplementary table 3), Allobaculum, Barnesiella and unclassified 
Porphyromonadaceae were significantly less abundant in both HFD-fed mouse groups than in 
both SD-fed mice (for all comparisons p<0.001) (Table 3). In contrast, Lactobacillus, 
unclassified Ruminococcaceae, Lactococcus, unclassified Desulfovibrionaceae, Oscillibacter, 
Clostridium XI, and Alistipes were more abundant in the HFD-fed group than in the SD-fed 
group (p<0.001-0.044).  
   The HFD also has an important adverse impact on the genus Bifidobacterium, which was 
significantly less abundant in HFD than in SD-fed mice (p<0.001) (Table 3). However, B. 
pseudocatenulatum CECT7765 administration partially restored this and other alterations induced 
by the HFD in the gut ecosystem. Intervention with the bifidobacterial strain significantly 
increased Bifidobacterium proportions (p<0.001) in obese mice. Searches for the closest 
reference sequence via BlastN showed that in SD-fed mice members or relatives of four different 
species were present with a dominance of B. pseudolongum (98.3%), while B. pseudocatenulatum 
was not detected (Supplementary Figure 3). In the SD+Bif-fed mice, B. pseudolongum still 
prevailed among the five species detected, representing 91% of all Bifidobacterium reads, 
whereas 5% of the reads belonged to B. pseudocatenulatum. In the HFD+Bif mouse samples 97% 
of the Bifidobacterium population consisted of B. pseudocatenulatum demonstrating that the 
administered bacteria colonized the gut of HFD mice despite the general adverse effect of this 
diet on Bifidobacterium levels. On the contrary, in the SD+Bif-fed mice B. pseudocatenulatum 
was not so dominant, probably due to the presence of autochthonous B. pseudolongum, which 
presumably contributes to gut colonization resistance against allochthonous bifidobacteria orally 
administered. Accordingly, real-time quantification of rRNA gene copy numbers also revealed a 
significant reduction of Bifidobacterium spp. in HFD mice compared to SD (p=0.001) (data not 
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shown). In HFD-fed mice, B. pseudocatenulatum CECT 7765 administration increased the gene 
copy numbers of Bifidobacterium spp. (p<0.001) contributing to gut ecosystem restoration. In 
SD-fed mice, B. pseudocatenulatum CECT 7765 also increased total bifidobacterial gene copy 
numbers (p=0.017). 
   Administration of B. pseudocatenulatum CECT7765 to the HFD-fed mice also resulted in an 
increase of the amounts of Allobaculum (p<0.001), unclassified Lachnospiraceae (p=0.027) and 
Dorea (p<0.001) prop ortions (Table 3). In parallel, it also reduced the proportions of 
Lactobacillus (p=0.047), uncl. Porphyromonadaceae (p=0.001) and Bacteroides (p<0.001) in 
HFD+Bif-fed mice compared to HFD mice receiving placebo (Table 3). Other bacterial groups 
were not significantly restored by the bifidobacterial intervention in the HFD-fed group, 
including unclassified Ruminococcaceae, Lactococcus, and unclassified Desulfovibrionaceae, 
which remained at elevated levels compared to SD mice (p<0.001 for SD and HFD+Bif-fed 
mice). Also Barnesiella and unclassified Porphyromonadaceae, which were reduced by the HFD, 
did not increase significantly as a result of the bifidobacterial intervention (p<0.001 for SD and 
HFD+Bif-fed mice). In all four mouse groups, approximately half of the reads belonged to 
phylotypes that could not be classified reliably at genus level (at 80% confidence), especially 
among the Firmicutes and also among Bacteroidetes. 
   BlastN comparisons against a 16S rRNA gene database were also performed to acquire 
additional information on the phylogenetic affiliation of the reads detected. However, sequence 
similarities of the identified phylotypes to reference sequences of bacterial species were relatively 
low (91.3±4.6% on average) (data not shown). Only 11% of the reads shared a similarity of 97% 
or higher with its closest reference, a value considered as a delimitation to define species 
affiliation among bacteria.  
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   Rarefaction curves did not differ significantly between the four groups with SD+Bif-fed mice 
showing the highest values and HFD and HFD+Bif-fed mice the lowest values (data not shown). 
Comparison of species richness, Shannon and Simpson indices for community diversity did not 
show significant differences between the four groups at any of the three similarity cut-offs (100, 
97 and 90%) tested (data not shown).  
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Figure 7. Cluster analysis of the fecal microbiota composition determined by pyrosequencing in different mouse 
groups after 14 weeks of dietary intervention. Mouse group affiliation is indicated in light-grey and dark-grey for the 
SD group and the SD+Bif group and light-blue and dark-blue for the HFD group and the HFD+Bif group mice, 
respectively. A: Heatmap of Bray-Curtis distances of 52 genera with abundances of at least 0.1% in at least one 
sample. Abundances are categorized in four classes: below 5%, 5 to 10%, 10 to 25% and above 25% of the sequence 
reads. B: Cluster dendrogram of the weighted UniFrac analysis of 1254 phylotypes with more than 10 reads in all 
samples of the four groups. 
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Figure 8. Microbiota composition as determined by pyrosequencing with the RDP multiclassifier in faeces from 
different mouse groups after 14 weeks of dietary intervention. Data are expressed as mean percentage values from 
each mouse group (n=8 per group). Phylum affiliation of the genera is indicated by blue tones for Firmicutes, orange-
red for Bacteroidetes, brown for Proteobacteria, green for Actinobacteria and yellow for Deferribacteres. Genera with 
abundances below 0.1% and between 0.1 and 0.25% are grouped. Reads that had confidence values below 80% at 
family level are shown as "unclassified". 
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Discussion 
B. pseudocatenulatum CECT 7765 reduces obesity-associated adipose tissue inflammation by 
reducing B cells and components of innate immunity 
   Our study has demonstrated for the first time that a Bifidobacterium strain (B. 
pseudocatenulatum CECT 7765) reduces B lymphocyte infiltration, thereby contributing to 
reducing adipose tissue inflammation in obese mice. This lymphocyte population was 
significantly increased in HFD-fed mice as described previously [27,28]. B lymphocytes are 
reported to be one of the first immune cells recruited into adipose tissue shortly after initiation of 
a HFD in mice, and they adversely influence glucose metabolism via activation of pro-
inflammatory T cells and macrophages [28]. The involvement of B cells in obesity-associated 
metabolic dysfunction is also supported by the increased insulin sensitivity found in B-cell-
deficient mice on HFD compared with wild-type controls [28]. Adipose tissue-associated B cells 
can contribute per se to production of inflammatory cytokines, such as IL-8 and IFN-γ [29]. 
Adipose tissue-associated B cells can also induce MHC-dependent release of pro-inflammatory 
cytokines (e.g. IFN-γ) from resident T lymphocytes and induce macrophage polarization into the 
M1 phenotype, thereby contributing to the inflammatory cascade [4,28]. Increased CD8+ T cell 
infiltration and accumulation have also been described as an additional critical event driving 
adipose tissue inflammation with production of pro-inflammatory cytokines (e.g. IFN-γ) that 
contribute to macrophage activation [6]. Increased CD8+ numbers were usually paralleled by 
decreases in CD4+ numbers and, therefore, increased CD8+/CD4+ ratio in HFD-fed mice [6,30]. 
An increased CD8+/CD4+ ratio has also been detected in adipose tissue of our obese mouse 
model, but the effects of our bifidobacteria on T lymphocyte proportions (CD8+/CD4+) were 
modest and non-significant. In our study, the proportion of Treg cells was drastically reduced in 
obese adipose tissue paralleled to increases in B cells, as described by other authors in obesity 
and insulin resistance animal models [5,6]. In contrast, Treg cells are described to be enriched in 
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the abdominal fat of normal mice and to have an unusual high state of activation, presumably 
contributing to down-regulate the inflammatory state and prevent insulin resistance [5,30]. A role 
for Tregs in glucose metabolism is supported by studies showing that diphtheria toxin-induced 
depletion of Tregs cells was accompanied by decreases in insulin-stimulated insulin-receptor (IR) 
tyrosine phosphorylation in epidydimal fat and liver [5]. However, no significant effects of B. 
pseudocatenulatum CECT 7765 intervention were detected in Tregs in this tissue. In contrast, 
Akkermansia muciniphila Muc
T
 has been shown to reduce adipose tissue inflammation by 
increasing the generation of Tregs, whereas effects on the CD4+/CD8+ ratio were not detected 
and effects on B cells were not evaluated [30]. 
   Our study also shows that B. pseudocatenulatum CECT 7765 effectively reduces adipose tissue 
inflammation by reducing innate immune mediators (macrophages and related cytokines). In 
particular, B. pseudocatenulatum CECT 7765 reduced the ratio of pro-inflammatory (M1) to anti-
inflammatory (M2) macrophages. Accordingly, the bifidobacteria also reduced the HFD-induced 
cytokines mainly produced by pro-inflammatory macrophages (TNF-α, IL-6) or acting as 
chemoattractants of macrophages (MCP-1 and IP-10). However, the effects of A. muciniphila 
Muc
T
 in reducing macrophage (M1/M2) polarization have not been consistent across studies 
[30,31]. A. muciniphila Muc
T
 administration also led to down-regulate IL-6 and IL-1β gene 
expression, but did not influence the expression of other key cytokines in adipose tissue 
inflammation such as TNF-α or chemokines [30].  
 
B. pseudocatenulatum CECT 7765 reduces obesity-associated liver inflammation by increasing 
Tregs and reducing macrophages and cytokine concentrations  
   Our study has also demonstrated for the first time that the administration of an indigenous 
human gut bacterium (B. pseudocatenulatum CECT 7765) reduced hepatic inflammation 
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associated with HFD-induced obesity in mice by shifting cellular components of adaptive 
immunity and, specifically, by increasing the Tregs population. B. pseudocatenulatum CECT 
7765 also tended to reduce B cells and the CD8+/CD4+ ratio, whose increase is associated with 
serious liver alterations (e.g. fibrosis), but these latter changes were not statistically significant. 
However, the fact that the bifidobacteria reduced the IFN-γ concentration in adipose tissue 
suggests that it also ameliorated lymphocyte infiltration responsible for the production of this 
cytokine. The administration of B. pseudocatenulatum CECT 7765 to SD-fed mice also reduced 
IFN-γ (p=0.054) suggesting that effects on this cytokine are mediated by the bacteria regardless 
the diet. IFN-γ is considered the hallmark pro-inflammatory cytokine produced by T lymphocytes 
that also enhance the production of other inflammatory cytokines (e.g. TNF-α) through 
macrophage activation in the adipose tissue, which can also be the case for liver. Unlike our 
results, the probiotic mixture VSl#3 was shown to exert a positive effect on insulin resistance and 
steatosis in liver of mice under HFD by restoration of an associated NKT cell depletion [32]. 
   B. pseudocatenulatum CECT 7765 administration significantly reduced both total macrophage 
infiltration and the M1/M2 ratio in the liver of obese mice, whose increases are characteristic of 
diet-induced obesity and contribute to insulin resistance [33,34]. Likewise, our bifidobacterial 
strain also reduced the HFD-induced increase of cytokines of innate immunity (TNF-α and IL-1β) 
parallel to improvements in metabolic markers and functions, including serum lipid 
concentrations, glucose tolerance and insulin sensitivity. In this context, the probiotic product 
VSL#3 administered to HFD-fed rats was also shown to reduce liver TNF-α levels and 
expression of iNOS and COX-2 and increased PPARα expression suggesting reductions in 
oxidative and inflammatory processes [33]. 
   MCP-1 is the dominant signal controlling the recruitment of macrophages in liver and it is 
reported to derive from circulating monocytes [35]. However, in our study this chemokine was 
not significantly increased in the liver of HFD-fed mice, suggesting that regulation of MCP-1 
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levels in other tissues such as the small intestine and the adipose tissue influences the recruitment 
of macrophages in the liver via communication through the gut-peripheral tissue axis. In contrast, 
liver macrophages seemed to be the main contributors to the locally increased IL-1β 
concentrations since their levels were not increased in gut, serum, or adipose tissue of HFD-mice.  
 
B. pseudocatenulatum CECT 7765 reduces obesity-associated inflammation by reducing 
metabolic endotoxemia and pro-inflammatory cytokine concentrations and by restoring the 
balance between Tregs and B lymphocytes in systemic circulation   
   The anti-inflammatory effects of the Bifidobacterium strain detected in the adipose tissue and 
liver could be partly related to its ability to reduce LPS translocation from the gut to the blood 
stream, thus reducing metabolic endotoxemia and systemic inflammation in obese mice. This 
hypothesis is supported by the ability of the Bifidobacterium  strain tested to reduce serum 
cytokines primarily produced by activated innate immune cells in response to LPS stimulation, 
such as TNF-α and IL-18. In obese mice, LPS could also reach peripheral tissues and activate 
inflammatory pathways locally via TLR4 signalling which lead to increased expression of 
inducible nitric oxide synthase (iNOS) that reacts with cysteine residues interfering with the 
insulin signalling pathway and leading to insulin resistance in the liver and adipose tissue. IL-18 
also contributes to inducing cell-mediated immunity and can stimulate certain T cells to release 
IFN-γ that in turn activates monocyte/macrophages, which can generate a positive feed-back loop 
inflammatory process. 
   B. pseudocatenulatum CECT 7765 also seems to reduce systemic inflammation by the 
activation of immunoregulatory mechanisms since its administration to HFD-fed mice increased 
Tregs and reduced B cells and IL-17A in peripheral blood/serum, which suggests an attenuation 
of the Th17 response described in obese mice. B cells have been reported to primarily contribute 
to inflammation and insulin resistance via induction of an inflammatory T cell ratio (reduced 
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Treg cells and increased Th1/Th17 cells) and production of pro-inflammatory cytokines (e.g. IL-
17A) in HFD-fed mice and also in obese human subjects [7,36]. A recent study also reported that 
obese mice fed a Western chow diet had higher serum IL-17 concentrations than control mice and 
that L. reuteri ATCC 6475 administration reduced the levels of this cytokine, presumably by 
restoring Foxp3+ Treg/Th17 balance [37]. In our study, the increased serum leptin concentration 
could also contribute to the enhanced Th17 response, suggested by the increased serum IL-17A 
levels in obese mice [38]. However, this effect could not be attributed to cytokines involved in 
Th17 cell differentiation and maintenance, such as IL-6 and IL-1β [38], because their 
concentrations were not significantly increased in serum of our obese mice.   
   In our study, the reduction of serum pro-inflammatory cytokines in HFD+Bif-fed-mice could 
also be related to the parallel reduction of leptin concentrations, which could be an additional 
mechanism by which the bifidobacteria reduce systemic inflammation. For example, leptin 
increases pro-inflammatory cytokine secretion (e.g. TNF-α) by mouse monocyte/macrophages 
[39] as could be the case for our study. The increased leptin levels found in diet-induced obese 
mice can contribute to shift the T lymphocyte subpopulations and the cytokine pool, increasing 
IFN-γ secretion for example in the adipose tissue [39]. Leptin has also been reported to be 
inversely related to Tregs numbers since it negatively controls their proliferative/survival 
capacity [5] and, accordingly, we detected an inverse relationship between both parameters in the 
peripheral circulation. 
 
B. pseudocatenulatum CECT 7765 contributes to reducing systemic inflammation by reducing the 
HFD-induced microbiota alterations and components of adaptive and innate immunity in the gut 
   In our study we confirm that HFD-induced gut microbiota alterations involve increases in 
Firmicutes and decreases in Bacteroidetes, as reported in other animal studies [19,31,40,41,42]. 
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We also detected that the HFD increased the proportions of the phylum Proteobacteria in partial 
agreement with a recent study reporting increases in Enterobacteriaceae, which belong to the 
phylum Proteobacteria [19]. The HFD-induced reductions in the candidate division TM7 and in 
Verrucomicrobia reported by Shim (2013) was also supported by our data, although these phyla 
represent a minor proportion (<1%) of all reads.  
   Our study also shows that B. pseudocatenulatum CECT 7765 administration to HFD-fed mice 
led to partial restoration of the microbiota composition towards the one found in the control 
group. This restoring effect was most pronounced for the Firmicutes phylotypes; this is revealed 
by the fact that the abundances of the three most prominent genera and groups belonging to this 
phylum (unclassified Lachnospiraceae, Allobaculum and unclassified Erysipelotrichaceae), did 
not differ significantly between the SD and HFD+Bif groups (p>0.05 in all cases, Table 3, Figure 
8). However, alterations in the proportions of Bacteroidetes phylotypes found in HFD-fed mice 
were not restored to those found in SD-fed mice by bifidobacteria administration. Some of these 
specific alterations in the microbiota had been reported in other studies. B. pseudocatenulatum 
CECT 7765 administration to HFD-fed mice increased Allobaculum abundance to levels similar 
as those found in SD and SD+Bif mice. This is in agreement with a study applying berberine to 
treat obesity and diabetes in HFD rats where Allobaculum and Blautia were also reversibly 
shifted [43]. A study on genetically obese mice (db/db) also reports significantly increased 
abundances of Alistipes and Oscillibacter, as well as exclusive presence of Delta-Proteobacteria, 
Rikenella and Odoribacter in obese animals, by contrast these groups were less abundant and 
absent, respectively, in lean animals [44]. All these taxa were also significantly increased in our 
HFD-fed mice and lowered by B. pseudocatenulatum CECT7765 administration.  
   The resilience of the indigenous mouse microbiota to modifications by B. pseudocatenulatum 
CECT7765 administration was clearly higher in SD-fed than in HFD-fed mice, suggesting that a 
disease-associated microbiota is more susceptible to probiotic intervention. However, not all 
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potentially probiotic bacteria have demonstrated the ability to mediate effects via modulation of 
the gut ecosystem in HFD-fed mouse models of obesity, as was the case for L. reuteri ATCC [37] 
and A. muciniphila MucT [30], which would suggest different modes of action.  
   B. pseudocatenulatum CECT 7765 also seems to play a role in reducing LPS translocation in 
obese mice by restoration of the HFD-induced microbiota alterations, which can contribute to 
reducing the luminal LPS content and/or the microbiota-induced increases in intestinal 
permeability and inflammatory tone. The correlations between the HFD-induced increases in 
Proteobacteria and serum LPS levels suggest a direct contribution of the obese microbiota to 
increased LPS concentrations. This mechanism is also supported by the ability of B. 
pseudocatenulatum CECT 7765 administration to reduce the HFD-induced increases of Gram-
negative bacteria, including Escherichia/Shigella and Desulfovibrionaceae, which can be 
possible sources of LPS. B. pseudocatenulatum CECT 7765 also reduced intestinal inflammatory 
markers (TNF-α) increased in HFD-fed mice that cause increases in paracellular permeability in 
different disease models [45], constituting an alternative mechanism by which it could reduce 
LPS translocation. Increasing intestinal bifidobacterial numbers by administering prebiotics has 
also been reported to reduce LPS circulating levels via improvement of the gut barrier function 
mediated by increased GLP-2 production and modulation of expression and localization of tight 
junction-related proteins [46]. However, the effects of A. muciniphila Muc
T
 in reduction of serum 
LPS levels and intestinal permeability have not been consistent across studies. While Everard et 
al. (2013) reported increases in the thickness of the mucus layer and reductions in metabolic 
endotoxemia related to improvements in gut barrier function, Shin et al. (2013) did not report 
improvements in intestinal permeability in HFD-fed mice. 
   B. pseudocatenulatum CECT 7765 also seems to contribute to reducing inflammatory signals 
and systemic circulation of inflammatory mediators, generated from the activated epithelia and 
the gut-associated lymphoid immune system by saturated fat and the HFD-induced microbiota 
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alterations. B. pseudocatenulatum CECT 7765 reduced HFD-induced TLR4 expression, which 
could amplify the innate immunity responses in the gut of obese mice [47]. In our study, TLR4 
expression could be increased directly by the HFD and/or indirectly by the HFD-induced 
microbiota alterations. Nevertheless, a recent study reported that the HFD-induced colonic 
inflammation required gut colonization by the microbiota [11] and that it was partially mediated 
by TLR4 signalling [19]. In obesity mouse models, TLR4 is known to be involved in the 
inflammatory response that culminates in insulin resistance and metabolic dysfunction as 
demonstrated when comparing wild-type to  CD14−/− mice [46], and to  TLR4−/− mice [19].  
   B. pseudocatenulatum CECT 7765 also influenced intestinal immune-cell distribution and 
related cytokines, thereby being able to exert systemic effects via the cross-talk between the gut 
and the periphery. In particular, the administration of the bacterial strain reduced the HFD-
increased intestinal B cell numbers parallel to their reductions in peripheral blood. However, 
intestinal Treg numbers were not influenced by the bifidobacteria, suggesting that intestinal 
changes in B cells are those primarily driving the effects also detected in peripheral blood, where 
B cell populations were also decreased parallel to increases in Treg numbers.  
   B. pseudocatenulatum CECT 7765 also reduced intestinal cytokine production, influencing all 
HFD-induced chemokines and cytokines of innate and adaptive immunity (TNF-α, MCP-1, IP-
10, IL-18, IL-4, IL-6 and IL-10). A reduction in TLR expression induced by the bifidobacteria 
could partly explain the local reduction of cytokine production mediated by TLR-signalling. 
These include TNF-α, IL-1β and IL-6 whose increases in obese mice are known to be dependent 
on TLR4 signalling [19,48]. Increases in adaptive immunity cytokines in obese mice could be 
explained by the increased CD8+/CD4+ ratio and B cells with pro-inflammatory phenotype 
which were at least partially reversed by B. pseudocatenulatum CECT 7765 together with related 
cytokines such as IFN-γ that could be produced by CD8+ and B cells and in turn increased other 
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inflammatory mediators such as IP-10 and TNF-α secreted by other immune cells (monocytes, 
macrophages, etc.). 
   Although a direct effect of the diet on gut inflammatory markers cannot be disregarded since it 
is known that long-chain fatty acids increase lymphocyte flux and enhance its proliferative 
response in intestinal lymph from mesenteric lymph duct [49], the fact that the intervention with 
B. pseudocatenulatum reversed the HFD-inflammatory effects suggests a primary role for the gut 
microbiota in the regulation of this process. Our study also supports the notion that the gut 
constitutes the primary origin of inflammation associated with obesity and metabolic dysfunction 
as expression of pro-inflammatory mediators were increased to a larger extent in the gut than in 
any other tissue. Furthermore, all inflammatory cytokines/chemokines significantly increased in 
the gut were also increased in some of the peripheral tissues studied, whereas not all these 
inflammatory markers were increased in every tissue of obese mice. These findings may be a 
logical consequence of being the place firstly exposed to this “noxious” dietary stimuli 
(“saturated fat”) and where there is an important load of microbes, which could contribute to 
inflammation under a HFD, and the largest mass of lymphoid tissue in the human body. In 
particular, Bifidobacterium spp. negatively correlated to IL-6 (R=-0.716, p=0.020), which is a 
cytokine that was only significantly increased in the gut and could contribute to the increased 
Th17 response seen in our model parallel to B cell increases and Tregs depletion described in 
obese mice. The gut could also be an important source of MCP-1 that could contribute to 
monocyte migration and macrophage infiltration in obesity, since its concentrations were 
markedly increased in this tissue while not in the liver. These findings also suggest a causative 
role of gut inflammation in obesity and metabolic dysfunction as suggested by other authors 
[11,19] and could lead to reconsider the generally accepted notion that adipose tissue 
inflammation is the primary origin of inflammation related to metabolic dysfunction in obesity 
[50].  Our findings also indicate that intervention in the gut ecosystem with potentially probiotic 
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bacteria could reduce the obesity-associated inflammation; however, effects and modes of action 
differ depending on the bacterial strain.  
 
Conclusions 
The present study demonstrates that intervention in the murine gut ecosystem with B. 
pseudocatenulatum CECT 7765 modulates the HFD-induced immune cell infiltration and 
inflammation in the gut and the periphery, parallel to improvements in metabolic dysfunction 
associated with obesity. The study also shows that the anti-inflammatory and regulatory effects 
exerted by this bifidobacterial strain involve components of both innate and adaptive immunity, 
involving for the first time B lymphocytes. Moreover, our results support the notion that 
inflammatory responses originated in the gut contribute to peripheral tissue inflammation 
associated with HFD-induced obesity rather than being a secondary consequence of obesity and 
lipid accumulation in the periphery. Furthermore, intervention in the gut ecosystem with B. 
pseudocatenulatum CECT 7765 leading to changes in microbiota structure was sufficient to shift 
the inflammatory profile of the gut and beyond, proving that gut signalling plays a primary role in 
the regulation of obesity-associated inflammation.  
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Supplementary Table 1. Adipocyte cell size in epididymal adipose tissue in different mouse groups after 14 weeks of intervention 
% Adipocyte cell sizes 
(µm
2
) 
Experimental Groups 
SD HFD SD+Bif HFD+Bif 
P- value 
(HFD vs. 
SD) 
P- value 
(SD+ Bif 
vs. SD) 
P- value 
(HFD+ Bif 
vs. HFD) 
                                             Mean           se              Mean           se            Mean           se              Mean              se 
<2000 76.27 20.26  0.00  0.00  65.22  20.83 10.17    5.80 <0.001*   0.490   0.006* 
2000-4000 24.01 9.71  13.10  2.20  34.76  20.89 53.43    1.57   0.008*   0.858 <0.001* 
4000-6000 0.00 0.00  40.63  16.10  0.00  0.00 32.47    5.51   0.008*  >0.999 0.365 
>6000 0.00 0.00  52.05  8.26  0.00  0.00 4.19    0.80   <0.001*  >0.999   0.005* 
SD: standard diet group receiving placebo (control) (n=10); SD+Bif: standard diet group receiving a daily dose of 1 x109 CFU B. pseudocatenulatum CECT 7765 by gavage 
during 14 weeks (n=14); HFD: high fat diet group receiving placebo (n=10); HFD+Bif: high fat diet group receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 
7765 by gavage during 14 weeks (n=10). Adipocyte cell sizes are expressed as area ranges subdivided as follows: <2000, 2000-4000, 4000-6000 and 6000- 7000 µm2. 
*Significant differences were established by ANOVA and post hoc Bonferroni’s test at p≤0.050. 
 
 
 
 
Supplementary  Figure 1. Distribution of adipocytes size in epididymal adipose tissue in different mouse groups after 14 weeks of 
intervention.  Photomicrographs 20X of representative HE-stained slides are shown. A: standard diet (SD) group receiving placebo (control) (n=10); B: SD 
group receiving a daily dose of 1 x109 CFU B. pseudocatenulatum CECT 7765 by gavage during 14 weeks (n=14); C: high fat diet (HFD) group receiving 
placebo (n=10); D: HFD group receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 7765 by gavage during 14 weeks (n=10). 
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Supplementary Table 2. Hepatic steatosis in different mouse groups after 14 weeks of intervention 
 Steatosis (%) 
Experimental Groups 
SD HFD SD+Bif HFD+Bif 
P- value 
(HFD vs. 
SD) 
P- value 
(SD+ Bif 
vs. SD) 
P- value 
(HFD+ Bif 
vs. HFD) 
                                         Mean          se           Mean           se          Mean           se            Mean           se 
Grade 0 36.05 19.25 0.00 0.00  49.91 26.50 55.29   5.03   0.004* 0.482  <0.001* 
Grade 1 37.75 6.69 13.69 11.00  25.32 16.67 44.71   5.03 0.055 0.285 0.016* 
Grade 2 26.18 21.00 43.88 13.94  25.05 4.48 0.00   0.00 0.195 0.947 0.002* 
Grade 3 0.00 0.00 43.21 26.40  0.00 0.00 0.00   0.00   0.043*   >0.999 0.043* 
SD: standard diet group receiving placebo (control) (n=10); SD+Bif: standard diet group receiving a daily dose of 1 x109 CFU B. pseudocatenulatum CECT 7765 by gavage 
during 14 weeks (n=14); HFD: high fat diet group receiving placebo (n=10); HFD+Bif: high fat diet group receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 
7765 by gavage during 14 weeks (n=10). The fat vacuoles were measured in 100 hepatocytes of two liver tissue sections per mouse and scored for the severity of steatosis 
according to the following criteria: for grade-0 steatosis, no fatty hepatocytes; grade-1 steatosis, fat occupying less than 30% of the hepatocyte; grade-2 steatosis, fat occupying 
less than 30 to 60 % of the hepatocyte; grade-3 steatosis, fat occupying more than 60 % of the hepatocyte. *Significant differences were established by ANOVA and post hoc 
Bonferroni’s test at p≤0.050. 
 
Supplementary Figure 2. Determination of hepatic steatosis in different mouse groups after 14 weeks of intervention.  Photomicrographs 
20X of representative HE-stained slides are shown. A: standard diet (SD) group receiving placebo (control) (n=10); B: SD group receiving a daily dose of 1 
x109 CFU B. pseudocatenulatum CECT 7765 by gavage during 14 weeks (n=14); C: high fat diet (HFD) group receiving placebo (n=10); D: HFD group 
receiving a daily dose of 1x109 CFU B. pseudocatenulatum CECT 7765 by gavage during 14 weeks (n=10). 
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Supplementary  
Table 3. 
Abundances relative to all reads in 
% 
    Permutation test of 
statistical significance 
  
Classification results of 
the RDP multiclassifier 
SD  SD 
 +Bif 
 HFD  HFD 
  +Bif 
  SD vs 
SD+Bif 
SD vs 
HFD 
HFD vs 
HFD+Bif 
HFD+Bif  
vs SD+Bif 
% relative to all reads Mean se Mean se Mean se Mean se  p-value p-value p-value p-value  
               
Phylum level               
Firmicutes 65,27 9,64 65,97 11,7
9 
83,83 5,41 87,24 6,12  0,900 0,001 0,254 0,001  
Bacteroidetes 31,17 8,25 31,71 11,8
7 
8,33 4,79 2,24 1,75  0,915 < 0.001 < 0.001 < 0.001  
Proteobacteria 0,54 0,27 0,52 0,21 6,12 2,40 4,26 1,56  0,989 < 0.001 0,117 < 0.001  
Actinobacteria 2,32 1,73 0,94 0,46 0,65 0,42 5,07 5,74  0,055 0,015 < 0.001 0,001  
Tenericutes 0,05 0 0,02 0 0 0 0 0  0,589 0,002 n.a. 0,025  
Verrucomicrobia 0,04 0,02 0,07 0,03 0,01 0 0 0  0,878 0,056 0,894 0,043  
TM7 0,04 0,04 0,04 0 0 0 0,01 0  1,000 1,000 n.a. 1,000  
Deferribacteres 0,07 0,05 0,19 0,19 0,68 1,17 0,56 1,04  0,732 0,467 1,000 1,000  
Cyanobacteria/Chloroplas
t 
0,03 0,01 0 0 0 0 0 0  0,200 0,201 n.a. n.a.  
Family level               
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Lachnospiraceae 22,63 19,7
6 
30,36 23,9
4 
27,13 10,2
9 
42,45 6,59  0,491 0,588 0,009 0,245  
Ruminococcaceae 2,31 1,02 4,56 3,30 14,41 7,41 11,15 2,87  0,089 < 0.001 0,225 0,002  
Peptococcaceae 1 0,03 0,02 0 0 0,04 0,05 0,04 0,02  0,468 0,079 0,775 0,002  
Clostridiales Incertae 
Sedis XIII 
0,02 0,01 0,02 0,01 0,03 0,02 0,03 0,01  0,554 0,074 0,602 0,516  
Eubacteriaceae 0,03 0,01 0,02 0,01 0,03 0,02 0,02 0,02  1,000 0,167 0,202 1,000  
Peptostreptococcaceae 0 0 0 0 2,22 1,56 1,18 0,26  n.a. < 0.001 0,069 < 0.001  
Clostridiaceae 1 0 0 0,04 0,03 1,02 0,57 0,01 0  0,078 0,007 0,007 0,077  
Clostridiales Incertae 
Sedis XI 
0 0 0 0 0 0 0,04 0  n.a. n.a. 1,000 1,000  
unclassified Clostridiales 1,47 0,53 1,74 0,72 2,05 1,22 2,18 1,09  0,418 0,244 0,338 0,040  
Erysipelotrichaceae 35,44 17,8
7 
26,94 19,2
9 
15,82 11,7
8 
23,62 8,47  0,364 0,022 0,097 0,806  
Lactobacillaceae 2,54 1,11 1,33 1,05 15,70 22,8
7 
2,06 2,51  0,044 0,041 0,048 0,703  
Streptococcaceae 0,02 0,01 0,02 0 4,08 1,22 2,94 1,74  0,180 < 0.001 0,220 < 0.001  
Enterococcaceae 0,07 0,07 0 0 0,01 0,00 0,18 0,08  0,468 0,850 0,202 0,202  
Aerococcaceae 0,02 0 0 0 0 0 0 0  1,000 1,000 n.a. n.a.  
unclassified 
Lactobacillales 
0,09 0,06 0,11 0,09 0,38 0,38 0,17 0,20  0,657 0,013 0,270 0,221  
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Staphylococcaceae 0,04 0,03 0,03 0 0,03 0,02 0,02 0,02  0,733 0,393 0,751 0,021  
Bacillales Incertae Sedis 
XI 
0,02 0 0 0 0,04 0 0 0  1,000 1,000 1,000 n.a.  
Bacillaceae 1 0 0 0 0 0,01 0,00 0 0  n.a. 0,469 0,466 n.a.  
Bacillales Incertae Sedis 
XII 
0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
unclassified Bacillales 0 0 0 0 0,00 0,01 0 0  n.a. 0,200 0,200 n.a.  
Veillonellaceae 0 0 0,03 0,02 0,01 0,00 0 0  0,077 0,201 0,198 0,076  
Porphyromonadaceae 26,42 6,77 28,12 10,8
0 
3,09 1,77 1,02 0,94  0,709 < 0.001 0,006 < 0.001  
Prevotellaceae 2,59 1,97 1,02 0,45 0,11 0,16 0,11 0  0,044 < 0.001 0,056 < 0.001  
Bacteroidaceae 0,28 0,23 0,31 0,13 1,08 1,17 0,19 0,14  0,792 0,010 0,001 0,100  
Rikenellaceae 0,37 0,11 0,24 0,14 1,97 1,76 0,63 0,68  0,059 0,001 0,037 0,193  
unclassified Bacteroidales 0,75 0,19 1,10 0,69 0,09 0,04 0,04 0,05  0,184 < 0.001 0,038 < 0.001  
Flavobacteriaceae 0 0 0 0 0,04 0,04 0 0  n.a. 0,466 0,468 n.a.  
Sphingobacteriaceae 0 0 0 0 0,00 0 0 0  n.a. 1,000 1,000 n.a.  
Desulfovibrionaceae 0,09 0,09 0,04 0,04 3,26 1,28 2,17 0,82  0,331 < 0.001 0,091 < 0.001  
Bdellovibrionaceae 0 0 0,01 0,00 0 0 0 0  0,468 n.a. n.a. 0,470  
unclassified 
Desulfovibrionales 
0,27 0,22 0,29 0,28 2,05 0,93 1,27 0,77  0,901 < 0.001 0,171 0,001  
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Sutterellaceae 0,14 0,15 0,12 0,09 0 0 0 0  0,793 < 0.001 n.a. < 0.001  
Comamonadaceae 0 0 0 0 0,00 0 0 0  n.a. 1,000 1,000 n.a.  
Oxalobacteraceae 0 0 0 0 0,03 0 0 0  n.a. 1,000 1,000 n.a.  
unclassified 
Burkholderiales 
0,01 0,02 0,01 0,01 0 0 0 0  0,550 0,200 n.a. 0,202  
Bradyrhizobiaceae 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Methylobacteriaceae 0 0 0 0 0 0 0,01 0  n.a. n.a. 1,000 1,000  
Sphingomonadaceae 0 0 0 0 0,02 0,00 0 0  n.a. 0,468 0,465 n.a.  
Enterobacteriaceae 0 0 0,04 0,02 0,11 0 0,02 0  0,199 1,000 1,000 0,202  
Moraxellaceae 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Pseudomonadaceae 0 0 0 0 0,03 0 0 0  n.a. 1,000 1,000 n.a.  
Xanthomonadaceae 0 0 0 0 0 0 0,02 0,01  n.a. n.a. 0,467 0,469  
Helicobacteraceae 0 0 0,03 0,02 0,00 0 0,03 0,02  0,198 1,000 0,200 1,000  
Bifidobacteriaceae 2,02 1,62 0,65 0,37 0,04 0,04 4,37 5,66  0,033 < 0.001 < 0.001 0,001  
Corynebacteriaceae 0,08 0 0 0 0,00 0,00 0 0  1,000 1,000 0,465 n.a.  
Propionibacteriaceae 0 0 0 0 0,50 0 0,01 0  n.a. 1,000 1,000 1,000  
Micrococcaceae 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Microbacteriaceae 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Coriobacteriaceae 0,28 0,16 0,29 0,18 0,56 0,43 0,69 0,27  0,914 0,104 0,395 0,003  
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Anaeroplasmataceae 0,05 0 0,02 0 0 0 0 0  1,000 1,000 n.a. 1,000  
Verrucomicrobiaceae 0,04 0,02 0,07 0,03 0,01 0 0 0  0,587 0,003 1,000 0,027  
Deferribacteraceae 0,07 0,05 0,19 0,19 0,68 1,17 0,56 1,04  0,878 0,057 0,894 0,044  
Chloroplast 0,03 0,01 0 0 0 0 0 0  0,200 0,202 n.a. n.a.  
Genus level               
Lachnospiraceae incertae 
sedis 
0,25 0,20 0,19 0,10 0,43 0,14 0,22 0,10  0,544 0,054 0,002 0,641  
Anaerostipes 0,02 0,01 0,03 0,02 0 0 0 0  0,928 0,199 n.a. 0,466  
Marvinbryantia 0,05 0,03 0,07 0,04 0,02 0,02 0,01 0,00  0,743 0,077 0,218 0,088  
Clostridium XlVa 0,17 0,10 0,20 0,14 0,09 0,10 0,08 0,03  0,416 0,189 0,825 0,013  
Clostridium XlVb 0,05 0,04 0,04 0,03 0,15 0,12 0,17 0,09  0,614 0,003 0,753 0,001  
Blautia 0,01 0,00 0 0 0,01 0 0,03 0,01  0,468 1,000 0,202 0,199  
Dorea 0,07 0,05 0,22 0,14 2,76 0,68 6,71 2,05  0,111 < 0.001 0,001 < 0.001  
Roseburia 0,02 0,01 0,03 0,01 0,76 1,19 0,07 0,09  0,376 0,374 0,591 0,663  
Robinsoniella 0,02 0 0,03 0,02 0,01 0,00 0,02 0,00  0,732 0,283 0,883 0,927  
Johnsonella 0,03 0,01 0,03 0,02 0,13 0,13 0,10 0,04  0,349 0,007 0,736 < 0.001  
Coprococcus 0 0 0,02 0,01 0,04 0,01 0,01 0  0,200 0,026 0,025 0,202  
Gemmiger 0 0 0,02 0,01 0,01 0 0,01 0  0,199 1,000 0,466 0,425  
Shuttleworthia 0 0 0 0 0,01 0,01 0,02 0,01  n.a. 0,467 0,733 0,468  
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Lactonifactor 0 0 0,04 0 0 0 0 0  1,000 n.a. n.a. 1,000  
Acetitomaculum 0 0 0,04 0 0 0 0 0  1,000 n.a. n.a. 1,000  
unclassified 
Lachnospiraceae 
22,05 19,6
4 
29,66 23,6
2 
23,26 9,30 35,10 7,00  0,495 0,892 0,027 0,635  
Flavonifractor 0,30 0,22 1,14 1,39 0,87 0,75 0,52 0,19  0,127 0,049 0,227 0,243  
Oscillibacter 0,20 0,12 0,38 0,23 2,27 1,41 2,23 0,80  0,048 < 0.001 0,886 < 0.001  
Clostridium IV 0,10 0,05 0,35 0,23 0,20 0,18 0,27 0,13  0,027 0,184 0,462 0,635  
Butyricicoccus 0,03 0,02 0,13 0,13 0,01 0 0,01 0,01  0,249 0,002 0,469 0,031  
Ruminococcus 0,08 0,05 0,08 0,08 0 0 0,03 0,01  0,909 0,001 0,078 0,029  
Pseudoflavonifractor 0,11 0,09 0,13 0,06 0,73 0,56 0,83 0,60  0,659 < 0.001 0,931 0,001  
Anaerotruncus 0,03 0,03 0,02 0,01 0,15 0,11 0,15 0,06  0,880 < 0.001 0,880 < 0.001  
Sporobacter 0,03 0,02 0,02 0,00 0,01 0,00 0,01 0  0,281 0,147 1,000 0,324  
Faecalibacterium 0,02 0,00 0 0 0,00 0 0,01 0  0,467 0,464 1,000 1,000  
Papillibacter 0,02 0 0 0 0,00 0 0 0  1,000 1,000 1,000 n.a.  
Acetivibrio 0 0 0 0 0,01 0,00 0,03 0  n.a. 0,465 1,000 1,000  
Acetanaerobacterium 0 0 0,02 0 0 0 0 0  1,000 n.a. n.a. 1,000  
unclassified 
Ruminococcaceae 
1,50 0,74 2,45 1,60 10,19 5,65 7,12 1,74  0,152 < 0.001 0,151 0,001  
Peptococcus 0,03 0,02 0 0 0,04 0,05 0,04 0,02  0,466 0,080 0,778 0,001  
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Anaerovorax 0,02 0,01 0,02 0,01 0,03 0,02 0,03 0,01  0,776 0,073 0,603 0,299  
Eubacterium 0,02 0 0,01 0,00 0,03 0,02 0,02 0,02  1,000 0,044 0,201 0,663  
Anaerofustis 0,03 0 0,03 0 0 0 0 0  1,000 1,000 n.a. 1,000  
Clostridium XI 0 0 0 0 1,94 1,42 1,03 0,19  n.a. < 0.001 0,074 < 0.001  
Sporacetigenium 0 0 0 0 0,07 0,04 0,04 0  n.a. 0,007 0,018 1,000  
Clostridium sensu stricto 0 0 0,02 0,01 0,79 0,45 0 0  0,076 0,007 0,007 0,077  
Sarcina 0 0 0 0 0,01 0,01 0 0  n.a. 0,198 0,201 n.a.  
Anaerosporobacter 0 0 0,02 0 0 0 0 0  1,000 n.a. n.a. 1,000  
unclassified 
Clostridiaceae 1 
 0 0,02 0,00 0,23 0,12 0,01 0  0,467 0,007 0,007 0,468  
unclassified 
Peptostreptococcaceae 
0 0 0 0 0,22 0,16 0,15 0,08  n.a. < 0.001 0,197 < 0.001  
Anaerococcus 0 0 0 0 0 0 0,04 0  n.a. n.a. 1,000 1,000  
unclassified Clostridiales 
Incertae Sedis XIII 
0 0 0,02 0 0 0 0 0  1,000 n.a. n.a. 1,000  
Allobaculum 27,24 12,0
6 
19,54 12,7
8 
4,89 3,17 16,11 6,29  0,230 0,001 < 0.001 0,620  
Turicibacter 0,17 0,03 0,11 0,10 0,02 0,00 0 0  0,565 0,199 0,201 0,001  
Coprobacillus 0,04 0,02 0,09 0,10 0,01 0,00 0 0  0,548 < 0.001 0,468 0,007  
Clostridium XVIII 0,02 0,00 0,06 0,05 0,33 0,12 1,11 0,65  0,067 < 0.001 0,003 < 0.001  
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Erysipelotrichaceae 
incertae sedis 
0 0 0 0 0,01 0,01 0 0  n.a. 0,469 0,469 n.a.  
unclassified 
Erysipelotrichaceae 
8,09 6,14 7,20 6,66 10,59 8,75 6,39 2,27  0,784 0,507 0,284 0,935  
Lactobacillus 2,49 1,11 1,29 1,04 15,49 22,6
3 
2,00 2,48  0,044 0,044 0,047 0,709  
Paralactobacillus 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
unclassified 
Lactobacillaceae 
0,05 0,03 0,05 0,02 0,20 0,30 0,07 0,06  0,950 0,058 0,146 0,520  
Streptococcus 0,02 0,01 0 0 0,12 0,04 0,12 0,11  0,077 < 0.001 0,909 < 0.001  
Lactococcus 0 0 0,02 0 3,95 1,19 2,81 1,66  1,000 < 0.001 0,206 < 0.001  
Enterococcus 0,07 0,07 0 0 0,01 0,00 0,16 0,08  0,468 0,853 0,200 0,199  
unclassified 
Streptococcaceae 
0 0 0 0 0,02 0,01 0,02 0,01  n.a. 0,077 0,987 0,200  
unclassified 
Enterococcaceae 
0 0 0 0 0 0 0,03 0,01  n.a. n.a. 0,467 0,465  
Aerococcus 0,02 0 0 0 0 0 0 0  1,000 1,000 n.a. n.a.  
Staphylococcus 0,04 0,03 0,03 0 0,03 0,02 0,02 0,02  0,734 0,392 0,751 0,021  
Gemella 0,02 0 0 0 0,04 0 0 0  1,000 1,000 1,000 n.a.  
Bacillus 0 0 0 0 0,01 0,00 0 0  n.a. 0,468 0,465 n.a.  
Exiguobacterium 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
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Dialister 0 0 0,03 0,02 0,01 0,00 0 0  0,078 0,200 0,202 0,078  
Barnesiella 12,97 3,54 11,92 1,77 0,87 0,72 0,30 0,25  0,470 < 0.001 0,030 < 0.001  
Odoribacter 0,22 0,15 0,28 0,12 0,76 0,74 0,17 0,17  0,365 0,003 0,001 0,110  
Parabacteroides 0,16 0,09 0,29 0,18 0,20 0,27 0,28 0,36  0,092 0,961 0,934 0,459  
Tannerella 0,01 0 0,02 0 0 0 0 0  1,000 1,000 n.a. 1,000  
unclassified 
Porphyromonadaceae 
13,07 3,29 15,63 9,97 1,28 0,78 0,35 0,23  0,506 < 0.001 0,001 < 0.001  
Prevotella 0,08 0,06 0,42 0,22 0 0 0 0  0,001 0,026 n.a. < 0.001  
Hallella 0 0 0,02 0,00 0 0 0 0  0,468 n.a. n.a. 0,468  
unclassified 
Prevotellaceae 
2,54 2,00 0,59 0,26 0,11 0,16 0,11 0  0,006 < 0.001 0,058 < 0.001  
Bacteroides 0,28 0,23 0,31 0,13 1,08 1,17 0,19 0,14  0,793 0,009 0,001 0,101  
Alistipes 0,36 0,12 0,20 0,13 1,84 1,78 0,63 0,68  0,028 0,007 0,066 0,125  
Rikenella 0,03 0,02 0,04 0,03 0,30 0,02 0,04 0  0,101 0,201 0,201 0,037  
unclassified Rikenellaceae 0 0 0,01 0 0,03 0,02 0 0  1,000 0,200 0,197 1,000  
Flavobacterium 0 0 0 0 0,04 0,04 0 0  n.a. 0,469 0,465 n.a.  
unclassified 
Flavobacteriaceae 
0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Sphingobacterium 0 0 0 0 0,00 0 0 0  n.a. 1,000 1,000 n.a.  
Bilophila 0 0 0 0 0,01 0,00 0,02 0  n.a. 0,464 1,000 1,000  
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Desulfovibrio 0 0 0 0 0 0 0,16 0  n.a. n.a. 1,000 1,000  
unclassified 
Desulfovibrionaceae 
0,09 0,09 0,04 0,04 3,26 1,28 2,15 0,79  0,331 < 0.001 0,082 < 0.001  
Vampirovibrio 0 0 0,01 0,00 0 0 0 0  0,467 n.a. n.a. 0,468  
Parasutterella 0,14 0,15 0,12 0,08 0 0 0 0  0,773 < 0.001 n.a. < 0.001  
Schlegelella 0 0 0 0 0,00 0 0 0  n.a. 1,000 1,000 n.a.  
Janthinobacterium 0 0 0 0 0,03 0 0 0  n.a. 1,000 1,000 n.a.  
unclassified Sutterellaceae 0 0 0,01 0 0 0 0 0  1,000 n.a. n.a. 1,000  
Rhizomicrobium 0,02 0 0 0 0 0 0 0  1,000 1,000 n.a. n.a.  
Bradyrhizobium 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Methylobacterium 0 0 0 0 0 0 0,01 0  n.a. n.a. 1,000 1,000  
Sphingomonas 0 0 0 0 0,02 0,00 0 0  n.a. 0,466 0,465 n.a.  
Escherichia/Shigella 0 0 0,04 0,01 0,11 0 0,02 0  0,201 1,000 1,000 0,201  
unclassified 
Enterobacteriaceae 
0 0 0,01 0 0 0 0 0  1,000 n.a. n.a. 1,000  
Acinetobacter 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Pseudomonas 0 0 0 0 0,03 0 0 0  n.a. 1,000 1,000 n.a.  
unclassified 
Xanthomonadaceae 
0 0 0 0 0 0 0,02 0,01  n.a. n.a. 0,466 0,466  
Helicobacter 0 0 0,03 0,02 0,00 0 0,02 0,01  0,202 1,000 0,202 0,884  
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unclassified 
Helicobacteraceae 
0 0 0 0 0 0 0,01 0  n.a. n.a. 1,000 1,000  
Bifidobacterium 1,95 1,58 0,58 0,33 0,03 0,04 4,26 5,48  0,030 < 0.001 < 0.001 < 0.001  
unclassified 
Bifidobacteriaceae 
0,08 0,06 0,07 0,06 0,01 0 0,11 0,19  0,711 < 0.001 < 0.001 0,391  
Corynebacterium 0,08 0 0 0 0,00 0,00 0 0  1,000 1,000 0,471 n.a.  
Propionibacterium 0 0 0 0 0,50 0 0,01 0  n.a. 1,000 1,000 1,000  
Arthrobacter 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Microbacterium 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Enterorhabdus 0,08 0,03 0,16 0,12 0,46 0,33 0,62 0,28  0,072 0,001 0,259 0,001  
Olsenella 0,02 0,00 0,02 0,00 0 0 0,03 0,01  0,150 0,008 0,007 0,040  
Collinsella 0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
Gordonibacter 0 0 0 0 0,00 0 0 0  n.a. 1,000 1,000 n.a.  
Eggerthella 0 0 0 0 0,02 0 0 0  n.a. 1,000 1,000 n.a.  
Anaeroplasma 0,05 0 0,02 0 0 0 0 0  1,000 1,000 n.a. 1,000  
Akkermansia 0,04 0,02 0,07 0,03 0,01 0 0 0  0,591 0,002 1,000 0,026  
TM7 genera incertae sedis 0,04 0,04 0,04 0 0 0 0,01 0  0,734 0,466 1,000 1,000  
Mucispirillum 0,07 0,05 0,19 0,19 0,67 1,17 0,56 1,04  0,876 0,055 0,886 0,044  
unclassified 
Deferribacteraceae 
0 0 0 0 0,01 0 0 0  n.a. 1,000 1,000 n.a.  
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Streptophyta 0,03 0,01 0 0 0 0 0 0  0,202 0,201 n.a. n.a.  
Foot note. Average 
percentage of 
pyrosequencing reads for 
the four experimental 
mouse groups (SD, 
SD+Bif, HFD and 
HFD+Bif, n=8 for all) are 
given and data are 
expressed as means and 
standard error of the 
means. Statistically 
significant differences 
were established by using 
a permutation tests at p-
values below 0.05 (in 
bold). n.a. not applicable. 
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Supplementary Figure 3. Quantitative identification of sequence reads assigned to Bifidobacterium spp. with the RDP multiclassifier 
detected in mouse faeces. Data are expressed as absolute number of reads having the respective reference sequence as best match in each mouse group (n=8 
per group). 
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RESUMEN 
La  microbiota intestinal parece estar implicada en la regulación no sólo en funciones 
intestinales sino también en la comunicación del eje intestino-cerebro influyendo en 
aspectos como la respuesta al estrés y el comportamiento.  El objetivo de este estudio ha 
sido evaluar los posibles beneficios de Bifidobacterium pseudocatenulatum CECT 7765 
en el modelo de estrés psicológico crónico inducido por separación materna  (SM) en 
ratones. Tras el periodo de aclimatación los ratones se subdividieron en cuatro grupos 
experimentales. Dos de ellos fueron sometidos a separación materna (SM) y uno recibió 
placebo y otro B. pseudocatenulatum CECT 7765 (B.p.) (dosis: 1x10
8
 CFU/ml) desde el 
día postnatal (P)2 hasta P21 y otros dos no fueron sometidos a SM y recibieron placebo 
o B.p. Las determinaciones incluyeron: tests de comportamiento (Elevated plus maze, 
Open field y Acute stress) y las concentraciones de citoquinas en íleon y suero, 
monoaminas en el cerebro (hipotálamo) e intestino y de corticosterona en heces,  en la 
infancia tras finalizar el periodo de SM (PN 21) y en la edad adulta (PN 41). Los 
ratones sometidos a SM  mostraron concentraciones basales de corticosterona 
superiores a los controles en P21. Además, dichos ratones sometidos a separación 
materna resultaron más sensibles al estrés agudo  en la edad adulta, como demostraron 
el aumento en corticosterona tras la exposición a un estrés agudo y el grado de  ansiedad 
tras la prueba de comportamiento EPM. Sin embargo, el tratamiento con el probiótico 
B. pseudocatenulatum CECT 7765 previno  las alteraciones inducidas por SM en el 
comportamiento. Asimismo,  el tratamiento con B. pseudocatenulatum CECT 7765 
restableció las alteraciones en el  en las concentraciones de neurotransmisores y 
citoquinas inducidas por la SM. Por lo tanto, B. pseudocatenulatum CECT 7765 es 
capaz de evitar las consecuencias del estrés crónico producido por la SM durante la 
infancia, mostrando pues un efecto ansiolítico en la infancia y en la edad adulta. 
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ABSTRACT  
The intestinal microbiota not only exerts local effects in the gut, but also beyond via 
the but-brain axis, influencing the stress response and behaviour. The objective of this 
study was to evaluate the potential benefits of Bifidobacterium pseudocatenulatum 
CECT 7765 in the murine model of maternal separation (MS), a model proven to be of 
great value in the study of stress-related disorders. Animal behaviour, cytokine 
concentrations in the intestine (ileum), levels of monoamines in the blood and brain 
(hypothalamus) and corticosterone were analysed in both early life and adulthood. Mice 
subjected to MS in early life were more sensitive to an acute stressor in adulthood, as 
indicated by significantly increased plasma corticosterone levels after a performance 
test in the elevated plus maze. Interestingly, treatment with the probiotic B. 
pseudocatenulatum CECT 7765 prevented this hyperreactivity to acute stress.  In 
addition, treatment with B. pseudocatenulatum CECT 7765 resulted in normalization of 
the immune response, reversed behavioral deficits and restored the profile of 
neurotransmitter release and in both the intestine and hypothalamus in mice subjected to 
early life MS. Therefore, B. pseudocatenulatum CECT 7765 is able to ameliorate the 
long-term consequences of early-life MS, and demonstrates anxiolytic-like properties. 
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Introduction 
Colonization of the newborn intestine is a critical event that influences many 
developmental and physiological processes and, thereby, the functioning of the immune 
and neuroendocrine systems with long-lasting effects on health. The gut-brain axis is a 
complex neuronal and humoral network of communication that provides a route for the 
gut microbiota to impact on brain function (Collins et al., 2009). This hypothesis is 
supported by differences found between germ-free and colonized mice in brain 
chemistry (e.g. neurotransmitter receptor expression and turnover), stress response and 
behaviour (anxiety, exploratory behaviour, motor activity, spatial memory changes, 
etc.), (Collins et al., 2009; Dinan and Cryan, 2012; Nishino et al., 2013). In this context, 
animal studies also suggests that there is a window of opportunity within the early 
developmental process where microbiota-based interventions could play a major role in 
programming the gut-brain axis communication and function and contribute to 
preventing mood and behavioural disorders in latter life (Sudo et al., 2004; Borre et al., 
2014). 
Early life chronic stress is associated with deregulation of the hypothalamic—
pituitary-adrenal axis (HPA) and alterations to subsequent responses to stressors and 
overproduction of glucocorticoids, which could be the origin of metabolic, immune and 
mental disorders and explain their high comorbidity (Dinan and Cryan, 2012). Neonatal 
maternal separation (MS) in rodents constitutes a well-established model of alterations 
in the gut-brain cross-talk induced by early life trauma resembling to some extent 
chronic psychological stress occurring in humans (O'Mahony et al., 2011). MS rodents 
show higher corticosterone levels both in basal conditions and in response to a 
subsequent stress (Gareau et al., 2007; O'Mahony et al., 2009; Barouei et al., 2012), 
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gastrointestinal dysfunction (increased motility or visceral/colonic sensitivity) 
(O'Mahony et al., 2009; Distrutti et al., 2013), increased intestinal permeability and 
inflammatory markers in the gut  (e.g. myeloperoxidase activity) or in peripheral blood 
(e.g. TNF-α, IL-6 secreted by stimulated blood cells ex vivo) and bacterial translocation 
(Barreau et al., 2004; García-Ródenas et al., 2006; Gareau et a.l, 2007; O'Mahony et al., 
2009; Desbonnet et al., 2010; Distrutti et al., 2013) compared to the control animals. 
MS also leads to anxiety and a depression-like phenotype associated with alterations in 
brain biochemistry (Desbonnet et al., 2010). A role of gut microbiota in the HPA axis 
deregulation and behavioural alterations induced by MS in early life has been supported 
by associations with alterations in intestinal bacterial adhesion or microbiota 
composition (Bailey and Coe, 1999; Barreau et al., 2004; García-Ródenas et al., 2006; 
Gareau et al., 2006, 2007; O'Mahony et al., 2009; Barouei et al., 2012). More direct 
evidence for a role of microbiota in the development and regulation of the HAP 
response to stressors has been demonstrated in a few intervention studies with fecal 
transplants or specific bacteria (known as probiotics)  in animal models submitted to 
different stress situations (Sudo et al., 2004,; Distrutti et al., 2013). Thus, Sudo et al 
(2004) demonstrated that neonatal colonization of germ-free mice with 
enteropathogenic Escherichia coli favored the exaggerated HPA-axis stress responses 
seen in germ-free mice, whereas colonization with a strain of Bifidobacterium infantis 
or specific pathogen-free faeces from control animals during infancy down-regulated 
the HPA axis hyperactivity against restrain stress in adulthood. Administration of B. 
infantis 35624 to MS rats in the adulthood also resulted in normalization of specific 
behavioural alterations (“behavioural despair”) and blood cell immune responses ex 
vivo (Desbonet et al., 2010). More recently, early life administration of VSL#3, a 
mixture of 8 probiotic bacteria strains, has been shown to protect against development 
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of visceral hypersensitivity driven by neonatal MS in rats and restore colonic expression 
of genes mediating pain and inflammation (Distrutti et al., 2013). Nevertheless, other 
pre-clinical trials with potential probiotics reported conflicting results regarding their 
effectiveness in reversing stress-induced HAP deregulation (Barouei et al., 2012, 2015). 
Thus, the maternal administration of Bifidobacterium animalis subsp lactis BB-12 and 
Propionibacterium jensenii 702 was associated with increased neonatal corticosterone 
levels until week 12 in the offspring submitted to MS in females and ACTH levels in 
adults (Barouei et al., 2015). The modes of action by which a specific probiotic 
bacterium may signal from the gut to the brain, thereby regulating the HPA axis stress 
response and behaviour are also largely unknown and deduced from fragmented 
evidence in different study models (Desbonet et al., 2009, 2010). These effects and 
modes of action also seem to differ across studies likely due to differences in 
experimental conditions as well as to bacterial strain-specific effects. Therefore, there is 
still a limited understanding of the extent to specific bacterial strains may help to reset 
psychological symptoms associated with chronic stress and  the precise mechanisms 
that orchestrate the well-functioning of the gut-brain axis particularly during early life 
and its impact in the long-term. 
Here, we have evaluated the ability of Bifidobacterium pseudocatenulatum CECT 
7765 (B.p.), a strain selected for its pre-clinical efficacy in ameliorating metabolic and 
liver disorders (Cano et al., 2013, Moya-Pérez et al., 2014; Moratalla et al., 2014, 2015), 
to reprogram short and long-term alterations induced by MS in the stress response and 
the behavioural phenotype when administered to mice during the early post-neonatal 
period (PN2 to PN 21). The ability of this bifidobacterial strain to re-shape gut 
microbiota composition and restore the immune and neuroendocrine network that may 
mediate long-lasting effects in behaviour have also been evaluated to progress in the 
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understanding of the mechanisms orchestrating the adaptation of the gut-microbiota-
brain axis to chronic stress.   
 
Methods and Materials 
Bacterial strain and culture conditions 
Bifidobacterium pseudocatenulatum CECT 7765 (B.p.) was isolated from healthy 
infants and identified by sequencing a 1.28 kb  of the 16S rRNA gene with the primers 
27f, 530f, U-968f as described previously (Favier, Vaughan, De Vos, & Akkermans, 
2002; Satokari, Vaughan, Akkermans, Saarela, & de Vos, 2001). Bacteria were grown 
in MRS agar or broth (Scharlau, Barcelona, Spain) supplemented with 0.05% (w/v) 
cysteine (MRS-C Sigma, St. Louis, MO), and incubated at 37◦ C for 22 h  under 
anaerobic conditions (AnaeroGen, Oxoid, Basingstoke, UK). Cells were harvested by 
centrifugation (6,000 g for 15 min), washed twice in phosphate buffered saline (PBS, 
130 mM sodium chloride, 10 mM sodium phosphate, pH 7.4), and re-suspended in 10% 
skimmed milk for oral administration to mice. Aliquots of these suspensions were 
frozen in liquid nitrogen and stored at -80°C until used. The number of live cells after 
freezing and thawing was determined by colony-forming unit (CFU) counting on MRS-
C agar after 48 h incubation.  
 
Study design in a mouse model of chronic stress induced by maternal separation 
(MS)  
Pregnant female mice (C57Bl/6J), 6-7 weeks old, were individually housed under 
standard conditions (room temperature 22 ± 1°C, 55 ± 5% humidity), in a 12-h 
light/dark cycle. After birth, male breast-fed pups and  their respective mothers were 
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randomly divided into 4 groups as follows: (1) Control group, a group which received a 
10% skimmed milk solution (placebo) from post-natal day 2 (P2) until  P21 but it was 
not submitted to  maternal separation (MS) ; (2) MS group, which  received a daily dose 
of a 10% skimmed milk solution (placebo) and was submitted to MS once daily;(3) B.p. 
group, which receiving a daily oral dose of  1x10
8
 CFU B. pseudocatenulatum CECT 
7765 from P2 until P21 but not submitted to MS  and (4) B.p.+MS group, which 
received a daily oral dose of  1x10
8
 CFU B. pseudocatenulatum CECT 7765 from P2 
until P21 and was submitted to MS once daily litter. MS was taken as a model of 
chronic stress on offspring (Desbonnet et al., 2010; O'Mahony et al., 2009). Pups (n=18 
per experimental group) were separated from their mother 3 hours per day during 20 
days.  Pups were nicely placed in a different clean cage in an adjacent room to prevent 
ultrasonic vocalizations with the mothers (Hofer et al., 1994). B.p. and placebo were 
orally administered to pups during the daily MS procedure and, therefore, mothers did 
not have direct contact with the bifidobacteria.  Body weight of mice was monitored at 
P21 and P41. The study protocol is schematically represented in Figure 1. 
Animal experiments were carried out in strict accordance with the recommendations 
in the Guide for the Care and Use of Laboratory Animals of University of Valencia 
(Central Service of Support to Research [SCSIE], University of Valencia, Spain) and 
the protocol was approved by its Ethic Committee (A1297079312093). 
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Figure 1. Schematic representation of the study’s protocol. C57BL/6 mice pups were divided in four 
experimental groups: control group received a 10% skimmed milk solution from postnatal day 2 (P2) 
until P21; MS group received a daily dose of a 10% skimmed milk solution and was submitted to 
maternal separation (MS) once daily until P21; B.p group received a daily oral dose of 1x108 CFU B. 
pseudocatenulatum CECT 7765 from P2 until P21; MS+B.p. group received a daily oral dose of 1x108 
CFU B. pseudocatenulatum CECT 7765 from P2 until P21 and was submitted to MS once daily. At P21 a 
half of the mice were sacrificed to determine effects on stress markers, neurotransmitters and cytokines. 
The rest of the animals remained undisturbed and underwent a battery of behavioral testing for anxiety 
and hyperactivity in the adulthood (P41); afterwards, they were sacrificed and biological samples were 
collected for detection of the same markers as in P21. Body-weight was monitored throughout the study.  
 
 
Acute Stress Response 
Physical immobilization was used as a model of acute stress as previously described 
(Dhingra & Chhillar, 2012; Mahanti et al., 2013). Mice were placed inside a hemi 
cylindrical plastic tube and were physically immobilized for 1 hour at P40. 
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Corticosterone concentration in stools was determined as a marker of the response to 
stress as described below. 
 
Corticosterone analysis  
Corticosterone concentrations were determined in stool samples that were taken after 
MS (chronic stress) at P21 and before and after 3 hours after applying acute stress at 
P41. Stools were collected and kept at -80ºC until use. Corticosterone was extracted 
from stool samples (0.1 grams per sample) using the, "Steroid Soil Extraction Protocol 
"(Assay Arbor, Michigan, USA). Briefly, 1 ml ethyl acetate was added to 0.1 g of solid 
faeces and then samples were centrifuged at 1000 x g for 15 minutes at 37ºC and the 
supernatant was collected and transferred to a clean tube for evaporation at 37ºC. 
Afterwards, the extract was re-suspended in 100 µl ethanol plus 400 µl buffer AB of the 
Corticosterone Enzyme Immunoassay Kit (Assays Arbor, Michigan, U.S.A.).  The 
concentration of corticosterone was calculated from a standard curve determined 
according to the manufacturer’s instructions and expressed in picograms per gram of 
fecal material (pg/g). The limit of detection was 16.9 pg/ml. 
 
Behavioral tests  
Elevated plus maze  
Anxiety was evaluated using the elevated plus maze (EPM) as it has been described 
as a simple method for assessing anxiety responses of rodents (Pellow et al, 1985) that 
challenges mouse proclivity towards dark and closed spaces (approach) and an 
unconditioned fear to heights/open spaces (avoidance) (Barnett and Smart, 1975). The 
EPM used is a grey-painted Plexiglas apparatus with four 30 cm-long and 5 cm-wide 
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arms (two open and two enclosed by 15.25 cm-high walls). Each arm of the maze is 
attached to sturdy metal legs such that it is elevated 40 cm off the ground. Each mouse 
(n=9 per group) was gently left in the middle of the elevated plus maze facing always 
the same arm. We video-recorded the freely moving task during single 5-minute testing 
sessions, and the different behaviors such as number of entries, time spent and 
immobility in the open arms, displayed by each animal were measured by a tracking 
software (Smart Junior, Panlab S.L., Harvard Apparatus, Spain).. Time in the open arm 
was scored when all four paws were in the open arm of the maze.  A decreased in the 
time spent in the open arm was interpreted as an anxious response. 
 
Open field 
General locomotor activity was examined in a square 40 cm X 40 cm open field 
(Panlab, sl). The open field was indirectly and homogeneously illuminated by a 350 lux 
at 1.50 m above the ground. Mice (n=9 per group) were exposed to the open field 20 
minutes per day during 2 consecutive days. They were nicely placed always on the 
inferior left corner of the open field. After each test, the open field was thoroughly 
wiped clean with 3-4% alcohol and dry. Every trial was recorded and analyzed using a 
computer software (Smart Junior, Panlab, sl). Several variables like mean speed and 
total distance travelled were selected for the analysis.  
 
Neurotransmitter analysis  
The monoamines noradrenaline (NA), adrenaline (A), serotonin (5-
hydroxytryptamine; 5-HT) and dopamine (DA) were measured in the hypothalamus and 
in gut tissue (ileum) using high-performance liquid chromatography (HPLC). The 
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samples were immersed (2.5 ml/g tissue) in 0.5M trifluoroacetic (TFA) acid and frozen 
immediately in liquid nitrogen until analyzed. Samples were homogenized using a 
Tissue Ruptor (Qiagen, Madrid, Spain) for 30 seconds. The samples were centrifuged 
10,000 g for 15 minutes at 4 ºC and the pellets were subjected to a second extraction 
cycle with the conditions described before.  
The chromatographic separation was performed in a HPLC Agilent 1220 infinity 
series system (Agilent, Waldbronn, Germany), which was equipped with a degasser, a 
binary pump and an auto-sampler. The neurotransmitters were analyzed using a 
Poroshell 120 EC-C18 column (4.6 x 50 mm, 2.7 µm i.d.). The mobile phase was 
composed of (A) 0.1% TFA in deionized water (18 Mcm) at pH = 2.2, and (B) 0.1% 
TFA in deionized water: acetonitrile (20:80, v/v) using the following gradient program: 
0-9 min, isocratic gradient 100% (A); 914 min, linear gradient 75% (B); 14-15.5 min, 
isocratic gradient 100% (B); 15.6-18 min, isocratic gradient 100% (A); A pre-
equilibration period of 5 minutes was used between each run. The flow rate was 0.8 mL; 
the column temperature was 25 ºC; the detector was set at a 254 nm wavelength; and the 
injection volume was 5 µL. Neurotransmitters were identified by their retention times as 
determined by using standards commercially available (Sigma-Aldrich, St Louis, MO, 
USA) which were run at regular intervals in parallel.  Results are expressed as ng of 
neurotransmitter per gram of fresh tissue weight. 
 
Cytokine analysis   
Cytokines (IFN-γ, IL-6, IL-10, TNF-α, IL-18 and MCP-1) were analyzed in serum 
and gut samples. Frozen intestine tissues (ileum) were weighted and homogenized using 
a Tissue Ruptor (Qiagen, Madrid, Spain) in RIPA buffer (Sigma, Madrid, Spain) for 10 
                                                                                                                          Capítulo IV 
191 
  
minutes. Then, samples were centrifuged at 10,000 g and 4 ºC for 5 min. Supernatants 
were collected and stored at - 80ºC until analyzed. Blood samples were collected in 
tubes containing EDTA and centrifuged (2,000 g for 10 min at 4 ºC) and the supernatant 
was used for cytokine quantification using the Mouse/Rat Basic Kit Flow Cytomix 
combined with a bead-based Analyte Detection Assay for each cytokine (FlowCytomix 
Simplex Kits; eBioscience, Affymetrix Company, Vienna, Austria).  Threshold 
sensitivities for each cytokine were: 6.5 pg/ml for IFN-γ, 2.2 pg/ml for IL-6, 13.3 pg/ml 
for IL-10, 2.9 pg/ml for TNFα, 116.9 pg/ml for IL-18 and 42 pg/ml for MCP-1. Data are 
expressed as pg per g of tissue weight.  
 
Gut microbiota analysis by 16S rRNA gene sequencing 
Stool samples from adult mice (P41) feces were weighed, diluted 1:5 (w/v) in PBS 
(pH 7.2), homogenised by shaking in a vortex and stored at -80 ºC till analysed. 
Aliquots(200µl) of this dilution were used for DNA extraction using the QIAamp DNA 
stool Mini kit (Qiagen, Hilden, Germany) after an initial step of mechanical disruption 
mixing (1:1) the stool sample with sterile zirconia/silica beads (diameter, 0.1mm) in a 
bead-beater during 2 minutes.  
Approximately, 40 ng DNA were used to amplify V4-V5 regions of 16S rRNA gene 
according to previous protocols (Claesson et al., 2010). Briefly, triplicate PCR reactions 
using primer pairs F563/R926 (encoding 6-mer DNA barcodes at 5' ends) and low 
cycling (22 cycles of amplification) generated ~360bp amplicons visible by agarose gel-
eletrophoresis. Triplicate reactions were pooled and amplicon DNA was purified by 
using GFX
TM
 PCR DNA and Gel Band Purification Kit (GE Healthcare). Amplicon 
DNA was quantified by using Quant-IT
TM
 PicoGreen® dsDNA Assay Kit 
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(LifeTechnologies). Samples were multiplexed by combining equimolar quantities of 
amplicon DNA (100ng per sample) and sent to Eurofins Genomics GmbH (Ebersberg, 
Germany) to perform Illumina MiSeq high-throughput sequencing with 300bp PE 
(paired ends) configuration. Bad quality and ambiguities-containing sequence reads 
were filtered out by using fastx-toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) and 
paired ends assembly was performed through Flash software (Magoc and Salzberg, 
2011). Sample de-multiplexing was carried out using read sequence information from 
dual DNA barcoding and Mothur platform (Schloss et al., 2009). Assembled and 
barcodes/primers free sequences were processed for chimera removal using Uchime 
algorithm (Edgar et al., 2011) and SILVA reference set of 16S sequences (Quast et al., 
2013). Diversity indexes were calculated with Mothur using default parameters and 
average method in the clustering step. Consequently, the Observed (Sobs) and Chao's 
richness, and Shannon's diversity as well as evenness indexes were computed using a 
high quality and a normalized subset of 10,000 sequences randomly selected after 
shuffling (10,000X) of original dataset. Taxonomy assignation of the subset of high-
quality reads was performed with Bayesian RDP Classifier (Wang et al., 2007) using an 
assignment confidence cutoff 0.8. Beta diversity was analyzed by performing Unifrac-
weighted analysis (Lozupone et al., 2011) and, then, Unifrac-weighted metrics was used 
to perform Clustering (Complete and Euclidean methods) and Principal Coordinates 
analyses.  
 
Statistical analysis 
Data of endocrine, immune and neurochemical determinations and behavioural tests 
were analyzed using Graph Pad Prism (LaJolla, Ca, USA). Data distribution was 
analyzed using the Kolmogorov-Smirnov normality test. For normally distributed data 
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statistical significance was assessed using one or two-way ANOVA (when necessary) 
with Bonferroni post hoc test (MS and B.p. treatment as factors). Non-normally 
distributed data were analyzed by applying the non-parametric Mann-Whitney U test. 
Differences were considered statistically significant at p<0.05. Data are expressed as 
mean ± standard error of the mean (sem).  
Statistical analyses and pairwise comparisons of 16S rRNA gene sequencing data 
were conducted on R v 3.1software. Pairwise T-test with Benjamini & Hochberg 
multiple testing corrections was applied to compare Sobs, Chao and Shannon indexes. 
A normalized number of reads assigned to specific taxonomy groups per sample were 
used to calculate two sample permutation test (10,000 permutations) using DAAG R 
package (Maindonald and Brown, 2010).  
 
Results 
B. pseudocatenulatum CECT 7765 reduces markers of the exaggerated HPA stress 
response induced by MS in juvenile mice 
The study protocol is schematically represented in Figure 1. Chronic stress produced 
by MS in mouse pups from birth until P21 recreated the expected effects on stress 
markers, like increased corticosterone concentration in stools parallel to body weight 
loss (Figure 2).  MS mice showed the highest levels of corticosterone (p=0.025) and 
weight loss (p<0.050) (Figure 2A and 2B) compared to controls. B. pseudocatenulatum 
CECT 7765 administration to MS mice did not normalized corticosterone 
concentrations although the MS-induced increase was slightly ameliorated. B. 
pseudocatenulatum CECT 7765 administration to MS mice did not prevent weight loss. 
The effect of B. pseudocatenulatum CECT 7765 on body weight in controls was not 
statistically significant (9.1 vs 7.7, p=0.167).  
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We also analyzed neurotransmitters concentrations in a dissected area containing the 
hypothalamus, because it  is known to be involved in the hormonal and behavioural 
stress response (Lucassen et al., 2014), and in the gut-brain axis communication. 
Neurotransmitter concentrations in hypothalamus and in the small intestine were also 
altered as a consequence of chronic stress (MS). In particular, in juvenile mice (P 21) A 
was increased (p=0.007) in the hypothalamus (Figure 2C) and the main catecholamines 
(DA, NA and A, p=0.040, 0.001 and 0.030, respectively) were also remarkably 
increased in the gut (Figure 2 D, E and F) of the MS mouse group compared to the 
control group. However, B. pseudocatenulatum CECT 7765 administration restored the 
MS-induced increase in neurotransmitter concentrations in both the hypothalamus and 
the small intestine. The effects of B. pseudocatenulatum CECT 7765 administration 
were particularly remarkable on A levels of the hypothalamus, which were completely 
normalized. This finding suggests that this bifidobacteria regulate A levels in the CNS 
via the gut-brain axis in a situation psychological chronic stress. Serotonin (5-HT) 
levels the small intestine were increased by MS which showed the same tendency but 
the differences were not statistically significant (control vs MS, p=0.05; MS vs 
MS+B.P., p=0.08). B. pseudocatenulatum CECT 7765 did not exert any effect on stress 
markers and neurotransmitters in control mice, suggesting that it plays a role in 
restoration of the gut-brain axis deregulation caused by chronic stress.    
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Figure 2. Effects of B. pseudocatenulatum CECT 7765 administration on mice submitted to chronic 
stress induced by maternal separation (MS) and controls on corticosterone and neurotransmitter 
concentrations in different experimental groups at juvenile age (P21). Data are expressed as means and 
standard error and statistically significant differences were determined by ANOVA with Bonferroni’s 
post hoc test a p≤0.050 
 
 
B. pseudocatenulatum CECT 7765 attenuates the MS-induced increase in cytokine 
concentrations in small intestine and serum in juvenile mice. 
The effect of MS and bifidobacteria intervention on several cytokines and 
chemokines (TNF-α, IFN-γ, IL-6, IL-10, IL-18 and MCP-1) concentrations in serum 
(Table 1) and small intestine (Table 2) of mice from different experimental groups were 
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analyzed at P21. INF-γ and IL-6 were not detected in serum and small intestine, 
respectively, of any of the experimental mouse groups. MS did not induced detectable 
changes in cytokine concentrations in serum (Table 1). B. pseudocatenulatum CECT 
7765 slightly increased the TNF-α serum levels compared to controls, but differences 
between MS and MS+B.p. mouse groups were not detected, indicating that this increase 
was independent of stress. B. pseudocatenulatum CECT 7765 significantly reduced the 
serum levels of IL-18 in MS mice compared with MS mice fed with placebo (p=0.013), 
which tended to increase as a consequence of chronic stress induced by MS (p=0.078, 
control versus MS). MS also increased INF-γ (p=0.012) and IL-10 (p=0.025) intestinal 
concentrations compared to control mice, suggesting the induction of a Th1-type stress-
associated inflammatory response and the simultaneous activation of regulatory 
mechanisms mediated by IL-10 to attenuate the inflammatory tone, presumably as a 
secondary consequence of CNS activation in response to chronic stress transmitted via 
the gut-brain axis. Interestingly, B. pseudocatenulatum CECT 7765 administration 
significantly reduced the MS-induced INF-γ increased in the small intestine (p<0.001). 
This effect was also detected in control mice fed the bifidobacteria (p=0.003, control 
versus control+ B.p.), suggesting a direct down-regulatory effect of the bifidobacateria 
on this immune activator of the Th1-type inflammatory response in early life in both 
normal and chroming stressful situations. The bifidobacteria also tend to reduce TNF-α 
concentration in the gut of MS mice but the effects were minor as expected since this 
strain tended to increase the basal levels of this cytokine also in control mice. MS also 
caused a slight increase in MCP-1 in the small intestine compared to control group 
(p=0.085), but significant effects of the bifidobacteria on this chemokine were not 
detected.  
 Table 1. Cytokine concentrations in serum from different mouse groups at PND 21  
    Cytokines 
  (pg/mL)  
                                                     Experimental Groups
a
 
     Control  
       (n=9) 
      MS 
     (n=9) 
Control+ B.p.  
       (n=9) 
      MS+ B.p. 
         (n=9) 
     
 MCP-1  277.6± 22.0  247.1± 22.7  478.9± 45.9  294.9± 80.3  
 
 TNF-α n.d.  n.d.  
 
64.6 ± 1.7 
 
51.9 ± 0.5  
 
              IL-6 
 
12.1 ± 0.5 
    
15.3 ± 2.1 
  
14.5 ± 5.2 
  
14.1 ± 1.6 
 
 
              IL-10 
 
108.9± 44.5 
  
108.9± 14.6 
  
214.1 ± 35.2 
  
187.2± 16.2 
 
 
              IL-18 
 
214.7 ± 10.1 
    
337.3 ± 41.9 
  
277.1 ± 21.2 
  
185.7 ± 2.9* 
 
 
              INF-γ 
 
n.d. 
  
n.d. 
  
n.d. 
  
n.d. 
 
 
 
aControl group received a 10% skimmed milk solution from P2 until P21; MS group received a daily dose of a 10% skimmed milk solution and was submitted 
to maternal separation (MS) once daily from P2 until P21; B.p group received a daily oral dose of 1x108 CFU B. pseudocatenulatum CECT 7765 (B.p) from 
P2 until P21; B.p.+MS group received a daily oral dose of  1x108 CFU B. pseudocatenulatum CECT 7765 from P2 until P21 and was submitted to MS once 
daily. Data are expressed as mean and standard error (SEM). Significant differences were established by ANOVA and post hoc Bonferroni test at P≤0.050. 
*Significant differences between MS and B.p+ MS mouse groups. n.d: non detectable values 
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Table 2. Cytokine concentrations in small intestine from different mouse groups at PND 21  
Cytokines 
        (pg/g tissue) 
Experimental Groups
a
 
     Control  
       (n=9) 
        MS  
       (n=9) 
Control+ B.p.  
      (n=9) 
 MS+ B.p.  
    (n=9) 
     
 MCP-1 2283.6 ± 218.5  3130.5 ± 226.9   2480.9± 918.6  2704.5 ± 80.2  
 
TNF-α 
 
189.4 ± 7.8 
   
216.1 ± 31.9 
   
341.8 ± 0.1 
   
291.1 ± 18.8∆ 
 
 
             IL-6 
 
n.d. 
  
n.d. 
  
n.d. 
  
n.d. 
 
 
             IL-10 
 
221.2 ± 44.6 
   
266.8 ± 14.6 
   
255.7 ± 35.0 
   
239.7 ± 16.2 † 
 
 
             IL-18 
 
276.3 ± 34.9 
   
274.4 ± 30.1 
   
220.1 ± 43.3 
   
199.7 ± 41.8 
 
 
             INF-γ 
 
25.6 ± 2.7 
   
129.8 ± 8.0 
   
1.9 ± 0.1 
   
38.9 ± 7.5 †*∆ 
 
 
 
aControl group received a 10% skimmed milk solution from P2 until P21; MS group received a daily dose of a 10% skimmed milk solution and was submitted 
to maternal separation (MS) once daily from P2 until P21; B.p. group received a daily oral dose of 1x108 CFU B. pseudocatenulatum CECT 7765 (B.p) from 
P2 until P21; B.p.+MS group received a daily oral dose of  1x108 CFU B. pseudocatenulatum CECT 7765 from P2 until P21 and was submitted to MS once 
daily. Data are expressed as mean and standard error (SEM). Significant differences were established by ANOVA and post hoc Bonferroni test at P≤0.050. 
†Significant differences between Control and MS mouse groups. ∆Significant differences between Control and Control+ B.p. mouse groups.  *Significant 
differences between MS and B.p.+ MS mouse groups. n.d: non detectable values. 
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B. pseudocatenulatum CECT 7765 reduces the MS-induced increase in vulnerability to 
stress in adulthood  
In order to test whether chronic stress induced by MS early in life had a long-lasting effect 
on the mouse’s ability to cope with a new stressing event (acute stress). Adult mice (P41) 
were subjected to acute immobilization and corticosterone concentrations were assessed 
before and after the immobilization.  Despite the chronic stress regimen had finished 3 weeks 
ago, MS group showed slightly higher corticosterone concentration in stools than control 
mice at baseline although the differences were not statistically significant (p=0.100, Figure 
3A). However, B. pseudocatenulatum CECT 7765 administration during early life (until P21) 
completely normalized the long-lasting effect of MS on basal corticosterone levels prevailing 
in adulthood (p=0.03; Figure 3A). The bifidobacteria also trend to reduce corticosterone 
concentrations basally in control mice compared to mice fed with placebo in adulthood 
although differences were not statistically significant (p=0.122); this could be an age 
dependent down-regulation of the stress response mediated by the bifidobacteria (Figure 3A) 
since this trend was not detected in juvenile mice (Figure 2B). Physical immobilization was 
used as a model of acute stress to analyze the possible different responses of the different 
mouse groups. One hour of physical immobilization was enough to increase by 10-fold 
corticosterone levels in stools of the control group in adulthood (Figure 3B). This increase in 
corticosterone in response to acute stress was higher the MS group (p=0.029), indicating that 
chronic stress during childhood has long-lasting effects on the adulthood’ stress response and 
could increase the sensitivity, promoting an exaggerated response (Figure 3B). The 
administration of the bifidobacteria also reduced this stress marker in response to an acute 
stressful event particularly in the MS group (p=0.050). 
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Figure 3.  Effects of B. pseudocatenulatum CECT 7765 administration in mice submitted to chronic stress 
induced by maternal separation (MS) during early life. Corticosterone levels under basal (3A) and acute stress 
conditions (3B). Anxiety behavior in the elevated plus maze (3C) and catecholaminergic levels in the 
hypothalamus (3D-F). Data are expressed as means and standard error and statistically significant differences 
were determined by ANOVA with Bonferroni’s post hoc test a p≤0.050 
 
 
B. pseudocatenulatum CECT 7765 reduces the MS-induced anxiety in adulthood  
In order to test whether the increased corticosterone production in adulthood induced by 
MS in childhood could be related to an altered behavioral phenotype (anxiety), mice were 
tested in the EPM. In this test, the open arms are perceived as “unsecure” and, consequently, 
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rodents spend the majority of the time in the closed arms of the maze. Mice submitted to 
chronic stress early in life tend to spend more time than normal in the close arm than in the 
open arm and any increase of trespassing or time in the open arm is considered a measure of 
spontaneous non-anxious exploratory behavior (Hata et al, 2001).  In addition, the percentage 
of time in the open arms is smaller when mice are more sensitive to stressful situations 
(Berman et al, 2014).  The MS group reduced by 10% the time spent in the open-arm 
compared to the control group (p=0.01). In contrast, B. pseudocatenulatum CECT 7765 
exerted an anti-anxiolytic effect on MS mice reversing their behavioral phenotype to normal 
in adulthood (p= 0.010; Figure 2C). 
In order to confirm that the open arm increased exploration in the MS group fed the 
bifidobacteria was not due to a general increase in locomotor activity, we run an open field 
test 20 days after the MS post-treatment. We founded no differences between control and  
control+B.p. mouse groups in the total distance travelled (7119 ± 1050 cm, n=4 in MS vs 
7170 ± 747.9 cm,  n=5 in  MS + B.p.) and the speed of movement (6.1 ± 0.8 cm/s, n=4 in MS 
vs 6.0 ± 0.6 cm/s,  n=5 in MS + B.p.). The results confirmed that B. pseudocatenulatum 
CECT 7765 was not altering horizontal exploratory behavior and it did not produce 
hyperactivity. Therefore, the results of the EPM test reflected an anxiolytic behavioral 
phenotype. 
 
B. pseudocatenulatum CECT 7765 reduced the MS-induced catecholaminergic 
hyperactivity in adulthood  
Mice subjected to MS during childhood exhibited clear catecholaminergic hyperactivity in 
the hypothalamus in adulthood reflected in the increased concentrations of DA (p=0.029), NA 
(p=0.004) and A (p=0.016) in MS mice compared to control mice (Figure 3D-F). B. 
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pseudocatenulatum CECT 7765 administration during the early postnatal period to MS mice 
reduced all catecholamine concentrations in the hypothalamus compared to MS mice fed 
placebo in adulthood, showing the most remarkable effects on NA (p=0.011) and A 
(p=0.046). These results suggest that MS early in life has a deep impact on the HAP-axis 
leading to a permanent activation of the CNS in adulthood and that B. pseudocatenulatum 
CECT 7765 administration in during infancy reprograms the HAP stress response and reset 
the neurotransmitters close to normal levels parallel to normalization of the behavioral 
phenotype. In contrast, the bifidobacteria increases DA (p=0.016) and slightly A in the 
hypothalamus of control mice (p=0.064)). Serotonin levels were drastically increased in the 
hypothalamus of MS group (p=0.029) and effectively reduced also in MS+B.P. (p=0.029). No 
significant differences were detected in the neurotransmitters analyzed in small intestine in 
adulthood as a result of MS or bifidobacteria administration during childhood. One the other 
hand, no significant effects were detected in the cytokine analyzed neither in serum nor in 
small intestine in adulthood as a result of MS or bifidobacteria administration during 
childhood.  
 
B. pseudocatenulatum CECT 7765 protects against stress-associated intestinal dysbiosis 
To establish whether the long-lasting effects of B. pseudocatenulatum CECT 7765 
administration on MS-induced behavioural and neurochemical alterations could be mediated 
by modifications in intestinal microbiota composition, the hypervariable 16S rDNA region 
V4-V5 of DNA extracted from stool samples of  adult mice (P41) was sequenced (Figure 4). 
The gut microbiota of MS mice showed an increase in species diversity as compared to 
control mice (p=0.029) revealing that chronic stress early in life exerted long-lasting effects 
(Figure 4A). However, B. pseudocatenulatum CECT 7765 administration attenuated this 
alteration since differences in diversity were not significant between the MS and the MS+ 
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B.p. groups (p=0.239). In contrast, B. pesudocatenulatum CECT 7765 administration to 
control mice early in life increased species richness in adulthood (p≤0.006 in comparison with 
all groups) (Figure 4A). MS also led to reduced microbiota evenness in adulthood in both 
mice groups (MS and MS+B.p) as analyzed by using the Shannon Evenness index (Figure 
4C). The administration of the bifidobacteria did not reverse this effect in MS mice but 
increase evenness in control mice (Figure 4C).  To determine the specific bacteria associated 
with the treatments (MS and B.p administration), beta diversity analysis as well as taxonomy 
assignment of sequence reads were determined and further analyzed. Principal Coordinate 
Analysis (PCoA) plotted in Figure 4B reflects the highest combined variability information 
from all samples analyzed (explaining more than 60% of variability among samples). The 
PC1 dimension derived from PCoA analysis almost perfectly discriminates between the 
microbiota of control mice and MS mice (except for some outliers), supporting the idea that 
stress induced intestinal dysbiosis. On the other hand, PC2 dimension discriminates control 
and MS mice from mice fed B. pseudocatenulatum CECT 7765 (Control+ B.p and MS+ B.p). 
To establish possible correlations between the abundance of specific taxonomic groups and 
the treatments, stress and B. pseudocatenulatum CECT 7765 administration, a linear 
regression analysis was performed. According to this analysis, the families Lachnospiraceae 
and Rikenellaceae showed a positive correlation with principal coordinate PC1. When 
comparisons between taxa abundance in different mouse groups were performed by a 
permutation test, we observed significant differences regarding Rikenellaceae family which 
perfectly match with above stated assumptions (Figure 4C). The proportion of normalized 
reads that belong to Rikenellaceae family was lower in MS mice than control mice (control vs 
MS, p=0.015); indicating members of this family belonging to the phylum Bacteroidetes 
(mainly Alistipes spp.) were strongly associated with controls. Interestingly, B. 
pseudocatenulatum CECT 7765 administration reverted the depletion of this taxa in the MS 
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mice, suggesting that part of its effects could be mediated by restoration of stress-induced 
dysbiosis (MS vs MS+B.p., p=0.029). The proportions of members of the family 
Erysipelotrichaceae and other Unclassified (UC) Firmicutes (Figure 4D and 4E) were more 
abundant in MS mice (MS vs control without 1 outlier, p=0.008). B. pseudocatenulatum 
CECT 7765 administration to MS mice reduced the proportion of those bacterial groups 
increased in MS mice fed placebo (MS vs MS+ B.p., p=0.029). This last correlation was also 
evidenced when family abundance data was compared with PC2 coordinate (data not shown). 
Consequently, Erysipelotrichaceae family showed a positive correlation with PC2 values, 
therefore also supporting the strong association of this taxa with chronic stress. Moreover; 
Peptostreptoccoccacea family (Figure 4F) was found to be negatively correlated with B. 
pseudocatenulatum CECT 7765 administration (B.p vs MS, p=0.002; B.p vs Control, 
p=0.002), which seems to promote depletion of members of this family (mainly Clostridium 
XI genus). As expected, abundance of the families Bifidobacteriaceae and Lactobacillaceae 
was positively correlated with B. pseudocatenulatum CECT 7765 administration, indicating 
that the bacteria has been stablished in gut microbiota in the long term.  
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Figure 4. Alpha and beta diversity analysis in gut microbiota from adult mouse feces. Hipervariable V4-V5 
regions from 16S rRNA gene were amplified and analyzed to explore microbial diversity. A - Alpha diversity 
parameters obtained from different mice groups. Chao Richness and Shannon diversity indexes were calculated 
from normalized reads accounting 10,000 randomly selected reads from every sample. Values from two 
principal coordinates (PC1 and PC2) showing the highest variability are depicted in a 2D scatter plot. C to F - 
Scatter plots representing linear correlations of microbial family abundance, which statistically showed different 
proportions among mice groups, against principal coordinates values obtained from FAST-UNIFRAC analysis. 
Pearson coefficient and p-value supporting such correlations are presented within plots. Diagonal dotted lines 
indicate respective slopes of correlations. 
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Discussion 
The present study expands our understanding of the gut microbiota’s role in early 
programing and latter responsiveness of the HAP axis to stress and the long-term 
consequences on brain chemistry and behavior. Our finding specifically indicate that 
alterations of the brain-gut communication induced by chronic stress (top-bottom effects) can 
be reprogrammed by intervention in the gut ecosystem with a specific bifidobacteria (B. 
pseudocatenulatum CECT 7765) that exerts a bottom-top regulatory action on the intestinal 
cytokine and neurotransmitter network in early stages of life with subsequent long-term 
effects on the CNS.  
Early life stress conditions, like those induced by maternal deprivation (separation) of mice 
pups, constitute a model of exposure to early-life adversity that trigger long-lasting molecular 
and cellular modifications in brain functions that could facilitate the appearance of mood and 
behavioral alterations (Vazquez et a, 2005; Paternain et al, 2012; Barreau et al., 2004; 
Varghese et al., 2006). MS is also a model of chronic stress that increases vulnerability to 
acute stress in the adulthood (Uchida et al, 2010) as well as colonic dysfunction (Gareau et al, 
2006) and a leaky gut (Moussaoui et al, 2014). It constitutes, therefore, an ideal model to 
study the interaction between CNS and gastrointestinal system.  
B. pseudocatenulatum CECT 7765 administration to MS mice attenuated the effects of the 
exaggerated stress response of the HAP axis such as reductions in body weight and increased 
basal corticosterone concentration in juvenile mice as well as the exaggerated corticosterone 
production in response to a subsequent exposure to stress in adulthood. In a different study 
animal model, Sudo et al. (2004) reported that monocolonization of germ-free mice with B. 
infantis or with stools from specific-pathogen-free mice in early life also reduced the 
increased plasma ACTH and corticosterone concentrations after 1 hour of restrain stress at 9 
weeks of age. Altogether, these studies confirm that gut colonization in early life influence 
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both early and latter endocrine responses to stress mediated by the HAP axis although effects 
cannot be generalized to all strains and pattern of administration (Barouei et al., 2015). Our 
study has also analyzed for the first time the chronic-stress induced effects locally in the gut 
and their relationship with central effects. Thus, we newly report that early intervention in the 
gut ecosystem with B. pseudocatenulatum CECT 7765 down-regulated the chronic stress-
induced intestinal inflammation (reducing IFN-γ) and the hypercatecholaminergic activity 
locally in the gut (reducing all intestinal catecholamines measured DA, NA, and A) with a 
long-term impact in the CNS of adult mice. In addition, bifidobacteria administration 
normalized the A levels in both gut and hypothalamus of juvenile MS mice, evidencing the 
gut-brain cross-talk at early stages of development. The systemic effects of B. 
pseudocatenulatum CECT 7765 administration to MS mice are also reflected in its ability to 
reduce the MS- induced systemic inflammation (reducing serum IL-18 concentrations). From 
a mechanistic point of view, Sudo et al. (2004) concluded that the effects of B. bifidum 
inoculated in germ-free mice early in life on the latter HAP stress response were not mediated 
by a cytokine-dependent pathway but by visceral information derived from bacterial 
colonization somehow transmitted to the brain. This study reported that while bifidobacteria 
colonization led to increased IL-6 serum concentrations and activation of the paraventricular 
nucleus reflected in an increased c-Fos mRNA expression, pre-treatment with the anti-
cytokine IL-6 antibody failed to inhibit the bacterial effect on the CNS (Sudo et al., 2004). 
However, this study only assessed plasma cytokines concentrations (IL-6 and IL-1β) during 
24 hours after mice inoculation, which limits the significance of the final conclusion (Sudo et 
al., 2004). More recently, in the study by Desbonnet et al. (2010), MS rat offspring were 
treated with B. infantis 35625 in adulthood (from postnatal day 50) and then subjected to the 
forced swim test (FST) to assess motivational state. The results indicated that MS reduced 
swim behavior and increased immobility in the FST (reflecting a state of behavioral despair) 
                                                                                                                          Capítulo IV 
208 
  
and enhanced peripheral interleukin (IL)-6 release by blood cells stimulated with ConA, 
which were alterations restored by the bifidobacteria administration in adulthood. However, 
the bifidobacteria did not reversed significantly the effect of MS on central neurotransmitters 
(e.g. NA content in the amygdaloid cortex) (Desbonnet et al., 2010), suggesting a role of 
probiotic intervention primarily via modulation of the immune system. Exposure of adult 
mice to a social stressor (called social disruption) also increased circulating cytokines (IL-6 
and MCP-1) along with shifts in intestinal microbiota that were blunted by antibiotic 
treatment, suggesting that gut microbiota is necessary for the stress-induced inflammatory 
response (Bailey et al., 2011). This theory is also supported by effects of stress on gut barrier 
dysfunction which could lead to bacterial product translocation and activation of immunity in 
the gut and beyond. Some neurotransmitters and particularly A (or norepinephrine) have also 
been shown to stimulate the growth and colonization of pathogenic enterobacteria which 
could also contribute to activate intestinal inflammation in response to chronic stress 
(Pasupuleti et al., 2014; Sharma et al., 2014), which theoretically could be down-regulated by 
specific probiotic interventions.   
Communication between the nervous system and immune system and their coordinated 
effects seem to play a critical role in maintaining homeostasis, while deregulation of this 
communication is associated with both mental and intestinal disorders and explain their 
comorbidity. Stress causes activation of the HAP-axis and production of corticotrophin 
releasing factor (CRF), which then stimulates the anterior pituitary gland to release the ACTH 
that in turn stimulates release of cortisol from the adrenal gland, which through a feed-back 
loop, regulates the levels of CRF and ACTH and supports the β adrenergic pathway through 
which the SNS perform an anti-inflammatory role (Straub et al., 2006). However, persistent 
activation of this axis results in down-regulation of the glucocorticoid receptors activity 
involved in the negative feedback controlling the HPA axis, which in turn, results in failure to 
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down-regulate inflammatory response (Cohen et al., 2012). A recent study demonstrated that 
a long-term stressful experience causes glucocorticoid receptor resistance, which refers to a 
decrease in the sensitivity of immune cells to glucocorticoid hormones that normally 
terminate the inflammatory response (Cohen et al., 2012). Chronic psychological stress is also 
known to activate both the HAP axis and the sympathetic-adrenal-medullary system, which 
results in an excessive catecholamine production by sympathetic nerves that in turn trigger 
immune activation (Cohen et al., 2007, 2012; Dhabhar et al., 2014). In the colon of an animal 
model of psychological stress (restrain stress) and in the lamina propia mononuclear cells of 
IBD patients, the expression of dopamine β-hydroxylase (DBH), the rate-limiting enzyme in 
regulation of catecholamine synthesis (e.g. DA, and A from DA), has also been shown to be 
induced, demonstrating that immune cells themselves can increase the production of 
catecholamines in response to psychological stress (Bai et al., 2015). This mode of disruption 
in the normal bidirectional communication between nervous and immune systems, 
implicating the HAP axis, could explain the results of our study in juvenile mice, showing 
enhancements of corticosterone production as well as of inflammatory cytokines and all 
catecholamines analyzed in the gut of the MS animals. The administration of B. 
pseudocatenulatum CECT 7765 down-regulated inflammation in juvenile mice with short and 
long term effects on neurotransmitter concentrations in the CNS and in the behavioral 
phenotype, suggesting this strain play a main role in immune regulation. Scientific evidence 
supports a role for different cytokine families (e-.g. IL-1 and Il-6) in the activation of the HAP 
axis with consequences in mood and behavior and whose concentrations could also be 
influenced by stimuli coming from the gut and the resident or transient microbes. Sudo et al. 
(2004) associated the exaggerated HAP response to restrain stress of germ-free mice 
monocolonized with E. coli EPEC to the enterobateria induced-increases in serum IL-1 and 
IL-6 concentrations. In the MS model, previous studies evidenced increases in inflammatory 
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markers or vulnerability to inflammatory insults (Barreau et al., 2004; Varghese et al., 2006) 
associated or not (O´Mahony et al., 2009) with increases in intestinal permeability in 
adulthood. Varghese et al., (2006) did not report increases in inflammatory intestinal markers 
(tissue levels of IL-1β), but reported enhanced vulnerability to chemically induced colitis in 
adulthood and depressive-like behavior (Varghese et al., 2006). Barreau et al. (2004) found 
that MS in early life led to bacterial translocation into the mesenteric lymph nodes and other 
organs, increased colonic MPO activity, mucosal mast cell density, and cytokine mRNA 
expression although central effects were not investigated. O´Mahony et al. (2009) reported 
that MS animals showed an increased immune response compared to control subjects in 
adulthood, but only in ex vivo stimulated blood cells and not in non-stimulated samples. These 
responses were characterized by increases in the secretion of TNF-α and IFN-γ and slightly 
but not significantly of IL-6 (O´Mahony et al., 2009). These overt inflammatory effects 
related in some studies to intestinal dysbiosis or to increased intestinal permeability have been 
suggested to contribute to HAP activation and CNS effects on behavior (O´Mahony et al., 
2009), as it can be the case for the present study in juvenile mice.   
In our study, stress induced by MS had a stronger impact on neurotransmitter 
concentrations in the gut than in the hypothalamus in juvenile mice, highlighting the 
important role of gut-related signals in early program and regulation of the HAP tress 
response and behavior to prevent later disease. MS exerted the strongest effects on the 
intestinal concentrations of A and NA which were reduced by the bifidobacterial intervention. 
These are the major neurotransmitters of the autonomic nervous system (ANS) that is 
regulated by the hypothalamus and whose afferent and efferent neurons innervate the gut by 
interacting with the enteric nervous system.  
Intestinal dysbiosis has also been related to stress although differences varied depending on 
the study, likely due to differences in the type of stress and experimental conditions, the 
                                                                                                                          Capítulo IV 
211 
  
animal genetic background, environmental factors (diet, contamination of animal facilities, 
etc.) and methodologies used for the analysis. Some studies reported that MS animals had 
reduced lactobacilli concentrations (Bailey and Coe, 1999; Gareau et al., 2007) or the 
microbiota profile (O’Maloney et al., 2009). Social stress in adulthood has been reported to be 
associated with reductions in diversity and bacteroides and with increases in clostridia parallel 
to activation of inflammatory makers (Bailey et al., 2011). 
Components of gut microbiota also seem to play a role in the generation of free 
catecholamines in the intestinal lumen, including DA and A (or NE), since these are lower in 
germ-free than in specific-pathogen free colonized mice (Asano et al., 2012). These 
mechanisms would be in agreement with the simultaneous effects detected in our study in 
both inflammatory cytokines and intestinal catecholamines, especially A, as a result of 
chronic stress exposure.  
In conclusion, we have shown that B. pseudocatenulatum CECT 7765 is able to reprogram 
chronic stress consequences on the HAP response produced by MS during infancy and 
adulthood, via modulation of the neurotransmitter and cytokine network with short and long-
term consequences in brain biochemistry and behavior. In particular, the findings support a 
role of this bacterial strain in regulating the communication between components of the 
adaptive immune system and the sympathetic component of the ANS nervous system in the 
gut with long-term effects on the HAP axis and the hypothalamus that leads to normalization 
of the anxiolytic phenotype induced by chronic stress in mice. Further investigations into the 
sequence of events and systems modulated by gut microbiota-based interventions with long-
term consequences on behavior are guaranteed. This will be crucial to support future human 
intervention trials which could aid in understanding the origin of mental diseases and in their 
management.   
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DISCUSIÓN GENERAL  
Eficacia de potenciales probióticos (Bifidobacterium 
pseudocatenulatum CECT 7765 y Bacteroides uniformis CECT 7771) 
para reducir alteraciones metabólicas asociadas a la obesidad en 
modelos murinos  
Numerosas evidencias científicas apoyan el papel de la microbiota 
intestinal en disfunciones inmunológicas asociadas con la obesidad, la 
dieta y las alteraciones metabólicas (Everard y Cani, 2013). De hecho, los 
resultados recopilados en esta tesis doctoral demuestran de forma 
evidente la interdependencia entre la dieta y la microbiota; pues la dieta 
constituye el mayor factor de influencia  sobre la función y estructura de 
la microbiota. Siendo la intervención con probióticos clave en estos 
procesos. 
Los resultados obtenidos en las tres primeras publicaciones que 
integran la presente tesis doctoral demuestran que la administración oral 
de B. uniformis CECT 7771 y de B. pseudocatenulatum CECT 7765 
podría ejercer efectos beneficiosos en la obesidad a diferentes niveles y a 
través de diversos mecanismos. 
Estos tres trabajos se llevaron a cabo empleando, como modelo 
animal, ratones de la cepa C57BL/6J y comparando la dieta estándar (SD) 
con una dieta rica en grasa (HFD). 
La administración tanto de B. uniformis CECT 7771 como de B. 
pseudocatenulatum CECT 7765 indujo cambios importantes en las 
ganancias de pesos en un modelo animal de obesidad inducida por una 
HFD. Además, B. uniformis CECT 7771 y B. pseudocatenulatum CECT 
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7765 incrementaron el número de adipocitos de menor tamaño en los 
ratones alimentados con la HFD, lo cual podría ser el paso previo a la 
reducción del peso de la masa grasa epididimal. 
Nuestros estudios con modelos murinos de obesidad, también 
demuestran que la administración de B. uniformis CECT 7771 y de B. 
pseudocatenulatum CECT 7765 redujo significativamente el grado de 
esteatosis hepática. Esta alteración es también característica de la 
obesidad debido a que se produce un aumento del flujo de ácidos grasos 
libres al hígado, tras la acumulación excesiva en el tejido adiposo, y dada 
la incapacidad de la insulina para suprimir la lipólisis en los adipocitos, 
por la resistencia a la insulina. Todo ello conduce a la esteatosis o 
enfermedad de hígado graso (Boden et al., 2005). 
Las dislipidemias son también un rasgo frecuente en sujetos 
obesos, siendo las mayoritarias y más conocidas las hipertrigliceridemias 
e hipercolesterolemias (Misra, 2000; Porkka y Raitakari, 1996). Ambas 
fueron inducidas por la HFD. Además, la alimentación con HFD provocó 
aumentos séricos significativos de colesterol y triglicéridos, al comparar 
con los ratones a los que se les alimentaba con la SD. Sin embargo, la 
administración de B. uniformis CECT 7771 y de B. pseudocatenulatum 
CECT 7765 redujo dichos valores en sangre en los animales sometidos a 
la HFD. Estos efectos podrían deberse en parte a una reducción de la 
absorción de grasa y, posiblemente, a la modulación de la expresión de 
genes y proteínas implicados en la homeostasis de lípidos en el intestino y 
el hígado. 
Por ello, y para profundizar más en estos aspectos, se evaluó la 
expresión en hígado de moléculas que podrían estar participando en la 
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regulación del metabolismo de la energía y en el transporte de los lípidos 
que se ven afectados por el consumo de la HFD, trabajando con B. 
pseudocatenulatum CECT 7765 (Capítulo II). 
Utilizando el modelo animal descrito, se analizaron y compararon 
los resultados de microarrays obtenidos para los cuatro grupos 
experimentales. Utilizando el Ingenuity Pathways Analysis (IPA) se 
identificaron factores de transcripción y genes regulados por la grasa y/o 
por la exposición a B. pseudocatenulatum CECT 7765 y que están 
implicados en la regulación del metabolismo lipídico y de hidratos de 
carbono en hígado; más concretamente, en la regulación del transporte de 
ácidos grasos y colesterol, de los niveles lipídicos (colesterol, LDL, HDL 
y TAGs) y del nivel de glucosa. 
Entre todos estos genes, se identificaron tres fundamentales que 
codifican reguladores implicados en respuestas metabólicas al estímulo 
nutricional: el receptor hormonal PPAR, el coactivador transcripcional 
PPARGC1A y el factor de transcripción “zinc finger” EGR1 (Gokey et 
al., 2011). Estos reguladores interactúan con y regulan a otros genes con 
funciones cruciales en el metabolismo energético del hígado, que también 
fueron identificados por sus variaciones con el análisis IPA. Los genes 
identificados en este caso se listan a continuación: “lipid carriers” 
implicados en el transporte de ácidos grasos y colesterol (CD36, FABP5 y 
APOA4) (He et al., 2011), genes implicados en la síntesis e hidrólisis de 
colesterol y triglicéridos (HMGCR, INSIG1 y PNPLA2) (Turpin et al., 
2011; Jeun et al., 2010), y genes implicados en la regulación del 
metabolismo de carbohidratos (PPP1R3B y IGFBP2) (Wheatcroft y 
Kearney, 2009; Luo et al., 2011). 
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Los resultados de los microarrays realizados se confirmaron por 
RT-PCR y a nivel proteico. Los niveles de expresión de CD36, EGR1, 
IGFBP2 y PPP1RB3 se analizaron usando ELISAs. De este modo se 
confirmó que B. pseudocatenulatum CECT 7765 contrarrestó 
significativamente los efectos causados por la HFD en el transportador de 
ácidos grasos CD36, en la transcripción del regulador de la biosíntesis de 
lípidos EGR1 y en los reguladores del metabolismo de la glucosa IGFB2 
y PPP1R3R, ambos tanto a nivel de mRNA como a nivel proteico. 
De acuerdo con el conjunto de los resultados obtenidos, todo 
parece indicar que tanto la administración de B. uniformis CECT 7771 
como la administración de B. pseudocatenulatum CECT 7765 podría 
mejorar significativamente la respuesta oral a la glucosa y reducir la 
glucemia en ayunas, lo que sugiere una mejora en el metabolismo de la 
glucosa y en la sensibilidad a la insulina. Así pues, con los avances 
obtenidos en el conocimiento sobre los principales genes y proteínas 
afectados por la HFD y/o por nuestra cepa bacteriana, se identificaron 
moléculas claves para el metabolismo hospedador.  
La administración de B. uniformis CECT 7771 y de B. 
pseudocatenulatum CECT 7765 también redujo los niveles de leptina en 
ratones obesos, lo que podría ser indicativo de una mejora en la función 
de la leptina o en la sensibilidad a ésta, que, en cualquier caso, lleva a 
reducir la producción de leptina (Jiang et al., 2009). La reducción de los 
niveles séricos de leptina también podría estar relacionada con 
reducciones en el tamaño de los adipocitos y con la reducción de la 
esteatosis hepática en ratones alimentados con HFD y suplementados con 
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la cepa bacteriana, debido al papel de la leptina en la acumulación de 
grasa en los tejidos periféricos (Guo et al., 2004). 
Con todo, nuestros estudios indican que la intervención en el 
ecosistema intestinal con cepas específicas puede mejorar la sensibilidad 
a la insulina inducida por la dieta y la tolerancia a la glucosa (Ma et al., 
2008).  
 
Eficacia de potenciales probióticos (B. pseudocatenulatum CECT 
7765 y B. uniformis CECT 7771) para reducir las alteraciones 
inmunológicas asociadas a la obesidad en modelos murinos y para 
restablecer las alteraciones provocadas en la microbiota intestinal 
Teniendo en cuenta que la obesidad conlleva alteraciones en la 
función del sistema inmunológico y que está asociada a un proceso 
inflamatorio crónico, también se evaluó la posibilidad de restablecer 
dichas alteraciones mediante el uso de potenciales probióticos. 
Concretamente, se evaluó la función fagocítica de los macrófagos, 
observándose que ésta se redujo con la HFD (Capítulo I), de acuerdo con 
resultados obtenidos por otros autores (Zhou et al., 2009). Es bien sabido 
que la función de los macrófagos está alterada en la obesidad, mostrando 
una reducción en su capacidad fagocítica y en el estallido respiratorio; lo 
que también ha sido relacionado con el incremento del riesgo y de la 
susceptibilidad a sufrir una mayor número de infecciones en los sujetos 
obesos (Smith et al., 2007; Amar et al., 2007). 
La administración de B. uniformis CECT 7771 estimuló la función 
fagocítica de los macrófagos tanto en los ratones a los que se les 
administró la SD como a los que se les alimentó con la HFD. Además, B. 
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uniformis CECT 7771 también restableció la capacidad de las células 
dendríticas para estimular la proliferación de los linfocitos T. Así, los 
resultados obtenidos indican que B. uniformis CECT 7771 puede mejorar 
tanto mecanismos innatos como adaptativos frente a infecciones, ante una 
situación de obesidad inducida por dieta. Dichos efectos se detectaron 
también en un estudio previo utilizando la cepa B. pseudocatenulatum 
CECT 7765 (Cano et al., 2013).  
A nivel de análisis de la microbiota intestinal, la HFD provocó 
cambios notables en su composición. La intervención con B. uniformis 
CECT 7771, sin embargo, permitió restablecerla parcialmente (por 
ejemplo, reduciendo el incremento provocado por la HFD en la familia 
Enterobacteriaceae e incrementando significativamente la proporción de 
Bifidobacterium spp., negativamente afectada por la HFD). 
En el Capítulo III, basándonos en la hipótesis de que la microbiota 
junto con los lípidos de la dieta originan las señales inflamatorias que se 
transmiten desde el intestino a la periferia causando, en última instancia, 
la inflamación crónica y disfunción metabólica, se investigaron los 
mecanismos celulares por los que B. pseudocatenulatum CECT 7765 
podría reducir la cascada inflamatoria que se inicia desde el intestino. En 
este estudio se puso de manifiesto que B. pseudocatenulatum CECT7765 
redujo la inflamación sistémica asociada a la obesidad mediante la 
restauración del equilibrio entre células Tregs y los linfocitos B, y la 
reducción de las citoquinas pro-inflamatorias de la inmunidad adaptativa 
(IL-17A) e innata (TNF-α), así como la endotoxemia. A nivel intestinal se 
restauraron parcialmente las alteraciones en microbiota inducidas por la 
HFD y la reducción de la abundancia de LPS de Proteobacterias y de 
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Firmicutes, en paralelo con la reducción de células B, macrófagos y 
citoquinas (IL-6, MCP-1, TNF-α, IL-17A). Todo ello podría contribuir a 
los efectos sistémicos apreciados. Además, en tejido adiposo, la 
administración de esta cepa bacteriana redujo las células B, mientras que 
en el hígado aumentó el número de Tregs. Así, la intervención en el 
ecosistema intestinal con B. pseudocatenulatum CECT7765 dio lugar a 
cambios en la estructura de la microbiota, lo que parece ser suficiente 
para cambiar el perfil inflamatorio a nivel intestinal. Además, ello 
demuestra que la señalización del intestino juega un papel primordial en 
la regulación de la inflamación sistémica asociada a la obesidad. 
 
Influencia de la microbiota y del uso de potenciales probióticos (B. 
pseudocatenulatum CECT 7765) en la respuesta a estrés y la ansiedad  
Finalmente, en el Capítulo IV, pudimos corroborar el hecho de 
que la administración de la B. pseudocatenulatum CECT 7765 durante los 
primeros 20 días de vida en las crías de ratones  tiene un efecto ansiolítico 
durante el régimen de estrés crónico por separación materna, y más 
sorprendente, durante situaciones estresantes agudas en la edad adulta. 
Los resultados publicados hasta la fecha sugieren que hay una “ventana” 
de tiempo crucial para influir en la microbiota intestinal durante su 
configuración postnatal (Borre et al., 2014). Esta “ventana” de tiempo no 
ha sido explorada en profundidad anteriormente. Este es el primer trabajo 
llevado a cabo para mostrar un efecto protector contra el estrés en ratones 
adultos cuando B. pseudocatenulatum CECT 7765 se administra en la 
infancia. 
IV-Discusión general 
226 
 
Con este objetivo, se evaluaron parámetros que se ven alterados 
ante una situación de estrés agudo y/o crónico, tales como: la 
corticosterona (Cavigelli et al., 2006), neurotransmisores (Desbonnet et 
al., 2010), parámetros de sistema inmunitario (Bartrop et al., 1977; Bauer 
et al., 2001) y pruebas de conducta establecidas para evaluar el grado de 
ansiedad-estrés (Desbonnet et al., 2009). Los ratones sometidos a estrés 
por separación materna resultaron más sensibles al estrés agudo en su 
edad adulta, como se puede deducir a partir de los niveles de 
corticosterona en la prueba inmovilización aguda, y de la expresión 
conductual de ansiedad en las diferentes pruebas evaluadas. Sin embargo, 
el tratamiento con B. pseudocatenulatum CECT 7765 previno esta 
sensibilidad al estrés agudo, adquirida por la separación de la madre en la 
infancia. Además, medidas de corticosterona y de neurotransmisores en el 
hipotálamo resultaron significativamente menores en condiciones basales, 
o inmediatamente después de un estrés agudo, en el adulto que había sido 
tratado en su infancia con B. pseudocatenulatum CECT 7765. Todo ello 
sugiere que B. pseudocatenulatum CECT 7765 podría provocar un efecto 
a largo plazo, que éste se lograría a través de la actividad del eje intestino-
cerebro y que hay una influencia de la microbiota en el Sistema Nervioso 
Central.  
Como perspectivas científicas de futuro, sabiendo que la obesidad 
puede derivar en depresión (Hryhorczuk et al., 2013) y partiendo de que 
ansiedad, depresión y estrés son tres caras de la misma moneda, resultaría 
interesante evaluar el estado de ansiedad de sujetos obesos, mediante 
diferentes ensayos de conducta e indicadores hormonales. Además 
convendría analizar el estado de ansiedad/depresión, a nivel del Sistema 
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Nervioso Central, con la evaluación de neurotransmisores que podrían 
verse afectados como consecuencia de la ingesta de una dieta rica en 
grasa, y evaluar si B. pseudocatenulatum CECT7765 presenta o no la 
capacidad de revertir dicha situación. Estos últimos estudios son de gran 
importancia teniendo en cuenta que el estado de ansiedad ligado a la 
obesidad se asocia con una inflamación hipotalámica y con una 
producción de citoquinas proinflamatorias que pueden causar resistencia a 
la leptina a nivel central, y por ende, provocar una reducción del control 
de la ingesta calórica y del gasto/almacenamiento energético. Además, la 
inflamación del Sistema Nervioso Central también contribuye a la 
resistencia sistémica a la insulina; principalmente a nivel hepático, vía 
cerebro-hígado y vía señal neuronal (Milanski et al., 2012). Así, podría 
abrirse camino hacia un posible tratamiento no farmacológico alternativo 
frente a la depresión, siendo necesario antes profundizar en sus 
mecanismos de acción y avanzar en el apasionante mundo de la 
comunicación Intestino-Cerebro. 
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CONCLUSIONES 
1. Bacteroides uniformis CECT 7771  y Bifidobacterium 
pseudocatenulatum CECT 7765 reducen la ganancia de peso 
corporal y el colesterol, los triglicéridos y los niveles de glucosa e 
insulina en suero y mejoran la tolerancia oral a la glucosa y la 
sensibilidad a la insulina en ratones obesos. 
2. B. pseudocatenulatum CECT 7765 modifica la expresión de genes 
reguladores clave del metabolismo y transporte  de ácidos grasos y 
de colesterol y las concentraciones de lípidos y glucosa en hígado, 
en ratones con obesidad inducida por una dieta rica en grasa. 
3. B. pseudocatenulatum CECT 7765 reduce la inflamación 
sistémica asociada a la obesidad inducida por una dieta rica en 
grasa, concretamente, mediante la restauración del equilibrio entre 
células T reguladoras  y linfocitos B y la reducción de las 
citoquinas pro-inflamatorias de la inmunidad adaptativa (IL-17A) 
e innata (TNF-α) y la  endotoxemia. Estos efectos están asociados 
a cambios en la estructura de la microbiota intestinal, que podrían 
ser responsables de parte de los efectos sobre la inflamación.   
4. La administración de B. pseudocatenulatum CECT 7765 en la 
infancia es capaz de reducir las consecuencias negativas del estrés 
crónico, producido por separación materna, sobre el 
comportamiento de los ratones en la infancia y la juventud, 
mediante la modulación de las concentraciones de 
neurotransmisores y corticosterona en el intestino y en el 
hipotálamo y de citoquinas en la infancia y/o en la juventud. 
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ABREVIATURAS 
 
-    A:                          Adrenalina  
-    ACTH:                  Adrenocorticotropina 
-    ACTB:                  Beta actina 
-    AGL:                     Ácidos grasos libres. 
-    ALT:                     Alanina aminotransferasa 
-    AMP:                    Monofosfato de adenosína  
-    APOA4:                Apolipoprotein A-IV 
-    AST:                     Aspartato aminotransferasa 
-    ATP:                     Trifosfato de adenosina. 
-    AUC:                    Área bajo la curva de glucosa 
-    B:                          Bacteroides uniformis CECT 7771 
-    BH:                       Brain Heart Infusion Broth 
-    Bif /B.p.:               Bifidobacterium pseudocatenulatum CECT 7765 
-    BSA:                     Albúmina de suero bovino. 
-    CD36:                   Antígeno  CD36  
-    CECT:                   Colección Española de Cultivos Tipo 
-    CFU:                     Unidades formadoras de colonias 
-    CRH:                     Hormona liberadora de corticotropina 
-    DA:                        Dopamina 
-    DCs:                      Células dendríticas 
-    DMEM:                 Medio Dulbeco’s Modified Eagles    
-    DNA:                     Ácido desoxirribonucleico 
-    EDTA:                   Ácido etilendiaminotetraacético, sal disódica. 
-    EFSA:                    Autoridad Europea de Seguridad Alimentaria 
-    EGR1:                    Early growth response 1 
-    ELISA:                   Ensayo por inmunoabsorción ligado a enzimas 
-    EPM:                      Elevated plus maze 
-    ER:                         Retículo endoplasmático 
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-    FABP5:              Fatty acid binding protein 5 
-    FAO:                  Organización de las naciones unidad para la 
Alimentación y la agricultura 
-    FBS:                   Suero fetal bovino 
-    FTO:                   Gen fat mass and obesity-associated 
-    GABA:                Ácido gamma-aminobutírico 
-    GF:                     Animales libres de gérmenes; Germ-free animals 
-    GHRF:                Factor liberador de hormona del crecimiento 
-    GLP-2:                Glucagon-like peptido 2  
-    GS:                      Sistema gastrointestinal 
-    GTT:                   Test de tolerancia oral a la glucosa 
-    HDL:                   Lipoproteína de alta densidad 
-    HFD:                   Dieta rica en grasa 
-    HMGCR:             3-hydroxy-3-methylglutaryl-Coenzyme A reductase 
-    HPLC:                 Cromatografía líquida de alta resolución. 
-     IFN-γ:                 Interferón gamma 
-     IGFBP2:             Insulin-like growth factor binding protein 2 
-     IL:                       Interleuquina. 
- iNOS:                 Óxido nítrico sintasa inducible. 
- IMC:                   Índice de Masa Corporal 
- INE:                    Instituto Nacional de Estadística 
- INSIG1:              Insulin induced gene 1 
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Abstract
Background & Aims: Intervention in the gut ecosystem is considered as a
potential strategy to treat liver diseases and their complications. We have
evaluated the effects of Bifidobacterium pseudocatenulatum CECT7765 on
bacterial translocation and the liver status in experimental cirrhosis. Animals
& Methods: Liver damage was induced in Balb/c mice by weight-controlled
oral administration of carbon tetrachloride. Laparotomies were performed at
week 12. One week prior to laparotomy, animals received B. pseudocatenula-
tum CECT7765 (109cfu/daily) or placebo intragastrically. All animals
received Escherichia coli (107cfu/single dose) intragastrically 24 hours before
laparotomy. A group of na€ıve non-treated animals was included as control.
Liver tissue specimens, mesenteric lymph nodes, intestinal content and blood
were collected. Liver histology, profibrogenic genes expression, bacterial
DNA translocation, serum endotoxaemia and liver cytokine levels were mea-
sured. Results: Bifidobacterium pseudocatenulatum CECT7765 showed no
significant effect on structural liver damage, as determined by histological
evaluation, alpha-smooth muscle actin distribution, profibrogenic gene
expression levels, total hydroxyproline levels and malon dialdehyde produc-
tion compared with mice receiving placebo. Interestingly, bacterial DNA
translocation and serum endotoxin levels were significantly decreased in mice
receiving the Bifidobacterium strain compared with placebo. Gut barrier
integrity markers were up-regulated in mice receiving B. pseudocatenulatum
CECT7765 and quantitatively correlated with intestinal gene copy numbers
of the bifidobacterial strain. Gene expression levels of several anti-inflamma-
tory mediators were also increased in mice receiving B. pseudocatenulatum
CECT7765 compared with placebo. Conclusion: Oral administration of B.
pseudocatenulatum CECT7765 is associated with improved gut barrier integ-
rity and shows a beneficial effect against induced bacterial antigen transloca-
tion in the CCl4-model of cirrhosis.
Translocation of bacteria or their products (BT) from
the intestinal lumen to the mesenteric lymph nodes
(MLNs) has been extensively documented as a frequent
complication in cirrhosis, not only at end-stage but also
in early stages of disease progression (1, 2). Mechanisms
proposed to explain these bacterial translocation epi-
sodes include an increased intestinal permeability (3–5),
an intestinal bacterial overgrowth (IBO) (6–8) and,
more recently, alterations in the gut microbiota compo-
sition (9, 10), which might contribute to increasing the
liver exposure to microbial products and inflammatory
signals coming from the gut. Therefore, the communi-
cation between the gut and the liver, the so-called gut-
liver axis, is thought to be involved in cirrhosis, being
gut microbiota a key regulator of inflammation and BT
in this setting (11). Consequently, probiotics have
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emerged as an alternative to antibiotic strategies in the
treatment and prevention of infectious complications of
cirrhosis.
Although the mechanisms by which probiotics may
induce protective effects are not completely understood,
they have been acknowledged to contribute to restoring
alterations in intestinal permeability, microbiota com-
position and inflammatory responses. Strains of the
genera Bifidobacterium and Lactobacillus have been
among the most extensively studied microorganisms.
Some Bifidobacterium strains seem to be implicated in
host protection by preventing increased intestinal per-
meability and promoting a healthier microvillus envi-
ronment (12, 13) whereas Lactobacillus strains have
been reported to improve immune defense mechanisms
(14, 15). Several studies report the restoration of neutr-
ophilic function (16) or the reduction in liver inflam-
mation and endotoxaemia by probiotics in patients with
cirrhosis (17).
However, other studies report non-beneficial effects
of probiotic supplementation on clinical or analytical
variables of patients with cirrhosis (18, 19) revealing the
controversy regarding their protective role in this condi-
tion. The primary aim of this study had been to evaluate
the effects of Bifidobacterium pseudocatenulatum CECT
7765, a strain that has already shown positive effects on
the metabolic and immunological dysfunction associ-
ated with obesity in high-fat diet fed mice (20), on
reducing MLN bacterial DNA translocation and serum
endotoxaemia in the model of toxic-induced liver dam-
age with carbon tetrachloride (CCl4) exposed to bacte-
rial challenge. Additionally, we have also evaluated the
effect of this bacterial strain on the liver structural dam-
age induced by CCl4 administration in this model.
Methods
Animals and study design
Female Balb/c mice (Harlan, Barcelona, Spain) were
included to run a 16-week study protocol, as described
below. Mice were caged at a constant room temperature
of 21 °C and exposed to a 12:12 light/dark cycle. Mice
weighing 18–20 g were fed standard rodent chow and
treated with 0.25 mmol/L phenobarbital in tap water
along study protocol. Animals received care according
to the criteria outlined in the Guide for the Care and
Use of Laboratory Animals. This study was approved by
the Animal Research Committee of Universidad Miguel
Hernandez (Alicante, Spain).
After a 4-week housing, animals were subjected to an
experimental cirrhosis induction with two weekly,
weight-controlled doses of CCl4 intragastrically admin-
istered for 12 weeks using a sterile pyrogen free syringe
with an attached stainless steel animal feeding tube
without anaesthesia as previously described (10). Briefly,
the first dose of CCl4 was 100 ll/kg (2 ll/mice) in min-
eral oil, and subsequent doses were adjusted based on
changes in weight 48 h after the last dose, reaching
100 ll/mice. One week prior to laparotomy, animals in-
tragastrically received B. pseudocatenulatum CECT7765
(CECT7765) (109 cfu daily) or placebo (vehicle), and
24 h before laparotomy, all animals received Escherichia
coli (107 cfu/intragastrically). A group of na€ıve non-trea-
ted animals was included as control. Laparotomies were
performed under anaesthesia with isofluorane at week
12 as previously described (10).
Bacterial strains and culture conditions
The strain CECT7765 and E. coli CECT45 were obtained
from Spanish Type Culture Collection (CECT). The
Bifidobacterium strain was grown in MRS broth (Schar-
lau, Barcelona, Spain) supplemented with 0.05% (w/v)
cysteine (MRS-C Sigma, St. Louis, MO, USA), and incu-
bated at 37 °C for 22 h (at stationary growth phase)
under anaerobic conditions (AnaeroGen, Oxoid, Bas-
ingstoke, UK). Cells were harvested by centrifugation
(6.000 g for 15 min), washed twice in phosphate buf-
fered saline (PBS, 130 mM sodium chloride, 10 mM
sodium phosphate, pH 7.4) and re-suspended in 10%
skimmed milk for oral administration to mice. E. coli
was grown in 0.5 ml of Thioglycolate with Resarzurin
(Biomerieux, Marzy L’Etoile, France) and incubated at
37 °C for 22 h. Cells were harvested by centrifugation,
washed twice in PBS and re-suspended in PBS for oral
administration to mice. Aliquots of these suspensions
were frozen in liquid nitrogen and stored at 80 °C
until used. The number of live cells after freezing and
thawing was determined by colony-forming unit (CFU)
counting on MRS-C agar or McConkey agar (Bio-
merieux), respectively, after 48-h incubation. For the
strains tested, more than 90% cells were alive upon
thawing and no significant differences were found dur-
ing storage time (2 months). One fresh aliquot was
thawed for every new experiment to avoid variability in
the viability of cultures.
Sample collection
After laparotomies, all detectable MLNs were aseptically
removed. Animals under anaesthesia were euthanized
by heart injection and total blood collection. Liver,
spleen, intestinal wall and content from caecum
(10 cm) and blood were collected. The liver was per-
fused in situ with 6 ml of Hanks balanced salt solution
(HBSS) without Ca2+ and Mg2+ at 37 °C at a rate of
1.5 ml/min. This was followed by perfusion with 12 ml
of HBSS containing 100 mM CaCl2 solution at the same
perfusion rate. The liver was then removed and rinsed
with 3 ml of HBSS.
Histological analysis
Liver biopsy specimens between 10 and 15 mm in size
were fixed in buffered formalin and embedded in
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paraffin. Histological changes were first evaluated by
routine haematoxylin and eosin (H&E) in four-micro-
meter thick sections. Hepatic fibrosis and architectural
distortion were estimated with the connective tissue
stain Masson trichrome. The amount of fibrosis was
blindly assessed semiquantitatively based on the Ishak
score (21) by a senior pathologist (GP), using a conven-
tional light microscope (Olympus BX50, Barcelona,
Spain). A morphometric analysis of fibrotic area in liver
histological sections (per cent blue area in Mason’s tri-
chrome–stained livers) was blindly performed using the
ImageJ software (http://rsbweb.nih.gov/ij/).
Immunohistochemistry
Immunohistochemical assay was carried out in serial
sections of paraffin-embedded liver tissue. We used
heat-induced antigen retrieval before exposure to the
primary antibody (monoclonal mouse anti-human
alpha–smooth muscle actin; clone 1A4; ready-to-use)
(Dako/Agilent Technologies; Carpinteria, CA, USA).
The staining was performed using the EnVisionTM
Flex detection system and an Autostainer Link 48
(Dako/Agilent Technologies). As a negative control,
staining was carried out in the absence of primary
antibody.
Tissue lysates and immunoblotting
Instestinal wall and liver samples were homogenized by
sonication. Tissue homogenates were then lysed with
RIPA buffer, protein concentration determined by Brad-
ford assay and protein extracts (15 lg protein/lane)
handled as previously described (22). The primary anti-
bodies used against alpha-smooth muscle actin (a-
SMA), occludin, tight junction protein (TJP)-1, as
markers of intestinal barrier dysfunction, tumour
necrosis factor alpha (TNF-a), TNF-a receptor I (TNF-
RI), TNF-RII, interleukin (IL)-10, IL-10 receptor
(IL-10R) and b-actin were purchased from Santa Cruz
Biotechnology (Heidelberg, Germany).
Liver hydroxyproline, malonyl dialdehyde, occludin and
TJP-1 levels
Quantitative levels of Hydroxyproline (Biomedical
Assay, Shanghai, China) and MDA BlueGene Biotech,
Shanghai, China) in the liver, and occludin and TJP-1
(Antibodies Online, Aachen, Germany) in the intesti-
nal wall samples were determined by enzyme-linked
immunosorbent assays (ELISA) according to the man-
ufacturers’ instructions after tissue sonication. All
samples were tested in duplicate and read in a Sunrise
Microplate Reader (Tecan, Mannedorf, Switzerland).
Lower limit of detection for the Hydryproline
assay was 10 ng/mg tissue, for the MDA assay was
10 pg/mg tissue and for occludin and TJP-1 was
100 pg/mg tissue.
Gene expression analysis
Total cellular RNA was isolated from 20 to 30 mg of
liver and 10cm of intestinal wall disrupted by sonication
(Hielscher UP100H Ultrasonic Processor, Teltow, Ger-
many) followed by QIAmp RNA Tissue Minikit (QIA-
gen, Hilden, Germany). a-SMA, collagen a-1, collagen
a-3, tumour growth factor beta (TGF-b)-1, tissue
inhibitor of metalloproteinase (TIMP)-1 and matrix
metalloproteinase (MMP)-2 genes. Occludin, TJP-1,
TNF-a, TNF-RI, TNF-RII, IL-10 and IL-10R gene
expression levels were determined in the disrupted
intestinal samples. Quantitec SYBR Green (QIAgen) was
used to perform all gene expression analyses in an IQ5
Real-Time PCR (BioRad, Hercules, CA, USA). Primer
pair sequences used in this study were designed using
Primer-BLAST tool from NCBI (Bethesda, MD, USA)
(National Center for Biotechnology Information, U.S.
National Library of Medicine) and are listed in
Table S1.
Identification of bacterial DNA and serum endotoxin
Bacterial DNA was detected and identified in MLN and
blood samples according to the methodology described
elsewhere (23, 24). The quantitative chromogenic limu-
lus amebocyte lysate test (BioWhittaker, Nottingham,
UK) was performed to evaluate serum endotoxin levels
according to the manufacturer’s instructions. All sam-
ples were tested in duplicate and read at 405 nm in a
Sunrise Microplate Reader.
Quantification of Bifidobacterium in the intestinal content
Samples of intestinal content from caecum were frozen
immediately after collection at 20 °C and stored until
analysed. Samples were weighted and diluted 1:5 (w/v)
in phosphate buffered saline solution (PBS, pH 7.2)
homogenized and one aliquot of this dilution was used
for DNA extraction using the QIAamp DNA stool Mini
kit (QIAgen) according to the manufacturer’s instruc-
tions. Specific primers (Table S1) targeting the genus
Bifidobacterium were used to quantify their total gene
copy numbers by qPCR using LightCycler 480 SYBR
Green I Master (Roche, Pleasanton, CA, USA) with an
ABI PRISM 7000-PCR sequence detection system
(Applied Biosystems, Cheshire, UK), as described previ-
ously (25). Data are expressed as log of gene copy num-
bers per gram of intestinal content.
Statistical analysis
Continuous variables are reported as mean ± standard
deviation and categorical variables as frequency or per-
centages. Quantitative data were analysed using the
Mann–Whitney U-test or the Kruskal–Wallis test
followed by pairwise comparisons using the Mann–
Whitney U-test with the post hoc Bonferroni correction
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for multiple comparisons. Differences in qualitative
variables were analysed using the Chi-square test. Bivar-
iate correlations between continuous variables were cal-
culated using the Spearman test. All reported P values
are 2-sided, and P values lower than 0.05 were consid-
ered to indicate significance. All calculations were
performed using the IBM SPSS Statistics 19.
Results
Characteristics of animals
A total of 65 animals were included in this study. Thir-
teen animals died during liver damage induction (20%).
Causes of death were CCl4 toxicity and liver insuffi-
ciency. Animals were grouped in basal (na€ıve) and
12 weeks of CCl4 administration (cirrhosis). None of
the CCl4-treated animals showed evidence of ascitic
fluid at laparotomy. Characteristics of mice in both
groups can be followed in Table S2.
Effect of B. pseudocatenulatum CECT7765 administration
on CCl4-induced liver damage
Figure 1 shows the liver damage after the 12-week
experimental protocol either treated or not with the bif-
idobacterial strain. As can be observed at histological
sections and their morphometric analysis, the extent of
fibrotic areas were decreased in animals receiving the
bifidobacteria compared with placebo, although differ-
ences did not reach statistical significance (Ishak scores:
3.8 ± 0.8 vs 4.4 ± 0.6, P = ns) (Fig. 1A). Histological
distribution, gene expression and protein quantification
(Fig. 1B-1D) revealed a non-significant effect of the bifi-
dobacterial strain on alpha-SMA expression in the liver
of CCl4-mice. Table 1 shows Hydroxyproline and MDA
levels, as well as gene expression levels of different pro-
fibrogenic markers in the liver of animals distributed by
the use of B. Pseudocatenulatum CECT7765. No signifi-
cant differences were observed for any of the studied
parameters between the bifidobacterial strain and the
use of placebo.
B. pseudocatenulatum CECT7765 administration reduces
bacterial antigen translocation in CCl4-treated mice
Escherichia coli administration to cirrhotic mice induced
bacterial antigen translocation into MLNs in 18 of 20 (90%)
mice treated with placebo. However, only 9 mice of 20
(45%, P = 0.01) treated with the bifidobacterial strain
showed bacterial DNA in MLNs (Fig. 2A). Spontaneous
bacterial antigen translocation was detected in 1 mouse
(8%) from the control group. Sequencing analysis iden-
tified E. coli in all cases. No bacterial DNA from bifido-
bacteria was identified in MLNs of any included mice.
The administration of B. pseudocatenulatum
CECT7765 also showed a significant reduction in the
serum endotoxin levels observed in cirrhotic mice after
being exposed to E. coli in comparison with mice receiv-
ing placebo (Fig. 2B). Figure S1 shows the effect of B.
pseudocatenulatum CECT7765 administration on bacte-
rial translocation in healthy control animals.
(A)
(B) (C) (D)
Fig. 1. Bifidobacterium pseudocatenulatum CECT7765 effect on liver damage. (A) Example of histological changes in CCl4-treated mice
receiving or not CECT7765 and morphometric analysis of fibrotic area in liver histological sections (per cent blue area in Mason’s trichrome–
stained livers). Hepatic sections stained with Masson Trichrome (original magnification 910), showing light to strong blue staining, as a
reflection of the collagen deposition: no histopathological changes (naive); marked fibrosis in the majority of portal spaces with frequent
portal-portal and portal-central bridging and architectural distortion (regenerative nodules). (B) Hepatic sections stained with alpha-SMA (ori-
ginal magnification 9100), showing positive staining in perivascular myoepithelial cells and scattered perisinusoidal spindle cells in a paren-
chyma without histopathological changes (naive); moderate to strong expression in areas with complete fibrous septa, as well as in
perisinusoidal spindle cells (cirrhosis). (C) Relative gene expression levels of alpha-SMA in study groups. Mean values in CCl4-treated mice
with or without CECT7765 (n = 20/group) ± standard deviation are represented. *P < 0.01 compared with naive mice; (D) Representative
immunoblot for alpha-SMA expression in the liver of CCl4-mice with or without CECT7765. SMA, smooth muscle actin.
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B. pseudocatenulatum CECT 7765 administration
ameliorates gut barrier integrity and inflammation
In order to elucidate possible mechanisms for the bifi-
dobacterial strain to reduce bacterial antigen transloca-
tion in cirrhotic mice, intestinal barrier integrity
markers were evaluated. Levels of occludin and TJP-1 in
animals receiving weekly doses of CCl4 were signifi-
cantly decreased compared with basal levels. Adminis-
tration of B. pseudocatenulatum CECT7765 significantly
increased occludin (Fig. 3A) and TJP-1 (Fig. 3B) both
at gene and protein expression levels.
Total gene copy numbers of Bifidobacterium spp.
were quantified in all cirrhotic animals and showed a
positive correlation with ELISA-measured protein
expression levels of occludin (Fig. 3C) and TJP-1
(Fig. 3D).
Gene expression levels of anti-inflammatory free fatty
acid and folate receptors Ffar2, Ffar3 and FolR, specifi-
cally induced by bifidobacterium spp., were up-regu-
lated in the intestinal wall of animals treated with CCl4
and the bifidobacterial strain compared with those
receiving CCl4 and placebo (Table 2). Pro-inflamma-
tory cytokine TNF-a and its receptors were significantly
increased in cirrhotic mice treated with placebo prior to
bacterial challenge with E. coli, whereas the expression
of these pro-inflammatory genes was down-regulated in
animals receiving B. pseudocatenulatum CECT7765.
Finally, IL-10 and IL-10R gene expression levels were
increased in intestinal wall samples from mice receiving
the bifidobacterial strain compared with those receiving
placebo (Table 2). Gene expression levels of anti-
inflammatory free fatty acid and folate receptors, IL-10
and IL-10R in healthy control mice are shown in
Table S3.
No significant differences in the gene expression lev-
els of gut integrity markers or studied inflammatory
mediators were observed between bacterial DNA-posi-
tive and bacterial DNA-negative mice considering all
CCl4-treated animals, either with or without B. pseudo-
catenulatum CECT 7765 (data not shown). Figure S2
shows the effect of B. pseudocatenulatum CECT7765
administration on gut barrier integrity in healthy con-
trol animals.
Discussion
In this study, we intended to evaluate the effect of B.
pseudocatenulatum CECT7765 on a well-known experi-
mental model of cirrhosis considering two main out-
comes: bacterial translocation and liver damage. Results
presented show that bacterial antigen translocation, a
Table 1. Hydroxyproline and MDA levels in the liver of CCl4-treated mice according to the administration of Bifidobacterium pseudocate-
nulatum CECT7765, and relative gene expression levels of different profibrogenic genes
Naive (n = 12) CCl4 (n = 20) CCl4 + CECT7765 (n = 20)
Hydroxyproline (ug/g liver) 144.4 ± 60.1 668.8 ± 224.6* 527.7 ± 191.4*
MDA (pg/mg liver) 31.5 ± 7.8 61.3 ± 10.6* 53.3 ± 11.7*
Collagen alpha-1 (mRNA) 1 26.5 ± 5.8* 21.7 ± 6.3*
Collagen alpha-3 (mRNA) 1 20.4 ± 6.2* 16.6 ± 5.6*
TGF-B (mRNA) 1 19.1 ± 4.2* 15.6 ± 5.8*
TIMP-1 (mRNA) 1 36.1 ± 7.9* 29.1 ± 8.6*
TIMP-1 (mRNA) 1 33.6 ± 8.2* 28.2 ± 7.2*
Mean values ± standard deviations are represented.
*P < 0.01 compared with na€ıve mice.
MDA, malondyaldehide; TGF-b, Tumour growth factor beta; TIMP-1, Tissue inhibitor of metalloproteinase 1; MMP-2, Matrix metalloproteinase 2.
(A) (B)
Fig. 2. Bifidobacterium pseudocatenulatum CECT7765 effect on bacterial translocation. (A) Bacterial DNA translocation into MLNs in CCl4-
mice either receiving or not B. pseudocatenulatum CECT7765; (B) Serum endotoxin levels in CCl4-mice either receiving or not B. pseudocate-
nulatum CECT7765. *P < 0.01 compared with naive mice; $P < 0.01 compared with CCl4-mice without B. pseudocatenulatum CECT7765.
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frequent complication in cirrhosis, is significantly
reduced although not erased after a bacterial challenge
with orally administered E. coli in mice receiving the bif-
idobacterial strain compared with placebo whereas no
significant effect is induced over the CCl4-modified liver
arquitecture.
The use of alternative strategies to antibiotics to
restore the intestinal homeostasis and reduce the
adverse stimuli reaching the liver via the gut-liver axis
is being investigated to improve the inflammatory
condition in chronic diseases such as cirrhosis, but
showing controversial results (16–19, 26, 27). In the
present investigation, we have used the strain B. pseud-
ocatenulatum CECT7765, which was previously
reported to exert protective effects in metabolic and
immune parameters in an animal model of obesity
(20), to evaluate its effects on the translocation of bac-
terial antigens, which have been related in the past with
an increased inflammatory outlook in this setting (28)
and, secondly, on fibrosis status in mice with CCl4-
induced cirrhosis.
As shown in Fig. 1 and Table 1, the effect of the B.
pseudocatenulatum CECT7765 on fibrosis and oxidative
damage was limited. Although all markers showed a
slight reduction in mice receiving the bifidobacterial
strain, the difference with mice receiving placebo was
not statistically significant. However, this trend might
justify the evaluation of B. pseudocatenulatum CECT
7765 higher doses or for longer periods of time as a
strategy to ameliorate the structural liver injure in cir-
rhosis. In fact, previous studies have investigated the
modulation of liver fibrosis after administration of dif-
ferent probiotic preparations. VSL#3, for instance, has
been reported to attenuate fibrosis in a diet-induced
non-alcoholic steatohepatitis model (29). Although that
study reported no effect over liver inflammatory mark-
ers, others have shown a reduced lipid peroxidation and
TNF-a secretion by an enhanced macrophage function
activity in CCl4-mice after administration of selenium-
enriched lactobacillus (30). Other strains of the species
B. pseudocatenulatum have been reported to induce
Table 2. Gene expression levels of inflammatory markers in intesti-
nal tissue samples
mRNA CCl4 (n = 20) CCl4 + CECT7765 (n = 20)
Ffar 2 0.70 ± 0.10* 20.65 ± 6.60†
Ffar 3 0.60 ± 0.15* 26.85 ± 5.12†
FolR 0.76 ± 0.20* 35.4 ± 7.42†
IL-10 2.60 ± 1.12* 15.89 ± 3.95†
IL-10 2.90 ± 0.82* 18.59 ± 7.10†
TNF-alpha 13.15 ± 3.80* 4.14 ± 1.06†
TNF-RI 14.12 ± 4.10* 5.95 ± 1.30†
TNF-RII 13.05 ± 4.40* 4.40 ± 1.62†
Mean values ± standard deviations are represented.
*P < 0.01 compared with na€ıve mice.
†P < 0.01 compared with mice receiving B. pseudocatenulatum
CECT7765.
FFAR, free fatty acid receptor; FolR, folate receptor; IL-10, interleukin
10; IL-10R, interleukin 10 receptor; TNF-a, tumour necrosis factor alpha;
TNF-RI, tumour necrosis factor alpha-receptor I; TNF-RII, tumour necro-
sis factor alpha-receptor II.
(A) (B)
(C) (D)
Fig. 3. Bifidobacterium pseudocatenulatum CECT7765 effect on gut barrier integrity markers. (A) Gene and protein expression levels of oc-
cludin (n = 20 each group). (B) Gene and protein expression levels of tight junction protein-1 (TJP) (n = 20 each group). A representative
immunoblot for each marker is shown for both groups. *P < 0.01 compared with CCl4-mice treated with placebo; (C) Correlation between
intestinal gene copy numbers of Bifidobacterium spp. and occludin protein levels; (D) Correlation between intestinal gene copy numbers of
Bifidobacterium spp. and TJP-1 protein levels; TJP-1: tight junction protein 1.
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IL-10 production by dendritic cells in previous studies
(31). In our study, gene expression levels of IL-10 and
its receptor IL-10R are increased in intestinal samples
from mice receiving B. pseudocatenulatum CECT7765
compared with placebo, suggesting a possible IL-10-
mediated anti-inflammatory mechanism as previously
shown in cirrhotic patients on norfloxacin as secondary
prophylaxis of SBP (22). Accordingly, pro-inflammatory
TNF-a, TNF-RI and TNF-RII were down-regulated in
the intestinal wall of mice treated with the bifidobacteri-
al strain.
The ability of B. pseudocatenulatum CECT7765 to
reduce bacterial translocation, a frequent and severe
complication in cirrhosis, was the primary goal of this
study. To evaluate this, bacterial translocation was
induced by administration of E. coli to all animals
24 h before laparotomies. Although the bifidobacterial
strain did not completely erase bacterial DNA translo-
cation, B. pseudocatenulatum CECT7765 significantly
reduced induced bacterial translocation, as demon-
strated by the reduction in the MLN bacterial DNA
translocation rate and in the serum endotoxin levels
in CCl4-mice treated with B. pseudocatenulatum
CECT7765 (Fig. 2) compared with CCl4-mice treated
with placebo. It is possible that an earlier administra-
tion of the bifidobacterial strain, for a longer period
of time or at a higher concentration might have
reduced bacterial DNA translocation rates even more.
Also, spontaneous bacterial DNA translocation has
been described in CCl4-induced experimental models
[50-80% in CCl4-mice (10) and 60-70% of CCl4-rats
(24)]. E. coli-induced bacterial translocation was per-
formed to guarantee bacterial translocation in all stud-
ied animals and significantly discriminate the effect of
B.pseudocatenulatum CECT775 on this process. The
identification by sequencing analysis confirmed in all
BT-positive cases the unique presence of the same
bacterial species than that orally administered. There-
fore, we consider that spontaneous BT may not be
affecting the presented results.
Concerning safety, no bacterial DNA from bifidobac-
teria was identified in MLNs of bacterial DNA-positive
samples in any case. Several studies had already investi-
gated the potential benefit of probiotics in reducing BT
rates, obtaining different results. For instance, a symbi-
otic preparation including several Lactobacillus strains
reduced hepatic inflammation and endotoxaemia in
patients with cirrhosis (17) and, in experimental animal
models, endotoxaemia and severity of alcoholic liver
disease was reduced by administration of Lactobacillus
spp. (32). On the other hand, although Guarner et al.
reported the effect of Lactobacillus johnsonii and antioxi-
dants on ameliorating BT by decreasing intestinal
bacterial overgrowth and intestinal oxidative damage in
rats with experimental cirrhosis (33), the same group
has recently proved that taken antioxidants out, Lacto-
bacillus johnsonii fails to reduce BT in these animals
(27). Similarly, Bauer et al. reported the failure of
Lactobacillus spp. to prevent BT in a rat model of
experimental cirrhosis (34).
Explaining the protective effect of B. pseudocatenula-
tum CECT7765 on the translocation of bacterial
antigens into MLNs, the administration of the bifido-
bacterial strain was associated with the improvement of
the gut barrier integrity, as evaluated by the occludin
and TJP-1 gene and protein expression in homogenized
extracts from the intestinal tissue. The expression of
these molecules was up-regulated in mice receiving B.
pseudocatenulatum CECT7765 compared with placebo
and quantitatively correlated with the total gene copy
numbers of the bifidobacterial strain in cirrhotic mice.
Furthermore, the administration of B. pseudocatenula-
tum CECT7765 was also associated with an anti-inflam-
matory environment promoted by the increased
production of specific receptors for FFAs and folate
(Fig. 3). The ligands for these receptors are produced by
certain clostridia and bifidobacterial strains (35–37)
and, in agreement with these results, they had already
been described to contribute to reduce BT events in
experimental cirrhosis in previous studies from our
group (10).
In summary, this study shows the beneficial effects of
B. pseudocatenulatum CECT7765 against induced bacte-
rial antigen translocation in the CCl4-model of cirrhosis
and provides rationale for evaluating its role in prevent-
ing bacterial complications in other experimental
models of liver injure.
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with advanced cirrhosis and can induce an immunogenic response
Conclusion: Norﬂoxacin not only reduces gram-negative intesti-
nal ﬂora but also participates in an IL-10-driven modulation ofwithout an overt infection. Norﬂoxacin is a gram-negative bacteri-
cidal drug able to maintain low endotoxin levels and stimulate
IL-10 production. We aimed at investigating the role of IL-10 in
decreasing endotoxin absorption in cirrhotic mice treated with
norﬂoxacin.
Methods: Cirrhosis was induced by carbon tetrachloride or bile
duct ligation in wild type and IL10-deﬁcient mice with or without
norﬂoxacin prior to an intragastrical administration of E. coli,
K. pneumonia or E. faecalis. Spontaneous and induced bacterial
translocation, free endotoxin and cytokine levels were evaluated
in mesenteric lymph nodes. Intestinal permeability was followed
by ﬂuorimetry and barrier integrity markers were measured in
disrupted intestinal samples. The inﬂammatory-modulating
mechanism was characterized in puriﬁed intestinal mononuclear
cells.
Results: Norﬂoxacin reduced spontaneous and induced MLN
positive-cultures in wild type and IL-10-deﬁcient animals. How-
ever, reduction of free endotoxin levels was associated with nor-
ﬂoxacin in wild type but not in IL-10-deﬁcient mice. Wild type
but not IL-10-deﬁcient mice treated with norﬂoxacin signiﬁcantly
normalized intestinal permeability and improved gut barrier
integrity markers. The toll-like receptor 4-mediated pro-inﬂam-
matory milieu was modulated by norﬂoxacin in a concentra-
tion-dependent manner in cultured intestinal mononuclear cells
of wild type mice but not of IL-10-deﬁcient mice. The restoration
of IL-10 levels in IL-10-deﬁcient animals reactivated the
norﬂoxacin effect on inﬂammatory-modulation, gut barrier
permeability, and luminal endotoxin absorption.Journal of Hepatology 20
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The process by which bacteria exit the intestinal lumen, access
the mesenteric lymph nodes (MLN) and colonize other organs
is known as bacterial translocation (BT) [1], and is considered
as the key spontaneous bacterial peritonitis (SBP)-leading
mechanism in patients with advanced cirrhosis. However, not
only viable bacteria but also their products translocate and
induce a similar inﬂammatory response to that developed
against SBP in the absence of an overt infection [2]. The pres-
ence of these enteric bacterial products such as DNA and lipo-
polysaccharide (LPS) in the bloodstream represents a threat
that may compromise patients’ clinical outcome, as reported
in studies revealing the association between their presence
and a marked hemodynamic derangement [3,4], and others
identifying LPS-binding protein and bacterial-DNA as indepen-
dent predictors of severe bacterial infections [5] and mortality
[6], respectively. Therefore, the management of bacterial prod-
ucts trespassing the intestinal barrier to the systemic circula-
tion is of utmost relevance.
Norﬂoxacin has been shown to effectively reduce the inci-
dence of bacterial translocation when used as secondary prophy-
laxis of SBP [7,8], and also to reduce non-infectious related
clinical complications, such as hepatorenal syndrome, when
administered as primary prophylaxis [9]. The selective decon-
tamination of intestinal gram-negative microbiota with norﬂoxa-
cin generates a temporal overload of free endotoxin in the
intestinal lumen and other bacterial products that may translo-
cate into the blood. Nevertheless, norﬂoxacin is associated with14 vol. xxx j xxx–xxx
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reduced serum free endotoxin levels in cirrhosis and has been
reported to modulate as well patients’ pro-inﬂammatory reac-
tion, showing a direct effect on neutrophil response to oxidative
stress, reducing the secretion of reactive oxygen species and
increasing the apoptosis rate [10].
IL-10 signalling induces the expression of heme oxygenase
(HO)-1, a stress-inducible protein that prevents ethanol-induced
inﬂammation in the intestine [11] and liver [12]. HO-1 correlates
with intracellular levels of norﬂoxacin in cultured cells of
cirrhotic patients on selective intestinal decontamination in
response to LPS [13]. Therefore, we hypothesized that IL-10
may be involved in the reduced luminal endotoxin absorption
induced by norﬂoxacin.
To investigate this, we studied luminal free endotoxin absorp-
tion in spontaneous and induced BT through the intragastrical
administration of bacteria in wild type (WT) and IL10-deﬁcient
(IL10/) cirrhotic mice treated with norﬂoxacin. The results were
controlled with the administration of a recombinant IL-10 pro-
tein to restore IL-10 levels in IL10/ mice.Methods
Animals and study design
Female Balb/c WT and IL10/ mice (Harlan, Barcelona, Spain) were included in a
16-week study protocol. Mice were caged at a constant room temperature of
21 C and exposed to a 12:12 light/dark cycle. Adult mice were fed standard
rodent chow and treated with 0.25 mmol/L phenobarbital in tap water along
study protocol. Animals received care according to the criteria outlined in the
Guide for the Care and Use of Laboratory Animals. The study was approved by
the Animal Research Committee of Universidad Miguel Hernandez (Alicante,
Spain).
After 4 weeks, animals were subjected to experimental cirrhosis induction
either with two weekly, weight-controlled doses of CCl4 intragastrically adminis-
tered [14], performing laparotomies under anaesthesia with isoﬂurane at week 16,
or with bile duct ligation (BDL) surgery [15], performing laparotomies 4 weeks
after BDL.
One week prior to laparotomy, WT and IL10/ animals received norﬂoxa-
cin (5 mg/kg intragastrically/daily; Sigma-Aldrich, Madrid, Spain) or placebo. A
subgroup of IL10/ animals also received a non-lytic interleukin-10/Fc
Chimera fusion protein (1000 units i.p./every two days; Sigma-Aldrich).
Twenty-four hours before laparotomy animals were distributed in spontaneous
or induced BT subgroups as shown in Supplementary Fig. 1. Induced BT sub-
groups received E. coli (serotype 0111:B4), K. pneumoniae or E. faecalis
(107 cfu/intragastrically). All detectable MLNs were aseptically removed (4–
5 MLNs/mouse without differences between groups), sonicated and liqueﬁed
for bacterial culture, DNA isolation and sequencing analysis [16,17]. We inoc-
ulated 100 lL of liqueﬁed MLNs on MacConkey agar (BioMerieux, Marcy l’Eto-
ile, France). Cultures were incubated in 5% CO2 at 37 C and examined daily for
visible growth. An additional subset of mice was euthanized at week 0 to serve
as naïve controls.
Animals under anaesthesia were euthanized by heart punction and total
blood collection. Liver, spleen, intestinal wall from ileum (10 cm) and blood were
collected. The liver was perfused in situ with HBSS without Ca2+ and Mg2+ at
37 C. This was followed by perfusion with HBSS containing 100 mM CaCl2 solu-
tion at the same perfusion rate. The liver was then removed and rinsed with
HBSS.Isolation and culture of intestinal mononuclear cells
The whole small intestine was removed from CCl4 and BDL mice. Intraepithelial
and lamina propria cells were isolated as previously described [18]. Resuspended
cells (0.5  106 cells/well) were cultured for 24 h at 37 C and 5% CO2 without
stimuli or with norﬂoxacin 0.5, 1, 2, 4, and 8 lg/ll. After that period, LPS
25 lg/ml (E. coli serotype 0111:B4; Sigma) was added to all wells and cells were
cultured for an additional 24 h period. Cells and supernatants were collected and
stored at 20 C until use.Please cite this article in press as: Gómez-Hurtado I et al. Role of interleukin
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Liver biopsy specimens, 10–15 mm in size, were ﬁxed in buffered formalin and
embedded in parafﬁn. Histological changes were ﬁrst evaluated by routine H&E
in 4 lm thick sections. Hepatic ﬁbrosis and architectural distortion was estimated
with the connective tissue stain Masson-trichrome. The amount of ﬁbrosis was
blindly assessed semiquantitatively based on the Ishak score [19], using a con-
ventional light microscope (Olympus BX50, Barcelona, Spain). A morphometric
analysis of the ﬁbrotic area was blindly performed using the ImageJ software
(http://rsbweb.nih.gov/ij/).
Immunohistochemistry
Immunohistochemistry was performed in serial sections of parafﬁn-embedded
liver tissue. We used heat induced antigen retrieval before exposure to the
primary antibody (monoclonal mouse anti-human alpha–smooth muscle actin
(a-SMA); clone 1A4; ready-to-use) (Dako/Agilent Technologies; Carpinteria,
CA). The staining was performed using the EnVision™ Flex detection system
and an Autostainer Link 48 (Dako/Agilent Technologies). As a negative control,
staining was carried out in the absence of the primary antibody.
FITC-LPS permeability assay
Intestinal permeability was evaluated administering ﬂuorescein isothiocyanate
(FITC)-LPS from E. coli O111:B4 (Sigma) by gastric gavage 4 h before sacriﬁce.
Whole blood was obtained by cardiac puncture at the time of killing. Dilutions
of FITC-LPS in PBS were used as standard curve and FITC-LPS measurements were
performed in 100 ll of plasma or standard in a ﬂuorimeter at 488 nm.
Tissue lysates and gene expression analysis
Total cellular RNA was isolated from 20 to 30 mg of liver and 10 cm of intestinal
wall disrupted by sonication. Gene expression levels of collagen a-1, tumour
growth factor beta (TGF-b)-1, tissue inhibitor of metalloproteinase (TIMP)-1 and
matrix metalloproteinase (MMP)-2 in liver and IL10, IL10R, HO-1, Bcl-3, TNF-a,
Toll-like receptor (TLR)-4, chemokine (C-C Motif) receptor 7 (CCR7), chemokine
(C-X-C Motif) ligand 11 (CXCL11), chemokine (C-C Motif) ligand 18 (CCL18) in
cultured intestinal mononuclear cells were determined. Occludin and TJP-1
were evaluated in intestinal samples. Primer-pair sequences used are listed in
Supplementary Table 1.
ELISAs
The quantitative chromogenic limulus amebocyte lysate test (BioWhittaker, Not-
tingham, UK) was performed to evaluate endotoxin levels according to the man-
ufacturer’s instructions. IL-10 (R&D Systems, Minneapolis, MN), occludin
(Antibodies Online, Aachen, Germany) and TJP-1 (BioMedical Assay, Shanghai,
China) assays were performed after sonication in disrupted intestinal and liver
samples.
Statistical analysis
Continuous variables are reported as mean ± standard deviation and categorical
variables as frequency or percentages. Quantitative data were analysed using
the Mann-Whitney U test for simple comparisons or the Kruskal-Wallis test fol-
lowed by pairwise comparisons using the Mann-Whitney U test with the post-hoc
Bonferroni correction for multiple comparisons. Differences in qualitative vari-
ables were analysed using the v2 test. Bivariate correlations between continuous
variables were calculated using the Spearman test. All reported p values are 2-
sided, and p values lower than 0.05 were considered to indicate signiﬁcance.
All calculations were performed using the IBM SPSS Statistics 19.Results
Characteristics of animals
A total of 100 WT and 170 IL10/ mice started the protocol for
cirrhosis induction with CCl4. During the 16-week protocol, 2210 in norﬂoxacin prevention of luminal free endotoxin translocation in
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Fig. 2. Spontaneous and induced BT in cirrhotic mice with or without norﬂoxacin. (A) Percentage of culture-positive MLNs. (B) Number of CFUs in culture-positive
MLNs. (C) Intestinal gene copy numbers of Enterobacteriaceae. Mean values ± standard deviations are represented in all panels. ⁄p <0.05 compared with the paired
norﬂoxacin group. Nﬂx, norﬂoxacin; ex, exogenous.
Research Article(22%) WT and 36 (21.2%) IL10/ mice died as a consequence of
CCl4 toxicity and liver insufﬁciency. In the BDL protocol, 60 WT
and 135 IL10/ mice were initially included. During the 6-week
protocol, 12 (20%) WT and 34 (25.2%) IL10/ mice died. The
remaining animals were randomly allocated into different sub-
groups in both protocols, according to the study design described
in Supplementary Fig. 1. After bacterial species administration
and before laparotomies, 15 WT (19%) and 20 IL10/ mice
(15%) died in the CCl4 protocol and 9 (18.7%) WT and 15
(14.8%) IL10/ mice died in the BDL protocol, without signiﬁcant
differences between the described subgroups. Characteristics ofFig. 1. Liver structural damage. (A and F) Histological changes in CCl4 (A) and BDL (F)
magniﬁcation 100), showing strong blue staining, as a reﬂection of the collagen deposit
trichrome–stained livers) in liver histological sections from CCl4 (B) and BDL (G) mice. (C
with a-SMA (original magniﬁcation 100), showing moderate to strong expression in
Hydroxyproline levels in the liver of CCl4 (D) and BDL (I) WT and IL10/mice. (E and J) Re
(J) WT and IL10/ mice. (K) Colon sections stained with hematoxylin/eosin (original m
inﬁltrating cells in CCl4 and BDL WT and IL10/ mice. Mean values ± standard deviations
metalloproteinase 2; TGF-b, Tumour growth factor beta; TIMP-1, Tissue inhibitor of me
Please cite this article in press as: Gómez-Hurtado I et al. Role of interleukin
mice with cirrhosis. J Hepatol (2014), http://dx.doi.org/10.1016/j.jhep.2014.05
4 Journal of Hepatology 201mice ﬁnally going into laparotomy are detailed in Supplementary
Table 2.
Cirrhosis was conﬁrmed for both protocols of liver damage in
all animals. No statistically signiﬁcant differences were present
between WT and IL10/ mice livers either histologically, in the
protein expression levels of a-SMA and hydroxyproline, or in
the mRNA expression levels of main pro-ﬁbrogenic genes (Fig. 1).
As IL10/ mice may develop spontaneous colitis, colon sec-
tions were studied in both protocols. As can be followed in
Fig. 1, no signs of inﬂammation were observed in either WT or
IL10/mice after protocols of cirrhosis.WT and IL10/ mice. Hepatic sections stained with Masson Trichrome (original
ion. (B and G) Morphometric analysis of ﬁbrotic area (percent blue area in Mason’s
and H) Hepatic sections from CCl4 (C) and BDL (H) WT and IL10/ mice stained
areas with complete ﬁbrous septa and in perisinusoidal spindle cells. (D and I)
lative gene expression levels of proﬁbrogenic genes in the liver of CCl4 (E) and BDL
agniﬁcation 200) showing normal colonic mucosa, crypts length and number of
are represented in all panels. a-SMA, alpha–smooth muscle actin; MMP-2, Matrix
talloproteinase 1.
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Fig. 3. Gut barrier permeability and IL-10 modulation effect on free endotoxin absorption in cirrhotic mice with or without norﬂoxacin in spontaneous or induced
BT conditions. (A) Serum endotoxin levels. (B) MLN endotoxin levels. (C) Fold induction of FITC-LPS recovery in plasma. Mean values ± standard deviations are represented
in all panels. ⁄p <0.05 compared with the paired norﬂoxacin group. FITC, Fluorescein isothiocyanate; Nﬂx, norﬂoxacin; ex, exogenous.
JOURNAL OF HEPATOLOGYSelective intestinal decontamination by norﬂoxacin is IL-10
independent
As shown in Fig. 2A a signiﬁcant percentage of spontaneous BT
was observed in both WT and IL10/ mice with both liver dam-
age protocols without differences between them. E. coli and E.
faecalis administration further increased this rate in all subgroups
(Fig. 2A). Among the non-bacteria–treated 25 mice with MLN
positive-cultures, sequencing analyses identiﬁed 14 E. coli, 4 E.
faecalis, 3 K. pneumoniae, 2 P. vulgaris, 1 S. pneumoniae and 1 C.
freundi. Among the E. coli–treated 36 mice with MLN positive-
cultures, sequencing analyses identiﬁed 27 E. coli (same strain
as intragastrically administered), 3 S. aureus, 2 E. faecalis,
2 K. pneumoniae, 1 S. pneumoniae and 1 S. ﬂexneri. Among the
E. faecalis–treated 33 mice with MLN positive-cultures, sequenc-
ing analyses identiﬁed 24 E. faecalis (same strain as intragastrical-
ly administered), 4 E. coli, 3 S. aureus and 2 S. agalactiae (Fig. 2A).
Norﬂoxacin was able to reduce the rate of MLN positive cultures
in all cases.
The number of CFUs per MLN was not different between sub-
groups of non-bacteria-treated animals with MLN positive-
cultures in both protocols of liver injury. Bacteria administration
induced an overall increment of 35% in the number of CFUs per
MLN compared with non-bacteria-treated animals (24 ± 8 vs.Please cite this article in press as: Gómez-Hurtado I et al. Role of interleukin
mice with cirrhosis. J Hepatol (2014), http://dx.doi.org/10.1016/j.jhep.2014.05
Journal of Hepatology 20117 ± 9 CFUs/MLN, p = 0.05). Norﬂoxacin was able to signiﬁcantly
reduce the amount of CFUs/MLN in WT mice and in IL10/ mice
supplemented with exogenous IL-10. Regarding IL10/ mice,
the amount of CFUs/MLN in animals treated with norﬂoxacin
decreased from 22 ± 7 to 15 ± 8, p = 0.05 in the CCl4 protocol,
and from 18 ± 8 to 10 ± 4, p = 0.02 in the BDL protocol (Fig. 2B).
Finally, norﬂoxacin was able to induce intestinal decontamination
of the aerobic gram-negative ﬂora both inWT and IL10/mice, as
evidenced by the reduction of the total gene copy numbers of
Enterobacteriaceae cluster in the intestinal content of all studied
animals, even in those treated with E. coli that signiﬁcantly
increased their Enterobacteriaceae counts compared with mice
not challenged with the administered E. coli strain. Animals trea-
ted with E. faecalis showed no signiﬁcant increment in the total
gene copy numbers of Enterobacteriaceae cluster compared with
non-bacteria-treated mice (Fig. 2C).
In mice with MLN positive-cultures, the amount of CFUs/MLN
and Enterobacteriaceae counts in the intestinal content of K.
pneumoniae-treated subgroups were similar to those described
for the E. coli-treated subgroups and are detailed in the Supple-
mentary Table 3. Among the K. pneumoniae–treated 32 mice
with MLN positive-cultures, sequencing analyses identiﬁed 21
K. pneumoniae (same strain as intragastrically administered),
5 E. coli, 3 S. aureus and 3 E. faecalis.10 in norﬂoxacin prevention of luminal free endotoxin translocation in
.031
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Table 1. Occludin and TJP-1 protein levels in disrupted intestinal samples.
Occludin (pg/g tissue) TJP-1 (pg/g tissue)
 No Yes No Yes
Spontaneous BT WT
Norfloxacin
9.3 ± 2.2 17.4 ± 5.8 * 13.4 ± 7.6 21.6 ± 7.5 *
IL10-/- 7.4 ± 2.8 9.2 ± 3.2 12.8 ± 6.5 11.7 ± 8.0 
IL10-/- (+ IL-10) 8.6 ± 2.6 16.5 ± 7.1 * 12.0 ± 6.4 23.1 ± 10.1 *
E. coli induced BT WT 10.2 ± 4.8 18.6 ± 6.6 * 14.2 ± 5.5 23.8 ± 9.9 *
IL10-/- 9.8 ± 3.5 10.0 ± 2.4 12.7 ± 6.8 13.2 ± 5.6 
IL10-/- (+ IL-10) 9.4 ± 3.2 17.3 ± 6.4 * 13.8 ± 5.8 24.8 ± 10.6 *
E. faecalis induced BT WT 9.4 ± 1.8 15.8 ± 4.4 * 13.5 ± 4.8 20.6 ± 6.5 *
IL10-/- 8.4 ± 2.2 9.1 ± 3.3 14.4 ± 5.2 13.8 ± 6.2
IL10-/- (+ IL-10) 9.0 ± 2.1 16.4 ± 2.8 * 14.1 ± 4.5 21.7 ± 4.0 *
K. pneumoniae induced BT WT 10.1 ± 2.6 18.0 ± 3.5 * 12.3 ± 5.4 19.5 ± 3.5 *
IL10-/- 9.3 ± 2.2 9.5 ± 2.7 13.6 ± 6.1 14.2 ± 3.8
IL10-/- (+ IL-10) 9.0 ± 2.5 17.1 ± 3.2 * 13.4 ± 5.5 20.6 ± 5.4 *
A
B
Occludin (pg/g tissue) TJP-1 (pg/g tissue)
 No Yes No Yes
Spontaneous BT WT
Norfloxacin
11.0 ± 4.1 19.4 ± 6.8 * 16.4 ± 7.1 30.2 ± 10.1 *
IL10-/- 10.5 ± 3.5 11.1 ± 6.4 15.6 ± 4.8 16.1 ± 6.7
IL10-/- (+ IL-10) 10.2 ± 4.1 20.0 ± 7.2 * 14.6 ± 6.2 26.5 ± 5.8 *
E. coli induced BT WT 11.3 ± 5.0 19.5 ± 5.8 * 17.1 ± 8.0 28.6 ± 7.1 *
IL10-/- 10.6 ± 4.3 11.4 ± 5.8 16.3 ± 4.6 14.8 ± 8.0
IL10-/- (+ IL-10) 9.8 ± 2.8 21.1 ± 6.7 * 16.5 ± 4.6 27.6 ± 7.5 *
E. faecalis induced BT WT 12.4 ± 5.5 22.3 ± 6.5 * 16.2 ± 7.2 19.3 ± 8.8
IL10-/- 11.6 ± 3.8 10.5 ± 3.4 15.8 ± 6.5 14.3 ± 4.0
IL10-/- (+ IL-10) 13.1 ± 5.5 19.8 ± 4.6 * 16.0 ± 4.7 22.5 ± 5.8 *
K. pneumoniae induced BT WT 11.6 ± 3.6 22.3 ± 7.1 * 16.8 ± 5.5 30.4 ± 7.7 *
IL10-/- 12.5 ± 4.1 13.1 ± 4.9 16.7 ± 6.1 15.8 ± 6.1
IL10-/- (+ IL-10) 12.5 ± 4.8 20.1 ± 5.6 * 15.6 ± 4.6 28.6 ± 7.5 *
⁄p <0.05 compared to without norﬂoxacin.
Research ArticleAltered gut barrier permeability in IL10/ mice is related to
increased serum free endotoxin levels
Endotoxin translocation into blood andMLNs was evaluated in all
subgroups of animals. WT animals with norﬂoxacin showed
lower serum and MLN free endotoxin levels than WT animals
without norﬂoxacin (Fig. 3A and B), probably as a consequence
of the spontaneous BT rates described in Fig. 2 for those animals.
Interestingly, norﬂoxacin was not associated with a decrease in
serum or MLN free endotoxin levels in IL10/ mice compared
with WT mice in any of the experimental models. In support of
IL-10 requirement for the reduction of endotoxin translocation
in cirrhotic mice, IL-10 protein levels were restored in IL10/
mice by administration of recombinant IL-10 protein. A signiﬁ-
cant reduction in serum and MLN endotoxin levels was achieved
in IL10/ mice with norﬂoxacin and exogenous IL-10 restoration
(Fig. 3A and B).
TNF-a and IL-6 protein levels in MLNs (Supplementary
Table 4) did not decrease with norﬂoxacin in IL10/ mice and
correlated with MLN endotoxin levels in both protocols
(r = 0.74, p = 0.001, for CCl4-mice; r = 0.77, p = 0.001, for BDL-
mice).Please cite this article in press as: Gómez-Hurtado I et al. Role of interleukin
mice with cirrhosis. J Hepatol (2014), http://dx.doi.org/10.1016/j.jhep.2014.05
6 Journal of Hepatology 201WT mice treated with norﬂoxacin signiﬁcantly reduced the
recovery of administered FITC-LPS compared with WTmice with-
out norﬂoxacin in both mice models (Fig. 3C). Interestingly, nor-
ﬂoxacin failed to normalize intestinal permeability in IL10/
mice, whereas the restoration of IL-10 levels with the recombi-
nant IL-10 protein in IL10/ mice receiving norﬂoxacin was
again associated with a signiﬁcant decrease of FITC-LPS recovery
and the exogenous administration of IL-10 restored FITC-LPS
recovery rates in IL10/ mice to levels present in WT animals
in both experimental models. Mice challenged with intragastrical
administration of E. coli or E. faecalis behaved similarly (Fig. 3C).
The comparison of spontaneous and induced BT in WT and
IL10/ mice discarded any baseline effect of intragastrical bacte-
rial administration on gut permeability. Overall, FITC-LPS recov-
ery rates were higher in the CCl4 vs. the BDL model, although
differences were not statistically signiﬁcant.
Results of serum and MLN free endotoxin levels, and in the
recovery percentage of FITC-LPS in the K. pneumoniae-treated
subgroups were similar to those described for the E. coli-treated
subgroups and are detailed in the Supplementary Table 5.
Occludin and TJP-1 protein levels in disrupted intestinal
samples conﬁrmed that the administration of norﬂoxacin was10 in norﬂoxacin prevention of luminal free endotoxin translocation in
.031
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Table 2. Relative gene expression levels of inﬂammatory markers in intestinal mononuclear cells. (A) CCl4, (B) BDL.
WT 
(spontaneous BT)
WT 
(E. coli induced BT)
WT 
(E. faecalis induced BT)
WT 
(K. pneumoniae induced BT)
No Yes No Yes No Yes No Yes
IL-10
Norfloxacin
Norfloxacin
10.5 ± 7.2 28.4 ± 9.6 * 9.3 ± 4.8 30.8 ± 9.3 * 10.3 ± 4.9 36.1 ± 12.2 * 11.0 ± 5.3 31.2 ± 12.1 *
IL-10R 11.6 ± 5.6 30.6 ± 14.6 * 11.5 ± 3.5 27.4 ± 7.2 * 11.0 ± 5.5 31.4 ± 9.5 * 10.2 ± 3.4 32.3 ± 11.4 *
HO-1 10.5 ± 5.5 21.4 ± 7.6 * 11.1 ± 3.8 27.4 ± 7.8 * 10.5 ± 6.0 28.2 ± 8.4 * 9.9 ± 4.4 22.9 ± 9.2 *
Bcl-3 11.5 ± 4.8 21.3 ± 7.2 * 15.4 ± 6.4 26.0 ± 8.8 * 13.6 ± 4.5 26.2 ± 9.0 * 10.1 ± 5.0 26.7 ± 8.7 *
TNF-alpha 17.0 ± 4.3 10.2 ± 4.5 * 29.6 ± 10.4 12.5 ± 5.0 * 27.5 ± 10.2 11.3 ± 5.7 * 24.8 ± 8.7 14.0 ± 8.6 *
WT 
(spontaneous BT)
WT 
(E. coli induced BT)
WT 
(E. faecalis induced BT)
WT 
(K. pneumoniae induced BT)
No Yes No Yes No Yes No Yes
IL-10 11.3 ± 6.6 25.5 ± 10.1 * 10.0 ± 5.1 28.7 ± 10.1 * 8.8 ± 4.0 32.0 ± 14.7 * 10.4 ± 4.5 26.5 ± 10.5 *
IL-10R 10.2 ± 6.1 27.3 ± 12.2 * 10.7 ± 4.4 25.6 ± 9.5 * 11.6 ± 4.8 29.5 ± 9.3 * 11.5 ± 6.0 25.1 ± 9.2 *
HO-1 9.6 ± 4.3 20.5 ± 5.9 * 11.4 ± 3.6 25.5 ± 6.5 * 9.8 ± 4.1 25.6 ± 10.3 * 10.7 ± 4.8 19.8 ± 10.5
Bcl-3 10.8 ± 5.0 22.6 ± 6.7 * 13.6 ± 5.2 27.5 ± 9.4 * 10.6 ± 3.9 28.0 ± 10.3 * 8.9 ± 4.3 23.5 ± 8.2 *
TNF-alpha 19.8 ± 4.6 10.6 ± 4.8 * 30.3 ± 9.6 11.8 ± 5.6 * 25.6 ± 9.4 11.8 ± 6.2 * 22.6 ± 10.1 13.8 ± 6.7 *
A
B
⁄p <0.05 compared to without norﬂoxacin.
JOURNAL OF HEPATOLOGYassociated with an improvement of the intestinal gut barrier
integrity only when IL-10 is expressed in mice either spontane-
ously or with bacterial species administration (Table 1). Conﬁrm-
ing these results, the restoration of IL-10 protein levels in IL10/
mice with norﬂoxacin increased occludin and TJP-1 protein levels
up to those induced by norﬂoxacin in WT mice.
Norﬂoxacin induces IL-10 in intestinal mononuclear cells and
downregulates the pro-inﬂammatory response by a TLR-4
modulating mechanism
As detailed in Table 2, the administration of norﬂoxacin was
associated with signiﬁcantly increased gene expression of IL-10
and its receptor IL-10R, as well as with the expression of IL-10-
inducible HO-1 and Bcl-3 genes in puriﬁed intestinal mononu-
clear cells from WT mice compared with those not receiving
norﬂoxacin. As a control, cells from IL10/ mice showed no gene
expression levels of IL-10 and the administration of exogenous
recombinant IL-10 protein to these mice induced similar gene
expression levels of IL-10R, HO-1 and Bcl-3 (data not shown).
On the other hand, the administration of norﬂoxacin was
associated with a signiﬁcantly decreased gene expression of
TNF-a. IL10 mRNA levels correlated with occludin and TJP-1
mRNA levels in WT mice without norﬂoxacin (r = 0.71; p = 0.01
and r = 0.75; p = 0.001, respectively) and with norﬂoxacin
(r = 0.74; p = 0.01).
We conﬁrmed in vitro IL-10 induction by norﬂoxacin. Puriﬁed
intestinal mononuclear cells from WT and IL10/ cirrhotic mice
without norﬂoxacin treated with the CCl4 and BLD protocols were
cultured with increasing amounts of norﬂoxacin. After 24 h, cul-
tured cells were stimulated with LPS for 24 h. Cells and superna-
tants were then collected for cytokine production measurement.
Secreted IL-10 levels in WT CCl4-mice were signiﬁcantly
increased with higher concentrations of norﬂoxacin, whereas
TNF-a was signiﬁcantly decreased (Fig. 4A). In IL10/ CCl4-mice,
norﬂoxacin was not able to reduce TNF-a levels (Fig. 4B). RelativePlease cite this article in press as: Gómez-Hurtado I et al. Role of interleukin
mice with cirrhosis. J Hepatol (2014), http://dx.doi.org/10.1016/j.jhep.2014.05
Journal of Hepatology 201gene expression levels of TLR-4, the speciﬁc receptor for
endotoxin, were signiﬁcantly downregulated by increasing con-
centrations of norﬂoxacin in monocytes from WT CCl4-mice,
whereas the expression of TLR-4 was not affected by increasing
concentrations of norﬂoxacin in monocytes from IL10/
CCl4-mice. Finally, the restoration of IL-10 levels in IL10/ mice
brought TLR-4 levels back down as norﬂoxacin concentrations
increased (Fig. 4C). These results provide a mechanism for nor-
ﬂoxacin to modulate inﬂammation and suggest a non-classically
activated monocyte population in the presence of norﬂoxacin. In
fact, studying the molecular phenotype of monocytes from WT
CCl4-mice by gene expression analyses of the chemokine receptor
CCR7 and the chemokine ligand CXCL11 suggested a transition
towards a M2 phenotype with signiﬁcantly increased expression
of IL-10R and CCL18 (Fig. 4D and E). Results were similar in all
cases for intestinal mononuclear cells isolated fromWT BDL-mice
and can be followed in Supplementary Table 6.Discussion
In the present study, we demonstrate that IL-10 is required to
normalize gut barrier permeability and to downregulate luminal
free endotoxin absorption in cirrhotic animals with norﬂoxacin.
These ﬁndings provide rationale for considering IL-10 as a key
regulator of serum free endotoxin in cirrhosis, opening a
hypothetical IL-10-mediated therapeutic ﬁeld to explore.
The selective lysate of intestinal gram-negative microbiota
with norﬂoxacin, which has been shown to reduce the incidence
of bacterial infections in patients with cirrhosis [7,8], generates a
temporal overload of free endotoxin in the intestinal lumen, as
well as other bacterial products that needs to be managed prop-
erly to avoid its translocation into the blood. It is not rare though,
to detect free endotoxin or bacterial-DNA in blood of a signiﬁcant
portion of patients with decompensated cirrhosis that can cause
an inﬂammatory response [2]. Elegant experimental studies from10 in norﬂoxacin prevention of luminal free endotoxin translocation in
.031
4 vol. xxx j xxx–xxx 7
A B C
D E
120
100
80
60
40
20
0
120
100
80
60
40
20
0
150
100
50
0
C
on
ce
nt
ra
tio
n 
(p
g/
m
l)
C
on
ce
nt
ra
tio
n 
(p
g/
m
l)
50
40
30
20
10
0
m
R
N
A
50
40
30
20
10
0
m
R
N
A
TL
R
4 
m
R
N
A *
* *
* *
*
*
* *
*
**
*
* * * *
*
**
$
$
$ $
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
TNFα
IL-10
CXCL11
CCR7
IL-10R
CCL18
TNFα
IL-10
Co
ntr
ol
Nf
lx 
1
Nf
lx 
2
Nf
lx 
3
Nf
lx 
4
Nf
lx 
5
Co
ntr
ol
Nf
lx 
1
Nf
lx 
2
Nf
lx 
3
Nf
lx 
4
Nf
lx 
5
Co
ntr
ol
Nf
lx 
1
Nf
lx 
2
Nf
lx 
3
Nf
lx 
4
Nf
lx 
5
Co
ntr
ol
Nf
lx 
1
Nf
lx 
2
Nf
lx 
3
Nf
lx 
4
Nf
lx 
5
Co
ntr
ol
Nf
lx 
1
Nf
lx 
2
Nf
lx 
3
Nf
lx 
4
Nf
lx 
5
WT
IL10-/- 
IL10-/- (+ IL-10)
Fig. 4. Puriﬁed intestinal mononuclear cells cultured with different norﬂoxacin concentrations in cirrhotic mice. (A and B) Secreted levels of TNF-a and IL-10 in
response to LPS. (C) Gene expression levels of TLR-4 in response to LPS. (D and E) Gene expression levels of CXCL11 and CCR7 (D) and IL-10R and CCL18 (E) in response to LPS.
Mean values ± standard deviations are represented in all panels. ⁄p <0.01 compared with control; $p <0.01 compared with previous norﬂoxacin concentration. Nﬂx 1–5,
norﬂoxacin 0.5, 1, 2, 4, and 8 lg/ll, respectively; TLR-4, toll-like receptor 4; CXCL11, chemokine (C-X-C Motif) ligand 11; CCR7, chemokine (C-C Motif) receptor 7; IL-10R,
interleukin 10 receptor; CCL18, chemokine (C-C Motif) ligand 18.
Research ArticleSchnabl et al. demonstrated the important role of gut permeability
in modulating endotoxin translocation and highlighted the rele-
vance of the gut barrier integrity in preventing the trespassing
of these bacterial antigens [20]. In the present study, we demon-
strate that norﬂoxacin is not only effective in decontaminating
gram-negative ﬂora, therefore reducing the translocation of
viable bacteria into MLNs, but provides also a mechanism by
which norﬂoxacin may improve gut barrier integrity, preventing
as well the translocation of luminal free endotoxin into the
blood. Without IL-10, gut permeability is increased and, despite
effective intestinal decontamination, luminal free endotoxin
may translocate more easily into the blood.
The evaluation of viable bacteria translocation into MLNs of
cirrhotic mice revealed ﬁrst that spontaneous BT occurred in up
to 50% of WT cirrhotic mice, matching the rates reported in pre-
vious studies in a rat model [17] and offering an explanation for
the differences observed in free endotoxin levels in the serum of
WT cirrhotic vs. naive animals used as controls. Second, norﬂox-
acin was shown to be effective in killing viable bacteria in ani-
mals challenged with intragastrical E. coli. A signiﬁcant
reduction in the total gene copy numbers of Enterobacteriaceae
in WT animals receiving norﬂoxacin was observed in our study
compared with cirrhotic mice used as control. Besides, no
differences were observed in the total gene copy numbers of
Enterobacteriaceae between WT and IL10/ animals, discarding
possible baseline differences between groups interfering with
the results.Please cite this article in press as: Gómez-Hurtado I et al. Role of interleukin
mice with cirrhosis. J Hepatol (2014), http://dx.doi.org/10.1016/j.jhep.2014.05
8 Journal of Hepatology 201But more interestingly, the administration of norﬂoxacin was
associated with a decrease in the circulating free endotoxin levels
in serum of WT cirrhotic mice. This fact was correlated in vitro
with the puriﬁed intestinal mononuclear cell production of IL-
10 and with the normalization of the gut barrier permeability,
increasing the gene and protein expression levels of barrier integ-
rity markers in these mice up to those present in naive control
mice (Fig. 3). However, norﬂoxacin could not be associated either
with a decrease in serum free entoxin levels, a normalization of
the gut barrier permeability or an increase in gut barrier integrity
markers in IL10/ cirrhotic mice. These results suggest an impor-
tant role for IL-10 in the maintenance of gut barrier integrity dur-
ing cirrhosis and are in agreement with previous studies
reporting the beneﬁcial effect of IL-10 in intestinal mucosal bar-
rier permeability and the regulation of the immune response to
enteric microbiota [21]. We consider that the translocation of via-
ble bacteria is inhibited by norﬂoxacin mainly through its antag-
onizing activity on bacterial-DNA gyrase, which is required for
bacterial-DNA replication [22,23]. This activity is IL-10-indepen-
dent and leads to bacterial-DNA cleavage and degradation. How-
ever, degraded bacterial products still may translocate and we
hypothesize that IL-10 is required to avoid this, at least for LPS,
inducing an IL10-driven TLR-4 downregulation and reducing
intestinal permeability.
In a previous study by our group, we demonstrated an IL-10-
mediated mechanism for modulating the cellular pro-inﬂamma-
tory response in patients receiving norﬂoxacin [13]. In this10 in norﬂoxacin prevention of luminal free endotoxin translocation in
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investigation, we show that norﬂoxacin stimulates IL-10 produc-
tion and increased gene and protein expression levels of IL-10-
inducible genes in puriﬁed intestinal monocytes in WT cirrhotic
animals. In support of these results, in vitro experiments demon-
strated the dose-dependent effect of norﬂoxacin on TNF-a reduc-
tion after LPS stimulation in WT cirrhotic mice, whereas TNF-a
production by puriﬁed cultured monocytes from IL10/ mice
was not affected by different concentrations of norﬂoxacin.
We also show that TLR-4 expression in cultured intestinal
mononuclear cells is norﬂoxacin dose-dependent and requires
IL-10, as demonstrated by the unresponsiveness of TLR-4 to
norﬂoxacin in cultured monocytes from IL10/ mice (Fig. 4). As
TLR-4 represents the speciﬁc receptor for endotoxin, a powerful
pathogen-associated molecular pattern in gram-negative bacte-
ria, the link between norﬂoxacin and bacterial endotoxin down-
regulation can be clearly established through IL-10 regulation
of the pro-inﬂammatory environment. In fact, when the inﬂam-
matory milieu is characterized in intestinal monocytes, CXCL11
and CCR7 are decreased whereas IL-10R and CCL18 are increased
with increasing concentrations of norﬂoxacin, pointing to the
transition of monocytes from a M1 to a M2 phenotype as a
possible mechanism for modulating TLR-4 expression and the
inﬂammatory response. The inﬂuence of antibiotics on the
macrophages phenotype has been previously described [24]
and these results are in line with previous studies in which
IL10-inducible genes negatively regulate LPS-induced TNF-a
production in macrophages [25], and others where the lack of
tolerance to bacterial antigens is associated with the absence of
IL-10 during bacterial exposure, leading to intestinal inﬂamma-
tion [26].
It has been demonstrated that LPS can bind to the TLR and
induces a proﬁbrotic response [15]. Accordingly, the reduction
of serum free endotoxin levels by norﬂoxacin in cirrhotic mice
should have resulted in a reduction of liver ﬁbrosis. Although
we observe a reduction in the expression of proﬁbrogenic genes,
differences were not signiﬁcant, probably due to the short
period of norﬂoxacin administration. It is also relevant to men-
tion that IL10/ mice were shown to be partially protected
against CCl4-induced liver damage in the past [27]. This discrep-
ancy with our results may rely on the different experimental
models used, since Louis et al. evaluated the role of IL-10 in an
acute hepatitis model with intraperitoneal CCl4 injections instead
of a chronic model with a long-term intragastrical CCl4
administration.
In conclusion, norﬂoxacin participates in an IL-10-driven
modulation of gut barrier permeability, thus reducing luminal
free endotoxin absorption in spontaneous and induced BT chal-
lenges in two experimental models of cirrhosis.Financial support
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Animals and methods Cirrhosis was induced by intra-
gastrical administration of carbon tetrachloride in Balb/C 
mice. One week prior to laparotomy, animals received B. 
pseudocatenulatum CECT7765 (107, 109 or 1010 cfu/daily) 
or placebo. Chemokine receptor and cytokine expression 
were evaluated in intestinal lymphocytes. Gut permeability 
was studied by FITC-LPS recovery in vivo. Luminal anti-
gens, inflammation and functional markers were evaluated 
in liver samples.
Results Bifidobacterium pseudocatenulatum CECT7765 
decreased the expression of pro-inflammatory chemokine 
receptors CCR6, CCR9, CXCR3 and CXCR6 in intesti-
nal lymphocytes from cirrhotic mice in a concentration-
dependent manner. The bifidobacterial strain induced 
a shift towards an anti-inflammatory cytokine profile 
in this cell subset. B. pseudocatenulatum CECT7765-
induced inflammatory modulation was TLR2-mediated, 
as in vitro TLR2 blockade inhibited the reduction of 
TNF-alpha and its receptors and the increase of IL-10 
and IL-10 receptor secretion. The recovery rate of admin-
istered fluorescence-labelled endotoxin was significantly 
and dose-dependently lowered with the bifidobacterial 
strain. The reduced intestinal permeability was associated 
with a decreased burden of bacterial antigens in the liver 
of mice treated with B. pseudocatenulatum CECT7765. 
Liver function and inflammation were improved with the 
use of the bifidobacterial strain at the highest dose tested 
(1010 cfu).
Conclusion Bifidobacterium pseudocatenulatum CECT7765 
improves gut homeostasis and prevents gut-derived compli-
cations in experimental chronic liver disease.
Keywords Cirrhosis · Endotoxin · B. pseudocatenulatum 
CECT7765 · Inflammation · Toll-like receptor 2 · Intestinal 
lymphocytes
Abstract 
Background Intestinal homeostasis plays an important 
role in bacteria-derived complications in cirrhosis. Intes-
tinal lymphocytes are responsible for immune effector 
functions and can be modulated by certain probiotics. We 
evaluate the interaction between Bifidobacterium pseu-
docatenulatum CECT7765 and intestinal lymphocytes in 
mice with cirrhosis.
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Introduction
Bacteria-derived complications are frequent in cirrhosis 
[1, 2]. Most episodes of bacterial translocation (BT) are 
due to endogenous microoganisms coming from the gut. 
Since alterations in the gut microbiota composition have 
been described to increase inflammatory signals and the 
liver exposure to microbial products [3, 4], the possibil-
ity of re-shaping gut microbiota composition to improve 
immune homeostasis and to prevent the translocation of 
commensal bacteria or their products into mesenteric 
lymph nodes (MLNs) is of increasing interest in cirrhosis 
[5–7].
We have recently shown that the oral administration of 
a bifidobacterial strain (Bifidobacterium pseudocatenula-
tum CECT7765) to CCl4-treated mice is associated with 
a reduced inflammatory environment and lower BT rates 
compared with animals not receiving the probiotic strain 
[8]. However, the mechanism by which this strain interacts 
with intestinal lymphocytes (ILs), responsible for the even-
tual effector functions after antigen recognition, remains 
unclear. This crosstalk would help in explaining homeosta-
sis restoration and the reduction of gut permeability by B. 
pseudocatenulatum CECT7765.
The intestinal lamina propria is loaded with pre-acti-
vated T-helper cells coming from the MLNs. This expan-
sion into the intestinal mucosa is mediated by cell adhe-
sion molecules present on the T cell surface and plays a 
central role in chronic intestinal inflammation [9, 10]. One 
of the main receptors involved in bacterial product recog-
nition and in regulating adaptive immune responses is the 
Toll-like receptor (TLR) family. For instance, B. breve 
activates intestinal dendritic cells to produce interleu-
kin (IL)-10 and IL-27 in a TLR2-dependent manner and 
induce IL-10-producing regulatory T cells [11]; C. butyri-
cum can suppress TLR-4 expression in intestinal epithe-
lial cells by induction of IL-10-producing macrophages 
[12, 13]; and B. fragilis is able to restore the Th1/Th2 
balance by stimulation of IL-10-producing CD4+ T cells 
[14].
In addition, the ability of commensal bacteria to increase 
TLR expression has been reported [15–17], showing the 
susceptibility of TLR responses to intestinal microbiota 
products. With this background, and considering that cir-
rhosis is associated with a dysbiosis in the microbiota 
composition, we hypothesise that B. pseudocatenulatum 
CECT7765 will induce its regulatory effect by changing 
the TLR expression profile in intestinal T cells of mice 
with chemically induced cirrhosis. To evaluate this, our 
objective has been to determine the pathway of intestinal 
immune response modulation by B. pseudocatenulatum 
CECT7765 in experimental cirrhosis.
Animals and methods
Experimental model and design
Female Balb/C (Harlan, Barcelona, Spain) with 18–20 g 
initial body weight were included in a cirrhosis induction 
protocol by intragastrical administration of 2 weekly doses 
of CCl4 during 12 weeks. Phenobarbital (0.25 mmol/L) was 
given in drinking water along study protocol. Mice received 
2 uL of CCl4 in mineral oil at the beginning of the protocol 
(100 uL/kg), and the dose was increased based on changes 
in weight 48 h after the previous dose, reaching 100 uL/
mice. CCl4 was administered using a sterile pyrogen-free 
syringe with an attached stainless steel animal feeding tube 
without anaesthesia as previously described [4]. One week 
prior to laparotomy, animals received B. pseudocatenula-
tum CECT7765 (107, 109 or 1010 cfu administered daily 
intragastrically) or placebo (vehicle). A group of naïve non-
treated animals were included as a control group. Laparoto-
mies were performed under anaesthesia with isofluorane 
at week 12. After laparotomies, all detectable MLNs were 
aseptically removed. Animals under anaesthesia were 
euthanised by heart injection and total blood collection. 
Liver, spleen, complete small intestine, content from cae-
cum and blood were collected. The liver was perfused in 
situ with 6 mL of Hanks’ balanced salt solution (HBSS) 
without Ca2+ and Mg2+ at 37 °C at a rate of 1.5 mL/min as 
previously described [8]. Animals received care according 
to the criteria outlined in the Guide for the Care and Use of 
Laboratory Animals. The study was approved by the Ani-
mal Research Committee of Universidad Miguel Hernan-
dez (Alicante, Spain).
B. pseudocatenulatum CECT7765 culture conditions
The strain B. pseudocatenulatum CECT7765 was obtained 
from Spanish Type Culture Collection (CECT). The 
strain was grown in MRS broth (Scharlau, Barcelona, 
Spain) supplemented with 0.05 % (w/v) cysteine (MRS-C 
Sigma, St. Louis, MO, USA) and incubated at 37 °C for 
22 h (at stationary growth phase) under anaerobic condi-
tions (AnaeroGen, Oxoid, Basingstoke, UK). Cells were 
harvested by centrifugation (6.000g for 15 min), washed 
twice in phosphate-buffered saline (PBS, 130 mM sodium 
chloride, 10 mM sodium phosphate, pH 7.4) and re-sus-
pended in 10 % skimmed milk for oral administration to 
mice or in PBS for in vitro/culture experiment. Aliquots 
of these suspensions were frozen in liquid nitrogen and 
stored at −80 °C until used. The number of live cells was 
determined by colony-forming unit (CFU) counting on 
MRS-C agar (Biomerieux) after 48-h incubation at 37 °C. 
For the strains tested, more than 90 % cells were alive upon 
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thawing and no significant differences were found during 
storage time (2 months). One fresh aliquot was thawed for 
every new experiment to avoid variability in the viability of 
cultures.
Intestinal lymphocytes (IL) isolation and culture
The whole small intestine was removed from naïve and 
CCl4-treated mice. Peyer’s patches, fatty tissue and mesen-
tery were dissected out. The gut was cut into small pieces 
(1 cm), cleaned by flushing with a syringe filled with cold 
phosphate-buffered saline (PBS) calcium and magne-
sium free (Euroclone, Milano, Italy), supplemented with 
2 % foetal bovine serum (FBS; LifeTechnologies, Madrid, 
Spain) and open longitudinally. Intraepithelial mononuclear 
cells were liberated by incubating in HBSS supplemented 
with 5 % FBS, with dithiothreitol (DTT; Sigma-Aldrich, 
St Louis, MO, USA) during 20 min, twice. Epithelial cells 
were discarded after incubating with EDTA (BioRad, 
Madrid, Spain) in HBSS calcium and magnesium free (GE 
Healthcare Europe GmbH, Barcelona, Spain) and wash-
ing with 1,640 medium (LifeTechnologies) supplemented 
with 5 % FBS. Thereafter, segments were incubated dur-
ing 45 min at 37 °C in RPMI, containing 2 mg/mL of col-
lagenase D (Roche Diagnostic, Barcelona, Spain) and 1 % 
FBS, and later passed through a stainless steel sieve to 
obtain the lamina propria mononuclear cell suspension. 
Intraepithelial and lamina propria collected mononuclear 
cells were filtered through a packed nylon wool fibre col-
umn (Polysciences Europe GmbH, Eppelheim, Germany) to 
remove mucus and dead cells. Erythrocytes were lysed using 
a hypertonic solution (EasyLyse; Dako, Barcelona, Spain). 
Intestinal T cells were positively selected from filtered cells 
using CD3 MicroBeads (Miltenyi Biotec, Madrid, Spain). 
IL enrichment was evaluated by flow cytometry using a 
FACS CANTO (Becton–Dickinson, San Jose, CA) and can 
be followed in Supplementary Fig. 1. Cells were adjusted to 
1 × 106/mL in DMEM (Euroclone) for culture experiment.
IL cells, obtained as described before, from 5 CCl4-
treated mice not receiving the bifidobacterial strain were 
used for in vitro assays. Cells (0.5 × 106/well) were incu-
bated at 37 °C with 5 % CO2 for 24 h in the following con-
ditions: unstimulated, stimulated with LPS (0.2 ug/mL E. 
coli serotype 0111: B4), stimulated with B. pseudocatenu-
latum CECT7765 107 cfu/100 uL PBS and stimulated with 
B. pseudocatenulatum CECT7765 109 cfu/100 uL PBS. 
Half of all conditions were also incubated with 10 ug/mL 
blocking monoclonal antibody anti-TLR-2 (Antibodies 
Online GmbH, Aachen, Germany). Cells and supernatants 
were collected for gene expression analyses and cytokine 
secretion, respectively.
As supporting in vitro experiment, IL cells from an addi-
tional batch of CCl4-treated mice were incubated at 37 °C 
with 5 % CO2 for 24 h in the following conditions: unstim-
ulated, stimulated with LPS (0.2 ug/mL E. coli serotype 
0111: B4), B. breve, B. adolescentis, B. animalis and B. 
pseudocatenulatum CECT7765 (in all cases 109 cfu/100 uL 
PBS). Supernatants were collected for cytokine secretion 
assays.
Chemokine receptor and inflammatory cytokine expression 
in ILs
Gene expression levels of chemokine receptors CCR6, 
CCR9, CXCR3 and CXCR6, as well as TNF-α, TNF recep-
tor (TNFR) I, TNFRII, IL-10, IL-10 receptor (IL-10R), 
and TLRs, were quantified in total RNA from ILs using 
Quantitec SYBR Green (QIAgen) in an IQ5 Real-Time 
PCR (BioRad, Hercules, CA, USA). B2-microglobulin was 
used as housekeeping gene in all gene expression analyses. 
Primer pairs used in the study can be followed in Supple-
mentary Table 1.
Western blots were performed in RIPA buffer-lysed cell 
pellets. The primary antibodies used against CCR6, CCR9, 
CXCR3 and CXCR6 and β-actin were purchased from 
Santa Cruz Biotechnology (Heidelberg, Germany).
Enzyme-linked immunosorbent assays (ELISA) from 
R&D Systems (Minneapolis, MN, US) were performed 
according to the manufacturers’ instructions for quanti-
tation of IL-secreted TNF-α and IL-10 in vitro. ELISA 
kits were also used for determining quantitative levels of 
TNF-α and IL-6 in liver samples. All samples were tested 
in duplicate and read in a Sunrise Microplate Reader 
(Tecan, Mannedorf, Switzerland).
FITC-LPS permeability assay and gut barrier integrity 
markers analysis
Intestinal permeability was evaluated administering fluo-
rescein isothiocyanate (FITC)-LPS from E. coli O111: B4 
(Sigma) by gastric gavage 4 h before killing. Whole blood 
was obtained by retro-orbital puncture at the time of kill-
ing. Dilutions of FITC-LPS in PBS were used as a stand-
ard curve, and FITC-LPS measurements were performed in 
100 μL of plasma or standard in a fluorometer at 488 nm. 
Gene expression levels of occludin and tight junction pro-
tein (TJP)-1 were evaluated using Quantitec SYBR Green 
as described above. Primers are detailed in Supplementary 
Table 1.
Analysis of luminal antigen translocation and liver function
Bacterial DNA was detected and identified by broad-range 
PCR and partial sequencing analysis in MLNs, blood and 
liver samples according to the methodology described 
elsewhere [18, 19]. The quantitative chromogenic limulus 
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amebocyte lysate test (BioWhittaker, Nottingham, UK) was 
performed to evaluate endotoxin levels in MLNs, blood and 
liver samples according to the manufacturer’s instructions. 
All samples were tested in duplicate and read at 405 nm in 
a Sunrise Microplate Reader.
Liver function was evaluated by determining ALT and 
total bilirubin levels by handling ELISA kits from Cloud-
Clone Corp (Houston, TX, US) and Cusabio Biotech Ltd. 
(Wuhan, China), respectively, according to the manufactur-
ers’ instructions. All samples were tested in duplicate and 
read at 450 nm.
Statistical analysis
Continuous variables are reported as mean ± SD and cat-
egorical variables as frequency or percentages. Statisti-
cal differences were analysed using the Chi-squared test 
for categorical data applying the Yates correction when 
required. The Kolmogorov–Smirnov test was used to iden-
tify normal distribution of the data. Differences in quan-
titative data were analysed using the Student’s t test for 
variables with normal distribution and the Mann–Whitney 
U test for quantitative data without normal distribution. 
Multiple comparisons were analysed using analysis of vari-
ance (ANOVA) or the Kruskal–Wallis test for data with and 
without normal distribution, respectively, followed by pair-
wise comparisons using the post hoc Bonferroni correction. 
Bivariate correlations were calculated using the Pearson or 
Spearman test according to data distribution. All reported 
p values are two-sided. p values lower than 0.01 were 
considered significant. All calculations were performed 
using the R-2.14.1 2011 (The R Foundation for Statistical 
Computing)
Results
Study groups and characteristics of animals
Cirrhosis was induced by oral administration of CCl4 in 
a starting series of 70 mice. Seventeen mice died during 
the cirrhosis induction protocol (24 %), with no statisti-
cally significant differences between groups. Causes of 
death were CCl4 toxicity and liver insufficiency. Finally, 
10 naïve mice, 12 mice in the CCl4 group, 12 mice in 
the CCl4 + CECT7765 1 × 107 cfu/daily, 10 mice in the 
CCl4 + CECT7765 1 × 109 cfu/daily and 11 mice in the 
CCl4 + CECT7765 1 × 1010 cfu/daily were subjected to 
laparotomy. Cirrhosis was histologically confirmed by 
collagen deposition and regenerative nodules in all CCl4-
treated animals, with no significant differences according 
to the administration of the bifidobacterial strain. Neither 
CCl4 induction of cirrhosis nor B. pseudocatenulatum 
CECT7765 administration had any visual effect on intes-
tinal wall morphology (Supplementary Fig. 2). Body and 
spleen weights in animals from all groups are detailed in 
Supplementary Table 2. Liver and spleen weights in all 
CCl4 animals were significantly higher compared with 
naïve mice.
IL chemokine receptors and cytokine response are 
regulated by B. pseudocatenulatum CECT7765
The expression of an array of chemokine receptors 
involved in the inflammatory balance and T cell migra-
tion from MLNs was evaluated in ILs from cirrhotic mice, 
either treated or not with the bifidobacterial strain. The 
administration of B. pseudocatenulatum CECT7765 sig-
nificantly reduced both the gene and protein expression of 
all studied chemokine receptors in a dose-dependent fash-
ion (Fig. 1).
Soluble mediators of inflammation TNF-alpha and 
IL-10 were also evaluated in ILs from the different study 
groups. Gene expression levels of TNF-alpha and its recep-
tors TNF-RI and TNF-RII significantly decreased with the 
administration of B. pseudocatenulatum CECT7765 com-
pared with mice not receiving the bacterial strain. In addi-
tion, this inflammatory inhibition was dependent on the B. 
pseudocatenulatum CECT7765 concentration administered 
(Fig. 2a). Inversely, gene expression levels of IL-10 and 
IL-10R were significantly increased in mice with B. pseu-
docatenulatum CECT7765, and these increments were also 
dependent on the bifidobacterial concentration adminis-
tered (Fig. 2b). These results clearly show the IL response 
to B. pseudocatenulatum CECT7765 administration.
Fig. 1  Relative gene expression levels of chemokine receptors 
CCR6, CCR9, CXCR3 and CXCR6 in ILs from naïve and CCl4-
mice, either receiving or not B. pseudocatenulatum CECT7765 
at different concentrations. ILs intestinal lymphocytes, CCR C-C 
chemokine receptor, CXCR C-X-C chemokine receptor. *p < 0.01 
compared with naïve mice; #p < 0.01 compared with CCl4 mice with-
out B. pseudocatenulatum CECT7765 and/or the previous bifidobac-
terial strain concentration
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After evaluating the homeostatic effect of B. pseudo-
catenulatum CECT7765 in ILs, we aimed at delineating 
the mechanism by which B. pseudocatenulatum CECT7765 
might interact with this cell population. Gene expression 
levels of TLRs in ILs were measured to determine the sig-
nalling pathway for B. pseudocatenulatum CECT7765 to 
induce cytokine secretion. Only TLR-2 was significantly 
upregulated with increasing concentrations of B. pseu-
docatenulatum CECT7765 (Fig. 2c), and its expression 
inversely correlated with the TNF-alpha gene expression 
levels shown in the different groups of animals (Fig. 2d). 
The rest of TLRs tested showed a B. pseudocatenulatum 
CECT7765-independent expression.
B. pseudocatenulatum CECT7765 promotes a 
TLR-2-dependent modulation of IL cell-secreted cytokine 
profile
To confirm the relevance of TLR-2 signalling in the bifi-
dobacterial strain regulatory mechanism, ILs from 
CCl4-treated mice were isolated and cultured with LPS and 
B. pseudocatenulatum CECT7765 in the presence/absence 
of an anti-TLR-2 antibody. As can be followed in Fig. 3a, 
TNF-alpha secretion by cultured cells was significantly 
increased after 24-h stimulation with LPS, whereas stimu-
lation with two concentrations of B. pseudocatenulatum 
CECT7765 did not induce TNF-alpha secretion in vitro. 
However, the inhibition of TLR-2 signalling significantly 
induced TNF-alpha secretion by ILs in the presence of B. 
pseudocatenulatum CECT7765 to the levels observed in 
cells from unstimulated CCl4-treated mice.
On the other hand, stimulation with B. pseudocatenula-
tum CECT7765 induced significantly increased levels of 
IL-10 in cell supernatants compared with levels induced 
by LPS or in unstimulated cells (Fig. 3b). When TLR-2 
was blocked, secreted IL-10 significantly decreased in B. 
pseudocatenulatum CECT7765-stimulated cells to levels 
observed in unstimulated cells. These data demonstrate a 
TLR-2-mediated anti-inflammatory effect of B. pseudo-
catenulatum CECT7765 in ILs from cirrhotic mice.
Fig. 2  Relative gene expression levels of TNF-alpha and TNF-alpha 
receptors (a), IL-10 and IL-10 receptor (b) and TLRs (c) in ILs from 
naïve and CCl4 mice either receiving or not B. pseudocatenulatum 
CECT7765 at different concentrations. d Correlation between TNF-
alpha and TLR-2 gene expression levels in ILs from naïve and CCl4 
mice either receiving or not B. pseudocatenulatum CECT7765 at dif-
ferent concentrations. ILs intestinal lymphocytes, TNF-alpha tumour 
necrosis factor alpha, TNF-RI tumour necrosis factor alpha-receptor 
I, TNF-RII tumour necrosis factor alpha-receptor II, IL-10 interleu-
kin 10, IL-10R interleukin 10 receptor; TLRs Toll-like receptors. 
*p < 0.01 compared with naïve mice; #p < 0.01 compared with CCl4-
mice without B. pseudocatenulatum CECT7765 and/or the previous 
bifidobacterial strain concentration
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As all commensal bacteria are expected to stimulate 
TLR-2 at some degree, we ran an in vitro experiment to 
determine the relative sensitivity of B. pseudocatenulatum 
CECT7765 to TLR-2-dependent proinflammatory reduc-
tion compared with other bifidobacterial strains obtained 
from collections. The results are shown in Supplementary 
Fig. 3. Although all the bifidobacterial strains showed an 
increment in TNF-alpha and IL-6 after TLR-2 blockade 
compared with unstimulated conditions, B. pseudocatenu-
latum CECT7765 showed a significantly higher increment 
in both cytokine secreted levels after TLR-2 blockade com-
pared with the rest of bifidobacterial strains.
B. pseudocatenulatum CECT7765 reduces intestinal 
permeability
The reduction in the intestinal inflammatory environment 
was significantly associated with a dose-dependent reduc-
tion of gut permeability. As can be observed in Fig. 4a, 
the administration of the bifidobacterial strain signifi-
cantly reduced FITC-LPS recovery rates among cirrhotic 
animals, restoring permeability to values similar to those 
observed in naïve mice. Accordingly, B. pseudocatenula-
tum CECT7765 was associated with improved gut barrier 
integrity markers in CCl4-treated mice, providing a possi-
ble explanation for the observed reduction in gut perme-
ability assay (Fig. 4b). Despite these results, as commented 
before, no visual effects of gut barrier morphology could be 
observed (Supplementary Fig. 1).
B. pseudocatenulatum CECT7765 reduces liver 
inflammation and improves liver function
We were interested in testing whether a reduction in intes-
tinal permeability might improve liver inflammation. 
Spontaneous bacterial antigen translocation into liver was 
significantly reduced after administration of increasing 
concentrations of B. pseudocatenulatum CECT7765. As 
shown in Fig. 4c, d, the oral administration of 1 × 1010 cfu/
daily for a week significantly reduced the translocation rate 
of bactDNA and endotoxin in the liver to levels present in 
naïve control mice. No B. pseudocatenulatum CECT7765 
DNA was identified in any of the bactDNA-positive sam-
ples. Translocating bacterial species belonged to the family 
Enterobacteriaceae in all cases: E. coli (n = 9), K. pneu-
moniae (n = 4), E. cloacae (n = 2), S. marcescens (n = 1). 
Liver endotoxin levels inversely correlated with the con-
centration of B. pseudocatenulatum CECT7765 adminis-
tered (r = −0.72; p = 0.001).
The reduced bacterial antigen translocation rates were 
associated with the statistically significant downregulation 
of TNF-alpha (Fig. 5a) and IL-6 (Fig. 5b) levels in the liver. 
Also, an improved liver function was significantly associ-
ated with the administration of the bifidobacterial strain at 
1 × 1010 cfu/daily, as can be observed for ALT and total 
bilirubin levels in Fig. 5d, respectively. Both parameters 
were significantly decreased compared with CCl4-treated 
mice without the bifidobacterial strain, although levels 
remained higher than those observed in naïve mice, even 
after administration of the highest dose of Bifidobacteria.
Discussion
Intestinal homeostasis is fundamental in preventing bacte-
rial complications, frequently present in cirrhosis. A bal-
anced immunological response at the edge between a vast 
luminal commensal microbiota population and the rest of 
host’s territories guarantees a reduced permeability envi-
ronment for bacteria or their products to translocate. In 
the present study, we demonstrate that ILs, responsible for 
the local immune effector functions, are modulated by B. 
Fig. 3  TNF-alpha (a) and IL-10 (b) levels secreted by isolated ILs 
cultured in unstimulated conditions and after stimulation with LPS 
and B. pseudocatenulatum CECT7765 at different concentrations in 
the presence/absence of a blocking monoclonal antibody anti-TLR-2. 
Mean values ± SD from three different experiments are repre-
sented. #p < 0.01 compared with cells from unstimulated CCl4 mice; 
*p < 0.01 compared with cells not receiving the blocking anti-TLR-2; 
TLR Toll-like receptor, LPS lipopolysaccharide
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pseudocatenulatum CECT7765, reducing their pro-inflam-
matory chemokine receptors expression and inducing a 
shift in their cytokine profile. In vitro assays demonstrate 
that the IL reduced pro-inflammatory cytokine secretion 
induced by the bifidobacterial strain is dependent on TLR2 
expression.
The gut-associated lymphoid tissue (GALT), where 
effector CD4+ T cells reside after priming at MLNs, con-
stitutes a central element in maintaining intestinal homeo-
stasis and host’s immunity against the translocation of 
bacterial antigens [20, 21]. The homing signals for ILs to 
migrate back to the LP are chemokine receptors expressed 
in their surface, mainly CCR6, CCR9, CXCR3 and CXCR6 
among others [22], that also account for the host defence 
and repair processes. We here report the B. pseudocatenu-
latum CECT7765 dose-dependent reduction of these 
chemokine receptors in ILs from mice with cirrhosis com-
pared with animals not receiving the bifidobacterial strain 
(Fig. 1). In fact, it has been recently reported that CCR9 is 
increased in mononuclear cells and activated hepatic stel-
late cells during liver fibrosis and that CCR9 deficiency 
reduces liver inflammation in CCl4-treated mice [23]. 
Similarly, CCR6 has been shown to stay upregulated in 
CD4+ cells in experimental fibrosis and intrahepatically in 
patients with chronic liver diseases [24].
The reduced pro-inflammatory IL expansion was con-
firmed by the shift observed in the profile of cytokine 
production with the administration of the probiotic strain. 
Whereas IL TNF-alpha and TNFRs were significantly 
decreased, IL-10 and IL-10R expression was increased 
after the probiotic treatment in a bifidobacterial strain 
concentration-dependent manner. We further identified 
TLR2 as the IL receptor for the bifidobacterial strain-
induced immune modulation (Figs. 2, 3). TLRs have been 
shown to induce downstream intracellular signalling and 
subsequent cytokine secretion in response to specific pro-
biotics [25, 26]. In our study, the inhibition of B. pseudo-
catenulatum CECT7765 capacity to change the cytokine 
secretion pattern by blocking TLR-2 reveals the central 
role for this receptor in the bifidobacterial recognition and 
induction of the host’s cytokine response. In fact, similar 
results had been obtained in the past showing the anti-
inflammatory properties of TLR-2 [27–29] and the induc-
tion of a pro-inflammatory cytokine response by B. breve 
after blocking TLR-2 [30]. In contrast to this and the previ-
ously mentioned studies, an inflammatory downregulation 
Fig. 4  a FITC-LPS recovery rates after LPS oral administration in 
naïve and cirrhotic mice with different concentrations of B. pseu-
docatenulatum CECT7765. Mean values ± SD from five differ-
ent experiments are represented. Bacterial DNA translocation b and 
endotoxin levels c into liver samples from all naïve and CCl4 mice 
either receiving or not B. pseudocatenulatum CECT7765 at different 
concentrations. Mean values ± SD are represented. *p < 0.01 com-
pared with naïve mice; #p < 0.05 compared with CCl4 mice with-
out B. pseudocatenulatum CECT7765 and/or with the previous dose 
of the bifidobacterial strain. FITC fluorescein isothiocyanate, LPS 
lipopolysaccharide
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in monocytes from lamina propria in TLR2-deficient mice 
with bile duct ligation has been reported [31]. Several 
aspects, such as the distinct experimental model used and 
the intestinal monocyte population used rather than ILs, 
may explain this difference. Anyhow, considering the incre-
ment in pro-inflammatory mediators that comes along with 
fibrosis progression and cirrhosis [4, 32], the possibility of 
an immune response repolarisation by B. pseudocatenula-
tum CECT7765 becomes an appealing strategy to self-limit 
inflammation and derived complications that should be fur-
ther pursued and confirmed in human immune cell subsets.
The bifidobacterial strain induction of a reduced inflam-
matory environment had an impact on gut permeability, as 
evaluated in vivo by measuring FITC-LPS recovery after 
oral administration in cirrhotic mice with different con-
centrations of B. pseudocatenulatum CECT7765. Several 
studies have shown the improvement in gut barrier integ-
rity markers with the use of probiotic strains [33–37]. How-
ever, although a distorted gut barrier may facilitate BT, the 
study of integrity markers cannot confirm the actual pas-
sage of bacterial products. In the present study, besides an 
increased expression of tight junction proteins, the perme-
ability assay demonstrates the decreased rate of LPS trans-
location through the gut barrier with increasing amounts of 
the bifidobacterial strain. Accordingly, the rate of bacterial 
antigens reaching the liver is also significantly reduced, as 
shown in Fig. 3.
Regarding liver damage, the administration of B. pseu-
docatenulatum CECT7765 did not show any significant 
effect on histology architecture, despite a significant reduc-
tion in the profibrogenic TIMP-1 and MMP-2 gene expres-
sion levels (Supplementary Fig. 1). Despite one study 
showed fibrosis amelioration with the administration of 
VSL#3 in an experimental model of NASH [38], results 
presented herein are consistent with previous findings from 
our group working on this bifidobacterial strain [8] and with 
results obtained with VSL#3 in the rat model of cirrhosis 
[37]. However, an interesting result of the study is that the 
administration of B. pseudocatenulatum CECT7765 at 1010 
cfu/daily to CCl4-treated mice significantly reduced liver 
TNF-alpha and IL-6 levels together with ALT and total 
bilirubin levels, suggesting an improvement in liver func-
tion also dependent on B. pseudocatenulatum CECT7765 
concentration. Although these results have to be consid-
ered with caution and confirmed with further specifically 
designed studies on the bifidobacterial strain effect on liver 
function, the possibility of reducing liver inflammation and 
ameliorating functional markers such as ALT had already 
been reported in ob/ob mice treated with VSL#3 [39].
In summary, the present study shows that chemokine 
receptors expression and cytokine profile of ILs in mice 
with cirrhosis are modulated by the oral administration 
of B. pseudocatenulatum CECT7765. This homeostatic 
effect favours a reduced intestinal permeability that lowers 
Fig. 5  Serum ALT (a) and total bilirubin levels (b) in naive and 
CCl4-treated mice receiving or not B. pseudocatenulatum CECT7765 
at different concentrations. Mean values ± SD are represented. 
*p < 0.01 compared with naïve mice; #p < 0.05 compared with CCl4 
mice not receiving B. pseudocatenulatum CECT7765 and/or with the 
previous dose of the bifidobacterial strain. ALT alanine aminotrans-
ferase
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the burden of bacterial antigens reaching the liver. These 
promising results encourage further studies on the bifido-
bacterial interaction with different immune cell subsets 
from patients with cirrhosis aimed at eventually testing B. 
pseudocatenulatum CECT7765 supplementation in patients 
with cirrhosis.
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Abstract 
The gut microbiota structure, dynamics and function results from interactions with 
environmental and host factors, which jointly influence the communication between the gut 
and peripheral tissues, thereby contributing to health programming and disease risk. Incidence 
of both type-1 and type-2 diabetes has increased during the past decades, suggesting there 
have been changes in the interactions between predisposing genetic and environmental 
factors. Animal studies show that gut microbiota and its genome (microbiome) influence 
alterations in energy balance (increased energy harvest) and immunity (inflammation and 
autoimmunity), leading to metabolic dysfunction (e.g. insulin resistance and deficiency). 
Thus, although they have different origins, both disorders are linked by the association of the 
gut microbiota with the immune-metabolic axis. Human studies have also revealed shifts in 
microbiome signatures in diseased subjects as compared to controls and, a few of them, 
precede the development of these disorders. These studies contribute to pinpointing specific 
microbiome components and functions (e.g. butyrate-producing bacteria) that can protect 
against both disorders. These could exert protective roles by strengthening gut barrier function 
and regulating inflammation, as alterations in these are a pathophysiological feature of both 
disorders, constituting common targets for future preventive approaches. 
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Introduction 
The bacterial ecosystem (microbiota) living in our intestine plays a fundamental role in the 
normal functioning of both metabolic and immune systems, beyond genetic determinants. 
Consequently, imbalances in gut microbiota (dysbiosis) are a possible causal factor of 
metabolic and autoimmune diseases. The initial colonization of the newborn intestine is 
particularly relevant to the proper development of the host’s immune and metabolic functions 
and to determine disease risk in early and later life (1). Gut microbiota signatures seem to be 
highly specific for each individual, resulting in large inter-individual variations that depend on 
both host genetics and environmental factors (1,2). This specificity has hindered our 
understanding of the microbiota’s role in health and disease. However, the fact that gut 
microbiota shows certain plasticity, particularly in response to the diet, also makes it possible 
to develop intervention strategies that promote a healthy gut ecosystem to reduce disease risk 
(3). Breast-milk-associated bifidobacteria in infants are a hallmark of the host-gut microbiome 
response to diet, promoting a particular microbial community structure and presumably  
contributing to the role of breast-feeding in reducing disease risk (e.g. infections, obesity and 
type-2 diabetes) (4). Although microbiota seems to be more sensitive to environmental factors 
in infants than in adults, the latter also respond to dietary intervention with variations of at 
least 10% (2). There is also evidence that gut microbiota and their products have large and 
diverse effects on immunity and immune-mediated disorders (5). Furthermore, bacterial 
interactions (mutualism and antagonism) that define the gut ecosystem are known to be 
indirectly mediated by the host immune system and particularly by its innate components 
(6,7). These findings reveal the two-way communication between the gut microbiota and the 
host, which might be shifted by diet and influence the risk of developing immune-mediated 
disorders, particularly at early stages of development. 
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In the light of this evidence, the increased incidence of diet-associated inflammatory diseases 
(obesity and type-2 diabetes) and autoimmune disorders (e.g. type-1 diabetes) could be 
partially explained by changes in gene-environment interactions, including diet-induced 
changes in microbiota. Systemic inflammation and autoimmunity are detectable years prior to 
the onset of overt disease, promoting the development of metabolic and autoimmune diseases 
(8). This suggests that subjects predisposed to disease might benefit from interventions 
targeting the immune system directly or indirectly before the disease manifests. Thus, new 
biomarkers of disease progression, including those related to the microbiome, must be 
identified to discover the pathophysiological determinants of these disorders and develop 
preventive interventions in the form of personalized health-care and nutrition-based strategies. 
Here, we will consider two diseases, type-1 and type-2 diabetes, as both disorders are linked 
to the gut microbiota association with the immune-metabolic axis (Figure 1). We will provide 
a comprehensive review of the extent to which available evidence supports a role for gut 
microbiota composition and function in disease risk. We will also identify the gaps in the 
understanding of the respective roles of gut microbiota, dietary habits and host factors in 
disease progression and prevention. 
 
Gut microbiota and risk of developing obesity and type-2 diabetes   
Obesity results from a positive imbalance between energy intake and expenditure and is also 
associated with low-grade inflammation leading to chronic metabolic disease (type-2 
diabetes). The steady increase in obesity prevalence has mainly been attributed to socio-
economic factors, dietary changes and sedentary lifestyle. Nevertheless, recent evidence 
suggests that our gut microbiota and microbiome also contribute to the host genetic make-up 
and to the whole metabolic activity of the body and immune function and, therefore, could 
play a role in these disorders.   
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Mechanisms behind the role of gut microbiota in obesity and type-2 diabetes in animals 
Alterations in gut microbiota structure and function detected in both genetically and diet-
induced obesity models led to initially establishing a role of microbiota in body-weight 
regulation (9). Nevertheless, gut microbiota alterations associated with obesity were also 
proposed to be a secondary consequence of the diets inducing obesity or of the genotype (6). 
However, comparison of germ-free and conventionally colonized mice has demonstrated that 
gut microbiota colonization leads to impaired glucose metabolism and increased macrophage 
accumulation in white adipose tissue not only in mice fed a high-fat diet (HFD) but also fed a 
standard diet, suggesting that microbiota effects are partly independent of diet (10). Also 
animals with a common genotype and fed the same diet can develop different metabolic 
phenotypes (either diabetic or non-diabetic) as a function of their specific gut microbiota 
profile, suggesting that gut microbiota per se determines the risk of developing metabolic 
dysfunction to some extent (11). 
Figure 2 provides a summary of evidence for the possible mode of action of the microbiota in 
obesity and the associated co-morbidities, including type-2 diabetes. Initially, comparisons 
between germ-free and conventional colonized mice indicated that the microbiota, as a whole, 
increases our ability to extract energy from the diet and store this energy in peripheral tissues 
(liver, adipose tissue, etc.), leading to impairment of insulin sensitivity (12). The fact the 
microbiota breaks down indigestible dietary components (mainly plant-derived 
polysaccharides) is considered one of the mechanisms improving the host’s ability to extract 
energy from the diet. This is consistent with evidence that the microbiome of human feces is 
enriched in genes involved in the utilization of complex dietary polysaccharides (13). This 
activity leads to the generation of short-chain fatty acids (SCFAs; butyric, acetic and 
propionic) and gases (e.g. hydrogen), which can also be further metabolized, activating the 
overall colonic fermentation and increasing the efficiency of energy extraction from ingested 
A
ce
pt
ed
 m
an
us
cr
ip
t
ACCEPTED ARTICLE PREVIEW 
© 2014 International Pediatric Research Foundation, Inc. All rights reserved 
nutrients (14). Although the energy contribution of complex plant polysaccharides is by far 
lower than that produced by digestible carbohydrates, their metabolism can constitute a 
survival strategy mediated by our symbiotic microbiota. However, the role of the gut 
microbiota in supplying extra energy from the diet could be less prominent in the context of 
Western diets rich in fats and simple carbohydrates. This theory of “increased energy harvest” 
is somehow contradictory to the benefits on metabolic health attributed to high dietary fiber 
intake and the short-chain fatty acids generated. Some of the SCFAs resulting from intake of 
high fiber diets and, particularly butyrate, are considered to exert beneficial effects in the 
context of obesity and associated co-morbidities. One of the proposed modes of action of 
SCFAs (specially of butyrate) is related to their ability to increase satiety and decrease calorie 
intake and postprandial glycaemia via modification of gut peptide production (glucagon-like 
peptide (GLP)1 and gastric inhibitory peptide). In addition, butyrate is the main energy source 
for enterocytes and, therefore, regulates cell proliferation and differentiation and induces 
GLP-2 production, which altogether strengthens the gut barrier function. Butyrate also 
reduces oxidative damage and inflammation by inhibiting histone deacetylases and the 
activation of the transcription factor NF-κB and the associated cytokine production (15,16; 
Figure 2).  
Inflammation seems to be one of the major pathophysiological factors leading to insulin 
resistance and progressively to type-2 diabetes. Gut microbiota alterations can also contribute 
to this inflammatory condition. Obesogenic diets may promote the growth of pathobionts 
(potential pathogens), which could trigger an inflammatory response via local activation of 
innate immune receptors (e.g. TLR4, TLR2) with production of pro-inflammatory cytokines 
(17,18) or via production of toxic compounds (e.g. hydrogen sulphide) (19). Both 
mechanisms could also lead to a leaky gut, translocation of microbial molecules and, overall, 
promote systemic inflammation. Also, saturated fatty acids of obesogenic diets might favor a 
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leaky gut by inducing expression and activation of innate immune receptors (Toll-like 
receptors) and increasing lymphocyte flux and proliferation; altogether this may lead to the 
production of cytokines (e.g. TNF-α, IFN-γ) that increase intestinal permeability, facilitating 
translocation of bacterial products regardless of possible alterations in the gut microbiota 
composition. LPS can also translocate via a transcellular epithelial pathway together with 
chylomicrons formed to incorporate dietary long-chain fatty acids in the form of triglycerides 
or through intestinal-epithelial microfold (M) cells (9). Murine models of HFD-induced 
obesity have also demonstrated that live Gram-negative commensal intestinal bacteria 
(Escherichia coli) can translocate to the blood and adipose tissue and that this process is 
mediated by dendritic cells and depends on innate immunity pattern-recognition receptors 
(TLR4 and Nod1) (20) . However, intervention in the gut ecosystem with specific prebiotics 
or potential probiotics reduces the HFD-induced metabolic endotoxemia, inflammatory tone, 
bacterial product translocation and metabolic dysfunction, demonstrating that these effects are 
partly mediated by gut microbiota-induced changes in animal models (20,21).  
 
Evidence supporting a role of gut microbiota in obesity in humans 
In humans a large number of studies have established relationships between alterations in gut 
microbiota structure and function, and obesity, although there is no consensus on the key 
players in this disorder yet. Numerous studies report reduced proportions of Bacteroidetes or 
its subgroups (e.g. Bacteroides) in obese subjects compared to lean subjects, parallel to 
increased proportions of Firmicutes or its subgroups (22, 23). However, other studies have not 
found consistent results (22, 24). These include a recent metagenomic study reporting that 
subjects with low bacterial richness (low gene count) gained more weight and had increased 
inflammatory tone (C reactive protein and leptin), insulin resistance and dyslipidemia as 
compared to subject with high bacterial gene counts (24). This finding supports the idea that a 
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less diverse microbiota is less resilient to the invasion of unhealthy microbes, which may 
contribute to disease. Bacteroides and Ruminococcus spp. were more abundant in subjects 
with low gene counts and metabolic dysfunction, whereas Faecalibacterium prausnitzii, 
Bifidobacterium, Lactobacillus, Alistipes, Akkermansia, among others, were more dominant in 
subjects with high gene counts and healthier metabolic phenotypes. Nonetheless, not all 
subjects with either a high or low gene counts have a similar metabolic phenotype, suggesting 
that findings could be influenced by confounding factors.  
Proteobacteria or enterobacteria were positively associated with obesity in a few studies, 
including one in pre-school children, as well as Staphylococcus spp. in pregnant woman (22-
24). By contrast, Akkermansia spp. was associated with a lean phenotype in two human 
studies, one conducted in children (22). 
Diet is a major driver of gut microbiota composition, which may partly explain why 
microbiota alterations are associated with an obese phenotype in humans. However, the 
microbiota structure resulting from unhealthy dietary habits is also thought to contribute to 
body weight regulation (25). In this context, higher energy intake leading to an increased ratio 
of Firmicutes to Bacteroidetes has also been related to increased energy absorption from diet 
(25). Human intervention studies have also revealed that the individual’s microbiota 
composition and richness could influence the effectiveness of dietary interventions in 
improving the metabolic phenotype (26,27). Furthermore, transplantation experiments of 
human microbiota in mouse models reveal that the influence of diet-microbiota interactions 
on the host metabolic phenotype is transmissible. A recent study has shown that when 
microbiota from subjects discordant for obesity (uncultured fecal communities and the 
corresponding fecal bacterial cultures) is transplanted in germ-free mice, these mice develop 
the corresponding phenotype when fed a low in fat and high in plant polysaccharides chow 
diet (28). The same study showed cohousing mice harboring the obese human microbiota with 
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mice containing the lean human microbiota prevented the development of an obesity-
associated metabolic phenotype due to the  invasion of the obese mouse intestine with specific 
members of Bacteroidetes (e.g. Bacteroides uniformis, B. caccae, B. cellulosilyticus, etc.) 
from the lean microbiota. However, this effect was diet-dependent and positive only in the 
context of a chow diet representing low–saturated fat, high fruit and vegetable intake, but not 
in the context of a chow diet, representing high saturated fat, low fruit and vegetable intake 
(28). These findings were also supported by administration of a selected Bacteroides strain (B. 
uniformis CECT 7771) from humans to a mouse model of diet-induced obesity in an 
independent study (29). Furthermore, recent fecal transplants to type-2 diabetic subjects 
beneficially influenced glucose metabolism and insulin resistance, proving that microbiota 
replacement strategies could help to protect from metabolic disease in humans (30). 
Despite all this evidence, prospective epidemiological studies are necessary to establish 
whether specific microbiota features constitute risk factors and predict obesity and the 
associated metabolic disorders; however only a couple of studies have been published to date. 
A follow-up study including 49 infants has reported that differences in fecal microbiota 
composition at 6 and 12 months of age precede subsequent overweight in children at 7 years 
of age. Children maintaining normal weight showed a greater number of bifidobacteria, while 
children who became overweight harbored a greater number of Staphylococcus aureus during 
infancy (31). A more recent and larger study of 330 healthy Danish infants from 9 to 36 
months of age, reported a positive correlation between the increase in body mass index and 
the increase in SCFA-producing clostridia (the Clostridum leptum group and Eubacterium 
hallii) (32). Taking into consideration the positive associations established between rapid 
infant weight gain and later-life obesity, these microbiological differences could play a role in 
obesity; however direct evidence must be established. Santacruz et al. (33) detected positive 
correlations between mother’s E. coli numbers and birth body weight, but data for the effects 
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on offspring were not followed-up. Another study concluded that microbiota in 79 infants 
born large for gestational age differed significantly compared to microbiota in infants born 
with an average weight for gestational age. Gram-negative Proteobacteria were more 
abundant in neonates born large for gestational age, whereas Gram-positive Firmicutes were 
more abundant in neonates born average for gestational age (34). Due to the fact that high 
birth weight is a risk factor for the development of metabolic disorders, these findings suggest 
that early microbiota could be a factor programming immune and metabolic health but data 
from follow-up studies were not reported. 
Evidence supporting the role of gut microbiota in type-2 diabetes in humans 
Studies reporting associations between shifts in gut microbiota composition and function and 
type-2 diabetes in humans are summarized in Table 1. Some of the findings suggest that 
metabolic markers of disease could be relevant for defining the relationships between obesity 
and gut microbiota (35). A recent metagenomic study also led to the development of a 
mathematical model to identify metagenomic markers for type-2 diabetes and diabetes-like 
metabolism (38). Nevertheless, the discriminant metagenomic markers were shown to differ 
between different cohorts of subjects, revealing that our understanding is insufficient to 
enable prediction of an individual’s disease risk based solely on the gut microbiome. 
Notwithstanding, a decreased abundance of some butyrate-producing bacteria (e.g. Roseburia, 
Akkermansia muciniphila, or Faecalibacterium prausnitzii) and an increased abundance of 
opportunistic pathogens (e.g. Clostridium clostridiiforme) could be a potential microbiome 
signature of reduced glucose tolerance and type-2 diabetes. However, prospective 
epidemiological studies in well-controlled populations are needed to provide sounder 
evidence of the microbiome features that constitute risk factors for these disorders, as well as 
dietary intervention studies to establish causality. 
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In relation to the mechanisms of action, it has been proposed that the microbiota could 
contribute to triggering the chronic-low grade inflammation underlying insulin resistance and 
type-2 diabetes. This hypothesis is supported by the detection of lipopolysaccharide (LPS) 
from Gram-negative bacteria in the blood of subjects with metabolic syndrome and type-2 
diabetes (40). Moreover, bacterial DNA (mostly belonging to the phylum Proteobacteria) was 
detected in the blood of subjects before diabetes onset, and was higher in those who had 
abdominal adiposity (20).  
 
Gut microbiota and risk of developing type-1 diabetes 
Type-1 diabetes is an autoimmune disease caused by destruction of insulin-producing β cells 
in the pancreatic islets of Langerhans by immune mediated mechanisms that lead to insulin 
deficiency in genetically predisposed individuals (41). Although the etiology of the disease is 
not completely understood, increased intestinal permeability, aberrant immune responses and 
intestinal dysbiosis have been proposed as the “perfect storm” that triggers the development 
of type-1 diabetes (42). Insufficient regulation of immune attacks on β cells, due to genetic 
and other modifiable factors (e.g. microbiota) is characteristic of disease (43). Increased 
intestinal permeability has also been described in type-1 diabetes patients (44-46), their 
relatives (45) and type-1 pre-diabetic patients (45,46). In this context, it is unclear whether the 
altered immune status causes intestinal integrity disruption or whether intestinal integrity 
disruption by an environment trigger (e.g. infections or dysbiosis) causes an abnormal 
immune response. Possibly both processes are involved. 
 
Mechanisms behind the role of gut microbiota in type-1 diabetes in animals 
Animal studies support the involvement of intestinal microbiota in the early events that 
precede and lead to type-1 diabetes, and some suggest that interactions with the host immune 
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system mediate the effects of microbiota in this disorder. Some studies described changes in 
microbiota composition preceding its onset in diabetic-prone BioBreeding (BB-DP) rats (47). 
Others describe that germ-free mice have increased diabetes incidence or that specific 
monocolonization of germ-free non-obese diabetic (NOD) mice delays the onset and reduces 
the incidence of diabetes (48). A number of animal studies also demonstrate that exposure to 
bacterial antigens or infection in the early neonatal period prevents type-1 diabetes, thereby 
supporting the notion that microbial immunostimulation may beneficially affect the 
maturation of the postnatal immune system and protect against type-1 diabetes (48). The role 
of the microbiota and its interaction with the innate immune system in type-1 diabetes was 
demonstrated in a study showing that NOD mice deficient in the innate signaling molecule 
MyD88 were protected from developing type-1 diabetes (5). This protection was lost when 
Myd88−/− NOD mice were housed under germ-free conditions, suggesting that the 
microbiota exerted a protective role. The absence of MyD88 in NOD mice led to changes in 
microbiota composition, characterized by increases in bacteria of the phylum Bacteroidetes, 
which could suppress the development of diabetes, presumably through the production of an 
immunomodulatory compound (5). A more recent study demonstrated that the protective 
functions of the microbiota against type-1 diabetes development could be transferred (7). Gut 
bacteria from MyD88-deficient mice, administered over a 3-week period, stably altered the 
composition of the gut microbiome (increasing Lachnospiraceae and Clostridiaceae and 
decreasing Lactobacillaceae), reducing insulitis and delaying the onset of diabetes. This 
affected the mucosal immune system, increasing the concentration of IgA and TGFβ in the 
lumen and of CD8+CD103+ and CD8αβ T cells in the lamina propria of the large intestine, 
possibly delaying the development of autoimmune diabetes. Administration of the probiotic 
product VSL#3 (a combination of strains of the genera Bifidobacterium, Lactobacillus and 
Streptococcus) to NOD mice also attenuated destructive insulitis, and preserved beta cells. 
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This was presumably due to the induction of IL-10 producing lymphocytes that recirculated 
from the gut to pancreatic islet (49). Recently, a gluten-free diet has been demonstrated to 
reduce the diabetic outcomes in NOD mice due to changes in the mouse microbiome 
(increased Bacteroides and Akkermansia numbers), via stimulation of a higher percentage of 
CD4+CD25+Foxp3 regulatory cells (50).  
 
Evidence supporting a role of gut microbiota in type-1 diabetes in humans 
Studies reporting associations between shifts in gut microbiota composition and function and 
type-1 diabetes in humans are summarized in Table 2. Although results on the gut microbiota 
components and functions contributing to type-1 diabetes are not fully consistent, butyrate 
producing bacteria and bifidobacteria seem to be protective whereas 
Proteobacteria/enterobacteria seem to constitute risk factors for disease. From a functional 
point of view, the protective role of the commensal intestinal microbiota against this disorder 
could be mediated by the fact the microbiota and its metabolites (SCFAs) can strengthen 
mucosal integrity, modulate gut hormone production improving glucose metabolism and 
reduce inflammation and prevalence of potential pro-inflammatory bacteria (e.g. 
enterobacteria) (51,53). 
Other environmental factors with an impact on the gut microbiota and immune system have 
also been linked to the risk of developing type-1 diabetes, including viral infections, type of 
delivery (natural birth or caesarian) and infant feeding practices (42). A meta-analysis showed 
that birth by caesarean section increased the risk of developing the disease by 20% regardless 
of the gestational age, weight, maternal age, breast-feeding practices and maternal diabetes 
(55). The lack of breast-feeding has also been associated with type-1 diabetes (reviewed in 
Pereira et al., 2014 (56). Thus, it is plausible that differences in the acquisition and evolution 
of the newborn microbiota in caesarian versus vaginally born infants, and in formula versus 
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breast-fed infants, may also influence the risk of developing type-1 diabetes (57). The 
association of these factors with other autoimmune disorders such has celiac disease (CD) has 
been reported (58). Type-1 diabetes and CD are autoimmune disorders with common genetic 
determinants (HLA-DQ) that frequently co-exist. In fact, CD affects at least 10% of diabetic 
patients at some point in their life (59). The influence of the HLA-DQ2/8 genotype on the 
intestinal microbiota composition of infants at family risk of CD has been described (1,60) . 
However, the influence of the HLA-DQ genotype on the microbiota in subjects at risk of type-
1 diabetes has not been specifically studied, although they share some genetic determinants of 
CD. 
There are also speculations on the role of infections in the risk of developing type-1 diabetes 
although no clear conclusions can be drawn from existing human data. For instance, the 
reduction in the antibody levels against Helicobacter pylori, cytomegalovirus, Epstein-Barr 
virus and Toxoplasma in type-1 diabetic patients support the “hygiene hypothesis” according 
to which reduced exposure to microbial stimulus increases the disease risk (61). Infections by 
two coxsackieviruses (B3 and B6) have also been linked to a reduced risk of type-1 diabetes, 
which was considered to be a result of immunological cross-protection (62). By contrast, 
intestinal infections by rotavirus (63) and other enterovirus (62, 64) have been associated with 
the onset or with the risk of disease, suggesting that they may contribute to triggering type-1 
diabetes. In this vein, an observational study involving type-1 diabetics under 15 years of age 
described that perinatal infections were associated with an increased risk in the autoimmune 
disorder; conversely, attendance to preschool day-care, which promotes microbial exposure, 
decreased type-1 diabetes risk (65). Overall, the findings suggest that the type of microbial 
agent, as well as time of exposure, can determine its role in disease risk, although 
confounding factors could also be a major source of variation in the results.  
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Conclusions 
Gut microbiota has recently been recognized to play a major role in regulating the metabolic-
immune axis and, consequently, changes in gut microbiota related to lifestyle (type of 
delivery, hygienic measures, diet, etc.) may contribute to the increased incidence of 
autoimmune and metabolic diseases in developed countries. Type-1 and type-2 diabetes 
represent two examples of diseases mediated by interactions between the gut microbiota and 
the immune system with subsequent development of specific organ autoimmunity and/or 
metabolic dysfunction. Knowledge of the role gut microbiota plays in these two diseases 
could be use to develop intervention strategies to prevent and/or treat imbalances that lead to 
the inflammation preceding overt manifestations of autoimmune and metabolic disorders. The 
specific microbiome components promoting or protecting against these disorders and the 
possible molecular targets for intervention are still under debate. Nonetheless, mechanistic 
insights from human and animal studies point to the protective role of the intestinal bacteria 
that produce butyrate, which may strengthen the gut barrier function, and induce 
immunoregulatory mechanisms, commonly altered in both type-2 and type-1 diabetes. 
Nevertheless, well-controlled prospective human studies are still necessary to gain a better 
understanding of the contribution of specific gut microbiota and its response to environmental 
factors. Such information could be used to identify effective preventive strategies targeting 
specific component of the gut ecosystem.  
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Table 1. Changes in the intestinal microbiota associated with type-2 diabetes in human  
 
Microbiota changea Study groups  Methodology 
Phylum or Class Genus or specie Reference 
Diabetics vs. non-Diabetics 
(n=18 vs. n=18) Real-time PCR 
↑Betaproteobacteria 
↓Firmicutes (Clostridia) 
 35 
Diabetics vs. non-Diabetics 
(n=16 vs. n=12) Real-time PCR  
↓Bifidobacterium 
↓Bacteroides vulgatus 36 
Diabetics vs. non-Diabetic 
(n=71 vs. n=74) Shotgun sequencing  
↑Bacteroides caccae, 
↑Clostridium hathewayi 
↑Clostridium ramosum 
↑Clostridium symbiosum 
↑Eggerthella lenta 
↑Escherichia coli 
↑Akkermansia muciniphila 
↑Desulfovibrio 
↓Clostridiales sp. SS3/4 
↓Eubacterium rectale 
↓Faecalibacterium prausnitzii 
↓Roseburia intestinalis 
↓Roseburia inulinivorans 
37 
Diabetics vs. non-Diabetics 
(n=53 vs. n=43) Shotgun sequencing 
 
 
↑Lactobacillus spp. 
↓Clostridium spp. 
↑Clostridium clostridioforme 
↓Roseburia 
38 
39 Non-Diabetics vs. pre-Diabetics 
(n=44 vs. n=64) 16S rDNA sequencing  
↑Akkermansia muciniphila 
↑Faecalibacterium prausnitzii 
 
Diabetics vs. pre-Diabetics 
(n=13 vs. n=64) 16S rDNA sequencing  
↓Bacteroides 39 
 
aArrows indicate increases or decreases of each bacterial group in the disease subject group compared to the control group (either non-Diabetic or pre-Diabetic). A
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Table 2. Changes in the intestinal microbiota associated with type-1 diabetes in humans  
 
Microbiota changea Study group  Methodology 
Phylum or Class Genus or specie Reference 
Autoimmune children 
 (positive in at least two 
autoantibodies) vs healthy children 
(n=4 vs. n=4) 
Shotgun sequencing  
↑Actinobacteria 
↑Bacteroidetes 
↑Proteobacteria 
↓Firmicutes 
↓Fusobacteria 
↓Tenericutes 
↓Verrucomicrobia 
↑Bifidobacterium 
↑Bacteroides 
↑Lactobacillus 
↑Lactococcus 
↑Streptococcus 
↑Veillonella 
↑Alistipes 
↓Prevotella 
↓Akkermansia 
↓Eubacterium 
↓Fusobacterium 
↓Anaerostipes 
↓Roseburia 
↓Subdoligranulum 
↓Faecalibacterium 
51 
Autoimmune children 
(positive in at least two 
autoantibodies) vs healthy children 
(n=4 vs. n=4) 
16S rDNA sequencing 
↑Bacteroidetes 
↓Firmicutes 
↓Clostridia 
↑Bacteroides 
↑Bacteroides ovatus 
↓Eubacterium 
↓Faecalibacterium 
↓Bacteroides vulgatus 
↓ Bacteroides fragilis 
52 
Children with T1D vs healthy 
children  
(n=16 vs. n=16) 
Real-time PCR 
↑Bacteroidetes 
↓Firmicutes 
↓Actinobacteria 
↑Bacteroides 
↑Veillonella 
↑Clostridium 
↓Prevotella 
↓Lactobacillus 
↓Bifidobacterium 
↓Blautia coccoides-Eubacterium rectale 
53 
Children with T1D vs healthy 
children  
(n=35 vs. n=35) 
Plate counting  
↑Cantida albicans 
↑Enterobacteriaceae other than Echerichia coli 
↓Bifidobacterium 
54 
aArrows indicate increases or decreases of each bacterial group in the disease subject group compared to the control group (healthy subjects). 
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Figure legends 
 
Figure 1. Schematic representation of the interaction of the gut microbiota with the immune-
metabolic axis and the different mechanisms proposed to explain its implication in health and 
disease risk. In type-1 diabetes, the intestinal dysbiosis and the increased gut  
permeability and altered immunoregulatory mechanisms seem to trigger the autoimmune 
response leading to the destruction of β cells in the pancreatic islets. In type-2 diabetes, 
saturated fat and dysbiosis due to “obesogenic” diets cause inflammation and alterations in 
gut permeability contributing to disease onset. 
 
Figure 2. Main mechanisms of action of gut microbiota and derived metabolites in obesity 
and associated metabolic dysfunctions (insulin resistance and type-2 diabetes). Gut 
microbiota contributes to the hydrolysis of complex polysaccharides from dietary fibre and, 
thereby, might contribute to increasing energy harvest and to generating SCFAs (acetic 
propionic and butyric acid) that affect the host’s metabolism in different ways. SCFAs might 
activate the G-protein coupled receptor (Gpr) 41 inducing the expression of peptide YY, an 
intestinal hormone that inhibits gut motility, increases intestinal transit rate, and reduces 
energy harvest from the diet. SCFAs might also activate Gpr43 and Gpr41 inducing glucagon-
like peptide 1 (GLP-1) secretion, increasing insulin sensitivity and inducing satiety. Butyrate 
provides energy to enterocytes, exerting a trophic effect and inducing the synthesis of GLP2 
thereby, strengthening the gut barrier function. Butyrate may also promote the formation of 
peripheral regulatory T cells (Treg) by its ability to inhibit the histone deacetylases 6 and 9 
that leads to acetylation of Histone H3, which promotes the expression of the Treg-specific 
forkhead transcription factor FoxP3. Intestinal dysbiosis, which could be partly caused by 
“obesogenic” diets rich in saturated fats, may lead to the growth of potential pathogens 
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(Gram-negative bacteria and derived lipopolysaccharide (LPS)) with pro-inflammatory effects 
via generation of cytotoxic compounds (H2S) or interaction with  innate immune receptors 
(TLR4, TLR2) and contribute to inflammatory cytokine production, attraction of 
inflammatory cells and translocation of bacterial products (LPS, DNA) by transcellular and 
paracellular pathways that activate inflammation in peripheral tissues.  
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Figure 1 
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Bacteroides uniformis CECT 7771 Ameliorates Metabolic
and Immunological Dysfunction in Mice with High-Fat-
Diet Induced Obesity
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Abstract
Background: Associations have been made between obesity and reduced intestinal numbers of members of the phylum
Bacteroidetes, but there is no direct evidence of the role these bacteria play in obesity. Herein, the effects of Bacteroides
uniformis CECT 7771 on obesity-related metabolic and immune alterations have been evaluated.
Methods and Findings: Adult (6–8 week) male wild-type C57BL-6 mice were fed a standard diet or a high-fat-diet HFD to
induce obesity, supplemented or not with B. uniformis CECT 7771 for seven weeks. Animal weight was monitored and
histologic, biochemical, immunocompetent cell functions, and features of the faecal microbiota were analysed after
intervention. The oral administration of B. uniformis CECT 7771 reduced body weight gain, liver steatosis and liver
cholesterol and triglyceride concentrations and increased small adipocyte numbers in HFD-fed mice. The strain also reduced
serum cholesterol, triglyceride, glucose, insulin and leptin levels, and improved oral tolerance to glucose in HFD fed mice.
The bacterial strain also reduced dietary fat absorption, as indicated by the reduced number of fat micelles detected in
enterocytes. Moreover, B. uniformis CECT 7771 improved immune defence mechanisms, impaired in obesity. HFD-induced
obesity led to a decrease in TNF-a production by peritoneal macrophages stimulated with LPS, conversely, the
administration of B. uniformis CECT 7771 increased TNF-a production and phagocytosis. Administering this strain also
increased TNF-a production by dendritic cells (DCs) in response to LPS stimulation, which was significantly reduced by HFD.
B. uniformis CECT 7771 also restored the capacity of DCs to induce a T-cell proliferation response, which was impaired in
obese mice. HFD induced marked changes in gut microbiota composition, which were partially restored by the intervention.
Conclusions: Altogether, the findings indicate that administration of B. uniformis CECT 7771 ameliorates HFD-induced
metabolic and immune dysfunction associated with intestinal dysbiosis in obese mice.
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Introduction
Obesity is considered a major health issue due to its increasing
prevalence and associated co-morbidities (e.g. type 2 diabetes, fatty
liver and cardiovascular disease) affecting both the developed and
the developing world [1–2]. This disorder is the result of a long-
term positive energy imbalance and is associated with a chronic
state of low grade inflammation and immune dysfunction [3–5].
The microbiota of the human gastrointestinal tract has been
considered as an organ that contributes to human physiological
diversity by encoding additional metabolic capacities and regulat-
ing gene expression of pathways involved in host nutrient
metabolism [6]. Animal studies indicate that colonisation of adult
germ-free mice with a distal gut microbial community harvested
from conventionally raised mice influences energy-balance by
increasing both nutrient digestion and absorption, and adiposity
[7]. This effect is mediated by different mechanisms, including
microbial fermentation of dietary polysaccharides that are
otherwise indigestible by the host, subsequent intestinal absorption
of monosaccharides and short-chain fatty acids, conversion of
these metabolites to more complex lipids in the liver; and
microbial regulation of host genes that promote lipid accumulation
in adipocytes [8].
In humans, the gut microbiota composition is also thought to
play a role in energy balance, as inferred from observational
studies reporting associations between obesity or weight loss and
shifts in gut microbiota composition. It has been reported that 80–
90% of bacterial phylotypes are members of two phyla, namely
Bacteroidetes (including the genera Bacteroides and Prevotella) and
Firmicutes (including the genera Clostridium, Enterococcus, Lactobacil-
lus and Ruminococcus), followed by the phyla Actinobacteria
(including the genus Bifidobacterium) and Proteobacteria (including
Helicobacter and Escherichia) [9–10]. Therefore, relative proportions
of Firmicutes and Bacteroides are considered good indicators of
major changes in intestinal microbiota constitution. So far, most
studies have reported associations between obesity and reduced
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41079
proportions of the phylum Bacteroidetes [11] which, in some
cases, were accompanied by increased proportions of Actinobac-
teria [6] or Firmicutes [12], as also observed in mice [9,13]. In
addition, weight loss in obese human subjects subjected to dietary
or surgical interventions has been associated with increases in
Bacteroidetes [12] or in Bacteroides spp., Bacteroides-Prevotella spp. or
Bacteroides fragilis group [14–17]. Nevertheless, few observational
studies have found no associations between weight-loss or obesity
and numbers of Bacteroides spp. or Bacteroides-Prevotella spp. [18–19],
reported opposite associations between obesity, and the relative
proportion of Bacteroidetes to Firmicutes [19] or the numbers of
Prevotellaceae, a subgroup of Bacteroidetes [20]. These discrepancies
could partly be explained by differences in the analytical
techniques used since, for example, real-time PCR or FISH target
only specific groups of Bacteroidetes and underestimate some
members of this phylum present in faecal samples [21]. By
contrast, DNA sequence analyses of the phylum Bacteroidetes can
cover up to 46 species of bacteria belonging to seven different
genera of the order Bacteroidales [6], encompassing a taxonomic
unit that is too broad to assess its possible implication in obesity
[21].
In this study, we hypothesised that modification of the gut
microbiota structure by increasing numbers of specific Bacteroides
spp. could contribute to restoring obesity-related metabolic and
immune dysfunction. To obtain direct evidence of the role of
Bacteroides spp. in obesity and thus confirm such a hypothesis, we
have evaluated in vitro the immunologic properties of different
intestinal Bacteroides spp. on macrophages. Furthermore, we have
assessed the effect of the selected strain (B. uniformis CECT 7771)
on metabolic and immune parameters of mice with high-fat-diet
induced obesity.
Methods
Bacterial Strain and Culture Conditions
The following Bacteroides spp. and strains from the IATA-CSIC
and Spanish Culture Collection (CECT) were studied: Bacteroides
dorei SS1, Bacteroides ovatus SU2, Bacteroides distasonis CAY3,
Bacteroides uniformis CECT 7771 (or CY1), Bacteroides thetaiotaomicron
SAC4, Bacteroides fragilis SX3, Bacteroides caccae SV3 and Bacteroides
finegoldii SX2. These strains were isolated from stools of healthy
infants (mean age 5.7 years, range 1.0–10.8 years). Briefly, fresh
stool samples were diluted (1:10 [w/v]) in phosphate-buffered
saline (PBS) solution (130 mM sodium chloride, 10 mM sodium
phosphate, pH 7.2) and homogenised. Then, aliquots of serial
dilutions in PBS and aliquots were plated on Schaedler Agar
(Scharlau, Barcelona, Spain) supplemented with kanamycin
(100 mg/L), vancomycin (7.5 mg/L) and vitamin K (0.5 mg/L)
and incubated under anaerobic conditions at 37 uC for 48 hours.
Individual colonies were isolated from the highest dilution plate
from each subject and their cellular morphology and Gram-
staining characteristics were examined. The isolated clones were
identified at species level by sequencing of amplified 16S rDNA
regions with the primers 27f and 1401r as previously described
[22]. The PCR products obtained were purified using the GFXtm
PCR DNA and Gel Band DNA Purification Kit (GE Healthcare,
Buckinghamshire, UK) for DNA sequencing. DNA sequencing
was carried out by an ABI PRISM-3130XL Genetic Analyser (Applied
Biosystems, California, USA). The closest relatives of the partial
16S rRNA gene sequences were sought in GenBank using the
Basic Local Alignment Search Tool (BLAST) algorithm, and
sequences with more than 97% similarity were considered as
belonging to the same species. All new data has been deposited in
GenBank (Accession numbers: JX183979, JX262250, JX183978,
JX183977, JX183984, JX183983, JX183981 and JX183982,
respectively).
For experimental purposes, the bacterial strains were grown in
Brain Heart Infusion Broth (BH) (Scharlab, SL- Barcelona, Spain)
at 37 uC in microaerophilic conditions (AnaeroGen; Oxoid,
Basingstoke, UK). Cells were harvested by centrifugation (6,000 g
for 15 min), washed twice in phosphate buffered saline (PBS,
1306 sodium chloride, 10 mM sodium phosphate, pH 7.4), and
re-suspended in PBS plus 15% glycerol for in vitro trials and in 10%
skimmed milk for animal trials. Aliquots of these suspensions were
frozen in liquid nitrogen and stored at -80uC until used. The
number of live cells after freezing and thawing was determined by
colony-forming unit (CFU) counting on BH agar after 48 h
incubation. For the strain tested, more than 90% cells were alive
upon thawing and no significant differences were found during
storage time (2 months). One fresh aliquot was thawed for every
new experiment to avoid variability in the viability of cultures.
Effect of Bateroides Strains on Induction of Cytokine
Production by Macrophages
To evaluate the immunological properties of different Bacteroides
strains, the RAW 264 macrophage cell line, obtained from the
American Type Culture Collection (Rockville, MD, USA), was
cultured overnight in 24-well flat-bottom polystyrene microtiter
plates (Corning, Cultek, Madrid, Spain) at a concentration of
16105 cells per ml in Dulbeco’s Modified Eagles Medium
(DMEM) (SigmaTM– St. Louis, MO/USA). Media were changed
before stimulation and, then, cells were incubated in the presence
of 100 ml of a cell suspension (16107 cfu/ml) of each Bacteroides
strain for 24 h. Purified LPS from Salmonella enterica serotype
Typhimurium (Sigma Chemical Co, Madrid, Spain) was used at a
concentration of 1 mg/ml as a positive control. Non-stimulated
Raw 264.7 cells were also evaluated as controls of basal cytokine
production. The cell culture supernatants were collected and
stored at 220uC until used for cytokine determination. TNF-a
and IL-10 were quantified by ELISA Ready SET Go! Kit (BD
Bioscience, San Diego, CA, USA). Every parameter was assayed
in triplicate in two independent experiments.
Animals, Diets and Experimental Design
Animal experiments were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of University of Valencia (Central Service of
Support to Research [SCSIE], University of Valencia, Spain) and
the protocol was approved by its Ethic Committee (approval ID
A1245740259386). Adult (age 6–8 week) male wild-type C57BL-6
mice were purchased from Harlan Laboratories. During the
adaptation period (7 days), six animals were housed in each
stainless-steel cage in a temperature-controlled (23 uC) room with
a 12-h light/dark cycle and 40–50% relative humidity. Then, mice
were randomly divided into four groups (n = 628 mice per group)
as follows: (1) a control group, receiving a standard diet (SD); (2) an
obese group, receiving a high-fat diet (HFD); (3) a group receiving
a SD and a daily dose of 5.06108 CFU B. uniformis CECT 7771 by
gavage; and (4) an obese group receiving the HFD and a daily dose
of 5.06108 CFU B. uniformis CECT 7771 by oral gavage. To
induce obesity, mice were switched from the SD (CA.170481-
AIN-76A Purified Diet-Rats/Mice, Harlan Laboratories, Madi-
son, WI 53744-4220) administered during the adaptation period to
all mice, to a HFD (TD.06414 - Adjusted Calories Diet - 60/Fat,
Harlan Laboratories, Madison, WI 53744-4220) for 7 weeks. The
HFD provided 18.4% kcal as protein, 21.3% kcal as carbohydrate
and 60.3% kcal as fat (5.1 kcal/g), whereas the SD provided
18.8% kcal as protein, 68.8% kcal as carbohydrate and 12.4% kcal
Bacteroides uniformis and Obesity
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as fat (3.8 kcal/g). Therefore, there was an increase in fat at
expenses of a reduction in carbohydrates in the HFD. Mice had
free access to feed and sterile water.
Body weight was measured once a week and, at the end of
study, animals were fasted for 16 h, anaesthetised, bled by aortic
puncture and sacrificed by cervical dislocation. To analyse the
metabolic parameters, blood samples were collected in tubes
containing EDTA and centrifuged to obtain plasma that was
stored at -20uC. Stools were collected at the end of the
experimental period (7 weeks) for microbiological analyses. The
liver, white adipose (perirenal and epididymal) and small intestinal
tissues were excised and rinsed with saline solution, and sections
were fixed in 10% neutral formalin buffered solution for
histological analysis. The white adipose deposits (perirenal and
epididymal) were previously weighed. Liver sections were also used
for lipid extraction and quantification as described below.
Histology of Liver, White Adipose Tissues and Small
Intestine
Paraffin-embedded tissues were sectioned to a thickness of 4–
5 mm and fixed to glass slides. Slides were deparaffinised and stained
with haematoxylin-eosin. The severity of steatosis was determined in
100 hepatocytes of two liver tissue sections per mouse and scored as
follows: grade 0 when fat was not detected in hepatocytes; grade 1
when fat occupied less than 30% of hepatocytes; grade 2 when fat
occupied between 30 and 60% of hepatocytes; grade 3, when fat
occupied more than 60% of hepatocytes.
Adipocyte cell sizes were measured in 100 cells of two sections of
epididymal adipose tissue per mouse [23]. Adipocyte cell sizes
were expressed as area ranges using the following ranges: ,2000,
2000–4000,4000–6000 and 6000–7000 mm2.
The ratio of fat micelles to enterocyte was determined in 100
cells from two sections of small intestinal tissue of each mouse by
counting ten 100X light microscope fields. All parameters were
measured in a NIKON Eclipse 90i Microscopic, using the NIS
Elements BR 2.3 basic research software (Kingston, Surrey, KT2
5PR, England). All histological analyses were conducted by an
experienced histologist in a blind fashion.
Analysis of Serum and Liver Biochemical Parameters and
Glucose Tolerance
Biochemical parameters were quantified in plasma using
enzymatic assay kits for glucose (Glucose Liquid Kit; Quı´mica
Analı´tica Aplicada SA, Spain), cholesterol (Cholesterol Liquid kit,
Quı´mica Analı´tica Aplicada SA, Spain) and triglycerides (Triglyc-
eride Liquid kit, Quı´mica Analı´tica Aplicada SA, Spain). Serum
leptin concentration was determined by enzyme-linked immuno-
sorbent assay (ELISA) (BD Bioscience, San Diego, CA, USA).
Serum insulin was determined by Ultrasensitive Mouse Insulin
ELISA (Mercondia AB, Sweden, 2010).
Triglycerides and cholesterol were also quantified in liver.
Lipids were extracted by homogenising the tissue with 2:1
chloroform-methanol (v/v) making a 20-fold dilution, and filtering
the homogenate through a nylon filter (Cell Strainer 40
micrometros Nylon.BD Falcon; BD BIOSCIENCIES). Non-
lipidic substances were eliminated by adding 5-volumes of CaCl2
solution (5 mg/L) in water to the filtrate fraction. After
centrifugation (4,000 g, for 5 minutes, at room temperature) the
upper phase, containing all of the non-lipidic substances, was
discarded. This process was repeated three times. Extracted lipids
were dried under vacuum (Concentrator Plus 5301, Eppendorf
Inc., NY, USA) and then triglyceride and total cholesterol
concentrations were determined as described above.
Oral glucose tolerance tests were performed in vivo after 6 weeks
of treatment. Food was removed 2 h after the onset of the daylight
cycle and, after a 4-h fasting period, glucose was administered
orally at a dose of 2 g/kg and blood samples were taken with
heparinised capillary tubes from the tail vein before and 15, 30,
60, 90 and 120 minutes after glucose administration. Plasma
glucose levels were analysed with glucose test strips (Ascensia
Esyfill, Bayer, Tarrytown, NY; USA) and a glucometer (Ascensia
VIGOR, Bayer Tarrytown, NY; USA), with a detection level
ranging from 30 to 550 mg glucose/dl.
Isolation and Assessment of Cytokine Production by
Peritoneal Macrophages
Peritoneal cells were collected by washing the peritoneal cavity
of different groups of mice, with 5 ml of sterile cold DMEM
(Sigma), containing 10% inactivated (56uC for 30 min) foetal
bovine serum (FBS) (Gibco, Barcelona, Spain), 100 mg/ml
streptomycin and 100 U/ml penicillin (SigmaTM– St. Louis,
MO/USA). Isolated macrophages were plated in flasks (Corning,
Cultek, Madrid, Spain) at a concentration of 16106 cells per ml in
DMEM and incubated for 2 h at 37uC in an atmosphere
containing 5% CO2. Non-adhered cells were washed out with
warm PBS. To evaluate differences in the response to a common
stimulus, macrophages from different mouse groups were incu-
bated in the presence of purified LPS from Salmonella enterica
serotype Typhimurium (Sigma Chemical Co, Madrid, Spain) at a
concentration of 1 mg/ml. Non-stimulated peritoneal macrophag-
es were also evaluated as controls of basal cytokine production. To
evaluate microbiota-related immune properties of faecal samples,
macrophages from control mice were incubated in the presence of
faecal samples (30 ml of 10-fold dilution) from the different mouse
groups for 24 h. Stool samples used as stimuli were collected from
six mice of each experimental group at the end of the study,
diluted 10-fold in PBS and homogenised for 3 min. Macrophage
culture supernatants were collected and stored at 220uC until
used for cytokine determination. TNF-a and IL-10 were
quantified by ELISA Ready SET Go! Kit (BD Bioscience, San
Diego, CA, USA). Each parameter was assayed in triplicate in two
independent experiments.
Bactericidal Activity of Peritoneal Macrophages
The bactericidal activity of peritoneal macrophages was
analysed according to Vieira et al. [24] Cells were washed with
serum-free DMEM and nitroblue tetrazolium (NBT – SigmaTM–
St. Louis, MO/USA) at 0.5 mg/ml together with a bacterial
extract (Stimulant, No. 840-15-SigmaTM– St. Louis, MO/USA)
in an equivalent concentration of McFarland Scale 2 in Lab-tek
chamber slide w/cover (Nalge Nunc International, USA). After
1 h of incubation at 37 uC in 5% CO2 atmosphere, the cells were
washed with PBS, then fixed with 4% paraformaldehyde and
observed in a NIKON Eclipse 90i Microscope, using the NIS
Elements BR 2.3 basic research software (Kingston, Surrey, KT2
5PR, England). One hundred cells were counted per mouse and
the percentage of NBT positive cells was determined. This
measurement was taken in triplicate, in two independent
experiments.
Isolation and Cytokine Production by Bone Marrow-
derived Dendrite Cells (DC)
DCs were generated from bone marrow as described previously
[25]. Cells were seeded at a concentration of 16106 (90–94%
DCs) in 1 ml of culture medium without rm GM-CSF in 24-well
plates (Corning, Cultek, Madrid, Spain) and incubated in the
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presence of faeces (30 ml) from the respective mouse group at 37uC
under 5% CO2 for 24 h. Purified LPS from S. enterica serotype
Typhimurium (Sigma Chemical Co, Madrid, Spain) was used at a
concentration of 1 mg/ml as a positive control. Non-stimulated
DCs were also evaluated as controls of basal cytokine production.
Stool samples were obtained and prepared as described above.
The cell culture supernatants were collected and stored at 220uC
until used for cytokine determination (TNF-a and IL-10) as
described above. Every parameter was assayed in triplicate, in two
independent experiments.
Interactions between DCs and CD4+ T Lymphocytes
CD4+ T lymphocytes were isolated from mouse spleens, which
were excised, suspended in complete medium and passed through
a stainless steel wire mesh. The obtained crude cell suspension was
washed once. CD4+ T cells were immune-magnetically isolated by
positive selection with ‘‘CD4+ (L3T4) microbeads’’ (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany), following the
manufacturer’s instructions. CD4+ T cells (purity exceeded 95%)
were used for mixed lymphocyte reaction.
Isolated DCs were incubated for 24 h in the presence of 1 mg/ml
LPS from S. Typhimurium (Sigma Chemical Co, Madrid, Spain).
Aliquots of mature DCs from different mouse groups were plated in
triplicate with allogeneic CD4+T cells (TL) at 1:1, 1:2, and 1:4 TL/
DC cell ratios, in 0.2 ml culture medium in 96-well flat-bottomed
plates (Corning, Cultek, Madrid, Spain) at 37 uC for 72 h.
Lymphocyte proliferation was measured with the cell proliferation
ELISA BrdU-colorimetric assay (Roche, Diagnostic, Germany).
Individual cultures of DCs and TL stimulated with or without ConA,
used as mitogen, were used as controls.
Samples and Microbial Analysis by Quantitative PCR
(qPCR)
Stool samples were weighed, diluted 1:5 (w/v) in PBS (pH 7.2),
homogenised by shaking in a vortex and stored at -20 uC till
analysed. One aliquot of this dilution was used for DNA extraction
using the QIAamp DNA stool Mini kit (Qiagen, Hilden,
Germany). Specific primers (Table 1) [26–30] targeting different
bacterial genera and species were used to characterise the
composition of the microbiota by qPCR using LightCyclerH 480
SYBR Green I Master (Roche, USA) with a an ABI PRISM 7000-
PCR sequence detection system (Applied Biosystems, UK), as
described previously [14].
Statistical Analyses
Statistical analyses were carried out using SPSS 11.0 software
(SPSS Inc., Chicago, IL, USA). Data of biochemical parameters
were normally distributed and significant differences were
determined by applying One-Way Anova with pos hoc Tukey’s
test. Remaining data were non-normally distributed and the
differences were determined by applying the Mann-Whitney U
tests. In every case, P-values ,0.05 were considered statistically
significant.
Results
Bacteroides Strain Selection Based on in vitro Ability to
Induce Cytokine Production
Results in Table 2 show the ability of different Bacteroides strains
to induce cytokine production by Raw264.7 macrophages. All
strains induced the production of significantly higher amounts of
the pro-inflammatory cytokine TNF-a than the non-stimulated
cells and LPS-stimulated macrophages, although the magnitude of
this effect was strain-dependent. The strains B. dorei SS1, B.
uniformis CECT 7771 and B. thetaiotaomicron SAC4 induced the
lowest TNF-a production. Different bacterial strains also induced
anti-inflammatory cytokine IL-10 production above basal levels to
different extents, except for B. thetaiotaomicron SAC4, B. fragilis SX3
and B. finegoldii SX2 whose effects were not significant. B. uniformis
CECT 7771 induced the highest IL-10 levels compared to the
other Bacteroides strains under study. Therefore, this strain was
selected for its greater anti-inflammatory properties.
Body Weight Gain, Adipose Tissue Weight and
Biochemical Parameters in Obese Mice
Body weight gain and total adipose tissue weight of mice after a
7-week intervention are shown in Table 3. The time course body
weight gain over the intervention period is also shown in Figure 1.
HFD-fed mice experienced significant greater weight gain
compared to SD-fed mice from the first 4 weeks of treatment till
the 7th week. The weights of total adipose tissues were also
statistically significantly greater in obese mice than in lean mice.
Table 1. Oligonucleotide primers used in this study.
Target
bacterial groups
Primers
(name) Sequence (59–39)
Size
(pb)
Annealing
Tmp (6C) References
Total bacteria
HDA 1,
HDA 2
TGGCTCAGGACGAACGCTGGCGGC
CCTACTGCTGCCTCCCGTAGGAGT
200 59 (26)
Bifidobacterium spp.
BiFid F,
BiFid R
CTCCTGGAAACGGGTGG
GGTGTTCTTCCCGATATCTACA
550 55 (26,27)
Bacteroides spp.
Bfra F,
Bfra R
ATA GCC TTT CGA AAG RAA GAT
CCA GTA TCA ACT GCA ATT TTA
287 55 (26,27)
Clostridium coccoides group
Ccoc F,
Ccoc R
AAA TGA CGG TAC CTG ACT AA
CTT TGA GTT TCA TTC TTG CGA A
440 50 (26,27)
Clostridium leptum group
ClepF,
Clep R3
GCA CAA GCA GTG GAG T
CTT CCT CCG TTT TGT CAA
239 50 (26,27)
Enterobacteriaceae
Entero 1,
Entero 2
CATTGACGTTACCCGCAGAAGAAGC
CTCTACGAGACTCAAGCTTGC
195 63 (28)
Lactobacillus group
Lac 1,
Lac 2
AGCAGTAGGGAATCTTCCA
ATTYCACCGCTACACATG
340 61 (29, 30)
doi:10.1371/journal.pone.0041079.t001
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The administration of B. uniformis CECT 7771 significantly
reduced body weight gain in HFD-fed mice by the end of the
intervention, but did not significantly modify total adipose tissue
weight (Table 3, Figure 1). No mice died and all of them remained
healthy throughout the study.
Serum concentrations of biochemical and hormonal parameters
of metabolic relevance are shown in Table 3. The HFD induced a
significant increase in all serum parameters analysed compared to
SD-fed mice. The administration of B. uniformis CECT 7771
significantly reduced serum glucose, insulin, triglycerides and
cholesterol concentrations in HFD-fed mice but not in SD-fed
mice. In HFD-fed mice B. uniformis CECT 7771 reduced
cholesterol levels by 18% and triglyceride levels by 25%.
B. uniformis CECT 7771 administration also significantly lowered
fasting glucose levels (Table 3) and improved glucose tolerance,
reducing the maximum peak and the area under the curve during
the oral glucose tolerance test (Figure 2). The increased serum
leptin concentrations induced by the HFD were significantly
reduced by the administration of B. uniformis CECT 7771 (Table 3).
The specific concentrations of cholesterol and triglycerides
present in total lipids extracted from the liver were also analysed
(Table 3). The HFD induced a significant increase in both
parameters compared to levels in SD-fed mice, while the
administration of B. uniformis CECT 7771 significantly reduced
triglycerides and cholesterol concentrations in the liver of HFD-fed
mice (Table 3).
Hepatic Steatosis, Adipocyte size, and Fat Absorption by
Enterocytes in Obese Mice
Figure 3 shows the effects on hepatic steatosis of the
administration of B. uniformis CECT 7771 to SD- or HFD-fed
mice. The bacterial strain significantly reduced steatosis in HFD-
fed animals, and also reduced lipid accumulation in the liver of
SD-fed mice. The administration of B. uniformis CECT 7771 to SD
mice significantly increased the number of hepatocytes with no
steatosis (0-grade) and reduced those with steatosis grades 1 and 2.
In HFD-fed animals, B. uniformis CECT 7771 administration
contributed to increasing the number of hepatocytes with 0- and 1-
grade steatosis and to reducing those with 2-and 3-grade steatosis.
The effects of the intervention on adipocyte size on epididimal
adipose tissue are shown in Figure 4. HFD induced a significant
increase in adipocyte size in the following ranges 2000–4000,
4000–6000 and 6000–7000 mm2, and reduced those of size ,2000
mm2. The administration of B. uniformis CECT 7771 in SD-fed
mice did not induce significant changes in adipocyte size, while a
significant increase in the number of small adipocytes (,2000) was
observed in HFD-fed mice.
The effects of the HFD and the administration of the bacterial
strain on the number of fat micelles per enterocyte, which indicate
dietary fat absorption, are shown in Figure 5. The HFD induced a
significant increase in fat micelles in enterocytes, whereas the
administration of B. uniformis CECT 7771 reduced these numbers.
In the SD group, no significant changes were observed due to
intervention with the aforementioned bacterium.
Macrophage Functionality
The results of cytokine production by LPS-stimulated peritoneal
macrophages from SD- and HFD-fed mice with and without B.
uniformis CECT 7771 supplementation are shown in Figure 6.
Obesity induced by a HFD led to a decrease in cytokine TNF-a
production by peritoneal macrophages stimulated with LPS
compared to macrophages of SD-fed mice (Figure 6A). The
administration of B. uniformis CECT 7771 significantly increased
the ability of LPS-stimulated macrophages to produce TNF-a in
HFD-fed mice but not in SD-fed mice (Figure 6A). The HFD did
not affect the ability of LPS-stimulated macrophages to produce
the anti-inflammatory cytokine IL-10 and this feature was not
modified by the administration of B. uniformis CECT 7771
(Figure 6A). The oxidative burst in peritoneal macrophage after
uptake of a microbial extract was also studied to analyse effects on
phagocytosis function (Figure 6B). The results indicated that the
oral administration of B. uniformis CECT 7771 stimulated this
function in macrophages in both SD- and HFD-fed mice
(Figure 6B).
Dendritic Cell (DC) Functionality
The results of cytokine production by LPS-stimulated DC from
SD- and HFD-fed mice, with and without B. uniformis CECT 7771
supplementation are shown in Figure 7A. The administration of B.
uniformis CECT 7771 to obese and lean mice increased the ability
of DC to produce TNF-a in response to LPS stimulation, which
was significantly reduced by the HFD (Figure 7A). In HFD-fed
mice, IL-10 production by LPS-stimulated DCs was significantly
increased. The administration of B. uniformis CECT 7771
increased IL-10 values even more in HFD-fed mice and also
stimulated this cytokine production in SD-fed mice (Figure 7A).
The results of the influence of HFD-induced obesity and oral
administration of B. uniformis CECT 7771 on the ability of
matured DCs to priming a T cell proliferative response are shown
in Figure 7B. DCs from SD-fed mice were able to induce a
significant increase in T cell proliferation in comparison to T cells
alone (data not shown) in all the examined DC:T cell ratios. The
HFD impaired the capacity of DCs to induce a T cell proliferation
response, but this function was restored by B. uniformis CECT 7771
administration, and the strongest effects were obtained at 1:4
DC:T ratio. This effect was also significant for SD-fed mice.
Microbiota Composition and Inflammatory Properties
The composition of the faecal microbiota in SD- and HFD-fed
mice is shown in Table 4. The HFD led to reductions in the gene
Table 2. Effect of different Bacteroides strains on cytokine
production by RAW264.7 macrophages.
Bacteroides strains Cytokine production
TNF-a (pg/ml) IL-10 (pg/ml)
DEMEN 491.2(112.1)a, b’ 97.2(10.8)a,a’
LPS 1425.4(77.6)b, a’ 162.3(37.6)a,a’
B. dorei SS1 3765.5(150.0)b,b’,a’’ 215.8(12.5)b,a’,b’’
B. ovatus SU2 4515.7(211.3)b,b’,b’’ 271.5(8.1)b,b’,b’’
B. distasonis CAY3 4462.4(173.9) b,b’,b’’ 215.8(9.7)b,a’,b’’
B. uniformis CECT 7771 2998.4(50.4) b,b’,a’’ 341.3(13.5)b,b’,a’’
B. thetaiotaomicron SAC4 2931.2(464.5) b,b’,a’’ 109.2(3.0)a,a’,b’’
B. fragilis SX3 6657.3(278.3) b,b’,b’’ 81.2(14.6)a,a’,b’’
B. caccae SV3 11622.0(818.3) b,b’,b’’ 171.7(12.9)b,a’,b’’
B. finegoldii SX2 6535.8(62.2) b,b’,b’’ 83.5(17.4)a,a’,b’’
Purified lipopolysaccharide (1 mg/ml) (LPS) from S. enterica serotype
Typhimurium was used as a positive control. Non-stimulated cells were also
evaluated as controls of basal cytokine levels (DEMEN). Results are expressed as
mean (SD) of duplicate measures determined in three independent
experiments. Significant differences were established at P,0.05 by applying
ANOVA and post hoc Tukey’ test. Means in the same columns with different
letters were significantly different in relation to non-stimulated cells (a-b) or to
LPS (a’-b’) or to B. uniformis CECT 7771 (a’’-b’’).
doi:10.1371/journal.pone.0041079.t002
Bacteroides uniformis and Obesity
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41079
copy numbers of most of the bacterial groups analysed, including
Lactobacillus, C. coccoides and C. leptum groups and the genus
Bifidobacterium. This diet also caused increases in gene copy
numbers of members of the Enterobacteriaceae family. In HFD-fed
mice, B. uniformis CECT 7771 administration increased the gene
copy numbers of the genera Bacteroides and Bifidobacterium and the
group C. coccoides and reduced those of members of the
Enterobacteriaceae family, partially restoring the alteration of the
microbiota associated with the HFD. In SD fed mice, the
administration of the strain led to an increase in the gene copy
numbers of total bacteria the genera Bacteroides and Bifidobacterium
Table 3. Biometric parameters and serum and liver biochemistry in mice fed either a high-fat diet (HFD) or standard diet (SD),
supplemented or not with B. uniformis CECT 7771.
Outcome measure Experimental Groups
SD HFD SD+B HFD+B
P- value
HFD vs
SD
P- value
(SD+B vs
SD)
P- value
(HFD+B vs
HFD)
Mean sd Mean sd Mean sd Mean sd
Biometric parameters
Body weight gain (%) 24.21 3.34 36.19 1.55 23.61 3.17 30.33 0.92 0.007* 0.890 0.005*
Adipose tissue (g)/100 g
body weight
0.06 0.04 0.15 0.03 0.03 0.02 0.14 0.04 0.016* 0.150 0.423
Serum parameters
Cholesterol (mg/dl) 120.00 13.67 176.02 14.91 128.22 11.91 143.97 17.29 ,0.001* 0.222 0.003*
Triglyceride (mg/dl) 130.31 11.56 156.99 27.47 129.77 13.94 118.21 10.04 0.041* 0.937 0.004*
Glucose (mg/dl) 219.81 26.41 485.92 140.63 372.41 13.50 233.52 30.62 0.001* 0.237 0.002*
Insulin (mg/l) 0.57 0.47 1.59 0.09 0.69 0.05 0.92 0.14 0.018* 0.892 0.018*
Leptin (ng/ml) 8.07 1.12 18.28 4.28 6.80 1.23 12.98 3.24 ,0.001* 0.048* 0.014*
Liver lipids
Cholesterol (mg/g ) 29.94 4.08 35.51 4.35 29.22 6.32 27.48 6.39 0.029* 0.801 0.024*
Triglyceride (mg/g ) 22.93 13.03 45.99 11.53 31.36 4.76 34.17 9.51 ,0.001* 0.142 0.039*
SD: standard diet group (control) (n = 6); SD+B: standard diet group receiving a daily dose of 5.06108 CFU B uniformis CECT 7771 by gavage for 7 weeks (n = 6); HFD:
high fat diet group (n = 6); HFD+B: high fat diet group receiving a daily dose of 5.06108 CFU B. uniformis CECT 7771 by gavage during 7 weeks (n = 6). Body composition
and biochemical parameters were determined after 7 weeks of intervention. Adipose tissue included epididymal and perirenal white adipose tissues. Values are
expressed as means and standard deviation (sd).
*Significant differences were established at P,0.050.
doi:10.1371/journal.pone.0041079.t003
Figure 1. Time course of relative body weight gain in control mice and mice with high fat diet-induced obesity, administered or not
B. uniformis CECT 7771. SD: standard diet group (control) (n = 6); HFD: high fat diet group (n = 6); HFD+B: high fat diet group receiving a daily dose
of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6).
doi:10.1371/journal.pone.0041079.g001
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and the group C. leptum. The numbers of the C. coccoides group
followed the same trend, but the differences were not significant.
To evaluate whether these changes in the microbiota could
modify the inflammatory signals coming from the gut in the
different mouse groups, the ability of faecal samples to induce the
production of cytokines by immunocompetent cells in vitro was
evaluated (Figure 8A and 8B). Stool samples from HFD-fed mice
induced a higher production of TNF-a than those from SD-fed
mice by macrophages (Figure 8A) and DCs (Figure 8B), indicating
that the HFD induced an increase in the pro-inflammatory signals
coming from the gut. The administration of B. uniformis CECT
7771 significantly reduced the production of this pro-inflammatory
cytokine in macrophages stimulated with stools from both mouse
groups (Figure 8A), and in DCs stimulated with stools from the
HFD group. Therefore, this bacterial strain seems to have ability
to reduce the inflammatory properties of the gut content, although
confirmatory studies measuring additional inflammatory markers
in the gut would be required to draw definitive conclusions.
In macrophages (Figure 8A) and DCs (Figure 8B), stool samples
of HFD-fed mice induced significantly higher production of the
Figure 2. Glucose tolerance in control mice and mice with high fat diet-induced obesity, administered or not B. uniformis CECT 7771.
SD: standard diet group (control) (n = 6); HFD: high fat diet group (n = 6); HFD+B: high fat diet group receiving a daily dose of 5.06108 CFU
B. uniformis CECT 7771 by gavage for 7 weeks (n = 6). A: Plasma glucose profile following 2 g/kg glucose oral challenge after 4 h fasting; B: Mean area
under the curve measured between 0 and 120 min after glucose administration.
doi:10.1371/journal.pone.0041079.g002
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anti-inflammatory cytokine IL-10 than those from SD-fed mice,
which could be due to the activation of regulatory mechanisms to
counteract other inflammatory signals inducing also TNF-a. Stool
samples from both SD and HFD mouse groups administered B.
uniformis CECT 7771 induced a significant increase in IL-10
production by DCs, suggesting an increase in the anti-inflamma-
Figure 3. Determination of hepatic steatosis (hepatic histology) in control mice and mice with high fat diet-induced obesity,
administered or not B. uniformis CECT 7771. SD: standard diet group (control) (n = 6); SD+B: standard diet group receiving a daily dose of
5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6); HFD: high fat diet group (n = 6); HFD+B: high fat diet group receiving a daily dose
of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6).The fat vacuoles were measured in 100 hepatocytes of two liver tissue sections
per mouse and scored for the severity of steatosis according to the following criteria: For grade-0 steatosis, no fatty hepatocytes; grade-1 steatosis, fat
occupying less than 30% of the hepatocyte; grade-2 steatosis, fat occupying less than 30 to 60% of the hepatocyte; grade-3 steatosis, fat occupying
more than 60% of the hepatocyte. Photomicrographs 20X of representative HE-stained slides are shown. (B) SD group, (C) SD+P group, (D) HFD group
and (F) HFD+P group. Data are expressed as means 6 SD and statistically significant differences are established at P,0.05.
doi:10.1371/journal.pone.0041079.g003
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tory signals emanating from the gut (Figure 8B). These B. uniformis
CECT 7771-related effects were not detected in macrophages
(Figure 8A).
Discussion
This study has provided direct evidence of the metabolic and
immune effects of B. uniformis CECT 7771 in a murine model of
diet-induced obesity. Previous scientific research was controversial
and had only established associations between either a lean
Figure 4. Distribution of adipocyte size in epididymal adipose tissue in control mice and mice with high fat diet-induced obesity,
administered or not B. uniformis CECT 7771. SD: standard diet group (control) (n = 6); SD+B: standard diet group receiving a daily dose of
5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6); HFD: high fat diet group (n = 6); HFD+B: high fat diet group receiving a daily dose
of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6). Adipocyte cell sizes were expressed as area ranges and were the following:
,2000, 2000–4000, 4000–6000 and 6000–7000 mm2. Data are expressed as means 6 SD and statistically significant differences are established at
P,0.05. Photomicrographs 20X of representative HE-stained slides are shown. (B) SD group, (C) SD+B group, (D) HFD group and (E) HFD+B group.
doi:10.1371/journal.pone.0041079.g004
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phenotype or weight loss with increased intestinal numbers of the
phylum Bacteroidetes phylum, or the groups Bacteroides-Prevotella or
Bacteroides fragilis [9,11–20]. The selection of the specific strain
tested was based on its lower inflammatory potential in vitro on
macrophages compared to strains belonging to other intestinal
Bacteroides spp. This trait could be relevant in the context of obesity
since it is considered a chronic inflammatory disorder, largely
mediated by macrophage infiltration in the adipose tissue [31–33].
Our study demonstrated that B. uniformis CECT 7771 induced low
TNF-a production and the highest IL-10 production in compar-
ison with other strains of Bacteroides spp. Our recent studies also
demonstrated that the prevalence of B. uniformis CECT 7771 in the
gut of infants is favoured by breast-feeding [22] and breast-feeding
seems to protect against later development of obesity as compared
to formula feeding [34–35]. Considering these data altogether led
us to hypothesise that the oral administration of B. uniformis CECT
7771 could exert beneficial effects in an obesity model as reported
in this study.
In our mouse obesity model, B. uniformis CECT 7771
administration induced significant modifications in total body
weight gain by the end of intervention, although differences in
adipose tissue weight were not significant, probably due to the
limited duration of the trial. However, B. uniformis CECT 7771
increased the number of small adipocytes in obese mice, which
could precede fat weight reduction. In contrast, colonisation of
germ-free mice by B. thetaiotaomicron and Methanobrevibacter smithii
augmented de novo lipogenesis and adiposity [36]. In this context, it
was proposed that gut colonisation by the conventional microbiota
or by specific commensal bacteria (e.g. B. thetaiotaomicron) provides
the hydrolases necessary to utilise complex polysaccharides and
the resulting products are absorbed or metabolised to short-chain
fatty acids. Subsequently, the latter are delivered to the liver and
converted to triacylglycerols and, then, part of these de novo
synthesised lipids are deposited in adipocytes [37–38]. In addition,
it was considered that the gut microbiota could reduce the fasting-
induced adipose factor (Fiaf, also known as angiopoietin-like
protein-4), a secreted lipoprotein lipase (LPL) inhibitor [8],
promoting storage of fatty acids released by the LPL in the host
adipose tissue, but this mechanism was not confirmed in a latter
study [39]. Although the animal models used in our and previous
studies are not comparable, the results suggest that different
Bacteroides spp. might exert different effects on energy balance and
lipid storage.
In obese subjects there is also an increased flux of free fatty acids
to the liver due to their excessive accumulation in the adipose
tissue and to the inability of insulin to suppress lipolysis in
adipocytes due to insulin resistance, which leads to steatosis or
fatty liver disease [40–41]. In our study, the administration of B.
uniformis CECT 7771 significantly reduced steatosis in obese
animals and, interestingly, also reduced liver cholesterol and
triglyceride accumulation. In obese mice, liver steatosis and
adipocyte hypertrophy is reported to be related to an increased
energy input via intestinal lipid absorption, which is transported in
the form of chylomicrons to peripheral tissues [42]. Therefore, we
also analysed the number of fat micelles per enterocyte, which
partly represents fat absorbed from the diet. B. uniformis CECT
7771 administration significantly reduced the fat micelles in
enterocytes, particularly in obese mice, indicating that this is a
mechanism by which this bacterial strain exerts a positive effect on
liver steatosis and serum lipids. Other studies also demonstrated
that specific lactobacilli or bifidobacterial strains might reduce the
absorption of dietary fat, but this is the first evidence that a
Bacteroides strain exerts this effect depending on the diet [40,42,43].
However, the involvement of other mechanisms, such as reduction
of endogenous biosynthesis or reduction of lipid uptake by
hepatocytes, cannot be disregarded [44].
Dyslipidaemia is also a frequent feature of obese subjects, with
the most common being hypertriclyceridaemias and hypercholes-
Figure 5. Number of fat micelles per enterocyte in control mice and mice with high fat diet-induced obesity, administered or not B.
uniformis CECT 7771. SD: standard diet group (control) (n = 6); SD+B: standard diet group receiving a daily dose of 5.06108 CFU B. uniformis CECT
7771 by gavage for 7 weeks (n = 6); HFD: high fat diet group (n = 6); HFD+B: high fat diet group receiving a daily dose of 5.06108 CFU B. uniformis
CECT 7771 by gavage for 7 weeks (n = 6). The relation fat micelles/enterocyte was determined in 100 cells from two sections of the small intestine of
each mouse by counting ten 100X light microscope fields. Data are expressed as means 6 SD and statistically significant differences are established
at P,0.05.
doi:10.1371/journal.pone.0041079.g005
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terolaemias [45,46], which are also induced by HFD in mice. In
this study, HFD-fed mice showed higher values of serum
cholesterol and triglyceride levels than SD-fed mice. B. uniformis
CECT 7771 administration reduced serum cholesterol and
triglyceride levels in HFD-fed mice. These effects could also be
partially related to a reduction of dietary fat absorption and
possibly to modulation of the expression of genes and proteins
involved in lipid homeostasis in the gut and liver, as indicated
previously.
Hyperglycaemia and insulin resistance are also frequently
associated with obesity in humans [1–2]. This feature was also
reproduced in our mice obesity model, which showed increased
fasting glucose levels and reduced glucose tolerance. However, the
administration of B. uniformis CECT 7771 significantly improved
Figure 6. Cytokine production in LPS-stimulated peritoneal macrophages and phagocytosis function of control mice and mice with
high-fat diet induced obesity, administered or not B. uniformis CECT 7771. SD: standard diet group (control) (n = 6); SD+B: standard diet
group receiving a daily dose of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6); HFD: high fat diet group (n = 6); HFD+B: high fat
diet group receiving a daily dose of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6). In the cytokine production study, peritoneal
macrophages were stimulated with purified lipopolysaccharide (LPS) from S. enterica serotype Typhimurium (Figure 6A). Non-stimulated peritoneal
macrophages were evaluated as controls of basal cytokine levels. In the phagocytosis study (Figure 6B), evidence of oxygen-radical production by
macrophages was determined by the NBT test after in vitro interaction with a bacterial extract. Figure 6A: TNF- a and IL-10 cytokines produced by
LPS-stimulated macrophages; Figure 6B: % NBT (+) cells. Data are expressed as mean and standard deviation of duplicate measurements determined
in two independent experiments. Statistically significant differences of data are established at P,0.05.
doi:10.1371/journal.pone.0041079.g006
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the response to an oral glucose challenge and reduced the fasting
glycaemia in parallel to insulin, suggesting an improvement in
glucose metabolism and insulin sensitivity. Comparisons between
germ-free and conventional mice indicated that the commensal
microbiota, as a whole, induced hyperglycaemia and insulin
resistance [44] while administration of antibiotics causing a
reduction in the intestinal bacterial load improved oral glucose
tolerance in ob/ob and HFD-fed mice [47,48]. The adverse effects
attributed to the microbiota were related to a reduction of AMPK
activity and, therefore, reduced insulin-stimulated glucose trans-
Figure 7. Influence of LPS stimuli on cytokine production and activation of T-lymphocyte proliferation by dendritic cells (DCs)
generated from control mice and mice with high-fat diet induced obesity, administered or not B. uniformis CECT 777. SD: standard
diet group (control) (n = 6); SD+B: standard diet group receiving a daily dose of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6);
HFD: high fat diet group (n = 6); HFD+B: high fat diet group receiving a daily dose of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks
(n = 6). In the cytokine production study, DCs were stimulated with purified lipopolysaccharide (LPS) from S. enterica serotype Typhimurium
(Figure 7A). Non-stimulated DCs were evaluated as controls of basal cytokine levels. In the lymphocyte proliferation study (Figure 7B), matured DCs
were used for priming a T-cell proliferative response at the following LT/CD ratios: 1:1, 1:2, 1:4. Lymphocyte proliferation was measured with the cell
proliferation ELISA BrdU-colorimetric assay. Figure 7A: TNF- a and IL-10 cytokines produced by LPS-stimulated CDs; Figure 7B: Lymphocyte
proliferation. Data are expressed as means 6 SD of duplicate measures determined in two independent experiments. Statistically significant
differences of data are established at P,0.05.
doi:10.1371/journal.pone.0041079.g007
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port in muscles [38] and to a reduction of inflammatory signals
coming from the gut, such as LPS from Gram-negative bacteria
and its correlation with intestinal and plasma TNF-a levels [49].
Nevertheless, our present and previous studies indicated that
intervention in the gut ecosystem with specific strains may improve
diet-induced insulin sensitivity and glucose tolerance above the
commensal microbiota effects [40].
Obesity often manifests with hyperleptinemia, associated with
leptin resistance, leading to different central and peripheral
adverse effects, including increased hunger and reduced energy
expenditure as well as increased lipid accumulation [50]. B.
uniformis CECT 7771 administration also led to reduced leptin
levels in obese mice, which could be indicative of an improvement
in leptin function or sensitivity, leading to lower leptin production
[51]. These improved leptin levels could be related to improve-
ments in glucose tolerance and reduced serum concentration since
leptin favours insulin function [52]. In addition, the reduction of
serum leptin levels could also be related to increases in smaller
adipocytes and reduced liver steatosis in HFD-fed mice supple-
mented with the bacterial strain due to the role of leptin in fat
accumulation in peripheral tissues [53].
Our study also showed that B. uniformis CECT 7771 adminis-
tration improves immune function of macrophages and DCs,
which is particularly important in obese mice. It is known that
macrophage function is impaired in obesity, showing reduced
phagocytic capacity and oxidative burst, which has been linked to
increased susceptibility to infections of obese subjects [54,55]. In
our study, phagocytic function of macrophages was slightly
reduced by the HFD, in accordance with others authors [56].
However, B. uniformis CECT 7771 administration stimulated the
oxidative burst of macrophages in both HFD and SD-fed mice.
Our study also demonstrates that B. uniformis CECT 7771
administration improved the ability of macrophages and DCs to
produce cytokines in response to a pathogenic bacterial stimulus
(LPS). B. uniformis CECT 7771 also restored the capacity of DCs to
present antigens and stimulate T lymphocyte proliferation. A
functional deficiency of DCs in ob/ob mice has also been described
previously, suggesting that this damage could be generalised to the
more frequent forms of obesity [41]. Altogether, our data indicates
that B. uniformis CECT 7771 can improve innate and adaptive
defence mechanisms against infections in diet-induced obesity.
This study also confirms that diet has a tremendous impact on
the intestinal microbiota composition and supports the hypothesis
that its modulation through the use of dietary strategies could
ameliorate the metabolic and immune dysfunctions associated
with imbalanced diets. The HFD reduced gene copy numbers of
Gram-positive bacteria, including Bifidobacterium spp. and C.
coccoides group, in accordance with previous studies [49]. Our
study also demonstrates that the HFD increased the gene copy
numbers of enterobacteria, while B. uniformis CECT 7771 slightly
reduced these numbers and increased those of C. coccoides group,
Bifidobacterium spp. and Bacteroides spp. Furthermore, the B. uniformis
CECT 7771-related changes in microbiota contributed to
reducing the gut inflammatory signals, which could affect other
peripheral tissues involved in obesity. In this context, endotoxins
(LPS) from enterobacteria, present in the gut, have been shown to
play an important role in the development of insulin resistance and
non-alcoholic fatty liver disease [57]. In ob/ob mice, reductions of
intestinal E. coli numbers by antibiotic treatment were associated
with the reduction of metabolic endotoxaemia and inflammatory
status as well as with improvements in insulin resistance [58].
Another recent study also reported that positive effects of
prebiotics (oligofructose and inulin mixture) on body weight and
fat and related metabolic parameters could be due to their ability
to increase numbers of both bacteroides and bifidobacteria in the
gut microbiota of obese JCR:LA-cp rats [13]. These changes were
related to modifying the expression of anorexigenic and orexigenic
peptides, but the role of each bacterial group on such effects
remains unclear.
In conclusion, the results support the hypothesis that the
B. uniformis CECT 7771 modulates the metabolic and immune
dysfunction induced by HFD at least in mice. The study provides
direct evidence of the potential beneficial roles played by
B. uniformis CECT 7771 in obesity, bringing us one step ahead
of the mere associations inferred from previous observational
studies. Therefore, the use of dietary strategies targeting the gut
ecosystem may be an additional tool to control metabolic
disorders. However, further studies are required to support this
hypothesis and to reveal plausible mechanisms of action of the
Table 4. Microbiota composition of stool samples from different mouse groups analysed by quantitative PCRa.
Bacterial group Experimental groups
SD HFD SD+B HFD+B
aMedian (IQR) aMedian (IQR) p- valueb aMedian (IQR) p- valuec aMedian (IQR) p- valued
Total bacteria 10.8 (10.6–11.1) 10.5 (10.3–10.8) 0.092 11.4 (11.3–11.6) 0.010* 11.0 (10.7–11.2.) 0.629
Lactobacillus group 9.9 (9.4–10.5) 9.4 (9.2–9.5) 0.040* 9.6 (9.3–9.8) 0.470 9.7 (9.5–10.1) 0.936
Bacteroides spp. 8.4 (8.3–8.6) 8.7 (8.3–9.0) 0.674 9.3 (9.1–9.5) 0.004* 9.0 (8.8–9.3) 0.016*
Bifidobacterium spp. 7.1 (6.8–7.2) 6.0 (5.9–6.3) 0.004* 8.1 (7.9–8.3) 0.013* 7.5 (7.0–7.7) 0.004*
C. leptum group 8.4 (8.3–8.6) 7.6 (7.5–7.7) 0.004* 9.6 (9.4–9.8) 0.004* 8.5 (8.1–8.7) 0.936
C. coccoides group 9.1 (8.6–9.3) 8.4 (8.2–8.5) 0.016* 9.9 (9.4–10.0) 0.054 9.6 (9.4–9.7) 0.036*
Enterobacteriaceae 7.3 (7.2–7.7) 8.1 (7.8–8.2) 0.019* 8.1 (7.6–8.2) 0.052 7.9 (7.5–8.0) 0.029*
SD: standard diet group (control) (n = 6); SD+B: standard diet group receiving a daily dose of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6); HFD:
high fat diet group (n = 6); HFD+B: high fat diet group receiving a daily dose of 5.06108 CFU B. uniformis CECT 7771 by gavage during 7 weeks (n = 6).
aData are expressed as median of log gene copy numbers of each bacterial group per gram of stools.
bSignificant differences in log gene copy numbers of specific bacterial groups between SD and HFD mouse groups.
cSignificant differences in log gene copy numbers of specific bacterial groups between SD and SD+B mouse groups.
dSignificant differences in log gene copy numbers of specific bacterial groups between HFD and HFD+B groups.
*Significant differences were established at P,0.05 by using Mann–Whitney U-test.
doi:10.1371/journal.pone.0041079.t004
Bacteroides uniformis and Obesity
PLoS ONE | www.plosone.org 13 July 2012 | Volume 7 | Issue 7 | e41079
specific bacterial strain used in this preclinical study. Furthermore,
safety issues should also be addressed before proposing the possible
use of the strain tested in humans.
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Figure 8. Influence of stool samples from mice fed standard diet or high-fat diet, supplemented or not with B. uniformis CECT 7771,
on cytokine production by peritoneal macrophages and dendritic cells (DCs) from control mice. SD: standard diet group (control) (n = 6);
SD+B: standard diet group receiving a daily dose of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6); HFD: high fat diet group
(n = 6); HFD+B: high fat diet group receiving a daily dose of 5.06108 CFU B. uniformis CECT 7771 by gavage for 7 weeks (n = 6). In the cytokine
production study, peritoneal macrophages (Figure 8A) and DCs (Figure 8B) were stimulated with stool stimuli. Non-stimulated peritoneal
macrophages and DCs were evaluated as controls of basal cytokine levels. Figure 8A: TNF- a and IL-10 cytokines produced by stool-stimulated
peritoneal macrophages; Figure 8B: TNF- a and IL-10 cytokines produced by stool-stimulated CDs. Data are expressed as means 6 SD of duplicate
measures determined in two independent experiments. Statistically significant differences of data are established at P,0.05.
doi:10.1371/journal.pone.0041079.g008
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http://dx.doi.org/10.1016/j.numecd.Abstract Background and aims: Bifidobacterium pseudocatenulatum CECT 7765 moderates
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High-energy diets and sedentary lifestyles have dramati-
cally increased the incidence of obesity and associated
disorders (dyslipidaemia, insulin resistance, diabetes, and
hepatic steatosis) stressing the need for therapeutic and
preventive measures [1]. Emerging evidence indicates that
the gut microbiota play a role in the development of
obesity [2]. Changes of the relative abundance of bacterial
phyla, gender or species have been positively or negatively
associated with obesity and metabolic alterations [3,4].
Animal studies have provided evidence for plausible
mechanisms by which the microbiota could play a role in
body weight regulation, including metabolic, immune and
neuroendocrine effects [4]. Thus it has been suggested that
intentional manipulation of the gut microbiota could be an
additional strategy to reduce the incidence of obesity and
associated disorders.
Diet has an important effect on gut microbiota compo-
sition, which opens the possibility of using dietary inter-
vention strategies to induced modifications that can have
an impact on human physiology. In recent years, several
bacterial strains (Lactobacillus spp. or Bifidobacterium
spp.) have been evaluated in different animal models of
obesity and metabolic alterations to understand their
possible role but differing effects have been reported [3,5].
For instance, Lactobacillus reuteri ATCC PTA 4659 reduced
body weight gain, adipose and liver weights and serum in-
sulin levels in Apoe/ mice [6] whereas Lactobacillus
ingluviei increased body and liver weight and inflammation
in BALB/c mice [7]. Strains of the genus Bifidobacterium
have been generally shown to exert beneficial effects
against obesity in animal models [8e10]. For example, a
mixture of Bifidobacterium spp. (including Bifidobacterium
pseudocatenulatum) exerted anti-obesity and lipid
lowering effects in HF-fed rats [9] and very recently, B.
pseudocatenulatum CECT 7765 was reported to ameliorate
metabolic and immunological alterations related to obesity
in HFD-fed mice [10].
Knowledge of the molecular mechanisms underlying the
effects of probiotics is very limited. The gut microbiota in-
teracts and regulates complex and multiple host metabolic,
signalling and inflammatory pathways connecting the gut
with the liver, adipose tissue, pancreas, muscle and brain
[11,12]. Evidence is also accumulating that gut microbiota
manipulation causes significant molecular changes in the
liver related to its lipid and glucose metabolism regulatory
roles [13]. Herein, we have applied a transcriptomic
approach using Affymetrix microarrays to identify key genes
significantly altered in the liver by a HFD and by simulta-
neous administration of B. pseudocatenulatum CECT 7765 to
progress in the understanding of the mechanisms of action of
this strain in lipid and glucose metabolism.ya-Pe´rez A, et al., Hepatic molecu
obesity, Nutrition, MetabolismMethods
Bacterial strain
B. pseudocatenulatum CECT 7765 was grown in MRS broth
(Scharlau, Barcelona, Spain) supplemented with 0.05%
(w/v) cysteine (MRS-C Sigma, St. Louis, MO), and incubated
at 37 C for 22 h under anaerobic conditions (AnaeroGen,
Oxoid, Basingstoke, UK). Cells were harvested (6000 g for
15 min), washed twice in phosphate buffered saline (PBS,
130 mM sodium chloride, 10 mM sodium phosphate, pH 7.4),
and re-suspended in 10% skimmed milk for oral adminis-
tration to mice. Aliquots of these suspensions were frozen
in liquid nitrogen and stored at 80 C until used. The
number of live cells after freezing and thawing was deter-
mined by colony-forming unit (CFU) counting on MRS-C agar
following 48 h incubation. More than 90% cells were alive
upon thawing and no significant differences were found
during storage (2 months). One fresh aliquot was thawed
each new experiment to avoid variability in the viability of
cultures.Animals and diets
Seven-week-old wild-type C57BL/6 male mice were pur-
chased from Charles River Laboratories International (Bar-
celona, Spain). This study was conducted in strict
accordance with the recommendations included in the
Guide for the Care and Use of Laboratory Animals of Uni-
versity of Valencia (Central Service of Support to Research,
University of Valencia, Spain) and the experimental proto-
col was approved by its Ethic Committee. Mice were housed
in stainless-steel cages in a temperature-controlled (23 C)
room with a 12 h light/dark cycle and 40e50% relative hu-
midity and fed a standard diet (SD) for 6 days before being
assigned to the experimental groups (n Z 5 animals per
group) as follows: (a) a control group fed the SD; (b) an
obese group fed a high-fat diet (HFD); (c) a group fed the SD
plus a daily dose of B. pseudocatenulatum CECT 7765
(1  109 CFU/day) by oral gavage (SD þ P); and (d) an obese
group fed the HFD and a daily dose of B. pseudocatenula-
tum CECT 7765(1  109 CFU/day) by oral gavage (HFD þ P).
This regime was maintained for 7 weeks. Mice had free
access to sterile water. Diets characteristics are indicated
in Supplemental Table 1. At the end of study, animals were
anaesthetized with isoflurane (2%) by inhalation, bled by
aortic puncture and sacrificed by cervical dislocation. All
efforts were made to minimize suffering. The livers were
rapidly removed, rinsed with cold PBS and one portion kept
in RNA Later (Qiagen, Madrid, Spain) at 80 C for RNA
isolation and another one directly frozen at 80 C for
protein determination. In order to minimize the variabilitylar responses to Bifidobacterium pseudocatenulatum CECT 7765 in
& Cardiovascular Diseases (2013), http://dx.doi.org/10.1016/
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from the same lobule and processed it rapidly under the
same conditions.
RNA extraction
Total RNA was isolated using the RNeasyPlus Mini Kit (Qia-
gen, Madrid, Spain), and quantified in a NanoDrop ND-1000
UVeVis spectrophotometer (NanoDrop Technologies, Wil-
mington, DE). Samples with a ratio Abs260/Abs280 between
1.8 and 2.1 and a concentration >100 ng/mL were used for
microarrays. RNA was kept at 80 C until further analysis.
Microarray analysis
RNA samples (n Z 5 per group) were hybridized on to the
GeneChip Mouse Gene 1.0 ST (Affymetrix, Santa Clara, CA,
USA) following the manufacturer’s protocol and using the
GeneChip Whole Transcript (WT) Sense Target Labelling
protocol, the Ambion WT Expression Kit (Life Technolo-
gies) and the WT terminal Labelling kit. Samples were hy-
bridized for 16 h at 45 C, washed and stained in the
Affymetrix Fluidics Station 450 and scanned using the
GeneChip Scanner 3000. The CEL files were used to extract
and normalize the data using Robust Multichip Average
(RMA) implemented with RMA Sketch for 1.0 ST arrays in the
GeneChip Expression Console software version 1.1.2 (Affy-
metrix). RMA-normalized data were tested for differential
gene expression between groups using the Class Comparison
tool and an empirical Bayes method (Limma) implemented
with Babelomics (http://babelomics.bioinfo.cipf.es).
Adjusted p-values were estimated by the false discovery
rate (FDR, Benjamini & Hochberg). Probes differentially
expressed between groups were defined as those with: 1) a
p-value < 0.0030 (corresponding to an FDR adjusted p-
value < 0.15) and 2) ratios  1.2 (up-regulation) or  0.83
(downregulation). Differentially expressed genes were
uploaded into Ingenuity Pathway Analysis (IPA) software
(Ingenuity Systems, Redwood City, CA) for functional an-
alyses. Minimum information about a microarray experi-
ment compliant data has been submitted to the Gene
Expression Omnibus database: accession number GSE40638.
RT-PCR analysis
Primers and probes were selected from Assays-on-demand
(Taqman system, Applied Biosystems, ABI, Madrid, Spain;
Suplemental Table 2). One-step real time RT-PCRs were run
on the ABI 7500 system following manufacturer’s conditions
(reaction volume25 mL, MicroAmp Optical 96-well plate,
optical adhesive covers, and Taqman Universal Master Mix,
ABI, Madrid, Spain). All assays for a particular gene were
undertaken at the same time under identical conditions and
in triplicate. The expression levels of target genes were
normalized to ACTB (beta actin) using the standard curve
method.
Protein analysis
Frozen liver samples (w200 mg) were homogenized in ice-
cold RIPA buffer (1  solution, 150 mM NaCl, 1.0% IGEPALPlease cite this article in press as: Moya-Pe´rez A, et al., Hepatic molecu
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j.numecd.2013.04.011CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50
mMTris, pH 8.0) (Sigma, Madrid, Spain) and centrifuged at
10000 g and 4 C for 10 min. Protein concentration was
determined in the filtered supernatants by the Lowry’s
method. The levels of IGFBP2, EGR1, and PPP1R3B were
determined using theIGFBP2 Mouse ELISA Kit (Abcam,
Cambridge, UK), EGR1 Mouse ELISA Kit (antibodies-online
GMBH, Aachen, Germany) and PPP1R3B Mouse ELISA Kit
(American Research Products, Inc. Waltham, MA, EEUU),
respectively. For the extraction of CD36, the first super-
natant was discarded and the pellet was incubated again
with fresh RIPA buffer at 4 C for 1 min prior to a second
centrifugation at 10,000 g and 4 C for 10 min. The protein
levels were determined using a CD36 Mouse ELISA Kit
(Abcam, Cambridge, UK). Results are presented as pg/g or
ng/g of tissue weight.
Statistical analysis
Results are expressed as the mean value  SD. Differences
between groups were established using an unpaired Stu-
dent’s t-test. Results with a two-sided p-value <0.05 were
considered statistically significant and p-values < 0.2 were
considered indicative of a trend.
Results
Effects of B. pseudocatenulatum CECT 7765 on
liver gene expression
Microarrays comparison between HFD-fed mice and SD-fed
mice (effect of the HFD) and between HFD-fed mice sup-
plemented with B. pseudocatenulatum CECT 7765
(HFD þ P) and HFD-fed mice (effect of the bacterial strain
on the HFD-fed mice) are shown in Supplemental Tables 3
and 4, respectively. Results revealed that only a small
number of probes (<2%) exhibited significant but moderate
changes with ratios between 1.2 and 1.5 (up-regulation)
and between 0.5 and 0.8 (downregulation). Differential
gene expression analysis between mice fed the SD þ P and
those fed the SD are also presented in Supplemental Table
5. Using the IPA software we identified several genes that
were modulated by the HFD and (or) exposure to B. pseu-
docatenulatum CECT 7765 and that are critically involved in
the regulation of lipid and carbohydrate metabolism in the
liver in response to nutritional stimuli (Table 1): three key
upstream transcription regulators PPARA, PPARGC1A, and
EGR1 which interact with and (or) regulate other genes with
crucial roles in lipid transport (CD36, FABP5 and APOA4),
synthesis and hydrolysis of lipids (HMGCR, INSIG1 and
PNPLA2) and carbohydrate metabolism (PPP1R3B and
IGFBP2). The HFD significantly increased the expression of
CD36 and PPP1R3B which was downregulated by the bac-
terial strain. The HFD also markedly decreased the
expression of EGR1 and IGFBP2 and the administration of B.
pseudocatenulatum CECT 7765 counteracted this effect.
The intake of the bacterial strain with the SD did not alter
significantly the expression of any of these four genes
(Table 1; Supplemental Fig. 1). The HFD downregulated the
levels of HMGCR and INSIG1 and B. pseudocatenulatum
CECT 7765 did not appear to modulate these changes.lar responses to Bifidobacterium pseudocatenulatum CECT 7765 in
& Cardiovascular Diseases (2013), http://dx.doi.org/10.1016/
Table 1 Relative changes in the expression of selected target genes involved in metabolic regulation in the liver of male
C57BL/6 mice fed a high-fat diet (HFD) or a standard diet (SD) alone or in the presence of B. pseudocatenulatum CECT 7765 (P)
as determined by Affymetrix microarrays and quantitative real time RT-PCR.
Gene
symbol
IPA identified biological function(s)
related to lipids and glucose
metabolism
Ratio HFD/SD Ratio HFD þ P/HFD Ratio SD þ P/SD
Microarraysa RT-PCRb Microarrays RT-PCR Microarrays RT-PCR
CD36 Transmembrane protein involved
in long chain fatty acid transport
in hepatocytes.
2.19
(0.0002)c
(0.062)d
1.94  0.67
(0.023)e
0.73
(0.009)
(NS )
0.59  0.37
(0.095)
1.08
NC
0.91  0.63
NC
PPP1R3B Regulation of glycogen metabolising
enzymes in muscle and liver. Also
associated with circulating
LDL-cholesterol.
1.35
(NS)
(NS)
2.42  0.52
(0.003)
0.76
(0.002)
(0.143)
0.68  0.32
(0.084)
0.68
(0.0001)
(NS)
1.06  0.72
NC
EGR1 Transcription regulator implicated
in the control of cholesterol
biosynthetic genes in liver.
0.33
(NS )
(NS )
0.17  0.02
(0.056)
2.64
(0.002)
(0.139)
7.68  0.17
(0.001)
0.69
(0.079)
(NS)
0.46  0.12
(NS)
IGFBP2 Regulation of glucose metabolism
and diabetes. Reduced expression
in obesity and Type 2 diabetes.
0.48
(0.008)
(NS )
0.40  0.11
(0.006)
1.50
(0.0006)
(0.094)
1.64  0.13
(0.089)
0.97
NC
0.92  0.10
NC
HMGCR Catalyses a rate-limiting step in
cholesterol and sterols biosynthesis.
0.59
(0.012)
(NS )
0.23  0.10
(0.002)
1.33
(0.003)
(NS )
0.78  0.18
(NS )
0.69
(0.0005)
(NS )
0.78  0.23
(0.167)
INSIG1 Plays a critical role in regulating
cholesterol concentrations in cells
by preventing the activation of the
genes for lipid biosynthesis.
Binds to the HMG CoA reductase.
0.73
(NS )
(NS )
0.78  0.12
(0.011)
1.30
(0.002)
(0.143)
0.91  0.10
NC
0.78
(0.003)
(NS )
0.56  0.26
(0.013)
PNPLA2 Triacyl glycerol lipase that catalyses
the first step in the hydrolysis of
triglycerides in lipids droplets.
0.81
(0.049)
(NS )
0.87  0.10
NC
1.06
NC
1.27  0.23
(0.085)
1.30
(0.002)
(NS )
1.53  0.33
(0.049)
PPARA Nuclear receptor involved in lipid
and glucose metabolism regulation:
negative regulation of cholesterol
storage, glycolysis and sequestering
of triglyceride.
1.20
(0.004)
(0.176)
1.24  0.20
(0.104)
1.07
(NS)
(NS)
0.87  0.45
NC
0.91
NC
NC
0.89  0.43
NC
PPARGC1A Transcriptional coactivator that
regulates genes involved in
oxidative energy metabolism.
It provides a direct link between
external physiological stimuli
and the regulation of mitochondrial
biogenesis.
0.64
(0.00001)
(0.016)
0.82  0.23
(0.150)
0.90
NC
0.61  0.47
(NS )
0.89
NC
1.05  0.31
NC
APOA4 Secreted to the extracellular space.
Member of LDL and HDL particles.
Regulates cholesterol, APOB,
chylomicron, triacyl glycerol,
D-glucose. Regulated by PPARA.
1.64
(0.00001)
(0.016)
1.51  0.48
(0.171)
1.10
NC
NC
1.01  0.74
NC
1.05
NC
NC
0.81  0.21
(NS )
FABP5 Intracellular lipid carrier. High
specificity for fatty acids. Regulates
D-glucose, triacyl
glycerol, cholesterol.
0.20
(0.0001)
(0.031)
0.43  0.35
(NS )
1.61
(0.074)
(NS )
0.80  0.84
(NS )
1.20
(NS )
(NS )
0.86  0.64
NC
p-value < 0.05 were considered statistically significant; p-values < 0.2 were considered indicative of a trend; (NS ): Not significant; NC:
No change: cut-off values  1.2 (upregulation) or  0.83 (downregulation).
a Microarrays changes (n Z 5 animals per group).
b RT-PCR values are shown as the mean  SD (n Z 5 animals per group).
c Non adjusted p-value microarrays.
d FDR adjusted p-value microarrays (Benjamini-Hochberg).
e Two-sided p-value as determined byan unpaired Student’s t-test.
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genes in mice fed the SD, more significantly for INSIG1.
Also, PNPLA2 was not significantly modified by the HFD
whereas the intake of B. pseudocatenulatum CECT 7765
both in HFD-fed mice and SD-fed mice slightly increased the
expression of this gene (Table 1; Supplemental Fig. 2). Our
analysis also indicated that the HFD moderately induced
the expression of PPARA and APOA4 and slightly down-
regulated PPARGC1A and FABP5 and that B. pseudocate-
nulatum CECT 7765 did not affect these genes (Table 1;
Supplemental Fig. 3).Effects of B. pseudocatenulatum CECT 7765 on
protein levels
CD36, EGR1, IGFBP2 and PPP1R3B proteins were expressed in
the liver of control animals as follows: IGFBP2
(51.4  17.3 mg/g) >> CD36 (0.78  0.04 mg/g) >> PPP1R3B
(4.2  0.9 ng/g) > EGR1 (1.7  0.5 ng/g). In agreement with
the mRNA changes, CD36 increased (Fig. 1a, fold-change:
1.2  0.1, pZ 0.015) whereas EGR1 and IGFBP2 decreased
(Fig. 1b and c, 1.7  0.5, p Z 0.027 and 1.7  0.6,
p Z 0.037, respectively) in the HFD-fed mice compared to
the SD-fed mice. The administration of B. pseudocatenula-
tum CECT 7765 decreased the protein levels of CD36
(1.2  0.1, p Z 0.019) and moderately upregulated the
protein levels of EGR1 and IGFBP2 (1.5  0.3, pZ 0.192 and
1.5  0.3, p Z 0.141, respectively). In contrast to the
observed gene expression induction of PPP1R3B, the levels of
this protein were significantly reduced in the HFD-fed miceFigure 1 Whisker box plots of protein levels for a) CD36, b) PPP1R
a standard diet (SD), a high-fat diet (HFD), a high-fat diet suppleme
(1  109 CFU/day) (HFD þ P) and a standard diet supplemented
(1  109 CFU/day) (SD þ P). Differences between groups were est
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a mouse model of diet-induced obesity, Nutrition, Metabolism
j.numecd.2013.04.011(1.5  1.1, p Z 0.024) and this effect was also counter-
acted by the administration of B. pseudocatenulatum CECT
7765 (1.4  0.3, pZ 0.046) (Fig. 1d).Discussion
In this study, sub-chronic supplementation with B. pseu-
docatenulatum CECT 7765 to HF-fed C57BL/6J mice was
found to modulate the liver expression of key molecules
involved in the regulation of energy metabolism and
transport of lipids that were affected by the HF intake.
Although the liver tissue contains different types of cells
and this heterogeneity may contribute to the variance of
the gene expression data, hepatocytes constitute w60% of
the tissue and perform the majority of metabolic liver
functions [14] and thus, our results may be indicative of
changes occurring mostly in hepatocytes.
We herein report that the hepatic steatosis and serum
hyperlipidaemia induced in the C57BL/6J mice by the HFD
[10] is accompanied by hepatic molecular changes that
indicate an activation of lipid metabolism (Fig. 2a). The key
metabolic sensors PPARA and PPARGC1A are known to
interact and to regulate molecules such as acyl CoA oxidase,
acyl CoA synthase, enoyl-CoA hydratase, malic enzyme, HMG
CoA synthase, carnitine palmitoyltrasnferase 1a (CPT1a),
fatty acid transporters and APO proteins, involved in the
regulation of fatty acid b-oxidation and cholesterol synthesis
and transport [15,16]. In agreement with this, our micro-
array data show that the HFD alters the expression of many
of these genes in the mice liver (Supplemental Table 3) and3B, c) EGR1 and d) IGFBP2 in the liver of C57BL/6 male mice fed
nted with the bacterial strain B. pseudocatenulatum CECT 7765
with the bacterial strain B. pseudocatenulatum CECT 7765
ablished using an unpaired Student’s t-test.
lar responses to Bifidobacterium pseudocatenulatum CECT 7765 in
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a) A high-fat intake increases body and fat weight, serum
cholesterol, triglycerides, glucose, insulin and leptin levels as 
well as liver steatosis in C57BL/6 male mice [10].
Selected target gene expression changes involved in lipid and 
carbohydrate metabolism and associated to a high-fat intake
in the liver of mice:
b) The consumption of B. pseudocatenulatum CECT 7765 
decreases body weight, serum cholesterol, triglycerides, glucose, 
insulin and leptin levels as well as steatosis in a high-fat fed
C57BL/6 male mice [10].
Selected target gene expression changes associated to the
intake of the bacteria in the high-fat fed mice:
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Figure 2 Ingenuity pathways analysis (IPA) software was used for the exploration of molecular interactions and to build a
graphical representation of a liver cell displaying the specific selected target genes involved in lipid and glucose metabolism and
that were: a) associated to the high-fat intake and b) to the administration of the bacterial strain B. pseudocatenulatum CECT 7765
in high-fat fed C57BL/6 male mice. Up or downregulation is indicated by the thick arrows. Some of the reported interactions
between these molecules are indicated by thin arrows. Molecules represented: CD36: CD36 molecule (thrombospondin receptor);
EGR1, early growth response 1; IGFBP2 insulin-like growth factor binding protein 2; PPP1R3B: protein phosphatase 1, regulatory
(inhibitor) subunit 3B; PNPLA2: patatin-like phospholipase domain containing 2; INSIG1: insulin induced gene 1; HMGCR: 3-hydroxy-
3-methylglutaryl-Coenzyme A reductase; PPARA: peroxisome proliferator activated receptor alpha; PPARGC1A: peroxisome pro-
liferative activated receptor, gamma, coactivator 1 alpha; APOA4: apolipoprotein A-IV; FABP5: fatty acid binding protein 5; ER:
endoplasmic reticulum.
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metabolism. Particularly, the HFD upregulated the levels of
CD36, involved in fatty acid uptake and reported to be
induced in subjects with steatosis [17], which could partially
explain the hepatic fat accumulation in the HFD-fed C57BL/6
mice [10]. The transcription factor EGR1 is predominantly
expressed in the liver and binds to cholesterol biosynthetic
promoters [18]. Its repression has been linked to reduced
cholesterol levels in association with the downregulation of
HMGCR, a rate-limiting enzyme in the synthesis of choles-
terol [18,19] also regulated by INSIG1 [19]. In accordance
with a general decrease of cholesterol synthesis, our data
confirmed the downregulation of EGR1, INSIG1 and HMGCR in
the HFD-fed mice. Additionally, the HFD upregulated the
mRNA levels of APOA4, a major component of lipoprotein
particles and activator of lecithin-cholesterol acyl trans-
ferase [20], which suggests an activation of cholesterol
reverse transport.Please cite this article in press as: Moya-Pe´rez A, et al., Hepatic molecu
a mouse model of diet-induced obesity, Nutrition, Metabolism
j.numecd.2013.04.011Administration of B. pseudocatenulatum CECT 7765 to
mice fed a HFD diminished the levels of serum cholesterol,
triglycerides, glucose, insulin and leptin as well as liver
steatosis [10] and some of the detected hepatic gene and
protein changes associated to the intake of the bacteria
support these effects (Fig. 2b). Notably, the bacteria coun-
teracted the effects of the HFD on the expression of CD36,
both at the transcript and protein levels. In agreement with
these results, a strain of Pediococcus pentosaceus LP28 was
also reported to reduce bodyweight and liver adiposity and to
downregulate the transcript levels of CD36 in a high-fat mice
model [21]. CD36 repression has been related to the preven-
tion of fatty liver [17] and, thus, reduction of the levels of this
molecule and of fatty acid uptake may be an important
contributor to the lipid lowering effects of potential pro-
biotics. Also, PNPLA2 which encodes for adipose triacyl glyc-
erol lipase (ATGL) and whose inactivation increases
triglycerides accumulation in the liver [22] was slightlylar responses to Bifidobacterium pseudocatenulatum CECT 7765 in
& Cardiovascular Diseases (2013), http://dx.doi.org/10.1016/
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be indicative of an increase in the hydrolysis of triglycerides
contributing to depletion of fat in the liver. The bacteria also
upregulated the mRNA and protein levels of EGR1 in the HF-
fed mice which suggest an activation of cholesterol meta-
bolism. On the other hand, the transcript levels of HMGCR or
INSIG1 were downregulated by B. pseudocatenulatum CECT
7765 only in the SD-mice. In a similar manner, Lactobacillus
plantarum KCTC3928 has been reported to lower plasma
cholesterol and triglycerides in mice and to marginally
downregulate the transcription of HMGCR [23]. Inhibition of
HMGCR is a major pharmacologic strategy to lower plasma
cholesterol levels [19] and probiotics may provide a dietary
alternative with a similar mechanism of action.
Two other important genes involved in hepatic energy
metabolism are IGFBP2 and PPP1R3B. IGFBP2 is implicated in
glucose regulation and insulin sensitivity. Its overexpression
diminishes weight gain, fasting glucose, insulin and leptin
levels [24] and may protect against the development of
obesity by HFDs. In our study, the mRNA and protein levels of
IGFBP2 were upregulated by the bacteria in the HF-fed mice
in accordance with the reported reduction of weight,
glucose, insulin and leptin levels [10]. PPP1R3B is also
involved in the control of plasma glucose by regulating
glycogen metabolism [25] and is associated with altered
serum cholesterol and hepatic steatosis [26,27]. The mRNA
and protein levels of PPP1R3B were also found to be signi-
ficatively modulated by the HF intake and counteracted by
the bacterial strain. At the time point of the analysis the
regulation of this transcript was not correlated with the
change in protein which may be due to differences in the
rate of transcription and translation and(or) in the half-life
and stability of the mRNA and protein molecules [28].
In relation to our work, the anti-obesity effects of pre-
biotics with an effect on the microbiota and the regulation of
molecular markers in the liver of C57BL/6J mice have been
investigated. In agreement with the metabolic benefits and
hepatic response to B. pseudocatenulatum CECT 7765,
C57BL/6Jmice treatedwith a mixture of fermentable dietary
fructo-oligosaccharides (FOS) exhibited higher caecal Bifi-
dobacterium spp., reduced hepatic triglycerides mediated by
PPARA stimulation of fatty acid oxidation and lessened
cholesterol accumulation by inhibiting cholesterol synthesis
[29]. Also recently, multiple-targeted analysis using micro-
arrays has been implemented to investigate the molecular
changes induced by L. ingluviei in liver. The authors reported
a significant increase in body and liver weight concomitant
with multiple changes in genes involved in metabolism and
inflammation [7]. We have also applied microarrays to anal-
yse the molecular changes associated with the intake of B.
pseudocatenulatum CECT 7765 with a HFD and have shown a
general modulation of the metabolism of lipids and carbo-
hydrates in the liver, more specifically, in the regulation of
fatty acid and cholesterol metabolism and transport, lipid
levels and glucose levels through the regulation of key genes
and proteins. These results corroborate some of the general
adaptative responses promoted in the liver by the intake of
probiotics. The precise mechanism(s) that links the oral
intake of B. pseudocatenulatum CECT 7765 with the liver
molecular response remains to be elucidated and it may
involve altering lipid absorption as suggested previously [10]
as well as the alteration of cell-signalling mechanisms viaPlease cite this article in press as: Moya-Pe´rez A, et al., Hepatic molecu
a mouse model of diet-induced obesity, Nutrition, Metabolism
j.numecd.2013.04.011the gutebrain axis. A full understanding of these processes
will require the combination of multi-organ and multi-target
analyses in an extended time scale.
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